Unnamed: 0,title,date,stock,sentiment
850715.0,"Shares of several healthcare companies are trading lower in sympathy with the overall market following an increase in coronavirus cases in some US states that have reopened, leading to concerns of a second wave of the virus.",2020-06-11 10:22:00-04:00,MRK,positive
850716.0,Johnson & Johnson To Start Coronavirus Vaccine Human Trials Ahead Of Schedule In July,2020-06-11 00:16:00-04:00,MRK,neutral
850717.0,"The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset",2020-06-10 07:30:00-04:00,MRK,positive
850718.0,Merck Announces That The Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA As Monotherapy And In Combination With Chemotherapy In Patients With Advanced Or Metastatic Urothelial Carcinoma,2020-06-09 16:13:00-04:00,MRK,positive
850719.0,"The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage",2020-06-07 13:43:00-04:00,MRK,neutral
850720.0,"The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid",2020-06-05 07:34:00-04:00,MRK,positive
850721.0,Merck Reports FDA Approved RECARBIO For Treatment Of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia,2020-06-05 06:52:00-04:00,MRK,positive
850722.0,Ex-FDA Chief On White House's Coronavirus Vaccine Shortlist: 'They Chose Very Novel Platforms',2020-06-04 11:02:00-04:00,MRK,positive
850723.0,"The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic",2020-06-04 08:13:00-04:00,MRK,positive
850724.0,Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics,2020-06-03 17:53:00-04:00,MRK,neutral
850725.0,Traders Share Their Health Care Picks,2020-06-03 17:17:00-04:00,MRK,positive
850726.0,"UPDATE: Five Companies Chosen For 'Vaccine Finalist' Are Moderna, Johnson & Johnson, Merck, Pfizer And AstraZeneca",2020-06-03 13:09:00-04:00,MRK,neutral
850727.0,Pharma Large And Mid-Caps Race Against COVID-19,2020-06-02 14:50:00-04:00,MRK,neutral
850728.0,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,2020-06-01 16:00:00-04:00,MRK,neutral
850729.0,'New Ebola epidemic' in northwest DR Congo: health ministry' -AFP,2020-06-01 08:39:00-04:00,MRK,neutral
850730.0,Merck and AstraZeneca's LYNPARZA Receives a Positive Opinion from the European Medicines Agency,2020-06-01 06:46:00-04:00,MRK,positive
850731.0,AstraZeneca Announces Lynparza Recommended for Approval in EU by CHMP for BRCA-mutated Metastatic Pancreatic Cancer,2020-06-01 05:31:00-04:00,MRK,negative
850732.0,"The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight",2020-05-30 09:25:00-04:00,MRK,neutral
850733.0,Merck Yesterday Announced KEYTRUDA plus LENVIMA Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma,2020-05-29 09:55:00-04:00,MRK,positive
850734.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,MRK,positive
850735.0,"Cramer Shares His Thoughts On Teva, Oxford Industries And More",2020-05-29 06:40:00-04:00,MRK,positive
850736.0,Merck's Keytruda (Pembrolizumab) Superior To Standard Of Care Chemotherapy In Patients With MSI-H Colorectal Cancer,2020-05-28 17:01:00-04:00,MRK,positive
850737.0,Merck CEO Can't Give A Timeline Or Date For COVID-19 Approval,2020-05-26 16:20:00-04:00,MRK,positive
850738.0,Merck CEO Ken Frazier To Appear On CNBC,2020-05-26 16:02:00-04:00,MRK,neutral
850739.0,'Merck chief casts doubt on coronavirus vaccine timeframe' -Financial Times,2020-05-26 11:24:00-04:00,MRK,negative
850740.0,"Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development",2020-05-26 10:48:00-04:00,MRK,negative
850741.0,"Benzinga Pro's Top 5 Stocks To Watch For Tues., May 26, 2020: NVAX, EWJ, SNY, SOXX, MRK",2020-05-26 08:13:00-04:00,MRK,positive
850742.0,Merck To Acquire Vaccine Company Themis Bioscience; Also Announces Collaboration With IAVI For Coronavirus Vaccine And Collaboration With Ridgeback Bio For Coronavirus Antiviral Candidate,2020-05-26 06:46:00-04:00,MRK,neutral
850743.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2020-05-24 14:40:00-04:00,MRK,neutral
850744.0,"US Health Official Says Vaccines From J&J, Sanofi, Merck May Be Added This Summer As They Complete Phase 1 Safety Studies",2020-05-22 13:50:00-04:00,MRK,positive
850745.0,"US Says Will Test Experimental Coronavirus Vaccines In 100,000+ People, Health Official Says Oxford Vaccine May Be Tested ""Side By Side"" With Moderna's Starting In July",2020-05-22 13:50:00-04:00,MRK,neutral
850746.0,64 Biggest Movers From Yesterday,2020-05-22 05:26:00-04:00,MRK,neutral
850747.0,Mid-Afternoon Market Update: Dow Falls 50 Points; L Brands Shares Spike Higher,2020-05-21 14:30:00-04:00,MRK,positive
850748.0,51 Stocks Moving In Thursday's Mid-Day Session,2020-05-21 13:18:00-04:00,MRK,neutral
850749.0,Mid-Day Market Update: Crude Oil Rises Over 1%; Aurora Cannabis Shares Jump,2020-05-21 12:13:00-04:00,MRK,negative
850750.0,Mid-Morning Market Update: Markets Mixed; Best Buy Tops Q1 Expectations,2020-05-21 10:14:00-04:00,MRK,positive
850751.0,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive",2020-05-21 08:01:00-04:00,MRK,neutral
850752.0,Mid-Afternoon Market Update: Crude Oil Up 5%; Surface Oncology Shares Spike Higher,2020-05-20 14:49:00-04:00,MRK,negative
850753.0,Why Surface Oncology's Stock Is Surging Higher,2020-05-20 12:37:00-04:00,MRK,neutral
850754.0,Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market,2020-05-20 08:33:00-04:00,MRK,negative
850755.0,"The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test",2020-05-20 08:12:00-04:00,MRK,neutral
850756.0,AstraZeneca And Merck Announce LYNPARZA Approved By FDA For Treatment Of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment With Enzalutamide Or Abiraterone,2020-05-20 06:56:00-04:00,MRK,negative
850757.0,AstraZeneca Says Lynparza Approved in the U.S. for Prostate Cancer,2020-05-20 05:22:00-04:00,MRK,negative
850758.0,Telemedicine A COVID-19 Winner,2020-05-19 16:46:00-04:00,MRK,positive
850759.0,Merck And UPMC Announces Infectious Disease Connect Has Combined  Merck's ILÃšM Health Solutions To 'Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship ',2020-05-19 07:05:00-04:00,MRK,positive
850760.0,Merck Reports KEYTRUDA Plus Chemo Showed Statistically Significant Improvement In Progression-Free Survival vs Chemo In Certain Patients With Metastatic Triple-Negative Breast Cancer,2020-05-13 17:06:00-04:00,MRK,positive
850761.0,Merck Reports KEYTRUDA Superior To Brentuximab Vedotin In Patients With Classical Hodgkin Lymphoma In Head-To-Head Phase 3 Trial,2020-05-13 17:05:00-04:00,MRK,positive
850762.0,Merck Reports New Combo Data For KEYTRUDA Showed Benefit In Stage 3 Non-Small Cell Lung Cancer,2020-05-13 17:04:00-04:00,MRK,negative
850763.0,Merck Reports Novel HIF-2a Inhibitor Showed Objective Response Rate Of Nearly 30% In Patients With von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma,2020-05-13 17:02:00-04:00,MRK,positive
850764.0,"AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst",2020-05-13 12:03:00-04:00,MRK,neutral
850765.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,MRK,neutral
850766.0,Merck Animal Health to Acquire U.S. Rights to SENTINEL Brand of Combination Parasiticides for Companion Animals for ~$400M in Cash,2020-05-13 05:26:00-04:00,MRK,neutral
850767.0,"UPDATE: Cocrystal Says Collaboration With Merck For Discovery, Development Of Certain Proprietary Flu A/B Antiviral Agents Ongoing",2020-05-11 08:31:00-04:00,MRK,negative
850768.0,AstraZeneca And Merck Announce LYNPARZA Approved In US As 1st-line Maintenance Treatment With bevacizumab For HRD-Positive Advanced Ovarian Cancer,2020-05-11 07:26:00-04:00,MRK,negative
850769.0,"AstraZeneca Announces Lynparza Approved in the U.S, as 1st-line Maintenance Treatment With Bevacizumab for HED-positive Advanced Ovarian Cancer",2020-05-11 05:22:00-04:00,MRK,negative
850770.0,5 Biopharmas Where BofA Would Put Its Money To Work,2020-05-08 11:23:00-04:00,MRK,neutral
850771.0,Merck Announces RECARBRIO Demonstrated Noninferiority Compared To Piperacillin And Tazobactam In Primary And Key Secondary Endpoints,2020-05-06 06:49:00-04:00,MRK,neutral
850772.0,Why Shares Of Gene Therapy Company Genprex Are Surging Higher,2020-05-05 12:38:00-04:00,MRK,positive
850773.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2020-05-03 09:25:00-04:00,MRK,neutral
850774.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,MRK,neutral
850775.0,"ServiceNow CEO Bill McDermott Says Company 'Hungry And Humble,' With $10B Ambitions",2020-04-30 10:33:00-04:00,MRK,neutral
850776.0,"Guggenheim Maintains Buy on Merck & Co, Lowers Price Target to $93",2020-04-29 13:36:00-04:00,MRK,negative
850777.0,"Barclays Maintains Overweight on Merck & Co, Lowers Price Target to $90",2020-04-29 11:18:00-04:00,MRK,negative
850778.0,"Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut",2020-04-29 11:04:00-04:00,MRK,positive
850779.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,MRK,positive
850780.0,"SVB Leerink Maintains Outperform on Merck & Co, Lowers Price Target to $95",2020-04-29 06:24:00-04:00,MRK,negative
850781.0,FDA Approves Merck's KEYTRUDA For Use At An Additional Recommended Dose Of 400 mg Every Six Weeks For All Approved Adult Indications,2020-04-28 16:36:00-04:00,MRK,positive
850782.0,A CURE For The Common Earnings Play,2020-04-28 14:48:00-04:00,MRK,positive
850783.0,Morning Market Stats in 5 Minutes,2020-04-28 10:32:00-04:00,MRK,neutral
850784.0,"Earnings Feast: Bring a Plate With Healthcare and Caterpillar in Morning, GOOGL And AMD Later",2020-04-28 10:06:00-04:00,MRK,neutral
850785.0,Merck shares are trading lower after the company issued FY20 guidance below consensus estimates.,2020-04-28 08:40:00-04:00,MRK,neutral
850786.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,MRK,neutral
850787.0,"Merck Sees FY20 EPS $5.17-$5.37 vs $5.56 Est., Sales $46.1B-$48.1B vs $48.72B Est.",2020-04-28 06:48:00-04:00,MRK,neutral
850788.0,"Merck & Co Q1 Adj. EPS $1.500 Beats $1.340 Estimate, Sales $12.100B Beat $11.460B Estimate",2020-04-28 06:47:00-04:00,MRK,neutral
850789.0,"Earnings Scheduled For April 28, 2020",2020-04-28 04:55:00-04:00,MRK,neutral
850790.0,"Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead",2020-04-27 09:44:00-04:00,MRK,positive
850791.0,Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers for Coronavirus,2020-04-27 06:50:00-04:00,MRK,neutral
850792.0,Lynparza Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-mutated Metastatic Castration-resistant Prostate Cancer,2020-04-27 05:41:00-04:00,MRK,negative
850793.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,MRK,negative
850794.0,"AstraZeneca, Merck Announce Lynparza Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-mutated Metastatic Castration-resistant Prostate Cancer",2020-04-24 05:24:00-04:00,MRK,negative
850795.0,Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.,2020-04-23 11:27:00-04:00,MRK,positive
850796.0,Merck Reports Resubmission Of Supplemental Biologics License Applications For KEYTRUDA 6-Week Dosing Schedule,2020-04-23 06:45:00-04:00,MRK,neutral
850797.0,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",2020-04-21 11:35:00-04:00,MRK,negative
850798.0,Merck Broadens Patient Support And Assistance Programs As Part Of Overall COVID-19 Relief Efforts,2020-04-21 06:46:00-04:00,MRK,positive
850799.0,Cue Biopharma Announces Clinical Trial Collaboration Agreement With Merck To Evaluate CUE-101 In Combination With KEYTRUDA As First-line Treatment For HPV+ Recurrent/Metastatic Head And Neck Cancer,2020-04-20 08:13:00-04:00,MRK,negative
850800.0,"Barron's Picks And Pans: Dropbox, Ford, Johnson & Johnson, Teladoc And More",2020-04-19 14:44:00-04:00,MRK,neutral
850801.0,Gilead's Encouraging Remdesivir Data: Rapid Reaction On The Stock,2020-04-16 19:10:00-04:00,MRK,positive
850802.0,S&P 500 Futures Up 3.2% After Hours; Many Other Stocks Moving Higher With Futures; Investors Reacting Favorably To White Phase Guidelines On Reopening Economy,2020-04-16 18:11:00-04:00,MRK,positive
850803.0,"Next 45 Days Will Be 'Most Critical Period' For US, Says Alan Lancz Who Predicted 1987 and 2008 Crises",2020-04-16 06:08:00-04:00,MRK,negative
850804.0,Every Member Of Trump's 'Great American Economic Revival' Industry Groups,2020-04-15 13:09:00-04:00,MRK,positive
850805.0,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",2020-04-15 08:03:00-04:00,MRK,neutral
850806.0,"Merck Announces US Launch Of ONTRUZANT (trastuzumab-dttb), A Biosimilar Of Herceptin (trastuzumab)",2020-04-15 06:51:00-04:00,MRK,neutral
850807.0,"UBS Maintains Buy on Merck & Co, Lowers Price Target to $92",2020-04-13 09:45:00-04:00,MRK,negative
850808.0,"AstraZeneca and Merck Announce Approval of KOSELUGO for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas",2020-04-13 06:57:00-04:00,MRK,positive
850809.0,FDA Approves Generic Version Of Merck's Proventil HFA Metered-Dose Inhaler,2020-04-08 13:48:00-04:00,MRK,positive
850810.0,"Merck Receives Priority Review From FDA For Second Application For KEYTRUDA Based On Biomarker, Regardless Of Tumor Type",2020-04-07 06:45:00-04:00,MRK,negative
850811.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,MRK,positive
850812.0,Cannabis Opportunity In The Time Of The Coronavirus,2020-04-02 17:59:00-04:00,MRK,positive
850813.0,"Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $89",2020-04-02 09:23:00-04:00,MRK,negative
850814.0,"Merck Reports KEYTRUDA Significantly Improved Progression-Free Survival As First-Line Treatment For MSI-H, dMMR Colorectal Cancer",2020-04-02 06:46:00-04:00,MRK,negative
850815.0,"RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $89",2020-04-01 09:31:00-04:00,MRK,negative
850816.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,MRK,negative
850817.0,Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.,2020-03-30 10:17:00-04:00,MRK,positive
850818.0,"Barron's Picks And Pans: Tech Picks, SoftBank, REITs, Tesla And More",2020-03-29 10:29:00-04:00,MRK,neutral
850819.0,"Cramer Reveals Stock Favorites, Says Intuitive Surgical A 'Winner'",2020-03-27 10:10:00-04:00,MRK,positive
850820.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 09:22:00-04:00,MRK,positive
850821.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,MRK,positive
850822.0,UPS Seeks To Accelerate Growth Of Drone-Delivery,2020-03-25 11:48:00-04:00,MRK,positive
850823.0,10 Biggest Price Target Changes For Tuesday,2020-03-24 09:01:00-04:00,MRK,neutral
850824.0,"Argus Research Maintains Buy on Merck & Co, Lowers Price Target to $95",2020-03-24 08:42:00-04:00,MRK,negative
850825.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,MRK,negative
850826.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,MRK,negative
850827.0,Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City,2020-03-22 11:54:00-04:00,MRK,neutral
850828.0,"Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.",2020-03-17 09:10:00-04:00,MRK,positive
850829.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,MRK,neutral
850830.0,Merck Announces Top-Line Results From Phase 3 Trials Evaluating Gefapixant For Refractory Of Unexplained Chronic Cough; Gefapixant Demonstrated Statistically Significant Decrease In 24-Hour Coughs Per Hour Compared To Placebo At Week 12 And 24,2020-03-17 06:51:00-04:00,MRK,positive
850831.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,MRK,negative
850832.0,"Barron's Picks And Pans: Roundtable Picks, Airline And Oil Stocks, And More",2020-03-14 12:58:00-04:00,MRK,neutral
850833.0,"Intec Pharma Posts Q4 Net Loss Of $6.6M, Down By Nearly Half Year-Over-Year",2020-03-13 14:43:00-04:00,MRK,negative
850834.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,MRK,positive
850835.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,MRK,negative
850836.0,Merck & Co shares are trading lower after the company announced its Phase 3 GY004 trial for Cediranib and LYNPARZA did not meet its primary endpoint.,2020-03-12 07:11:00-04:00,MRK,neutral
850837.0,WebMD Acquires Merck Subsidiary Staywell,2020-03-12 06:03:00-04:00,MRK,neutral
850838.0,AstraZeneca and Merck Announce Phase 3 GY004 for Cediranib and LYNPARZA in Platinum-Sensitive Relapsed Ovarian Cancer Did Not Meet the Primary Endpoint of Progression-Free Survival vs. Platinum-Based Chemotherapy,2020-03-12 05:16:00-04:00,MRK,negative
850839.0,Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.,2020-03-11 07:15:00-04:00,MRK,neutral
850840.0,CDC's Redfield Says Will Know By April If Ebola-Tied Drug Helps Coronavirus,2020-03-10 11:59:00-04:00,MRK,positive
850841.0,52 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-09 08:04:00-04:00,MRK,neutral
850842.0,"Barron's Picks And Pans: Coronavirus Picks, Bonds, Safe Havens And More",2020-03-07 17:09:00-05:00,MRK,positive
850843.0,"FDA Issues Warning On Merck's Singulair, Warns Of Mental Health Side Effects",2020-03-04 13:28:00-05:00,MRK,negative
850844.0,Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:16:00-05:00,MRK,positive
850845.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2020-03-02 16:46:00-05:00,MRK,neutral
850846.0,Merck shares are trading higher after the company's KEYNOTE-204 of KEYTRUDA met one of its primary endpoints of progression-free survival.,2020-03-02 10:10:00-05:00,MRK,positive
850847.0,Merck Announces New Data from Broad HIV Program at CROI 2020,2020-03-02 06:47:00-05:00,MRK,neutral
850848.0,A Peek Into The Markets: US Stock Futures Down Ahead Of Manufacturing Reports,2020-03-02 06:45:00-05:00,MRK,neutral
850849.0,Merck's Phase 3 KEYNOTE-204 Trial of KEYTRUDA Met One of its Primary Endpoints,2020-03-02 06:33:00-05:00,MRK,neutral
850850.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,MRK,negative
850851.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,MRK,positive
850852.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,MRK,negative
850853.0,What Drove Merck's Keytruda Shortfall In Q4,2020-02-24 09:31:00-05:00,MRK,neutral
850854.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,MRK,neutral
850855.0,"Benzinga's Bulls And Bears Of The Week: Merck, Nike, Target And More",2020-02-22 13:00:00-05:00,MRK,neutral
850856.0,Why Merck Has Had Underwhelming Start To 2020,2020-02-20 11:35:00-05:00,MRK,neutral
850857.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,MRK,negative
850858.0,Elanco Signs Agreement with Merck Animal Health to Divest Worldwide Rights for Vecoxan,2020-02-19 16:45:00-05:00,MRK,positive
850859.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,MRK,negative
850860.0,Merck Receives CRL from FDA for sBLAs for KEYTRUDA Six-Week Dosing Schedule,2020-02-19 05:20:00-05:00,MRK,neutral
850861.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,MRK,positive
850862.0,"Ervebo Now Registered In Four African Countries, Within 90 Days Of Reference Country Approval And WHO Prequalification",2020-02-14 11:21:00-05:00,MRK,positive
850863.0,Merck Says Keytruda In Combination With Chemotherapy Met Primary Endpoint Of Progression-Free Survival As First-Line Treatment For Metastatic Triple-Negative Breast Cancer,2020-02-12 06:47:00-05:00,MRK,negative
850864.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,MRK,positive
850865.0,"KalVista Pharma Reports Option Deal Between Co., Merck Related To Intravitreal Diabetic Macular Edema Candidate KVD001, Future Oral DME Molecules Has Expired",2020-02-10 16:30:00-05:00,MRK,neutral
850866.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,MRK,neutral
850867.0,"Barron's Picks And Pans: GM, Kraft Heinz, Tesla, Under Armour And More",2020-02-08 11:45:00-05:00,MRK,neutral
850868.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,MRK,negative
850869.0,"Twitter Up, Tesla Down: Strong User Numbers Help TWTR, But TSLA Selling Continues",2020-02-06 09:36:00-05:00,MRK,positive
850870.0,"UBS Maintains Buy on Merck & Co, Lowers Price Target to $96",2020-02-06 07:48:00-05:00,MRK,negative
850871.0,"Merck To Spin Off Slow-Growing Women's Health, Legacy, Biosimilars Businesses: What You Need To Know",2020-02-05 12:16:00-05:00,MRK,neutral
850872.0,"Earnings Bonanza: Results Keep Pouring In, With Investors Looking Over Merck, Disney",2020-02-05 10:00:00-05:00,MRK,neutral
850873.0,Merck & Co shares are trading lower after the company reported worse-than-expected Q4 sales results.,2020-02-05 08:25:00-05:00,MRK,neutral
850874.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,MRK,neutral
850875.0,Merck Reports Mixed Q4 Earnings,2020-02-05 07:27:00-05:00,MRK,neutral
850876.0,"Merck Sees FY20 Adj. EPS $5.62-$5.77 vs $5.61 Est., Sales $48.8B-$50.3B vs $49.53B Est.",2020-02-05 06:49:00-05:00,MRK,neutral
850877.0,"Merck & Co Q4 Adj. EPS $1.16 Beats $1.15 Estimate, Sales $11.87B Miss $11.98B Estimate",2020-02-05 06:48:00-05:00,MRK,negative
850878.0,"Merck To Spin Off Products From Its Women's Health, Trusted Legacy Brands And Biosimilars Business Into New Independent Publicly-Traded Co.; Co. Says Transaction Enables It To Achieve $2.4$B n Operating Efficiencies By 2024",2020-02-05 06:47:00-05:00,MRK,positive
850879.0,"10 Stocks To Watch For February 5, 2020",2020-02-05 05:28:00-05:00,MRK,neutral
850880.0,"Earnings Scheduled For February 5, 2020",2020-02-05 04:26:00-05:00,MRK,neutral
850881.0,Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates,2020-02-03 13:30:00-05:00,MRK,neutral
850882.0,Merck & Co shares are trading higher after the company's RECARBRIO supplemental new drug application was accepted for FDA review.,2020-02-03 11:13:00-05:00,MRK,positive
850883.0,"Surprise, Surprise: Stocks Wearing Their Rally Hats Despite China Market Tanking",2020-02-03 09:44:00-05:00,MRK,positive
850884.0,Merck's RECARBRIO Supplemental New Drug Application Accepted for FDA Review,2020-02-03 06:47:00-05:00,MRK,positive
850885.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,MRK,neutral
850886.0,"Position Scrimmage: Coronavirus, End-Of-Month Profit Taking Influencing Markets",2020-01-31 09:46:00-05:00,MRK,positive
850887.0,"February Market Outlook: Coronavirus, D.C. Proceedings, Earnings Season Could Mean Volatility",2020-01-29 14:53:00-05:00,MRK,neutral
850888.0,Turnaround Tuesday? Stocks Look To Bounce Back As Apple Earnings Loom Later,2020-01-28 09:39:00-05:00,MRK,negative
850889.0,A Peek Into The Markets: US Stock Futures Down; Dow Futures Tumble Over 400 Points,2020-01-27 07:06:00-05:00,MRK,neutral
850890.0,Merck's DIFICID Receives FDA Approval to Treat Clostridioides in Children Aged Six Months and Older,2020-01-27 06:51:00-05:00,MRK,positive
850891.0,"Shares of several companies in the healthcare and pharmaceutical space are trading lower, not currently seeing sector-specific news. NOTE: The global spread of the Wuhan coronavirus has caused equities across to sell off.",2020-01-24 11:40:00-05:00,MRK,neutral
850892.0,"The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study",2020-01-24 07:43:00-05:00,MRK,negative
850893.0,"UBS Maintains Buy on Merck & Co, Raises Price Target to $99",2020-01-23 09:54:00-05:00,MRK,neutral
850894.0,FDA Accepts Regulatory Submission Of Supplemental New Drug Application For Merck's LYNPARZA In HRR-Mutated Metastatic Castration-Resistant Prostate Cancer And Grants Priority Review,2020-01-21 06:56:00-05:00,MRK,negative
850895.0,"The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings",2020-01-20 14:04:00-05:00,MRK,neutral
850896.0,"Cannabis Media Company The Fresh Toast Expands Again, Announces It's Now Cash Positive",2020-01-17 13:48:00-05:00,MRK,positive
850897.0,AstraZeneca and Merck's Supplemental New Drug Application for LYNPARZA Granted Priority Review by the FDA,2020-01-13 07:46:00-05:00,MRK,positive
850898.0,"'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier",2020-01-10 12:55:00-05:00,MRK,positive
850899.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,MRK,positive
850900.0,"Merck Reports FDA Approval Of KEYTRUDA For Patients BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy",2020-01-08 16:31:00-05:00,MRK,negative
850901.0,"Merck Announces FDA Approves Pembrolizumab For BCG-Unresponsive, High-risk Non-muscle Invasive Bladder Cancer",2020-01-08 14:34:00-05:00,MRK,negative
850902.0,"The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering",2020-01-07 07:57:00-05:00,MRK,negative
850903.0,Merck's Announces Phase 3 Of KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint of Overall Survival; Results to be Presented at Upcoming Medical Meeting,2020-01-06 16:08:00-05:00,MRK,neutral
850904.0,Merck Buys Exclusive Global License from Taiho and Astex for its Small Molecule Inhibitor Candidates for $50M Upfront and Milestone Payments,2020-01-06 06:32:00-05:00,MRK,positive
850905.0,"Speaker Of The House Nancy Pelosi Says ""Enough is enough. @HouseDemocrats passed the bipartisan #LowerDrugCosts Now Act last year to stop Big Pharma from charging Americans more for our medicines than what they charge for the same drugs overseas.""",2020-01-02 16:36:00-05:00,MRK,negative
850906.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2020-01-01 18:00:00-05:00,MRK,neutral
850907.0,Merck-AstraZeneca's Lynparza Snags FDA Nod For Pancreatic Cancer,2019-12-30 11:41:00-05:00,MRK,negative
850908.0,Merck's LYNPARZA Approved By FDA As First-Line Maintenance Treatment Of Germline BRCA-Mutated Metastatic Pancreatic Cancer,2019-12-30 06:55:00-05:00,MRK,negative
850909.0,AstraZeneca Says FDA Approved Lynparza for Pancreatic Cancer,2019-12-30 05:27:00-05:00,MRK,negative
850910.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,MRK,neutral
850911.0,Merck & Co Option Alert: Jun 19 $92.5 Calls Sweep (49) above Ask!: 4764 @ $4.107 vs 5293 OI; Earnings 1/31 Before Open [est] Ref=$91.46,2019-12-27 12:23:00-05:00,MRK,positive
850912.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,MRK,neutral
850913.0,How The Dow Jones Industrial Average Changed Over The Past Decade,2019-12-22 10:00:00-05:00,MRK,neutral
850914.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,MRK,neutral
850915.0,NewLink Genetics Announces FDA Approval Of Ebola Vaccine V920,2019-12-20 10:15:00-05:00,MRK,positive
850916.0,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering",2019-12-20 08:12:00-05:00,MRK,positive
850917.0,Merck Reports FDA Approval For ERVEBO,2019-12-20 07:15:00-05:00,MRK,positive
850918.0,"Merck Reports KEYTRUDA Approved In Japan For 3 New First-Line Indications Across Advanced Renal Cell Carcinoma, Recurrent or Distant Metastatic Head and Neck Cancer",2019-12-20 06:46:00-05:00,MRK,negative
850919.0,FDA Approves First Ebola Vaccine,2019-12-20 02:45:00-05:00,MRK,positive
850920.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-19 10:29:00-05:00,MRK,neutral
850921.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,MRK,negative
850922.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,MRK,positive
850923.0,"Merck Reports FDA's Oncologic Drugs AdCom Recommends KEYTRUDA For Treatment Of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer",2019-12-17 17:15:00-05:00,MRK,negative
850924.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,MRK,positive
850925.0,"The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week",2019-12-15 15:49:00-05:00,MRK,neutral
850926.0,OncoSec Reports Interim Data From KEYNOTE-890 Study Evaluation TAVO In Combination With KEYTRUDA,2019-12-13 08:36:00-05:00,MRK,neutral
850927.0,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer",2019-12-13 08:10:00-05:00,MRK,positive
850928.0,EMA Reports Positive Opinion For Merck's Recarbrio By CHMP For Treatment Of Infections From Aerobic Gram-Negative Organisms In Adults,2019-12-13 06:18:00-05:00,MRK,positive
850929.0,Traders Circulating Materials From Merck's Keytruda Presentation At ESMO,2019-12-12 12:03:00-05:00,MRK,neutral
850930.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-12 10:21:00-05:00,MRK,neutral
850931.0,Merck Highlights Exploratory Analysis Of KEYTRUDA Which Showed Improved Overall Survival As Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status,2019-12-12 06:47:00-05:00,MRK,negative
850932.0,"Cantor Fitzgerald Says Thinks ArQule May See Other Bidders But Thinks Merck Makes A 'Great Strategic Fit,' Says Thinks Merck's Proposed Acquisition Is 'Fair'",2019-12-11 15:18:00-05:00,MRK,positive
850933.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,MRK,negative
850934.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-10 14:27:00-05:00,MRK,neutral
850935.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,MRK,positive
850936.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,MRK,neutral
850937.0,Mid-Afternoon Market Update: Dow Falls 90 Points; XBiotech Shares Spike Higher,2019-12-09 14:32:00-05:00,MRK,positive
850938.0,"PreMarket Prep Recap: Small Biotech Firms Looking Healthy, Street Fades Macy's Downgrade",2019-12-09 13:08:00-05:00,MRK,positive
850939.0,48 Stocks Moving In Monday's Mid-Day Session,2019-12-09 12:26:00-05:00,MRK,neutral
850940.0,Mid-Day Market Update: Synthorx Jumps Following Acquisition News; Biocept Shares Plunge,2019-12-09 12:07:00-05:00,MRK,positive
850941.0,Mid-Morning Market Update: Markets Mixed; Merck To Acquire ArQule For $20/Share,2019-12-09 10:13:00-05:00,MRK,neutral
850942.0,KalVista Shares Sink On Failed Mid-Stage Study Of Diabetic Macular Edema Drug,2019-12-09 09:15:00-05:00,MRK,negative
850943.0,"Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 9, 2019: MRK, PCG, M, DPLO, CHWY",2019-12-09 09:01:00-05:00,MRK,positive
850944.0,20 Stocks Moving In Monday's Pre-Market Session,2019-12-09 07:49:00-05:00,MRK,neutral
850945.0,ArQule To Be Acquired By Merck For $2.7B,2019-12-09 07:30:00-05:00,MRK,neutral
850946.0,A Peek Into The Markets: US Stock Futures Down; Crude Oil Falls 1%,2019-12-09 07:27:00-05:00,MRK,negative
850947.0,ArQule to be Acquired by Merck for $20/Share Cash,2019-12-09 06:45:00-05:00,MRK,neutral
850948.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,MRK,positive
850949.0,Stocks That Hit 52-Week Highs On Friday,2019-12-06 10:33:00-05:00,MRK,neutral
850950.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,MRK,positive
850951.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-05 10:16:00-05:00,MRK,neutral
850952.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,MRK,positive
850953.0,"AstraZeneca, Merck Announce Lynparza Approved in China as a 1st-line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer",2019-12-05 05:24:00-05:00,MRK,negative
850954.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-04 10:30:00-05:00,MRK,neutral
850955.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,MRK,neutral
850956.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,MRK,negative
850957.0,Stocks That Hit 52-Week Highs On Monday,2019-12-02 10:15:00-05:00,MRK,neutral
850958.0,Seattle Genetics Announces Collaboration with Merck to Evaluate its Enfortumab in Combination with KEYTRUDA,2019-12-02 08:01:00-05:00,MRK,neutral
850959.0,"Merck's KEYTRUDA Granted Priority Review by the FDA for Patients with High-Risk, Non-Muscle Invasive Bladder Cancer",2019-12-02 06:46:00-05:00,MRK,negative
850960.0,"National Business Daily Reports Drugmakers including Johnson & Johnson, Roche, Novartis and Merck have Agreed to Massively Cut the Prices of Some Drugs to Get Included in China's Medical Reimbursement List",2019-11-29 05:38:00-05:00,MRK,neutral
850961.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-27 10:14:00-05:00,MRK,neutral
850962.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,MRK,negative
850963.0,Merck Reports KEYTRUDA Now Approved In China For First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Combination with Chemotherapy,2019-11-26 06:50:00-05:00,MRK,negative
850964.0,AstraZeneca CEO: Closing In On A Cancer Cure,2019-11-22 15:39:00-05:00,MRK,negative
850965.0,"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are ""MUCH CHEAPER""",2019-11-22 14:08:00-05:00,MRK,neutral
850966.0,European Commission Approves Two New Regimens Of Merck's KEYTRUDA As First-Line Treatment For Metastatic Or Unresectable Recurrent Head And Neck Squamous Cell Carcinoma,2019-11-20 06:46:00-05:00,MRK,positive
850967.0,Merck Raises Quarterly Dividend From $0.55 To $0.61/Share,2019-11-19 12:47:00-05:00,MRK,neutral
850968.0,Merck and Bayer's Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure,2019-11-18 06:32:00-05:00,MRK,negative
850969.0,Merck Reports Its Animal Health Unit Announced US Approval Of BRAVECTO PLUS,2019-11-15 06:45:00-05:00,MRK,positive
850970.0,"AstraZeneca, Merck Report FDA Acceptance Of Regulatory Submission For New Drug Application For Selumetinib In Neurofibromatosis Type 1, Priority Review Granted",2019-11-14 06:55:00-05:00,MRK,positive
850971.0,AstraZeneca Announces FDA Accepts NDA for Selumetinib,2019-11-14 04:13:00-05:00,MRK,positive
850972.0,"Morgan Stanley Maintains Overweight on Merck & Co, Raises Price Target to $95",2019-11-13 08:12:00-05:00,MRK,negative
850973.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,MRK,neutral
850974.0,Merck Reports Its ERVEBO Granted Conditional Approval In EU,2019-11-11 15:00:00-05:00,MRK,positive
850975.0,NextCure Shares Give Back Some Gains After Data Readout,2019-11-11 10:24:00-05:00,MRK,positive
850976.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,MRK,neutral
850977.0,Biotech Stock On The Radar: Alkermes At A Crossroads,2019-11-07 11:53:00-05:00,MRK,neutral
850978.0,AstraZeneca Named The Most Innovative Global Pharma Company,2019-11-06 11:20:00-05:00,MRK,positive
850979.0,BioLineRx Announces Data Showing BL-8040 In Combination With KEYTRUDA Shows Clinical Activity In Heavily Pretreated Metastatic Pancreatic Cancer Patients,2019-11-05 09:06:00-05:00,MRK,negative
850980.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,MRK,neutral
850981.0,WeTrader Competition: Round Four Wrap-up,2019-11-01 17:15:00-04:00,MRK,neutral
850982.0,US Appeals Court Upholds Lower Court Ruling That Tossed $2.54B Jury Verdict For Merck In Patent Case Against Gilead,2019-10-30 09:54:00-04:00,MRK,negative
850983.0,"Decision Day: Fed On Tap Later, Followed by Apple, Facebook After Close",2019-10-30 09:52:00-04:00,MRK,neutral
850984.0,"Alphabet Misses On Earnings, But Drugmakers, Mastercard Beat Expectations",2019-10-29 10:45:00-04:00,MRK,negative
850985.0,28 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-29 08:33:00-04:00,MRK,neutral
850986.0,Merck & Co Inc Sees Increased Pricing Pressure In 2020; Says Demand For Gardasil Continues To Outpace Supply,2019-10-29 08:20:00-04:00,MRK,negative
850987.0,"Pharma Earnings: Merck, Pfizer Trade Higher On Q3 Beats",2019-10-29 07:57:00-04:00,MRK,neutral
850988.0,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study",2019-10-29 07:32:00-04:00,MRK,positive
850989.0,Merck & Co shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY19 EPS and sales guidance above analyst estimates.,2019-10-29 07:25:00-04:00,MRK,positive
850990.0,"Merck Sees FY19 Adj. EPS $5.12-$5.17 vs $4.92 Est., Sales $46.5B-$47.0B vs $45.98B Est.",2019-10-29 06:46:00-04:00,MRK,neutral
850991.0,"Merck & Co Q3 Adj. EPS $1.51 Beats $1.24 Estimate, Sales $12.4B Beat $11.63B Estimate",2019-10-29 06:45:00-04:00,MRK,neutral
850992.0,"12 Stocks To Watch For October 29, 2019",2019-10-29 05:23:00-04:00,MRK,neutral
850993.0,"Earnings Scheduled For October 29, 2019",2019-10-29 04:57:00-04:00,MRK,neutral
850994.0,More Earnings And A Fed Decision In Week Four Of The WeTrader Competition,2019-10-28 11:56:00-04:00,MRK,neutral
850995.0,"Merck Shares Fall 2% Following Report AstraZeneca Trial Of Imfinzi, Imfinzi Plus Tremelimumab Delayed Disease Progression In Phase 3 Trial",2019-10-28 11:38:00-04:00,MRK,positive
850996.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,MRK,neutral
850997.0,"Jim Cramer Gives His Take On AMD, Merck And More",2019-10-22 11:29:00-04:00,MRK,neutral
850998.0,Merck & Co shares are trading lower on seemingly no company-specific news. The stock touched the $85 resistance level and traded lower.,2019-10-22 09:16:00-04:00,MRK,negative
850999.0,"The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug",2019-10-22 07:51:00-04:00,MRK,positive
851000.0,8 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-22 07:30:00-04:00,MRK,neutral
851001.0,NewLink Genetics Announces EU Regulatory Committee Recommendation For Conditional Marketing Authorization For Ebola Vaccine V920,2019-10-21 16:37:00-04:00,MRK,neutral
851002.0,Exclusive: Plus Products Hires The Wonderful Company's Mackler As Chief Scientific Officer,2019-10-21 07:45:00-04:00,MRK,positive
851003.0,"WHO Says Ebola Concentrated In Congo Mining Area, Still An Emergency",2019-10-18 14:48:00-04:00,MRK,negative
851004.0,"Merck Reports Positive EU CHMP Opinion For 2 New Regimens Of KEYTRUDA As First-Line Treatment For Metastatic Or Unresectable Recurrent Head, Neck Squamous Cell Carcinoma",2019-10-18 07:00:00-04:00,MRK,positive
851005.0,Merck Reports Received EU CHMP Positive Opinion For Investigational V920 Ebola Vaccine For Protection Against Ebola Virus,2019-10-18 06:45:00-04:00,MRK,positive
851006.0,"Bank of America Reinstates Neutral on Merck & Co, Announces $90 Price Target",2019-10-17 07:21:00-04:00,MRK,neutral
851007.0,Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts,2019-10-16 16:22:00-04:00,MRK,neutral
851008.0,"The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings",2019-10-15 07:50:00-04:00,MRK,positive
851009.0,"The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings",2019-10-13 16:33:00-04:00,MRK,neutral
851010.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,MRK,positive
851011.0,"Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks",2019-10-08 11:08:00-04:00,MRK,positive
851012.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,MRK,positive
851013.0,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar,2019-10-03 15:49:00-04:00,MRK,positive
851014.0,What's Behind PDS Biotech's Rally?,2019-10-03 11:45:00-04:00,MRK,neutral
851015.0,"PDS Biotech Reports Clinical Collaboration With Merck For Evaluation Of Combo Of PDS0101, Merck's KEYTRUDA",2019-10-03 08:43:00-04:00,MRK,neutral
851016.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,2019-10-02 10:33:00-04:00,MRK,negative
851017.0,Merck's KEYTRUDA Now Approved as Monotherapy In China For First-Line Treatment Of Certain Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1,2019-10-02 06:47:00-04:00,MRK,positive
851018.0,FDA Accepts Two Applications For Merck's DIFICID To Treat Children Aged Six Months Up To 18 years With Clostridium difficile Infections,2019-10-02 06:31:00-04:00,MRK,positive
851019.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,MRK,negative
851020.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2019-09-30 16:32:00-04:00,MRK,neutral
851021.0,"Merck shares trading higher over the $82 level. The company announced its RESTORE-IMI study of RECARBRIO met its primary endpoint. Separately, the company and AstraZeneca highlighted new LYNPARZA data.",2019-09-30 14:31:00-04:00,MRK,positive
851022.0,"Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More",2019-09-30 13:13:00-04:00,MRK,positive
851023.0,"Merck, AstraZeneca Highlight Data LYNPARZA More Than Doubled Median Radiographic Progression-Free Survival In BRCA1/2, ATM Metastatic Castration-Resistant Prostate Cancer",2019-09-30 10:31:00-04:00,MRK,negative
851024.0,Merck's Pivotal RESTORE-IMI 2 Phase 3 Study of RECARBRIO Met its Primary Endpoint,2019-09-30 06:47:00-04:00,MRK,neutral
851025.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,MRK,positive
851026.0,"AstraZeneca , Merck Announced LYNPARZA Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer at ESMO 2019",2019-09-28 18:31:00-04:00,MRK,negative
851027.0,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company",2019-09-25 17:32:00-04:00,MRK,neutral
851028.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,MRK,neutral
851029.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,MRK,negative
851030.0,"The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering",2019-09-20 07:46:00-04:00,MRK,positive
851031.0,Merck's PIFELTRO And DELSTRIGO Receive FDA Approval For Use In Appropriate Adults Living With HIV-1 Who Are Virologically Suppressed,2019-09-20 06:46:00-04:00,MRK,positive
851032.0,NewLink Genetics Rallies After Ebola Vaccine Granted Priority Review Status,2019-09-18 10:21:00-04:00,MRK,positive
851033.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,MRK,neutral
851034.0,FDA Approves LENVIMA Plus KEYTRUDA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma,2019-09-18 04:14:00-04:00,MRK,positive
851035.0,Merck Press Release Confirms FDA Approval Of KEYTRUDA Plus LENVIMA Combo Treatment For Patients With Certain Types Of Endometrial Carcinoma,2019-09-17 17:59:00-04:00,MRK,positive
851036.0,FDA Says Granted Accelerated Approval To Lenvima In Combo With Keytruda For Treatment Of Patients With Advanced Endometrial Carcinoma,2019-09-17 11:56:00-04:00,MRK,positive
851037.0,"Merck Reports FDA Accepted Biologics License Application, Granted Priority Review For V920 For Ebola Zaire Virus",2019-09-17 06:45:00-04:00,MRK,positive
851038.0,"The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck",2019-09-15 11:18:00-04:00,MRK,positive
851039.0,Oracle Reports Early In Surprise Move As Trump Surprises With Positive Trade Tweet,2019-09-12 09:52:00-04:00,MRK,positive
851040.0,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.,2019-09-10 10:30:00-04:00,MRK,positive
851041.0,Merck & Co shares are trading lower. Not seeing any news to justify the price action.,2019-09-09 11:54:00-04:00,MRK,neutral
851042.0,Merck to Present Data From its Phase 3 Trial for KEYTRUDA as Neoadjuvant Therapy at the European Society for Medical Oncology,2019-09-09 06:47:00-04:00,MRK,neutral
851043.0,Aduro Biotech Announces First Patient Dosed In Phase 2 Study Of ADU-S100 In Combination With KEYTRUDA For First-Line Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma,2019-09-04 08:31:00-04:00,MRK,neutral
851044.0,European Commission Approves Merck's KEYTRUDA In Combination With Inlyta As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma,2019-09-04 06:46:00-04:00,MRK,positive
851045.0,Xynomic Pharma ReportsInterim Data From Phase 1b Study Of Abexinostat Combined With Keytruda In Multiple Solid Tumors,2019-08-30 08:44:00-04:00,MRK,positive
851046.0,"Deaths from E. Congo Ebola Outbreak Top 2,000; Cases Top 3,000",2019-08-30 04:04:00-04:00,MRK,positive
851047.0,Uganda Confirms Another Case Of Ebola - A 9-Year Old Girl Who Traveled Democratic Republic Of Congo,2019-08-29 14:57:00-04:00,MRK,neutral
851048.0,Stocks That Hit 52-Week Highs On Thursday,2019-08-29 10:15:00-04:00,MRK,neutral
851049.0,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,2019-08-28 08:02:00-04:00,MRK,neutral
851050.0,10 Biopharmaceutical Companies Trying To Cure Cancer,2019-08-24 13:46:00-04:00,MRK,negative
851051.0,"Jim Cramer Weighs In On Pfizer, Teva And More",2019-08-22 11:08:00-04:00,MRK,neutral
851052.0,Analysts Share Stocks To Buy On Fed Uncertainty,2019-08-22 08:21:00-04:00,MRK,negative
851053.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,MRK,positive
851054.0,"The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform",2019-08-21 07:40:00-04:00,MRK,neutral
851055.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,MRK,positive
851056.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,MRK,negative
851057.0,"Benzinga's Top Upgrades, Downgrades For August 16, 2019",2019-08-16 09:40:00-04:00,MRK,positive
851058.0,"SVB Leerink Initiates Coverage On Merck & Co with Outperform Rating, Announces $103 Price Target",2019-08-16 06:36:00-04:00,MRK,neutral
851059.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,MRK,negative
851060.0,AstraZeneca And Merck Announce LYNPARZA) Phase 3 PAOLA-1 Trial Met Primary Endpoint In Ovarian Cancer Patients,2019-08-14 06:56:00-04:00,MRK,negative
851061.0,Lynparza Phase Iii Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer,2019-08-14 04:40:00-04:00,MRK,negative
851062.0,"AstraZeneca, Merck Announce Lynparza Phase III PAOLA-1 Trial Met Primary Endpoint",2019-08-14 04:37:00-04:00,MRK,neutral
851063.0,ï»¿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,MRK,positive
851064.0,"Merck 10-Q Out; Shows Co. Received Set Of Investigative Interrogatories From California Attorney General's Office On Apr. 15, 2019 Related To Conduct, Deal That Allegedly Affected, Delayed Competition To Lantus In Insulin Market",2019-08-06 16:48:00-04:00,MRK,negative
851065.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,MRK,positive
851066.0,Universal Display and Merck Announce Research and Development Collaboration for OLED,2019-08-05 07:28:00-04:00,MRK,neutral
851067.0,"Bulls And Bears Of The Week: Boeing, GM, Pfizer, Starbucks And More",2019-08-03 10:25:00-04:00,MRK,neutral
851068.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,MRK,neutral
851069.0,SELLAS Advances Galinpepimut-S (GPS) In Combination With KEYTRUDA Program With Dosing Of First Patient In Phase 1/2 Basket Study,2019-07-31 08:18:00-04:00,MRK,neutral
851070.0,Merck Reports FDA Approved New Monotherapy Indication For KEYTRUDA: 'Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus in Patients Whose Tumors Express PD-L1 (CPS â‰¥10) With Disease Progression After One or More Prior Lines',2019-07-31 08:17:00-04:00,MRK,positive
851071.0,"Apple On Today's Menu, With Starring Roles From China Talks, Fed Meeting",2019-07-30 10:07:00-04:00,MRK,neutral
851072.0,33 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-30 09:16:00-04:00,MRK,neutral
851073.0,Merck & Co shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also issued FY19 guidance above analyst estimates.,2019-07-30 08:15:00-04:00,MRK,positive
851074.0,"A Peek Into The Markets: US Stock Futures Down Ahead of Fed Meeting, Apple Earnings",2019-07-30 08:12:00-04:00,MRK,neutral
851075.0,Merck Reports Q2 Earnings Beat,2019-07-30 07:27:00-04:00,MRK,neutral
851076.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,MRK,positive
851077.0,"Merck & Co. Sees FY19 Adj. EPS $4.84-$4.94 vs $4.75 Est., Sees Sales $45.2B-$46.2B vs $44.74B Est.",2019-07-30 06:47:00-04:00,MRK,neutral
851078.0,"Merck & Co Q2 Adj. EPS $1.3 Beats $1.16 Estimate, Sales $11.76B Beat $10.96B Estimate",2019-07-30 06:46:00-04:00,MRK,neutral
851079.0,"15 Stocks To Watch For July 30, 2019",2019-07-30 04:38:00-04:00,MRK,neutral
851080.0,"Earnings Scheduled For July 30, 2019",2019-07-30 04:05:00-04:00,MRK,neutral
851081.0,Merck Q2 Earnings Preview,2019-07-29 14:38:00-04:00,MRK,neutral
851082.0,Merck's Keytruda Gets A Double Dose Of Positive News,2019-07-29 09:30:00-04:00,MRK,positive
851083.0,Merck's KEYTRUDA in Combination with Chemotherapy Met One of the Dual Primary Endpoints in Pivotal Phase 3 KEYNOTE-522,2019-07-29 07:02:00-04:00,MRK,neutral
851084.0,Merck's KEYTRUDA in Combination with Inlyta as First-Line Treatment for Advanced Renal Cell Carcinoma Receives a Positive Opinion From the European Medicines Agency,2019-07-29 06:37:00-04:00,MRK,positive
851085.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,MRK,negative
851086.0,Merck Highlights Presentation Of Phase 2b Results For Investigational HIV-1 Therapy Islatravir (MK-8591) At IAS 2019,2019-07-24 11:00:00-04:00,MRK,neutral
851087.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,MRK,neutral
851088.0,Merck Reports Results From Phase 1 Study Of Investigational Nucleoside Reverse Transcriptase Translocation Inhibitor Presented At International AIDS Society Conference on HIV Science,2019-07-23 11:05:00-04:00,MRK,negative
851089.0,Eisai's Cancer Drug Combo Gets Breakthrough Therapy Designation For Liver Cancer,2019-07-23 09:25:00-04:00,MRK,negative
851090.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,MRK,negative
851091.0,Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA For KEYTRUDA Plus LENVIMA Combination Treatment,2019-07-23 06:58:00-04:00,MRK,neutral
851092.0,The Week Ahead In Biotech: Pharma Earnings Pick Up Pace,2019-07-20 09:53:00-04:00,MRK,neutral
851093.0,"WHO Emergency Committee Says It Recognises Shortage Of Supply Of Merck's Ebola Vaccine, Says Who Should Work With Member States And Manufacturers To 'Take All Measures' To Increase Supply",2019-07-17 13:54:00-04:00,MRK,negative
851094.0,WHO Emergency Committee Chairman Says Ebola Is A Regional Emergency And In No Way A Global Threat,2019-07-17 13:43:00-04:00,MRK,negative
851095.0,World Health Organization's Emergency Committee Says Congo's Ebola Outbreak Constitutes A Public Health Emergency Of International Concern,2019-07-17 13:42:00-04:00,MRK,negative
851096.0,"Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod",2019-07-17 10:07:00-04:00,MRK,positive
851097.0,FDA Approves Merck's RECARBRIO For the Treatment of Adults with Complicated Urinary Tract And Complicated Intra-Abdominal Bacterial Infections Where Limited Or No Alternative Treatment Options Are Available,2019-07-17 06:48:00-04:00,MRK,negative
851098.0,World Health Organization Chief Says Ebola Case In Congolese City Of Goma Could Be A Gamechanger,2019-07-15 07:37:00-04:00,MRK,neutral
851099.0,The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings,2019-07-13 17:04:00-04:00,MRK,neutral
851100.0,"Bulls & Bears Of The Week: Costco, DuPont, IBM, Merck And More",2019-07-13 14:42:00-04:00,MRK,neutral
851101.0,Washington Worries Trigger Bearish Merck Options Trades,2019-07-12 14:33:00-04:00,MRK,negative
851102.0,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug",2019-07-12 10:19:00-04:00,MRK,neutral
851103.0,Stock Market Eyes Records On Dovish Commentary From Federal Reserve,2019-07-12 10:17:00-04:00,MRK,neutral
851104.0,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.",2019-07-12 09:53:00-04:00,MRK,negative
851105.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,MRK,negative
851106.0,Merck To Present Results From Studies Evaluating Investigational Anti-HIV Agent MK-8591 At IAS 2019 On Jul. 21-24,2019-07-10 06:48:00-04:00,MRK,neutral
851107.0,Judge Rules Against Trump Proposal Forcing Pharma Companies To Disclose Drug Prices In Commercials,2019-07-09 10:03:00-04:00,MRK,neutral
851108.0,FDA Accepts Merck's Supplemental Biologics License Applications For KEYTRUDA Six-Week Dosing Schedule For Melanoma And Multiple Other Indications,2019-07-09 06:45:00-04:00,MRK,positive
851109.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,MRK,positive
851110.0,"The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight",2019-07-05 08:55:00-04:00,MRK,negative
851111.0,"Benzinga's Top Upgrades, Downgrades For July 3, 2019",2019-07-03 10:27:00-04:00,MRK,positive
851112.0,"Mizuho Initiates Coverage On Merck & Co with Buy Rating, Announces $97 Price Target",2019-07-03 06:37:00-04:00,MRK,neutral
851113.0,"Mizuho Initiates Coverage On Merck With Buy Rating, $97 Price Target",2019-07-02 16:14:00-04:00,MRK,neutral
851114.0,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,2019-07-01 07:14:00-04:00,MRK,neutral
851115.0,"The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO",2019-06-27 07:26:00-04:00,MRK,negative
851116.0,Intensity Therapeutics Announces Clinical Collaboration With Merck For A Phase 1/2 Clinical Trial To Evaluate Co'S Int230-6 In Combination With Keytruda For Multiple Solid Tumor Types,2019-06-25 07:39:00-04:00,MRK,negative
851117.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-06-22 15:07:00-04:00,MRK,neutral
851118.0,"Morgan Stanley Maintains Overweight on Merck & Co, Raises Price Target to $90",2019-06-21 08:18:00-04:00,MRK,negative
851119.0,"The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy",2019-06-21 07:18:00-04:00,MRK,negative
851120.0,Merck CEO Frazier At Investor Day Says The Company Has Less Appetite For Big Deals Than Mid Or Small-Sized Deals; Says Most Big Pharma Deals Have Not Created The Value They Said They Were Going To Create,2019-06-20 11:52:00-04:00,MRK,negative
851121.0,"The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge",2019-06-20 07:25:00-04:00,MRK,positive
851122.0,Merck Highlights 2019 Investor Day Presentation,2019-06-20 06:48:00-04:00,MRK,neutral
851123.0,Report: Merck Searching Internally For Next CEO,2019-06-19 15:43:00-04:00,MRK,neutral
851124.0,"Merck Prepping For CEO Departure, Has Begun Internal Successor Hunt",2019-06-19 12:37:00-04:00,MRK,positive
851125.0,"The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut",2019-06-19 07:51:00-04:00,MRK,positive
851126.0,"AstraZeneca,Merck Announce Lynparza Approved in Japan for 1st-line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer",2019-06-19 04:58:00-04:00,MRK,negative
851127.0,Merck Reports FDA Approved KEYTRUDA As Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy,2019-06-18 06:45:00-04:00,MRK,negative
851128.0,"AstraZeneca, Merck Report LYNPARZA Approved In EU For Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer",2019-06-18 06:31:00-04:00,MRK,negative
851129.0,"AstraZeneca, Merck Announce Lynparza Approved in the EU for 1st-line Maintenance Treatment Of BRCA-mutated Advanced Ovarian Cancer",2019-06-18 04:27:00-04:00,MRK,negative
851130.0,"'Measles cases in United States rise to 1,044- CNN",2019-06-17 15:50:00-04:00,MRK,positive
851131.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs",2019-06-15 12:38:00-04:00,MRK,neutral
851132.0,"From Earlier: 'Drug makers Amgen, Merck, Lilly and the Association of National Advertisers file suit to prevent the disclosure of drug prices in television ads.'",2019-06-14 14:43:00-04:00,MRK,neutral
851133.0,"JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $93",2019-06-14 09:38:00-04:00,MRK,neutral
851134.0,"IBM, Walmart, Merck Included In FDA Program To Test Blockchain Usage In US Drug Supply Chain",2019-06-13 09:01:00-04:00,MRK,neutral
851135.0,"IBM, KPMG, Merck, Walmart Report Have Been Selected By FDA To Be Included In Blockchain Program In Support Of US Drug Supply Chain Security Act To Address Requirement To Identify, Track, Trace Medicines, Vaccines Distributed In US",2019-06-13 08:07:00-04:00,MRK,positive
851136.0,"WHO Emergency Committee Meeting To Decide If Ebola Outbreak Constitutes An Int'l. Emergency Will Begin Jun. 14, 2019",2019-06-12 11:15:00-04:00,MRK,negative
851137.0,"The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana",2019-06-12 07:34:00-04:00,MRK,neutral
851138.0,"FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer",2019-06-11 09:14:00-04:00,MRK,negative
851139.0,FDA Approves Two New Indications For Merck's KEYTRUDA,2019-06-11 06:45:00-04:00,MRK,positive
851140.0,Merck Strikes $773M Deal For Privately Held Tilos Therapeutics,2019-06-10 13:19:00-04:00,MRK,negative
851141.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2019-06-10 06:52:00-04:00,MRK,neutral
851142.0,Merck Reports Purchase Of Tilos Therapeutics For Total Potential Consideration OF $773M,2019-06-10 06:47:00-04:00,MRK,neutral
851143.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-06-08 16:09:00-04:00,MRK,neutral
851144.0,Sanofi's Leadership Transition: What You Need To Know,2019-06-07 12:25:00-04:00,MRK,neutral
851145.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,MRK,positive
851146.0,'I believe it is wrong to charge Americans astronomical prices for life-saving drugs developed with taxpayer dollars. You will not find me encouraging pharmaceutical companies to continue ripping off Americans like my Republican colleagues.' -Sen Sanders,2019-06-04 11:42:00-04:00,MRK,negative
851147.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,MRK,negative
851148.0,Merck Reports LYNPARZA Phase 3 SOLO3 Trial Showed 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy,2019-06-03 16:15:00-04:00,MRK,negative
851149.0,FDA Grants Approval Of Zerbaxa To Merck & Co Inc,2019-06-03 15:28:00-04:00,MRK,positive
851150.0,Dynavax Highlights Presentation Of Results Showing 76% OVerall Response Rate In Advanced Melanoma Patients With SD-101 In Combination With KEYTRUDA,2019-06-03 14:18:00-04:00,MRK,positive
851151.0,Merck Sat. Highlighted 5-Year Survival Data From KEYTRUDA In NSCLC As First Keynote Trial At ASCO,2019-06-03 10:05:00-04:00,MRK,neutral
851152.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,MRK,neutral
851153.0,Merck Announces Five-Year Survival Data for KEYTRUDA in Advanced Non-Small Cell Lung Cancer from First KEYNOTE Trial at #ASCO19,2019-06-01 07:36:00-04:00,MRK,negative
851154.0,Merck Reports KEYTRUDA Showed Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial,2019-05-31 06:46:00-04:00,MRK,positive
851155.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Radar Tool For Tue., May 28, 2019",2019-05-28 12:55:00-04:00,MRK,positive
851156.0,"Goldman Sachs Initiates Coverage On Merck & Co with Neutral Rating, Announces $85 Price Target",2019-05-28 07:30:00-04:00,MRK,neutral
851157.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,MRK,neutral
851158.0,Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond,2019-05-22 12:38:00-04:00,MRK,neutral
851159.0,Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B,2019-05-21 10:39:00-04:00,MRK,neutral
851160.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,MRK,negative
851161.0,"Merck To Purchase Peloton Therapeutics For $1.05B In Cash, Will Be Eligible To Receive Further $1.15B Based On Regulatory, Sales Milestones",2019-05-21 06:46:00-04:00,MRK,neutral
851162.0,UPDATE: Merck Says KEYTRUDA Trial Did Not Meet Primary Endpoint Of Superior Overall Survival,2019-05-20 16:32:00-04:00,MRK,positive
851163.0,Merck Offers Update On Phase 3 KEYNOTE-19 Study Of KEYTRUDA in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer,2019-05-20 16:30:00-04:00,MRK,negative
851164.0,"Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines",2019-05-20 14:28:00-04:00,MRK,neutral
851165.0,5 ASCO Abstracts That Moved Stocks,2019-05-16 14:50:00-04:00,MRK,neutral
851166.0,"Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward",2019-05-16 12:30:00-04:00,MRK,negative
851167.0,"The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics",2019-05-16 07:40:00-04:00,MRK,neutral
851168.0,Intec Pharma Announces Research Collaboration Agreement With Merck,2019-05-16 06:00:00-04:00,MRK,positive
851169.0,"13F From Loeb's Third Point Shows Liquidated Stake In Merck, Cut Stake In American Express",2019-05-15 17:14:00-04:00,MRK,negative
851170.0,"The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi",2019-05-15 07:50:00-04:00,MRK,negative
851171.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,MRK,positive
851172.0,Merck Reports Results From Phase 2 Trial Of V114 In Infants: Met Primary Dndpoint,2019-05-08 09:01:00-04:00,MRK,neutral
851173.0,Merck's BELSOMRA C-IV Meets Primary Efficacy Endpoint In Phase 3 Trial For Treatment Of Insomnia In People With Mild-To-Moderate Alzheimer's Disease Dementia,2019-05-07 06:46:00-04:00,MRK,neutral
851174.0,Ebola Death Toll in Congo Rises to 979,2019-05-07 04:22:00-04:00,MRK,negative
851175.0,"Canopy Growth, Lockheed Martin, Merck And More: 'Fast Money Halftime Report' Picks For May 3",2019-05-03 07:40:00-04:00,MRK,positive
851176.0,"UBS Maintains Buy on Merck & Company, Inc. Common Stock (new), Raises Price Target to $88",2019-05-02 08:06:00-04:00,MRK,neutral
851177.0,"BMO Capital Maintains Market Perform on Merck & Company, Inc. Common Stock (new), Raises Price Target to $84",2019-05-01 09:46:00-04:00,MRK,neutral
851178.0,"Bank of America Maintains Buy on Merck & Company, Inc. Common Stock (new), Raises Price Target to $91",2019-05-01 08:19:00-04:00,MRK,neutral
851179.0,Alphabet Revenue Disappoints Ahead Of Apple Earnings After The Bell,2019-04-30 10:05:00-04:00,MRK,negative
851180.0,Merck & Co shares are trading higher after the company reported better-than-expected Q1 EPS and sales and issued strong FY19 guidance.,2019-04-30 09:23:00-04:00,MRK,positive
851181.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,MRK,positive
851182.0,"A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Meeting",2019-04-30 07:23:00-04:00,MRK,neutral
851183.0,"Merck & Co. Sees FY19 Adj. EPS $4.67-$4.79 vs $4.67 Est., Sales $43.9B-$45.1B vs $44.42B Est.",2019-04-30 06:47:00-04:00,MRK,neutral
851184.0,"Merck & Co Q1 Adj. EPS $1.22 Beats $1.06 Estimate, Sales $10.82B Beat $10.48B Estimate",2019-04-30 06:45:00-04:00,MRK,neutral
851185.0,"15 Stocks To Watch For April 30, 2019",2019-04-30 06:37:00-04:00,MRK,neutral
851186.0,"Earnings Scheduled For April 30, 2019",2019-04-30 06:18:00-04:00,MRK,neutral
851187.0,"This Week, Market Eyes China Talks, Fed Meeting As Earnings Continue",2019-04-29 10:06:00-04:00,MRK,neutral
851188.0,"AstraZeneca, Merck Announce Lynparza Receives Positive EU CHMP Opinion for 1st-line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer",2019-04-29 04:10:00-04:00,MRK,positive
851189.0,"The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug",2019-04-26 08:02:00-04:00,MRK,negative
851190.0,"Merck Offers Update On Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDAÂ® as Monotherapy, In Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma",2019-04-25 18:10:00-04:00,MRK,positive
851191.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,MRK,positive
851192.0,"OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO, Epacadostat And KEYTRUDA In Squamous Cell Head And Neck (SCCHN) Cancer",2019-04-23 08:01:00-04:00,MRK,negative
851193.0,Merck's KEYTRUDA in Combination with Inlyta Approved by the FDA as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma,2019-04-22 06:47:00-04:00,MRK,positive
851194.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,MRK,negative
851195.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,MRK,negative
851196.0,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,2019-04-16 15:34:00-04:00,MRK,negative
851197.0,"The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives",2019-04-16 08:10:00-04:00,MRK,neutral
851198.0,"Measles Cases Worldwide Rose Nearly Four-Fold In First Quarter Of 2019 To 112,163 Against Same Period Last Year, Provisional Data Shows",2019-04-15 10:49:00-04:00,MRK,neutral
851199.0,"The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug",2019-04-12 07:47:00-04:00,MRK,positive
851200.0,Merck Reports FDA Approval For Expanded Monotherapy Label For KEYTRUDA,2019-04-11 17:45:00-04:00,MRK,positive
851201.0,NYC Mandates Measles Vaccinations; Merck Is The Exclusive Manufacturer,2019-04-11 12:33:00-04:00,MRK,positive
851202.0,"The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug",2019-04-11 07:48:00-04:00,MRK,positive
851203.0,"AstraZeneca, Merck Announce Lynparza Approved in EU for the treatment of Germline BRCA-mutated HER2-negative Advanced Breast Cancer",2019-04-10 03:56:00-04:00,MRK,negative
851204.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-04-07 17:04:00-04:00,MRK,neutral
851205.0,"Myriad Genetics, AstraZeneca, Merck Report Expansion Of Companion Diagnostic Partnership",2019-04-04 07:18:00-04:00,MRK,neutral
851206.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,MRK,neutral
851207.0,"Biotech Winners, Losers In Q1",2019-04-01 15:19:00-04:00,MRK,negative
851208.0,Advaxis Shares Surge After Positive Clinical Trial Updates,2019-04-01 14:27:00-04:00,MRK,positive
851209.0,AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation,2019-04-01 11:19:00-04:00,MRK,negative
851210.0,Syndax Pharmaceuticals Highlights Presentation Of Updated Phase 2 Data From ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA At American Association For Cancer Research 2019 Annual Meeting,2019-04-01 10:35:00-04:00,MRK,negative
851211.0,Advaxis Says its Phase 1/2 KEYNOTE-046 Study Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer,2019-04-01 08:04:00-04:00,MRK,negative
851212.0,"Alkermes, Merck, Sage Therapeutics and Takeda Pharma Announce a Partnership to Qualify Biomarkers for Schizophrenia Drug Development",2019-04-01 07:07:00-04:00,MRK,neutral
851213.0,Merck's KEYTRUDA Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in Combination with Chemotherapy,2019-04-01 06:56:00-04:00,MRK,negative
851214.0,Merck and AstraZeneca's Selumetinib is Granted Breakthrough Therapy Designation in Neurofibromatosis Type 1,2019-04-01 06:33:00-04:00,MRK,positive
851215.0,"AstraZeneca, Merck Announce Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1",2019-04-01 04:22:00-04:00,MRK,positive
851216.0,Congo Health Ministry Says Has Recorded 15 New Confirmed Cases Of Ebola,2019-03-29 13:55:00-04:00,MRK,neutral
851217.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2019-03-29 12:45:00-04:00,MRK,neutral
851218.0,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",2019-03-27 07:52:00-04:00,MRK,positive
851219.0,Merck Shares Unaffected As Traders Circulate Business Insider Interview From Mon. Highlighting CEO Hinted He Could Step Down,2019-03-26 10:38:00-04:00,MRK,positive
851220.0,These Are Some Of The Best-Performing Leveraged ETFs Of The Year,2019-03-25 13:37:00-04:00,MRK,neutral
851221.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-23 12:20:00-04:00,MRK,neutral
851222.0,"The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback",2019-03-22 08:16:00-04:00,MRK,negative
851223.0,FedEx's Struggles May Be Less About Global Demand And More About 'NotPetya',2019-03-21 14:07:00-04:00,MRK,negative
851224.0,"Watching Stocks With Alzheimer's Treatment Candidates: Merck, Roche, AbbVie, Neurotrope, AC Immune, Denali, INmune Bio, BioXcel Therapeutics, Intra-Cellular, Anavex, Pain Therapeutics, Grifols",2019-03-21 07:37:00-04:00,MRK,negative
851225.0,Merck and NGM Bio Announce Extension Of Strategic Collaboration To 2022,2019-03-20 06:32:00-04:00,MRK,neutral
851226.0,"Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'",2019-03-18 14:26:00-04:00,MRK,negative
851227.0,"Enigma Biomedical Reports Exclusive License Deal With Merck For Global Development, Commercialization Of MK-6884, An Alzheimer's Treatment",2019-03-15 14:01:00-04:00,MRK,positive
851228.0,Merck Reports EC Approved KEYTRUDA In Combo With Chemo For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer,2019-03-14 06:45:00-04:00,MRK,negative
851229.0,"Merck & Co Option Alert: Jun, 2020 $85 Calls at the Ask: 1000 @ $4.901 vs 113 OI; Earnings 4/30 Before Open [est] Ref=$80.62",2019-03-07 10:02:00-05:00,MRK,positive
851230.0,"The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split",2019-03-06 07:39:00-05:00,MRK,negative
851231.0,Merck Begins Tender Offer To Acquire Immune Design,2019-03-05 06:45:00-05:00,MRK,positive
851232.0,BioXcel Therapeutics Announces Merck and Pfizer Join its Clinical Collaboration with Nektar Therapeutics to Evaluate a Triple Therapy for Pancreatic Cancer,2019-03-04 08:07:00-05:00,MRK,negative
851233.0,Merck Says the European Medicines Agency Adopts Positive Opinion for Merck's KEYTRUDA for Six-Week Dosing Schedule Across All Current Monotherapy Indications,2019-03-04 06:50:00-05:00,MRK,positive
851234.0,Merck Reports Positive CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer,2019-03-01 08:45:00-05:00,MRK,positive
851235.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,MRK,positive
851236.0,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",2019-02-27 08:13:00-05:00,MRK,neutral
851237.0,Sellas Reviews Strategic Options To Fund Clinical Development Programs,2019-02-26 10:49:00-05:00,MRK,neutral
851238.0,It Could Be Time For This Pharma ETF,2019-02-26 09:42:00-05:00,MRK,neutral
851239.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,MRK,positive
851240.0,"UPDATE: Merck, AstraZeneca Report Phase III POLO Trial Met Primary Endpoint",2019-02-26 06:57:00-05:00,MRK,neutral
851241.0,"Merck, AstraZeneca Report LYNPARZA Reduced the Risk of Disease Progression or Death as 1st-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer",2019-02-26 06:56:00-05:00,MRK,negative
851242.0,"AstraZeneca, Merck Announce Phase III POLO Trial Met its Primary Endpoint of Progression-free Survival",2019-02-26 04:01:00-05:00,MRK,neutral
851243.0,"Pharma M&A Wave: Spark Therapeutics, Clementia Pharma Among The Rare Disease Biotechs Acquired",2019-02-25 08:56:00-05:00,MRK,positive
851244.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,MRK,neutral
851245.0,"Cantor Fitzgerald Initiates Coverage On Merck & Co with Overweight Rating, Announces $95 Price Target",2019-02-22 10:01:00-05:00,MRK,negative
851246.0,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",2019-02-22 08:50:00-05:00,MRK,neutral
851247.0,65 Biggest Movers From Yesterday,2019-02-22 05:02:00-05:00,MRK,neutral
851248.0,Mid-Afternoon Market Update: Dow Falls 150 Points; Delphi Technologies Shares Spike Higher,2019-02-21 15:21:00-05:00,MRK,positive
851249.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-02-21 13:24:00-05:00,MRK,neutral
851250.0,Mid-Day Market Update: Immune Design Jumps Following Acquisition News; Carbon Black Shares Slide,2019-02-21 13:24:00-05:00,MRK,positive
851251.0,Mid-Morning Market Update: Markets Open Lower; Domino's Pizza Misses Q4 Views,2019-02-21 10:20:00-05:00,MRK,negative
851252.0,Merck To Buy Immune Design For $300M,2019-02-21 09:28:00-05:00,MRK,positive
851253.0,31 Stocks Moving In Thursday's Pre-Market Session,2019-02-21 08:09:00-05:00,MRK,neutral
851254.0,"Merck To Acquire Immune Design At $5.85/Share In Cash, Or ~$300M",2019-02-21 06:45:00-05:00,MRK,positive
851255.0,"The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering",2019-02-20 07:34:00-05:00,MRK,negative
851256.0,FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA Monotherapy For Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer,2019-02-20 06:46:00-05:00,MRK,negative
851257.0,Merck Reports Phase 3 KEYNOTE-240 Trial Evaluating KEYTRUDA Did Not Meet Co-Primary Endpoints,2019-02-19 16:43:00-05:00,MRK,neutral
851258.0,Merck Says US Patent & Trademark Office Issued Formal Notice Allowing Co.'s Patent Application Directed To Its Proxy-CRISPR Technology,2019-02-19 08:10:00-05:00,MRK,neutral
851259.0,FDA Approves Merck's KEYTRUDA For Adjuvant Treatment Of Patients With Melanoma With Involvement Of Lymph Nodes Following Complete Resection,2019-02-19 06:46:00-05:00,MRK,positive
851260.0,Merck Announces KEYTRUDA in Combination with Inlyta Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced RCC at ASCO GU 2019,2019-02-17 08:38:00-05:00,MRK,negative
851261.0,Merck Reports FDA Granted Priority Review For Co.'s Supplemental Biologics License Application for KEYTRUDA Combo With Inlyta For First-Line Treatment for Advanced Renal Cell Carcinoma,2019-02-15 06:48:00-05:00,MRK,positive
851262.0,Merck Highlights 3 New Phase 3 Trials,2019-02-14 06:55:00-05:00,MRK,neutral
851263.0,Hemispherx Biopharma Announces Commencement Of A New 45 Subject Clinical Trial Combining Ampligen And Merck's Keytruda In The Treatment Of Recurrent Ovarian Cancer,2019-02-11 08:34:00-05:00,MRK,negative
851264.0,Merck Granted FDA Priority Review for its Supplemental Biologics License Application for KEYTRUDA for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,2019-02-11 06:45:00-05:00,MRK,positive
851265.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,MRK,neutral
851266.0,"Third Point Dissolves Stakes in Netflix, Microsoft; Cuts Stake in PayPal, Merck, Visa, American Express, Baxter; Raises Stakes in Campbell Soup, Salesforce",2019-02-09 14:04:00-05:00,MRK,negative
851267.0,"Bank Of America Reiterates Buy And $84 Target On Merck Due To 'Keytruda driven upside, undemanding valuation + optionality (animal health spin + OM expansion)'",2019-02-07 11:01:00-05:00,MRK,neutral
851268.0,Drugmakers Offered C$9.6B in Price Cuts; Freeze of Drug Prices in Response to Proposed Crackdown by Canada Regulator,2019-02-06 04:18:00-05:00,MRK,negative
851269.0,Merck Says CEO Frazier Plans To Testify At Feb 26 Senate Drug Pricing Hearing,2019-02-05 12:48:00-05:00,MRK,neutral
851270.0,Codexis shares are trading higher after the company reported a multi-year agreement with Merck to perform technology upgrades.,2019-02-05 08:39:00-05:00,MRK,positive
851271.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,MRK,positive
851272.0,FDA Accepts For Review New Drug Application For Merck's Investigational Combination Of Imipenem/Cilastatin And Relebactam; Acceps Supplemental NDA For ZERBAXA,2019-02-05 06:49:00-05:00,MRK,positive
851273.0,UPDATE: Financial Terms Of Codexis/Merck Deal Were Not Disclosed,2019-02-04 16:21:00-05:00,MRK,neutral
851274.0,Codexis Reports Secured Multi-Year Technology Upgrade Package For CodeEvolver Protein Engineering Platform License With Merck,2019-02-04 16:21:00-05:00,MRK,positive
851275.0,Merck Announces the European Medicines Agency Gave a Positive Opinion on KEYTRUDA in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer,2019-02-04 06:50:00-05:00,MRK,negative
851276.0,"Barron's Picks And Pans: Corning, Merck, Microsoft And More",2019-02-02 13:43:00-05:00,MRK,neutral
851277.0,Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates,2019-02-01 13:30:00-05:00,MRK,neutral
851278.0,Merck & Co shares are trading higher after the company reported inline Q4 EPS figures and beat sales estimates.,2019-02-01 10:37:00-05:00,MRK,positive
851279.0,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of  Titan's Opioid Disorder Treatment Implant",2019-02-01 09:10:00-05:00,MRK,positive
851280.0,"Merck Sees FY19 Adj. EPS $4.57-$4.72 vs $4.69 Estimate, Sales $43.2B-$44.7B vs $44.54B Est.",2019-02-01 06:46:00-05:00,MRK,neutral
851281.0,"Merck Q4 EPS $1.04, Inline, Sales $10.998B Beat $10.96B Estimate",2019-02-01 06:45:00-05:00,MRK,neutral
851282.0,"12 Stocks To Watch For February 1, 2019",2019-02-01 04:46:00-05:00,MRK,neutral
851283.0,"Earnings Scheduled For February 1, 2019",2019-02-01 04:04:00-05:00,MRK,neutral
851284.0,Merck's Q4 Earnings Preview,2019-01-31 13:42:00-05:00,MRK,neutral
851285.0,How To Approach Q4 Earnings: The Technical Perspective,2019-01-29 13:11:00-05:00,MRK,neutral
851286.0,Evelo Biosciences Announces First Patient Does in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDAÂ® in Patients with Metastatic Melanoma,2019-01-28 06:06:00-05:00,MRK,neutral
851287.0,Barron's On: The Cost Of Climate Change,2019-01-27 17:12:00-05:00,MRK,neutral
851288.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-01-27 16:07:00-05:00,MRK,neutral
851289.0,Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug,2019-01-24 09:35:00-05:00,MRK,negative
851290.0,"Benzinga's Top Upgrades, Downgrades For January 23, 2019",2019-01-23 09:14:00-05:00,MRK,positive
851291.0,"BMO Capital Downgrades Merck & Co to Market Perform, Announces $80 Price Target",2019-01-23 06:40:00-05:00,MRK,neutral
851292.0,"Bank Of America, JPMorgan, Merck, Stratasys: 'Fast Money' Picks For January 15",2019-01-15 07:15:00-05:00,MRK,neutral
851293.0,"Merck Reports KEYTRUDA Reduced Risk Of Death By 31% Vs Chemotherapy In Previously-Treated Patients With Advanced Esophageal, Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1",2019-01-14 17:02:00-05:00,MRK,negative
851294.0,How 7 New Laws Affected Stocks In The Last Week,2019-01-09 16:59:00-05:00,MRK,negative
851295.0,5 Top-Selling Drugs With Growth Potential In 2019,2019-01-07 15:04:00-05:00,MRK,positive
851296.0,"Amunix Reports Licensing Deal With Merck For ProTIA Immune Activator Platform, No Terms Disclosed",2019-01-03 15:30:00-05:00,MRK,neutral
851297.0,"Cocrystal Pharma Announces Exclusive Worldwide License And Collaboration Agreement With Merck To Develop Influenza A/B Agents; Cococrystal Will Receive Upfront Payment On An Undisclosed Amount, Is Eligible For Up To $156M In Milestones Plus Royalties",2019-01-03 08:32:00-05:00,MRK,positive
851298.0,"The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen",2019-01-03 07:36:00-05:00,MRK,negative
851299.0,"Merck Reports KEYTRUDA Received 5 New Approvals In Japan, Including Advanced Non-Small Cell Lung Cancer, As Adjuvant Therapy for Melanoma, In Advanced Microsatellite Instability-High Tumors",2019-01-03 06:46:00-05:00,MRK,negative
851300.0,"Merck Reports Exercise Of Its Option For NGM Bio's NGM313 For Treatment Of NASH, Type 2 Diabetes",2019-01-03 06:39:00-05:00,MRK,neutral
851301.0,Merck Exercises Option for NGM Bio's Investigational Insulin Sensitizer NGM313 for Treatment of NASH and Type 2 Diabetes,2019-01-03 06:35:00-05:00,MRK,neutral
851302.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2018-12-31 09:00:00-05:00,MRK,neutral
851303.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,MRK,neutral
851304.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,MRK,neutral
851305.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,MRK,neutral
851306.0,"Merck Extends PDUFA Date For Supplemental Biologics Licence For Keytruda By Three Months To April 11, 2019",2018-12-20 16:22:00-05:00,MRK,positive
851307.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,MRK,positive
851308.0,"AstraZeneca, Merck Report LYNPARZA Met Primary Endpoint In Phase 3 SOLO-3 Trial For Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer",2018-12-20 06:36:00-05:00,MRK,negative
851309.0,FDA Approves Merck's KEYTRUDA For Treatment Of Recurrent Locally Advanced Or Metastatic Merkel Cell Carcinoma,2018-12-19 16:14:00-05:00,MRK,positive
851310.0,"AstraZeneca, Merck Report FDA Approval For LYNPARZA For First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer",2018-12-19 16:01:00-05:00,MRK,negative
851311.0,Merck Announces FDA Approval Of LYNPARZA For Ovarian Cancer,2018-12-19 15:25:00-05:00,MRK,negative
851312.0,Merck Receives FDA Approval For Pembrolizumab In Merkel Cell Carcinoma,2018-12-19 14:54:00-05:00,MRK,positive
851313.0,Merck's KEYTRUDA as Adjuvant Therapy for Adults with Resected Stage III Melanoma Approved by the European Commission,2018-12-17 06:33:00-05:00,MRK,positive
851314.0,"Stocks Trading Ex Dividend For Fri., Dec. 14 2018",2018-12-14 10:43:00-05:00,MRK,neutral
851315.0,A Peek Into The Markets: US Stock Futures Tumble Ahead Of Economic Reports,2018-12-14 07:42:00-05:00,MRK,neutral
851316.0,"Merck Reports Purchase Of Antelliq Group For â‚¬2.1B In Cash, Assume â‚¬1.15B In Co. Debt",2018-12-14 06:48:00-05:00,MRK,negative
851317.0,Merck and Instituto Butantan Announce Collaboration Agreement To Develop Dengue Infections Vaccine; Instituto Butantan To Receive $26M Upfront And Is Eligible For Up To $75M In Milestones,2018-12-12 10:31:00-05:00,MRK,positive
851318.0,"Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate",2018-12-11 12:42:00-05:00,MRK,positive
851319.0,Merck And Roche Enter Into Collaboration Agreement To Develop Companion Diagnostic Test To Identify Patients Eligible For PD-1 Therapy Based On The Status Of A Biomaker In Advanced Solid Tumors,2018-12-11 10:10:00-05:00,MRK,positive
851320.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,MRK,neutral
851321.0,"Merck Names Frank Clyburn Chief Commercial Officer, Michael Nally Chief Marketing Officer; BZ NOTE: These Positions Are Both New Roles For Merck",2018-12-10 16:33:00-05:00,MRK,positive
851322.0,Merck Reports FDA Orphan Drug Designation For M7824 In Biliary Tract Cancer,2018-12-10 10:21:00-05:00,MRK,negative
851323.0,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",2018-12-06 07:56:00-05:00,MRK,negative
851324.0,Ra Pharma Reports Received Development Milestone Payment Under Deal With Merck; Says Is Eligible To Earn Up To $59M In Added Milestone Payments,2018-12-06 07:31:00-05:00,MRK,neutral
851325.0,"Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details",2018-12-04 10:24:00-05:00,MRK,neutral
851326.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,MRK,neutral
851327.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,MRK,neutral
851328.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2018-11-30 13:09:00-05:00,MRK,neutral
851329.0,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018",2018-11-30 10:25:00-05:00,MRK,neutral
851330.0,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings",2018-11-30 08:25:00-05:00,MRK,negative
851331.0,Merck Is Up 40% In 2018: What's Driving The Rally?,2018-11-29 16:11:00-05:00,MRK,neutral
851332.0,Ebola Outbreak In Eastern Congo Now World's Second Largest Ever With 426 Cases,2018-11-29 15:09:00-05:00,MRK,neutral
851333.0,Merk shares rise after the European Commission approved Co's HIV treatments in Europe.,2018-11-29 14:46:00-05:00,MRK,positive
851334.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 28, 2018",2018-11-29 10:49:00-05:00,MRK,neutral
851335.0,"The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved",2018-11-29 08:09:00-05:00,MRK,neutral
851336.0,Merck Receives European Commission Approval For DELSTRIGO As Part OF An HIV-1 Treatment Regimen,2018-11-28 16:30:00-05:00,MRK,positive
851337.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,MRK,negative
851338.0,"Data Dive, Trade Talks And Powell: Busy Post-Holiday Week On The Way",2018-11-26 09:41:00-05:00,MRK,neutral
851339.0,"The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings",2018-11-25 09:41:00-05:00,MRK,neutral
851340.0,9 Policy Catalysts For Health Care Investors To Watch Before Year's End,2018-11-25 09:35:00-05:00,MRK,positive
851341.0,Stocks Of Vaccination Providers Do Not React Following Update From Health Ministry Suggesting 13 New Cases Of Ebola Were Reported In Eastern Congo Wed.,2018-11-21 14:43:00-05:00,MRK,neutral
851342.0,October's Biggest Losers And Most Surprising Winners,2018-11-21 10:48:00-05:00,MRK,positive
851343.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Nov. 19, 2018",2018-11-20 09:11:00-05:00,MRK,neutral
851344.0,"The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings",2018-11-20 08:29:00-05:00,MRK,negative
851345.0,Merck and Pfizer's Avelumab in Platinum-Resistant/Refractory Ovarian Cancer Did Not Meet Primary Endpoints,2018-11-19 07:15:00-05:00,MRK,negative
851346.0,"NewLink Genetics Announces Merck Has Begun Rolling Submission Of Licensure Application For Ebola vaccine V920 To U.S. FDA; In 2014, Co. Entered Ito License Agreement With Merck To Develop, Manufacture And Commercialize Ebola Vaccine",2018-11-15 09:02:00-05:00,MRK,positive
851347.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,MRK,neutral
851348.0,Merck Reports KEYTRUDA Significantly Improved Overall Survival Compared To Chemotherapy In Patients With Advanced Esophageal Or Esophagogastric Junction Carcnimoa Whose Tumors Express PD-L1,2018-11-14 06:54:00-05:00,MRK,positive
851349.0,Merck Reports Commencement Of Rolling Submission Of Licensure Application For V920 To FDA,2018-11-13 16:36:00-05:00,MRK,neutral
851350.0,World Health Organization's Emergency Response Chief Says We Expect Democratic Republic Of Congo's Ebola Outbreak To Last At Least Another Six Months,2018-11-13 10:36:00-05:00,MRK,negative
851351.0,October's biggest Losers And Most Surprising Winners,2018-11-12 13:19:00-05:00,MRK,positive
851352.0,Merck Announces the FDA Has Accepted a Supplemental New Drug Application for LYNPARZA,2018-11-12 06:56:00-05:00,MRK,positive
851353.0,"AstraZeneca, Merck Announce FDA Accepts Regulatory Submission for Lynparza Maintenance Therapy in Newly-diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review",2018-11-12 04:09:00-05:00,MRK,negative
851354.0,FDA Approves Merck's KEYTRUDA For Patients With Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated With Sorafenib,2018-11-09 16:21:00-05:00,MRK,positive
851355.0,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 8, 2018",2018-11-09 09:38:00-05:00,MRK,neutral
851356.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,MRK,neutral
851357.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,MRK,neutral
851358.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,MRK,negative
851359.0,"Merck Reports Early Phase 1 Data From MK-4280, MK-7684 Trial To Be Presented At SITC Meeting Nov. 9, 2018",2018-11-07 06:46:00-05:00,MRK,neutral
851360.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,MRK,neutral
851361.0,"Stocks Which Set New 52-Week High Yesterday, October 31st",2018-11-01 10:33:00-04:00,MRK,neutral
851362.0,"Citigroup Maintains Buy on Merck & Co, Raises Price Target to $84",2018-11-01 10:28:00-04:00,MRK,neutral
851363.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2018-11-01 09:26:00-04:00,MRK,neutral
851364.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,MRK,negative
851365.0,"Citigroup Maintains Buy on Merck & Co, Raises Price Target to $84",2018-10-31 10:21:00-04:00,MRK,neutral
851366.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,MRK,negative
851367.0,"Merck Reports FDA Approved KEYTRUDA In Combo With Carboplatin, Either Paclitaxel Or Nab-Paclitaxel For First-Line Treatment Of Patients With Metastatic Squamous Non-Small Cell Lung Cancer",2018-10-30 16:23:00-04:00,MRK,negative
851368.0,Wild Times: Market Seems To Seek Solid Ground After Monday's Manic,2018-10-30 10:45:00-04:00,MRK,positive
851369.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,MRK,neutral
851370.0,REMINDER: Merck Has PDUFA Date for KEYTRUDA+carboplatin-paclitaxel sBLA Today,2018-10-30 07:00:00-04:00,MRK,neutral
851371.0,"Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?",2018-10-29 13:10:00-04:00,MRK,positive
851372.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,MRK,neutral
851373.0,"BMO Capital Maintains Outperform on Merck & Co, Lowers Price Target to $80",2018-10-26 11:06:00-04:00,MRK,negative
851374.0,"Snapping Back, But Can Rally Attempt Last? Strong Earnings Might Power Market",2018-10-25 09:55:00-04:00,MRK,positive
851375.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,MRK,negative
851376.0,"A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings, Economic Reports",2018-10-25 07:17:00-04:00,MRK,neutral
851377.0,Merck Raises Qtr. Dividend From $0.48 To $0.55/Share; Adds $10B To Buyback,2018-10-25 06:48:00-04:00,MRK,neutral
851378.0,"UPDATE: Merck Raises FY18 Adj. EPS Guidance From $4.22-$4.30 As Of Jul. 27, 2018 To $4.30-$4.36 vs $4.29 Estimate",2018-10-25 06:48:00-04:00,MRK,neutral
851379.0,Merck Raises Guidance,2018-10-25 06:47:00-04:00,MRK,neutral
851380.0,"Merck & Co Q3 EPS $1.19 Beats $1.14 Estimate, Sales $10.794B Miss $10.88B Estimate",2018-10-25 06:46:00-04:00,MRK,negative
851381.0,Merck's Q3 Earnings Preview,2018-10-24 15:26:00-04:00,MRK,neutral
851382.0,"Stocks Which Set New 52-Week High Yesterday, October 22nd",2018-10-23 09:51:00-04:00,MRK,neutral
851383.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,MRK,positive
851384.0,11 Stocks That Moved From ESMO 2018,2018-10-22 13:39:00-04:00,MRK,neutral
851385.0,"Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report",2018-10-22 12:49:00-04:00,MRK,positive
851386.0,"BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $82",2018-10-22 11:15:00-04:00,MRK,neutral
851387.0,Merck Reports Presentation Of KEYTRUDA Showing Improved Overall Survival In Patients With Recurrent Or Metastatic Head And Neck Cancer; Results Being Presented At ESMO 2018 Congress,2018-10-22 10:32:00-04:00,MRK,negative
851388.0,European Medicines Agency Adopts Positive Opinion for Merck's KEYTRUDA as Adjuvant Therapy in Melanoma,2018-10-22 06:45:00-04:00,MRK,positive
851389.0,"REMINDER: ESMO 2018 Event Continues Today, Clinical Updates Presented Today Include: CytomX Therapeutics, Mirati Therapeutics, Merck, NuCana, Protagonist Therapeutics, SELLAS Life Sciences, Epizyme, Kura Oncology, Intra-Cellular Therapies, and AVEO Pharma",2018-10-22 05:56:00-04:00,MRK,neutral
851390.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,MRK,neutral
851391.0,"AstraZeneca, Merck Announce Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer at ESMO",2018-10-21 15:40:00-04:00,MRK,negative
851392.0,Leap Therapeutics Presents Promising Esophagogastric Cancer Data at ESMO 2018,2018-10-21 08:12:00-04:00,MRK,negative
851393.0,Merck Announces KEYTRUDA Showed a Complete Response Rate of Nearly 40% in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Standard of Care at ESMO 2018,2018-10-20 16:57:00-04:00,MRK,negative
851394.0,ImmunoGen Presents Encouraging Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018,2018-10-20 16:54:00-04:00,MRK,positive
851395.0,Dynavax Announces SD-101 in Combination with Merck's KEYTRUDA Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at ESMO 2018,2018-10-20 16:28:00-04:00,MRK,positive
851396.0,Merck Announces First Presentation of Early Data for Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018,2018-10-20 16:27:00-04:00,MRK,positive
851397.0,"The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut",2018-10-19 08:28:00-04:00,MRK,positive
851398.0,Merck Says 'Pivotal Phase 3 KEYNOTE-426 Trial Met Both Primary Endpoints; Data to be Filed with Global Regulatory Authorities',2018-10-18 06:58:00-04:00,MRK,neutral
851399.0,"Merck Reports KEYTRUDA In Combo With Pfizer's Inlyta Improved Overall Survival, Progression-Free Survival As First-Line Therapy For Advanced, Metastatic Renal Cell Carcinoma",2018-10-18 06:57:00-04:00,MRK,positive
851400.0,"World Health Organization's Emergency Committee Has Said The Ebola Outbreak In Congo Is Not Yet A Health Emergency Of Int'l. Concern, Warns Situation Likely To Deteriorate Significantly Unless Response Is Intensified",2018-10-17 13:27:00-04:00,MRK,negative
851401.0,"Citigroup Maintains Buy on Merck & Co, Raises Price Target to $79",2018-10-16 07:35:00-04:00,MRK,neutral
851402.0,U.S. FDA Grants Merck And AstraZeneca's LYNPARZA Orphan Drug Designation For Pancreatic Cancer,2018-10-16 06:35:00-04:00,MRK,negative
851403.0,"AstraZeneca, Merck Receive FDA Orphan Drug for Lynparza in Pancreatic Cancer",2018-10-16 04:51:00-04:00,MRK,negative
851404.0,OncoSec Initiates KEYNOTE-890 Phase 2 Clinical Trial Of TAVO In Combination With Merck's KEYTRUDA For Treatment Of Late-Stage Triple Negative Breast Cancer,2018-10-15 07:33:00-04:00,MRK,negative
851405.0,4 Major Market Opportunities For The Cannabis Industry,2018-10-14 13:26:00-04:00,MRK,positive
851406.0,"Barclays Maintains Overweight on Merck & Co, Raises Price Target to $78",2018-10-12 08:26:00-04:00,MRK,negative
851407.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,MRK,negative
851408.0,"Credit Suisse Maintains Outperform on Merck & Co, Raises Price Target to $81",2018-10-11 09:57:00-04:00,MRK,positive
851409.0,"Stocks Which Set New 52-Week High Yesterday, October 10th",2018-10-11 09:08:00-04:00,MRK,neutral
851410.0,"The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares",2018-10-11 07:39:00-04:00,MRK,positive
851411.0,"Stocks That Made New 52-Week Highs So Far Today Include: NextEra Energy, WEC Energy, Verizon, CMS Energy, Ameren, FirstEnergy, McCormick, AES, Merck, Public Service Enterprise, Express Scripts, and Public Service Enterprise",2018-10-10 14:25:00-04:00,MRK,positive
851412.0,"Stocks Which Set New 52-Week High Yesterday, October 9th",2018-10-10 10:57:00-04:00,MRK,neutral
851413.0,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares",2018-10-10 07:56:00-04:00,MRK,positive
851414.0,REMINDER: Merck Has FDA PDUFA Date Tomorrow October 6th For GARDASIL sBLA,2018-10-05 16:37:00-04:00,MRK,neutral
851415.0,"Stocks Which Set New 52-Week High Yesterday, October 3rd",2018-10-04 11:18:00-04:00,MRK,neutral
851416.0,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut",2018-10-04 07:59:00-04:00,MRK,neutral
851417.0,"A Peek Into The Markets: US Stock Futures Drop Ahead Of Jobless Claims, Factory Orders Data",2018-10-04 07:26:00-04:00,MRK,negative
851418.0,Merck Reports DELSTRIGO Phase 3 DRIVE-SHIFT Trial Met Primary Efficacy Endpoint,2018-10-04 06:45:00-04:00,MRK,neutral
851419.0,"Stocks Which Set New 52-Week High Yesterday, October 2nd",2018-10-03 12:59:00-04:00,MRK,neutral
851420.0,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",2018-10-03 07:54:00-04:00,MRK,positive
851421.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,MRK,neutral
851422.0,"The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares",2018-10-02 09:10:00-04:00,MRK,positive
851423.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2018-09-26 16:41:00-04:00,MRK,neutral
851424.0,Merck Board Rescinds Mandatory CEO Retirement Policy; Current CEO Kenneth Frazier To Continue In Role Beyond December 2019,2018-09-26 06:45:00-04:00,MRK,positive
851425.0,"Stocks Which Set New 52-Week High Friday, September 21",2018-09-24 09:43:00-04:00,MRK,neutral
851426.0,"OpGen Reports Partnership With New York State Dept. Of Health, Merck's ILUM Health Solutions To Detect Antimicrobial-Resistant Infections",2018-09-24 09:28:00-04:00,MRK,positive
851427.0,Democratic Republic Of Congo Confirms Ebola Case In Ituri Province Almost 200 KM Away From Closest Other Case And 50 KM From The Ugandan Border,2018-09-21 10:03:00-04:00,MRK,neutral
851428.0,"The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding",2018-09-21 08:51:00-04:00,MRK,negative
851429.0,"XOMA Reports Purchase Of Royalty Interest Position From Agenus On 7 Assets Being Developed By Merck, Incyte For $15M",2018-09-21 07:00:00-04:00,MRK,positive
851430.0,"Merck Reports Received Positive CHMP Opinion For ELSTRIGO, PIFELTRO In EU For Treatment Of HIV-1 Infection",2018-09-20 16:30:00-04:00,MRK,positive
851431.0,Merck Or Pfizer: Which Is The Better Large-Cap Pharma Stock?,2018-09-20 15:55:00-04:00,MRK,positive
851432.0,Accenture and Merck Collaborate with Amazon Web Services to Launch a Research Platform to Drive Innovation in Drug Discovery and Scientific Research,2018-09-17 08:30:00-04:00,MRK,positive
851433.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,MRK,neutral
851434.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,MRK,neutral
851435.0,"The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut",2018-09-14 08:38:00-04:00,MRK,neutral
851436.0,"Stocks That Will Be Trading Ex Dividend For Fri., Sep. 14, 2018",2018-09-13 09:44:00-04:00,MRK,neutral
851437.0,FDA Grants Priority Review to Merck's Application for KEYTRUDA Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1,2018-09-12 06:45:00-04:00,MRK,negative
851438.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,MRK,negative
851439.0,"A Peek Into The Markets: US Stock Futures Down Ahead Of Job Openings, Wholesale Inventories Data",2018-09-11 07:10:00-04:00,MRK,neutral
851440.0,IMV Inc. Announces Phase 2 Basket Trial With Merck To Evaluate DPX-Survivac In Combination With KEYTRUDA Across Five Solid Tumor Indications,2018-09-11 07:08:00-04:00,MRK,negative
851441.0,"Merck's ZERBAXA Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study, Co. To Submit Supplemental New Drug App. In U.S. And EU",2018-09-11 06:45:00-04:00,MRK,neutral
851442.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2018-09-10 07:02:00-04:00,MRK,neutral
851443.0,Merck's KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC Approved by the European Commission,2018-09-10 06:47:00-04:00,MRK,positive
851444.0,European Commission Approves Merck's KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC,2018-09-10 06:45:00-04:00,MRK,positive
851445.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,MRK,neutral
851446.0,Health Care Has Been On Fire. Will The Uptrend Continue?,2018-09-07 14:40:00-04:00,MRK,positive
851447.0,"Barclays Maintains Overweight on Merck & Co, Raises Price Target to $75",2018-09-07 07:21:00-04:00,MRK,negative
851448.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,MRK,positive
851449.0,"Ebola-Related Stocks Unaffected Amid Earlier Report Officials In Congo Announced The First Ebola Case In A Major Eastern City, Butembo",2018-09-05 07:56:00-04:00,MRK,neutral
851450.0,Eisai And Merck Announce China National Medical Products Administration (NMPA) Approval Of LENVIMA For Treatment Of Unresectable Hepatocellular Carcinoma (HCC),2018-09-05 06:46:00-04:00,MRK,positive
851451.0,"Eisai, Merck Announce China NMPA Approval of First Approval for LENVIMA for Treatment of Unresectable HCC",2018-09-05 04:40:00-04:00,MRK,positive
851452.0,Benzinga Pro's 5 Stocks To Watch Today,2018-09-04 09:19:00-04:00,MRK,neutral
851453.0,"FDA Grants Priority Review to Merck's Supplemental Biologics License Application for KEYTRUDA, Application Based on Data from Phase 2 KEYNOTE-017 Trial",2018-09-04 06:46:00-04:00,MRK,positive
851454.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2018-09-02 09:41:00-04:00,MRK,neutral
851455.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,MRK,positive
851456.0,Merck Announces FDA Aproval of DELSTRIGO,2018-08-30 16:05:00-04:00,MRK,neutral
851457.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,MRK,neutral
851458.0,30 Stocks Moving In Friday's Pre-Market Session,2018-08-24 08:08:00-04:00,MRK,neutral
851459.0,"Morgan Stanley Maintains Overweight on Merck & Co, Raises Price Target to $74",2018-08-23 07:42:00-04:00,MRK,negative
851460.0,Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA,2018-08-23 06:32:00-04:00,MRK,positive
851461.0,"Stocks Which Set New 52-Week High Yesterday, August 21st",2018-08-22 09:06:00-04:00,MRK,neutral
851462.0,"The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin",2018-08-22 08:20:00-04:00,MRK,negative
851463.0,"Incyte Has Quietly Risen 13 Percent In The Last Two Weeks, And That Uptrend Looks Like It Will Continue",2018-08-21 15:40:00-04:00,MRK,positive
851464.0,"Stocks Which Set New 52-Week High Tues., Aug. 21, 2018",2018-08-21 14:50:00-04:00,MRK,neutral
851465.0,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",2018-08-21 08:40:00-04:00,MRK,positive
851466.0,Rexahn Reports Clinical Collaboration With Merck For Evaluation Of RX-5902 In Combo With KEYTRUDA For Triple-Negative Breast Cancer,2018-08-21 08:12:00-04:00,MRK,negative
851467.0,FDA Approves Expanded Label for Merck's KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy for First-Line Treatment,2018-08-20 16:06:00-04:00,MRK,positive
851468.0,"Stocks Which Set New 52-Week High Yesterday, August 16th",2018-08-17 10:39:00-04:00,MRK,neutral
851469.0,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns",2018-08-17 08:15:00-04:00,MRK,negative
851470.0,Eisai And Merck Announce FDA Approval Of LENVIMA,2018-08-17 08:01:00-04:00,MRK,positive
851471.0,Eisai And Merck Announce FDA Approval Of LENVIMA (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC),2018-08-16 16:12:00-04:00,MRK,positive
851472.0,"Stocks Which Set New 52-Week High Yesterday, August 15th",2018-08-16 10:22:00-04:00,MRK,neutral
851473.0,"The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait",2018-08-16 09:37:00-04:00,MRK,negative
851474.0,Agenus Receives Milestone Payment From Merck Of $4M For Initiation Of Phase 1 Clinical Trial Of An Undisclosed Antibody Candidate Discovered By Agenus,2018-08-15 13:25:00-04:00,MRK,neutral
851475.0,CDC Says There's No Recommendation To Avoid Travel To Democratic Republic Of The Congo Following Ebola Outbreaks,2018-08-09 14:02:00-04:00,MRK,negative
851476.0,Perrigo Announces Rx-To-OTC Switch Licensing For Nasonex,2018-08-09 04:02:00-04:00,MRK,neutral
851477.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,MRK,neutral
851478.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,MRK,positive
851479.0,"Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronics, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney",2018-08-07 11:49:00-04:00,MRK,neutral
851480.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,MRK,neutral
851481.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,MRK,negative
851482.0,Congo Health Ministry Says Ebola Outbreak Likely to have Killed 33; Merck Vaccine Being Deployed to Control Spread of Outbreak,2018-08-05 08:03:00-04:00,MRK,negative
851483.0,"Merck Reports Co., AstraZeneca's Selumetinib Granted Orphan Designation In Europe For Neruofibromatosis Type 1",2018-08-03 06:30:00-04:00,MRK,positive
851484.0,Health Ministry Officials Say Ebola In Latest Congo Outbreak Is of the Zaire Strain Which Has Been Successfully Treated By A Vaccine In The Past,2018-08-02 18:02:00-04:00,MRK,positive
851485.0,"UPDATE: W.H.O. Says Depending On The Strain Of Ebola In Congo Outbreak, Merck Vaccine May Be 'An Option'",2018-08-02 11:46:00-04:00,MRK,negative
851486.0,"WHO Chief Says That It Has Started Moving Staff, Supplies To The Area Of Democratic Republic Of Congo's New Ebola Outbreak",2018-08-01 14:12:00-04:00,MRK,neutral
851487.0,"4 Samples From Northeastern Democratic Rep. Of Congo Test Positive For Ebola Virus, 20 Deaths From Hemorrhagic Fever Recorded In Northeastern Congo",2018-08-01 10:46:00-04:00,MRK,positive
851488.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-31 09:01:00-04:00,MRK,neutral
851489.0,"A Peek Into The Markets: US Stock Futures Up Ahead Of Earnings, Economic Data",2018-07-31 07:01:00-04:00,MRK,neutral
851490.0,Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation For LENVIMA In Combination With KEYTRUDA As Therapy For Previously Treated Patients With Advanced And/Or Metastatic Non-MSI-H/pMMR Endometrial Carcinoma,2018-07-31 06:36:00-04:00,MRK,positive
851491.0,"Eisai, Merck Announce FDA Breakthrough Therapy Designation for LENVIMA",2018-07-31 03:43:00-04:00,MRK,neutral
851492.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-30 09:05:00-04:00,MRK,neutral
851493.0,BioLineRx Expands its Immuno-Oncology Collaboration in Pancreatic Cancer with Merck,2018-07-30 07:13:00-04:00,MRK,negative
851494.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-27 08:55:00-04:00,MRK,neutral
851495.0,"Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter",2018-07-27 08:44:00-04:00,MRK,neutral
851496.0,Endo Int'l. Reports Par Pharma Has Begun Shipping Authorized Generic Version Of Merck's INVANZ,2018-07-27 07:31:00-04:00,MRK,neutral
851497.0,Merck Narrows FY18 Sales Guidance From $41.8B-$43B To $42B-$42.8B vs $42.07B Estimate,2018-07-27 06:49:00-04:00,MRK,neutral
851498.0,Merck Raises FY18 Adj. EPS From $4.16-$4.28 To $4.22-$4.30 vs $4.23 Estimate,2018-07-27 06:48:00-04:00,MRK,neutral
851499.0,"Merck & Co Q2 EPS $1.06 Beats $1.03 Estimate, Sales $10.465B Beat $10.29B Estimate",2018-07-27 06:46:00-04:00,MRK,neutral
851500.0,"12 Stocks To Watch For July 27, 2018",2018-07-27 04:56:00-04:00,MRK,neutral
851501.0,"Earnings Scheduled For July 27, 2018",2018-07-27 04:11:00-04:00,MRK,neutral
851502.0,Merck Q2 Earnings Preview,2018-07-26 14:57:00-04:00,MRK,neutral
851503.0,Sutro Pharma Earlier Reported Merck Was Part Of $85.4M Series E Funding Round,2018-07-26 11:13:00-04:00,MRK,neutral
851504.0,Merck Reports KEYTRUDA Approved By China National Drug Admin.,2018-07-26 06:50:00-04:00,MRK,positive
851505.0,"Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile",2018-07-25 08:41:00-04:00,MRK,positive
851506.0,Merck Reports Phase 3 KEYNOTE-048 Trial Investigating KEYTRUDA Met Primarry Endpoint Of Improving Overall SurvivalIn Head And Neck Squamous Cell Carcinoma Patients,2018-07-25 06:47:00-04:00,MRK,positive
851507.0,"Merck Announces KEYTRUDA Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1",2018-07-25 03:53:00-04:00,MRK,positive
851508.0,Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine,2018-07-24 06:47:00-04:00,MRK,neutral
851509.0,Morgan Stanley: Newly Public Neon Therapeutics Has Outperformance Potential,2018-07-23 14:42:00-04:00,MRK,neutral
851510.0,"Leap Therapeutics Announces Collaboration with Merck and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors",2018-07-23 07:31:00-04:00,MRK,positive
851511.0,Merck Announces Plans To Cut Drug Prices,2018-07-20 11:49:00-04:00,MRK,negative
851512.0,"UPDATE: Merck Says 'Going forward, we will continue to evaluate our portfolio of products to look for opportunities to further reduce costs for patients and the health care system'",2018-07-19 14:48:00-04:00,MRK,positive
851513.0,"UPDATE: Merck, Responding To Responsibility On Drug Pricing, Says 'We are also lowering our price on ZEPATIER by 60 percent and several other medicines by 10 percent to reduce out-of-pocket costs for patients across the country'",2018-07-19 14:48:00-04:00,MRK,negative
851514.0,Merck Says 'We commit to not increase the average net price across our portfolio of products by more than inflation annually',2018-07-19 14:48:00-04:00,MRK,positive
851515.0,PreMarket Prep Opening NYSE Imbalance Update: ExxonMobil 55k Shares To Sell; Pfizer 50k To Sell; Merck 26k To Sell; Coca-Cola 54k To Sell; Johnson & Johnson 54k To Sell; Ford 103k To Sell; Kroger 90k To Sell,2018-07-16 09:02:00-04:00,MRK,positive
851516.0,Cue Biopharma Produces Immuno-STAT Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck,2018-07-12 08:00:00-04:00,MRK,positive
851517.0,FDA Grants Merck Priority Review To Co.'s  Supplemental Biologics License Application For Its KEYTRUDA Hepatocellular Carcinoma Therapy,2018-07-11 06:56:00-04:00,MRK,positive
851518.0,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports,2018-07-09 14:39:00-04:00,MRK,positive
851519.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,MRK,neutral
851520.0,Merck's Supplemental Biologics License for KEYTRUDA in Combination with Chemotherapy is Granted Priority Review by the FDA,2018-07-02 06:46:00-04:00,MRK,positive
851521.0,"AstraZeneca, Merck Announce LYNPARZA Approved in Japan for BRCA-Mutated Metastatic Breast Cancer",2018-07-02 03:56:00-04:00,MRK,negative
851522.0,U.S. Supreme Court Agrees To Hear Merck Appeal Of Lower Court Ruling THat Revived Fosamax Warning Label Suits,2018-06-28 09:32:00-04:00,MRK,positive
851523.0,"UPDATE: Merck Says Non-Inferiority Was Not Demonstrated For Second Primary Outcome Of Blood Loss Of Greater Than Equal To 1,000 ml Of Blood Loss",2018-06-27 17:02:00-04:00,MRK,negative
851524.0,Merck Reports Study Results From Heat-Stable Formulation Of Carbetocin For Prevention Of Excessive Bleeding After Childbirth: Showed Clinical Non-Inferiority To Oxycontin For Primary Outcome Of Greater Than Equal To 500 ml Of Blood Loss,2018-06-27 17:01:00-04:00,MRK,positive
851525.0,AstraZeneca Reports LYNPARZA Phase III Trial First-Line SOLO-1 Trial For Ovarian Cancer Met Primary Endpoint,2018-06-27 07:02:00-04:00,MRK,negative
851526.0,"Merck To Report Q2 Earnings On Fri., Jul. 27, 2018 Before Market Open",2018-06-27 06:46:00-04:00,MRK,neutral
851527.0,"AstraZeneca, Merck Announce LYNPARZA S Met Primary Endpoint of Progression-Free Survival in Women with BRCA-Mutated Advanced Ovarian Cancer and Showed a Safety Profile Consistent with Previous Trials",2018-06-27 04:01:00-04:00,MRK,negative
851528.0,Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility,2018-06-26 12:18:00-04:00,MRK,positive
851529.0,Merck's Supplemental Biologics License Application for KEYTRUDA is Accepted by the FDA,2018-06-25 06:30:00-04:00,MRK,positive
851530.0,Merck Presents New Data from Comparative Trials with Sitagliptin Clinical Trial Program with JANUVIA at #ADA2018,2018-06-23 19:02:00-04:00,MRK,neutral
851531.0,40 Biggest Movers From Friday,2018-06-18 04:17:00-04:00,MRK,neutral
851532.0,Mid-Afternoon Market Update: Crude Oil Down Over 3%; Canada Goose Shares Gain Following Strong Q4 Results,2018-06-15 14:32:00-04:00,MRK,positive
851533.0,30 Stocks Moving In Friday's Mid-Day Session,2018-06-15 12:23:00-04:00,MRK,neutral
851534.0,Mid-Day Market Update: Dow Down Over 200 Points; Affimed Shares Plummet,2018-06-15 12:16:00-04:00,MRK,positive
851535.0,Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data,2018-06-15 10:56:00-04:00,MRK,positive
851536.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,MRK,neutral
851537.0,"Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi",2018-06-14 08:11:00-04:00,MRK,negative
851538.0,Merck's KEYTRUDA Receives FDA Approval For Treatment of Primary Mediastinal Large B-Cell Lymphoma,2018-06-13 16:06:00-04:00,MRK,positive
851539.0,FDA Grants Priority Review To Merck's Supplemental Biologics License Application (sBLA) For GARDASIL 9 In Women And Men Ages 27-45 For Prevention Of Certain HPV-Related Cancers And Diseases,2018-06-13 06:46:00-04:00,MRK,positive
851540.0,Merck Press Release Confirms FDA Approval Of KEYTRUDA For Cervical Cancer,2018-06-12 16:08:00-04:00,MRK,negative
851541.0,Merck Receives FDA Approval For KEYTRUDA in Advanced Cervical Cancer,2018-06-12 14:55:00-04:00,MRK,negative
851542.0,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More",2018-06-08 16:33:00-04:00,MRK,neutral
851543.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,MRK,positive
851544.0,Merck and Astrazeneca Pres Relase Announces LYNPARZA In Combo With Abiraterone Delayed Metastatic Prostate Cancer Disease Progression,2018-06-04 17:01:00-04:00,MRK,negative
851545.0,Merck Gives an Update on its Pivotal Trial of JAVELIN into ASCO,2018-06-04 08:24:00-04:00,MRK,neutral
851546.0,"Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'",2018-06-04 08:22:00-04:00,MRK,neutral
851547.0,Merck Says 'KEYTRUDA Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study',2018-06-04 07:46:00-04:00,MRK,negative
851548.0,Merck Announces New Analysis of Four-Year Data for KEYTRUDA from Phase 3 KEYNOTE-006 Study Showed 86 Percent of Patients Were Progression-Free 20 Months After Completing Two Years of KEYTRUDA,2018-06-04 07:30:00-04:00,MRK,negative
851549.0,Five Additional Ebola Cases Detected by Congo Health Officials,2018-06-04 04:07:00-04:00,MRK,neutral
851550.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,MRK,negative
851551.0,Merck Announces KEYTRUDA Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell RCC in Phase 2 KEYNOTE-427 Study at #ASCO2018,2018-06-03 19:15:00-04:00,MRK,positive
851552.0,"Eisai, Merck Announce Data from Investigational Studies of LENVIMA and KEYTRUDA Combination Therapy in Four Different Tumor Types AT #asco2018",2018-06-03 18:55:00-04:00,MRK,negative
851553.0,Merck Announces KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous NSCLC in Phase 3 KEYNOTE-407 Study,2018-06-03 07:48:00-04:00,MRK,positive
851554.0,Merck Announces KEYTRUDA Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-L1 (TPS â‰¥1%),2018-06-03 07:47:00-04:00,MRK,positive
851555.0,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,2018-06-01 13:22:00-04:00,MRK,neutral
851556.0,"EMA Says CHMP Has Recommended Restricting Use Of Merck's Keytruda, Tecentriq As First-Line Treatments For Urothelial Cancer",2018-06-01 07:34:00-04:00,MRK,negative
851557.0,"Merck, Premier Inc. Report Expansion Of Preventative, Chronic Disease Care Collaboration To Include New Effort Designed To Help Reduce Recurrence Of C. Diff",2018-05-31 09:03:00-04:00,MRK,positive
851558.0,41 Biggest Movers From Yesterday,2018-05-31 04:45:00-04:00,MRK,neutral
851559.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-05-30 12:26:00-04:00,MRK,neutral
851560.0,Mid-Morning Market Update: Markets Open Higher; Michael Kors Beats Q4 Estimates,2018-05-30 10:27:00-04:00,MRK,neutral
851561.0,"Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA",2018-05-30 08:14:00-04:00,MRK,positive
851562.0,"Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended",2018-05-25 09:19:00-04:00,MRK,negative
851563.0,"Eisai, Merck Provide Update on sNDA for Lenvatinib",2018-05-25 04:37:00-04:00,MRK,neutral
851564.0,Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival And Progression-Free Survival As First-Line Treatment For Squamous Non-Small Cell Lung Cancer (NSCLC) In Pivotal Phase 3 KEYNOTE-407 Trial,2018-05-23 06:46:00-04:00,MRK,negative
851565.0,Hearing A Suspected Ebola Case Is Being Treated At A Main Hospital In Congo's Capital City Kinshasa,2018-05-22 14:50:00-04:00,MRK,negative
851566.0,"4,000 Doses Of Ebola Vaccine Sent to Congolese City of Mbandaka on Saturday; Vaccination Campaign to Start Monday",2018-05-20 07:40:00-04:00,MRK,neutral
851567.0,12 Dow 30 Companies With Above-Average Salaries,2018-05-19 17:21:00-04:00,MRK,neutral
851568.0,"Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda",2018-05-18 11:33:00-04:00,MRK,positive
851569.0,WHO Official Says WHO Is Considering Using Mapp Biopharma's ZMapp Treatment For Ebola In Congo,2018-05-18 11:12:00-04:00,MRK,neutral
851570.0,"Merck Shares Dip Lower, Bristol-Myers Squibb Shares Spike Higher Following FDA Alert On Issue Found In Trials Of Keytruda, Tecentriq",2018-05-18 10:43:00-04:00,MRK,positive
851571.0,WHO Emergency Committee Says Ebola Outbreak In Congo Doesn't Yet Constitute A Public Health Emergency Of Intl. Concern,2018-05-18 10:23:00-04:00,MRK,negative
851572.0,WHO Says Ebola Vaccinations In Congo Will Begin Sun.,2018-05-18 10:21:00-04:00,MRK,neutral
851573.0,WHO Raises Risk Assessment of Congo's Ebola Outbreak to 'Very High',2018-05-18 03:55:00-04:00,MRK,negative
851574.0,WHO Says Will Convene Emergency Meeting On Fri. To Determine If Ebola Outbreak In Congo Is A Public Emergency Of Int'l. Concern,2018-05-17 07:28:00-04:00,MRK,negative
851575.0,WHO Says Ebola Outbreak has Spread to DR Congo city,2018-05-17 04:48:00-04:00,MRK,neutral
851576.0,First Batch of Experimental Ebola Vaccine Arrives in Congo; Vaccinations Could Begin this Weekend,2018-05-16 07:44:00-04:00,MRK,neutral
851577.0,"WHO Says 39 Cases Of Ebola Reported In Congo Outbreak So Far, Including 19 Deaths",2018-05-14 06:59:00-04:00,MRK,neutral
851578.0,"Jim Cramer Gives His Opinion On Exxon Mobil, Pfizer And Cisco",2018-05-09 07:12:00-04:00,MRK,neutral
851579.0,OncoSec Announces Clinical Collaboration with Merck  to Evaluate Combination of ImmunoPulse IL-12 and KEYTRUDA for Triple Negative Breast Cancer,2018-05-08 07:44:00-04:00,MRK,negative
851580.0,"Jim Cramer Advises His Viewers On Prestige Brands, CVS Health And More",2018-05-08 07:32:00-04:00,MRK,neutral
851581.0,AstraZeneca and Merck Announce LYNPARZA Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer,2018-05-08 06:47:00-04:00,MRK,negative
851582.0,PreMarket Prep Opening NYSE Imbalance Update: Alibaba 91k Shares To Sell; Merck 51k To Sell; Twitter 129k To Sell,2018-05-04 09:02:00-04:00,MRK,positive
851583.0,Moderna Snd Merck Expand mRNA Cancer Vaccines Collaboration,2018-05-03 18:25:00-04:00,MRK,negative
851584.0,Merck Says Phase 3 KEYNOTE-407 Met A Pre-Specified Secondary Endpoint Related To Overall Response Rate In A Cohort Of Participants At An Interim Analysis,2018-05-03 06:58:00-04:00,MRK,neutral
851585.0,"Apple Results, Fed Decision, Jobs Report In Focus; Merck, Pfizer Reports Mixed",2018-05-01 10:23:00-04:00,MRK,neutral
851586.0,Benzinga Pro's 5 Stocks To Watch Today,2018-05-01 08:24:00-04:00,MRK,neutral
851587.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,MRK,neutral
851588.0,"Merck Raises FY18 EPS Guidance From $4.08-$4.23 to $4.16-$4.28 vs $4.19 Est., Raises Sales From $41.2B-$42.7B to $41.8B-$43.0B vs $41.9B Est.",2018-05-01 06:48:00-04:00,MRK,neutral
851589.0,"Merck Reports Q1 Adj. EPS $1.05 Beats $1.00 Est., Sales $10.04B Misses $10.10B Est.",2018-05-01 06:47:00-04:00,MRK,negative
851590.0,"15 Stocks To Watch For May 1, 2018",2018-05-01 05:02:00-04:00,MRK,neutral
851591.0,"Earnings Scheduled For May 1, 2018",2018-05-01 04:59:00-04:00,MRK,neutral
851592.0,"The Week Ahead: Tesla And Apple Earnings, Dropbox Quiet Period Expires, Fed Rate Decision And More",2018-04-30 12:56:00-04:00,MRK,neutral
851593.0,Upcoming Earnings: Tech Giant Apple Reports After Tuesday's Close,2018-04-30 12:14:00-04:00,MRK,neutral
851594.0,Pharmaceutical Earnings: Pfizer And Merck Are Slated To Report Tuesday Morning,2018-04-30 11:58:00-04:00,MRK,neutral
851595.0,"Busy Week Begins With McDonald's Beating Estimates; Fed Meeting, Jobs Data Loom",2018-04-30 10:07:00-04:00,MRK,negative
851596.0,Merck is Granted Priority Review of its sBLA for KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy,2018-04-30 06:46:00-04:00,MRK,positive
851597.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,MRK,neutral
851598.0,Upcoming Earnings: McDonald's Reports On Monday As It Continues On New Growth Plan,2018-04-27 15:38:00-04:00,MRK,positive
851599.0,"BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position",2018-04-27 15:12:00-04:00,MRK,neutral
851600.0,Earnings Preview: Oil Giants Chevron And ExxonMobil Report Friday Morning,2018-04-26 12:18:00-04:00,MRK,neutral
851601.0,"Merck Reports EMA Validated Type II Variation For Co.'s KEYTRUDA In Combo With Pemetrexed, Platinum Chemotherapy As First-Line Therapy In Metastatic Nonsquamous NSCLC",2018-04-23 16:35:00-04:00,MRK,positive
851602.0,"Keytruda Is Key To The Merck Thesis, Goldman Sachs Says In Upgrade",2018-04-23 10:34:00-04:00,MRK,neutral
851603.0,"Benzinga's Top Upgrades, Downgrades For April 23, 2018",2018-04-23 09:24:00-04:00,MRK,positive
851604.0,Goldman Sachs Upgrades Merck & Co to Buy,2018-04-23 08:24:00-04:00,MRK,neutral
851605.0,AstraZeneca Shares Are Looking Very Weak Right Now,2018-04-20 14:37:00-04:00,MRK,negative
851606.0,"Stock Market Seems Directionless, Volatility Low As Investors Await News",2018-04-19 10:42:00-04:00,MRK,negative
851607.0,"Benzinga's Top Analyst Calls From April 18, 2018",2018-04-18 13:09:00-04:00,MRK,positive
851608.0,"One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings",2018-04-17 14:16:00-04:00,MRK,neutral
851609.0,Stock Market Gets Lift From Earnings As Geopolitical Fears Wane,2018-04-17 10:21:00-04:00,MRK,negative
851610.0,"Benzinga's Top Upgrades, Downgrades For April 17, 2018",2018-04-17 09:24:00-04:00,MRK,positive
851611.0,Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine,2018-04-17 08:30:00-04:00,MRK,neutral
851612.0,Morgan Stanley Upgrades Merck & Co to Overweight,2018-04-17 06:21:00-04:00,MRK,negative
851613.0,Morgan Stanley Upgrades Merck to Overweight from Equal Weight; Raises PT to $68 from $63,2018-04-17 04:25:00-04:00,MRK,negative
851614.0,"Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA, Results Showed 'Encouraging Response Rates'",2018-04-16 14:11:00-04:00,MRK,positive
851615.0,"UPDATE: Merck Says KEYTRUDA Combination Improved Overall Survival in Patients Regardless of PD-L1 Expression, Including Patients Who Tested Negative for PD-L1",2018-04-16 09:31:00-04:00,MRK,negative
851616.0,Merck's KEYTRUDAPlus Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study,2018-04-16 09:31:00-04:00,MRK,negative
851617.0,Merck Sunday Announced Updated Overall Survival Data for LYNPARZAÂ® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at #AACR18,2018-04-16 04:03:00-04:00,MRK,negative
851618.0,"Merck Announces KEYTRUDA Reduced Risk of Disease Recurrence or Death by More than 40% vs Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma",2018-04-15 13:53:00-04:00,MRK,negative
851619.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-13 11:38:00-04:00,MRK,neutral
851620.0,Mylan Shares Quiet Premarket; Co. Looking For Deal For Merck's Consumer Products Unit,2018-04-13 07:51:00-04:00,MRK,positive
851621.0,PreMarket Prep Opening NYSE Imbalance Update: Pfizer 149k Shares To Buy: ExxonMobil 81k Shares To Buy; Merck 50k Shares To Buy; General Electric 114k Shares To Sell; Ford 42k Shares To Buy,2018-04-11 08:59:00-04:00,MRK,positive
851622.0,40 Biggest Movers From Yesterday,2018-04-10 04:21:00-04:00,MRK,neutral
851623.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-09 12:32:00-04:00,MRK,neutral
851624.0,Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial,2018-04-09 10:29:00-04:00,MRK,negative
851625.0,20 Stocks Moving In Monday's Pre-Market Session,2018-04-09 08:06:00-04:00,MRK,neutral
851626.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2018-04-09 07:11:00-04:00,MRK,neutral
851627.0,Merck Reports its KEYTRUDA Monotherapey Met its Primary Endpoint in the Phase 3 KEYNOTE-042 Study,2018-04-09 06:46:00-04:00,MRK,neutral
851628.0,Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial,2018-04-06 08:50:00-04:00,MRK,negative
851629.0,UPDATE: Incyte Shares Down 20.5% After its Phase 3 ECGI-301/KEYNOT-252 Study With Merck Did Not Meet the Primary Endpoint,2018-04-06 08:01:00-04:00,MRK,positive
851630.0,'The first real test of the cancer immunotherapy combination thesis fails. $INCY $MRK' -Adam Feuerstein Tweet,2018-04-06 07:31:00-04:00,MRK,negative
851631.0,Incyte and Merck Says Phase 3 ECHO-301/KEYNOTE-252 Study Did Not Meet The Primary Endpoint Of Improving Progression-Free Survival,2018-04-06 07:31:00-04:00,MRK,positive
851632.0,Merck Spokesperson Tells Benzinga FDA Postponed PDUFA Date On sBLA For Keytruda In Mediastinal B-Cell Lymphoma To July 3rd After Co. Submitted Add'l Data; PDUFA Decision Was Originally Scheduled For April 3rd,2018-04-05 17:57:00-04:00,MRK,negative
851633.0,"Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO Business",2018-04-05 09:28:00-04:00,MRK,negative
851634.0,"Benzinga's Top Upgrades, Downgrades For April 5, 2018",2018-04-05 09:23:00-04:00,MRK,positive
851635.0,Barclays Upgrades Merck & Co to Overweight,2018-04-05 06:40:00-04:00,MRK,negative
851636.0,"Stocks That Made New 52-Wk Lows Today Include: Incyte, Merck, Mallinckrodt, Celgene, Cerner, Willams Cos., AMD, Albemarle, Kinder Morgan, Western Union, Walgreens, Kraft Heinz, Nielsen, and Alliance Data Systems",2018-04-03 12:15:00-04:00,MRK,positive
851637.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,MRK,neutral
851638.0,REMINDER: Merck Has FDA PDUFA Date Today For Keytruda sBLA in Primary Mediastinal Large B-Cell Lymphoma,2018-04-03 07:10:00-04:00,MRK,neutral
851639.0,"AstraZeneca, Merck Announces EMA Accepts Regulatory Submission for LYNPARZA in BRCA-Mutated HER2-Negative Metastatic Breast Cancer",2018-04-03 06:06:00-04:00,MRK,negative
851640.0,"The Week Ahead: Switch's Lockup Expires, Spotify Debuts, And More",2018-04-02 15:35:00-04:00,MRK,neutral
851641.0,What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy,2018-04-02 12:18:00-04:00,MRK,negative
851642.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences",2018-03-30 09:46:00-04:00,MRK,neutral
851643.0,Merck Reports Received Fast-Track Designation For Tepotinib In NSLCL In Japan,2018-03-27 08:41:00-04:00,MRK,neutral
851644.0,"Stocks That Made New 52-Wk Lows Today Include: Charter Comms., Vornado Realty, Colgate-Palmolive, Merck, Hasbro, Ventas, Dentsply Sirona, Johnson Controls, Goodyear Tire, Clorox, GE, Kinder Morgan, Comcast, DISH Network, Stericycle and Patterson Cos.",2018-03-26 12:01:00-04:00,MRK,positive
851645.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-26 07:48:00-04:00,MRK,neutral
851646.0,"Merck Announces Anticancer Agent Lenvima Approved for Additional Indication of Unresectable HCC in Japan,",2018-03-23 06:04:00-04:00,MRK,positive
851647.0,Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season,2018-03-20 11:29:00-04:00,MRK,neutral
851648.0,"Jim Cramer Shares His Thoughts On Merck, Five Below And More",2018-03-15 07:21:00-04:00,MRK,positive
851649.0,Merck's Supplemental Biologics License Application for KEYTRUDA Granted Priority Review by the FDA for Treatment of Advanced Cervical Cancer,2018-03-13 07:04:00-04:00,MRK,negative
851650.0,"The Market In 5 Minutes: Coincheck, Gun Violence, Oil And More",2018-03-12 09:03:00-04:00,MRK,negative
851651.0,Immutep Announces Clinical Trial Collaboration and Supply Agreement With Merck to Evaluate Combination of IMP321 with Keytruda,2018-03-11 19:41:00-04:00,MRK,positive
851652.0,'Pharma Bro' Martin Shkreli Gets 7 Years In Prison For Securities Fraud,2018-03-09 14:10:00-05:00,MRK,negative
851653.0,"Eisai, Merck Report Global Strategic Oncology Collaboration For LENVIMA, Will Jointly Develop, Commercialize",2018-03-07 17:07:00-05:00,MRK,neutral
851654.0,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts,2018-03-07 11:31:00-05:00,MRK,neutral
851655.0,7 Biotech Stocks With Clinical Trial Outcomes In March,2018-03-05 12:01:00-05:00,MRK,neutral
851656.0,"Pharma Stock Roundup: AstraZeneca, Merck, AbbVie And More",2018-02-23 11:26:00-05:00,MRK,neutral
851657.0,"Merck, AstraZeneca Reports LYNPARZA Received Positive EU CHMP Opinion In Platinum-Sensitive Relapsed Ovarian Cancer",2018-02-23 07:30:00-05:00,MRK,negative
851658.0,Merck to Acquire Viralytics for ~$394M,2018-02-21 04:10:00-05:00,MRK,neutral
851659.0,"Gilead, Merck Quiet As Traders Circulate Reuters Article From Feb. 17th Titled 'Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict'",2018-02-20 10:23:00-05:00,MRK,positive
851660.0,"Merck Reports Co., AstraZeneca Won Orphan Drug Designation By FDA For Selumetinib For Treatment Of NF1",2018-02-15 06:38:00-05:00,MRK,positive
851661.0,AstraZeneca Says Selumetinib Granted Orphan Drug Designation by FDA for Neurofibromatosis Type 1,2018-02-15 03:59:00-05:00,MRK,positive
851662.0,Cramer Looks At The Dow's Biggest Losers,2018-02-14 10:31:00-05:00,MRK,negative
851663.0,"BMO Capital Maintains Outperform on Merck & Co, Lowers price target to $65.00",2018-02-14 09:26:00-05:00,MRK,negative
851664.0,"Credit Suisse Maintains Outperform on Merck & Co, Lowers price target to $65.00",2018-02-14 07:39:00-05:00,MRK,positive
851665.0,"Merck Discontinues Alzheimer's MK-8931 Study, Unlikely That Positive Benefit/Risk Could Be Established",2018-02-13 16:30:00-05:00,MRK,positive
851666.0,DZ Bank Upgrades Merck & Co to Buy,2018-02-13 08:25:00-05:00,MRK,neutral
851667.0,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,2018-02-08 09:41:00-05:00,MRK,negative
851668.0,"Leerink Swann Maintains Market Perform on Merck & Co, Lowers Price Target to $67.00",2018-02-06 09:08:00-05:00,MRK,negative
851669.0,"Merck Sees FY18 Adj. EPS $4.08-$4.23 vs $4.11 Est., Sales $41.2B-$42.7B vs $41.1B Est.",2018-02-02 06:45:00-05:00,MRK,neutral
851670.0,"Merck Reports Q4 Adj. EPS $0.98 vs $0.94 Est., Sales $10.4B vs $10.49B Est.",2018-02-02 06:45:00-05:00,MRK,neutral
851671.0,"12 Stocks To Watch For February 2, 2018",2018-02-02 04:35:00-05:00,MRK,neutral
851672.0,"Earnings Scheduled For February 2, 2018",2018-02-02 04:10:00-05:00,MRK,neutral
851673.0,Hang On: Rate Fears In Focus As Futures Point Lower After Monday's Big Losses,2018-01-30 10:47:00-05:00,MRK,negative
851674.0,"The Week Ahead: Big Tech Earnings, Fed Rate Decision Likely To Dominate Headlines",2018-01-29 14:45:00-05:00,MRK,negative
851675.0,"PFE, LLY, MRK Write Up 'Scripts For Q4",2018-01-29 10:52:00-05:00,MRK,neutral
851676.0,"Fed, Earnings Are Meaty Filling Between Slices Of Job, Price Data",2018-01-29 09:55:00-05:00,MRK,neutral
851677.0,Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?,2018-01-23 10:58:00-05:00,MRK,positive
851678.0,Will Johnson & Johnson's Pharma Segment Pull Up Its Q4 Earnings?,2018-01-19 12:48:00-05:00,MRK,neutral
851679.0,"Merck Reports First-Time Data For KEYTRUDA In Patients With Previously-Treated Advanced HCC: 'showed an overall response rate (ORR) of 16.3 percent (95% CI, 9.8-24.9) (n=17/104) with KEYTRUDA as monotherapy'",2018-01-19 06:45:00-05:00,MRK,positive
851680.0,Merck Reports LYNPARZA For Treatment Of Advanced Ovarian Cancer Received Approval In Japan,2018-01-19 06:30:00-05:00,MRK,negative
851681.0,Watching Shares Of AstraZeneca and Merck As White House Doctor Says Pres. Trump Takes Crestor For Cholesterol and Propecia For Hair Loss,2018-01-16 15:44:00-05:00,MRK,neutral
851682.0,Early Keytruda Results Win Merck An Upgrade,2018-01-16 13:19:00-05:00,MRK,positive
851683.0,Merck Shares Up 5.8% On Earlier News That Phase 3 KEYNOTE-189 Trial Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival,2018-01-16 09:50:00-05:00,MRK,positive
851684.0,SunTrust Robinson Humphrey Upgrades Merck & Co to Buy,2018-01-16 09:49:00-05:00,MRK,neutral
851685.0,"FDA Approves AstraZeneca and Merck's Lynparza, For Breast Cancer With A Certain Inherited Genetic Mutation",2018-01-12 09:42:00-05:00,MRK,negative
851686.0,A Strategy That Beat The S&P 500: Here Are Your 2018 'Dogs Of The Dow',2018-01-11 17:14:00-05:00,MRK,neutral
851687.0,Key Takeaways From The J.P. Morgan Healthcare Conference,2018-01-11 12:06:00-05:00,MRK,neutral
851688.0,Merck Announces Breakthrough Designation from the FDA for LENVIMA and KEYTRUDA as Combination Therapy for Renal Cell Carcinoma,2018-01-09 06:46:00-05:00,MRK,neutral
851689.0,Alzheimer's Takes Another Hit As Pfizer Ends Research In The Area,2018-01-08 12:22:00-05:00,MRK,neutral
851690.0,Merck's KEYTRUDA  Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma,2018-01-08 06:46:00-05:00,MRK,positive
851691.0,Merck Announces FDA Accepts NDA For Doravirine,2018-01-08 06:32:00-05:00,MRK,positive
851692.0,"Lower Jobs Growth in December, But Some Positive Signs For Economy",2018-01-05 11:46:00-05:00,MRK,positive
851693.0,4 Reasons To Consider Adding Celldex To Your Portfolio,2018-01-02 12:09:00-05:00,MRK,neutral
851694.0,Merck's KEYTRUDA Approved in Japan for Use in the Treatment of Patients with Urothelial Carcinoma,2018-01-02 07:01:00-05:00,MRK,positive
851695.0,"Merck Shares Down 0.12%, Pfizer Shares Up 0.11%; Earlier Companies Together Announced FDA Approvla For Their Collaboration Treatment STEGLATRO, STEGLUJAN and SEGLUROMET",2017-12-26 15:48:00-05:00,MRK,positive
851696.0,Merck's Diabetes Drugs Get FDA Nod As Adjunct Therapies,2017-12-26 12:45:00-05:00,MRK,neutral
851697.0,FDA Approves Merck's SGLT2 Inhibitor STEGLATRO and Fixed-Dose Combination STEGLUJAN for Adults with Type 2 Diabetes,2017-12-22 07:00:00-05:00,MRK,positive
851698.0,Merck Reports FDA Granted Breakthrough Therapy Designation For Avelumab In Combo With INLYTA In Advanced Renal Cell Carcinoma,2017-12-21 13:01:00-05:00,MRK,positive
851699.0,3 Biotech Pipeline Areas To Keep An Eye On In 2018,2017-12-20 12:37:00-05:00,MRK,neutral
851700.0,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More",2017-12-15 07:33:00-05:00,MRK,positive
851701.0,UPDATE: Merck Says Progression Free Survival Did Not Show Statistical Significance In PD-L1 Positive Population,2017-12-14 16:49:00-05:00,MRK,positive
851702.0,Merck Announces KEYTRUDA Did NOT Meet Primary Endpoint In Phase 3 KEYNOTE-061 Study,2017-12-14 16:45:00-05:00,MRK,neutral
851703.0,Merck Says PREVYMIS Expected To Be Available In Canada By Year-End,2017-12-14 13:22:00-05:00,MRK,neutral
851704.0,Merck's Keytruda Gets FDA Priority Review For Rare Lymphoma,2017-12-13 12:34:00-05:00,MRK,neutral
851705.0,PreMarket Opening NYSE Imbalance Update: AT&T 168k Shares To Sell; Nike 54k Shares To Sell; Square 33k To Buy; Disney 41k To Buy; US Steel 53k Shares To Sell; Pfizer 50k Shares To Sell; Merck 28k Shares To Buy;,2017-12-13 09:06:00-05:00,MRK,positive
851706.0,3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise,2017-12-11 12:52:00-05:00,MRK,positive
851707.0,"Merck Reports FDA Accepted sBLA, Assigned Priority Review For KEYTRUDA For Treatment Of Relapsed, Refractory PMBCL",2017-12-11 06:30:00-05:00,MRK,positive
851708.0,Loncar Investment's Brad Loncar Tweets: Roche is trading slightly down in Europe and $MRK seems not to be doing anything in this early pre-market hour. IMpower150 basically in line with high expectations.,2017-12-07 07:19:00-05:00,MRK,neutral
851709.0,Merck Announces Publication Of Phase 3 PREVYMIS Study Results In NE Journal Of Medicine,2017-12-06 17:02:00-05:00,MRK,neutral
851710.0,FDA Decisions In November: The Month In Review,2017-12-01 14:05:00-05:00,MRK,neutral
851711.0,Merck Raises Qtr. Dividend From $0.47 To $0.48/Share,2017-11-28 14:33:00-05:00,MRK,neutral
851712.0,Merck Reports $10B Buyback Plan,2017-11-28 14:33:00-05:00,MRK,neutral
851713.0,"Bank of America Reinstates Buy on Merck & Co, Announces $64.00",2017-11-28 09:14:00-05:00,MRK,neutral
851714.0,"Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement; Peregrine Board Reconstituted with Four New Independent Directors",2017-11-28 08:05:00-05:00,MRK,positive
851715.0,"UPDATE: Merck, Pfizer On JAVELIN Trial Of Avelumab, Say, 'Safety profile was consistent with that observed in previously reported studies of avelumab; no new safety signals were identified'",2017-11-28 08:04:00-05:00,MRK,positive
851716.0,"UPDATE: Merck, Pfizer Says Phase III JAVELIN Study Investigating Avelumab 'did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy'",2017-11-28 08:04:00-05:00,MRK,positive
851717.0,"Merck, Pfizer Offer Update Related To Phase III JAVELIN Gastric 300 Study In Patients With Pre-Treated Advanced Gastric Cancer",2017-11-28 08:03:00-05:00,MRK,negative
851718.0,5 Biggest Price Target Changes For Friday,2017-11-24 10:00:00-05:00,MRK,neutral
851719.0,"Merck Will Miss a Promised Deadline for Filing an Ebola Vaccine License with the FDA, According to STAT News",2017-11-17 15:28:00-05:00,MRK,positive
851720.0,"Cue Biopharma Reports Strategic Research Collab, License Deal With Merck; Terms Not Disclosed, However cue Will Receive Up-Front Payment, Co. Eligible To Earn Up To $374M Milestone Payments In Addition To Tiered Royalities",2017-11-16 08:13:00-05:00,MRK,neutral
851721.0,13G Filing Shows Merck Reporting 6.5% Stake In Spero Therapeutics,2017-11-15 16:54:00-05:00,MRK,neutral
851722.0,Merck Revisits Low Of Move And Rebounds,2017-11-15 13:22:00-05:00,MRK,negative
851723.0,Merck Receives a Positive CHMP Opinion for PREVYMIS in the European Union,2017-11-13 08:00:00-05:00,MRK,positive
851724.0,Pharma ETFs Down Post Q3 Earnings,2017-11-09 12:34:00-05:00,MRK,neutral
851725.0,"Merck Reports Received FDA Approval For PREVYMIS For Prevention Of CMV Infection, Disease In Adult Allogeneic Stem Cell Transplant Patients",2017-11-09 06:46:00-05:00,MRK,positive
851726.0,"Pharma Stock Roundup: Pfizer, Teva, Novartis, And More",2017-11-06 12:19:00-05:00,MRK,neutral
851727.0,"Pre-Market Imbalance Update: Alibaba 278K Shares To Buy, BofA 111K Shares To Sell, Merck 85K To Buy, GE 8.5K To Buy",2017-11-02 09:04:00-04:00,MRK,positive
851728.0,"Benzinga's Top Upgrades, Downgrades For October 31, 2017",2017-10-31 09:25:00-04:00,MRK,positive
851729.0,"The Market In 5 Minutes: A Halloween Scare For Under Armour, Qualcomm And Other Big Tech Names",2017-10-31 09:02:00-04:00,MRK,negative
851730.0,"A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Mastercard, Kellogg Earnings",2017-10-31 07:14:00-04:00,MRK,neutral
851731.0,Jefferies Upgrades Merck & Co to Hold,2017-10-31 06:50:00-04:00,MRK,neutral
851732.0,40 Biggest Movers From Yesterday,2017-10-31 04:54:00-04:00,MRK,neutral
851733.0,35 Stocks Moving In Monday's Mid-Day Session,2017-10-30 12:30:00-04:00,MRK,neutral
851734.0,The Bull Thesis For Merck Is Evaporating,2017-10-30 11:14:00-04:00,MRK,neutral
851735.0,Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application,2017-10-30 10:08:00-04:00,MRK,negative
851736.0,8 Technical Levels Highlighted On Monday's PreMarket Prep,2017-10-30 09:59:00-04:00,MRK,neutral
851737.0,5 Biggest Price Target Changes For Monday,2017-10-30 09:45:00-04:00,MRK,neutral
851738.0,"Benzinga's Top Upgrades, Downgrades For October 30, 2017",2017-10-30 09:22:00-04:00,MRK,positive
851739.0,Barclays Downgrades Merck & Co to Equal-Weight,2017-10-30 08:17:00-04:00,MRK,neutral
851740.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-30 08:05:00-04:00,MRK,neutral
851741.0,SunTrust Robinson Humphrey Downgrades Merck & Co to Hold,2017-10-30 07:15:00-04:00,MRK,neutral
851742.0,Morgan Stanley Downgrades Merck & Co to Equal-Weight,2017-10-30 06:40:00-04:00,MRK,neutral
851743.0,"8 Stocks To Watch For October 30, 2017",2017-10-30 04:59:00-04:00,MRK,neutral
851744.0,Merck Announces It Has Withdawn KEYTRUDA European Application,2017-10-27 16:19:00-04:00,MRK,neutral
851745.0,"A Peek Into The Markets: U.S. Stock Futures Climb After Amazon, Alphabet Results",2017-10-27 07:04:00-04:00,MRK,positive
851746.0,Merck Raises FY17 Sales Guidance From $39.4B-$40.4B As Of Jul. 28 To $40B-$40.5B vs $40.3B Est.,2017-10-27 06:47:00-04:00,MRK,neutral
851747.0,Merck Raises FY17 Adj. EPS Outlook From $3.76-$3.88 As Of Jul. 28 To $3.91-$3.97 vs $3.87 Est.,2017-10-27 06:46:00-04:00,MRK,neutral
851748.0,"Merck Reports Q3 Adj. EPS $1.11 vs $1.03 Est., Sales $10.3B vs $10.55B Est.",2017-10-27 06:45:00-04:00,MRK,neutral
851749.0,"12 Stocks To Watch For October 27, 2017",2017-10-27 04:36:00-04:00,MRK,neutral
851750.0,"Earnings Scheduled For October 27, 2017",2017-10-27 04:14:00-04:00,MRK,neutral
851751.0,Healthcare ETFs Set To Soar As Q3 Earnings Unfold,2017-10-24 12:35:00-04:00,MRK,neutral
851752.0,The Week Ahead: Earnings Season Starts In Earnest,2017-10-23 09:00:00-04:00,MRK,positive
851753.0,8 Firms To Debut On The Markets This Week,2017-10-23 08:55:00-04:00,MRK,neutral
851754.0,"AstraZeneca, Merck Rapidly Advance LYNPARZA in Japan With a NDA To Japan's Pharmaceuticals and Medical Devices Agency",2017-10-23 06:58:00-04:00,MRK,neutral
851755.0,A Preview Of Next Week's Blue-Chip Earnings,2017-10-22 19:44:00-04:00,MRK,neutral
851756.0,"Fierce Pharma Reports Merck Lays Off 1,800 U.S. Sales Reps To Overhaul Primary Care Marketing",2017-10-20 11:35:00-04:00,MRK,positive
851757.0,OncoSec Shares Spike 17% After New Data Defended,2017-10-19 14:38:00-04:00,MRK,positive
851758.0,White House 'Shenanigans' Represent A Buying Opportunity: Cramer,2017-10-19 12:02:00-04:00,MRK,positive
851759.0,"Benzinga's Top Upgrades, Downgrades For October 18, 2017",2017-10-18 09:28:00-04:00,MRK,positive
851760.0,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever",2017-10-18 09:07:00-04:00,MRK,positive
851761.0,"Merck Reports FDA Accepted Regulatory Submission For LYNPARZA In Metastatic Breast Cancer, Grants Priority Review",2017-10-18 06:55:00-04:00,MRK,negative
851762.0,UPDATE: Merck Highlights KEYTRUDA Data 'Showed Median Overall Survival of 30.0 Months for KEYTRUDA Group Compared to 14.2 Months for Chemotherapy Group',2017-10-18 06:47:00-04:00,MRK,neutral
851763.0,Merck Reports KEYTRUDA More Than Doubled Median Overall Survival Compared to Chemotherapy After 2 Years of Follow Up in First-Line Treatment of Patients with Metastatic NSCLC with High Levels of PD-L1,2017-10-18 06:47:00-04:00,MRK,neutral
851764.0,Citigroup Upgrades Merck & Co to Buy,2017-10-18 06:24:00-04:00,MRK,neutral
851765.0,Merck Reports 9.9% Passive Stake in KalVista Pharmaceuticals -13G,2017-10-16 19:25:00-04:00,MRK,positive
851766.0,Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea's AEB1102 (pegzilarginase) with Merck's KEYTRUDA (pembrolizumab) for the Treatment of Small Cell Lung Cancer,2017-10-16 08:10:00-04:00,MRK,negative
851767.0,"Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback",2017-10-13 12:19:00-04:00,MRK,neutral
851768.0,Bank Of America Sees NewLink Genetics As 'Undervalued',2017-10-13 09:58:00-04:00,MRK,neutral
851769.0,UPDATE: Merck Says Co. Will Not Submit Apps For Regulatory Approval For Anacetrapib,2017-10-11 16:45:00-04:00,MRK,positive
851770.0,Merck Offers Update On Anacetrapid Development Program,2017-10-11 16:45:00-04:00,MRK,neutral
851771.0,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 12:52:00-04:00,MRK,positive
851772.0,Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result,2017-10-09 15:56:00-04:00,MRK,positive
851773.0,"Pre-Market Imbalance Update: GE Shares 198K To Buy, Macy's 75K To Buy, Pfizer 71K To Sell, Merck 56K To Buy, Citi 50K To Buy, P&G 40K To Buy, ExxonMobil 38K To Sell, Barrick Gold 30K To Buy, BofA 28K To Buy, Chevron 25K To Sell, JP Morgan 10K To Buy",2017-10-09 09:14:00-04:00,MRK,positive
851774.0,Heaps Of Healthy Health Care ETFs,2017-10-06 10:02:00-04:00,MRK,positive
851775.0,"Galena Biopharma Shares Up 10.6% Following Earlier SEC Filing Showing SELLAS Life Sciences Entered Collab., Supply Deal With Merck For Initiation Of Phase 1/2 Trial With Galinpepimut-S, KEYTRUDA",2017-10-02 10:33:00-04:00,MRK,positive
851776.0,"Merck To Offer New, Updated Data On KEYTRUDA At World Conference On Lung Cancer, No Further Details Given",2017-09-29 07:00:00-04:00,MRK,negative
851777.0,"Merck Reports Discontinuation Of MK-3682B, MK-3682C Development Programs",2017-09-29 06:59:00-04:00,MRK,neutral
851778.0,Cramer's Guide To Profit From Market Rotations,2017-09-23 08:56:00-04:00,MRK,positive
851779.0,Agilent Technologies Receives FDA Approval For Use Of Dako PD-L1 For Treatment With Merck's KEYTRUDA In Gastric or Gastroesophageal Junction Cancer,2017-09-22 16:32:00-04:00,MRK,negative
851780.0,REMINDER: Merck's KEYTRUDA In Gastric Or Gastroesophageal Cancer Indication Has PDUFA Date Today,2017-09-22 08:53:00-04:00,MRK,negative
851781.0,Merck and Pfizer Get European Commission Approval for Bavencio,2017-09-21 06:25:00-04:00,MRK,positive
851782.0,This Analyst Predicts Bullish Growth Outlook For Incyte,2017-09-12 09:28:00-04:00,MRK,positive
851783.0,"Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers",2017-09-11 09:15:00-04:00,MRK,neutral
851784.0,Merck Reports Findings From Phase 3 Study OF KEYTRUDA vs Standard Of Care In Patients With Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,2017-09-11 09:00:00-04:00,MRK,positive
851785.0,What Pharmaceuticals Spend On Lobbying To Influence Trump,2017-09-09 16:28:00-04:00,MRK,negative
851786.0,"Incyte, Merck Announce Positive Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with KEYTRUDA in Patients with Advanced Melanoma at ESMO 2017",2017-09-09 10:41:00-04:00,MRK,positive
851787.0,"Merck Reports KEYTRUDA Plus Pemetrexed, Carboplatin Showed Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC",2017-09-08 10:34:00-04:00,MRK,positive
851788.0,"European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5",2017-09-08 09:15:00-04:00,MRK,neutral
851789.0,Merck Reports Updated Data For KEYTRUDA In Patients With Advanced Gastric Cancer Across Treatment Settings,2017-09-08 08:02:00-04:00,MRK,negative
851790.0,"Wall Street's M&A Chatter From September 6: Cabelas, Merck-Rigontec, Altice-Charter, Amazon-Kohl's",2017-09-07 07:19:00-04:00,MRK,neutral
851791.0,"Merck Announces Acquisition of Rigontec for EUR 115M Cash, May Make up to EUR 349M of Additional Payments",2017-09-06 06:32:00-04:00,MRK,neutral
851792.0,Eisai Signs Agreement with Merck to Expand Enrollment of Combination Study for Lenvima  and Pembrolizumab in Endometrial Carcinoma,2017-09-06 06:04:00-04:00,MRK,positive
851793.0,Merck's KEYTRUDA Approved by the European Commission for a Type of Bladder Cancer,2017-09-05 06:31:00-04:00,MRK,negative
851794.0,"Merck Shares Down 0.5% Over Last Few Mins., Remain Up ~0.1% For Session",2017-08-31 10:53:00-04:00,MRK,positive
851795.0,"Merck Shares Move To Session Lows, Up 0.4% For Session, As Traders Circulating FDA.gov Alert 'FDA Alerts Healthcare Professionals and Oncology Clinical Investigators about Two Clinical Trials on Hold Evaluating KEYTRUDAÂ® in Patients w/ MM'",2017-08-31 10:52:00-04:00,MRK,positive
851796.0,Born On The Battlefield: AcelRx Awaits FDA Ruling On Device That Delivers Potent Opioid To Wounded Soldiers,2017-08-30 12:07:00-04:00,MRK,negative
851797.0,"Merck Announces Presentation of Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease",2017-08-29 04:04:00-04:00,MRK,neutral
851798.0,"Jon Najarian Sees Unusual Options Activity In Marathon Petroleum, Caesars And Merck",2017-08-25 07:07:00-04:00,MRK,neutral
851799.0,"Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva",2017-08-24 13:46:00-04:00,MRK,positive
851800.0,"AstraZeneca, Merck Issue Release Confirming Added, Broad Approval Of LYNPARZA In US For Ovarian Cancer",2017-08-17 15:36:00-04:00,MRK,negative
851801.0,"You Can't Quit, Because You're Fired! Trump Disbands Manufacturing Council, Policy Forum",2017-08-16 13:36:00-04:00,MRK,negative
851802.0,Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive',2017-08-16 11:59:00-04:00,MRK,neutral
851803.0,"Martin Shkreli Calls Merck CEO Ken Frazier 'Self-Indulgent,' 'Pathetic'",2017-08-15 11:49:00-04:00,MRK,neutral
851804.0,The Market In 5 Minutes,2017-08-15 08:34:00-04:00,MRK,neutral
851805.0,Merck Higher Despite Trump Bashing,2017-08-14 11:43:00-04:00,MRK,neutral
851806.0,Doug Kass Tweets: I am buying $MRK just on principle.  @maddow @MSNBC @carlquintanilla @jimcramer @tomkeene @andrewrsorkin @BeckyQuick,2017-08-14 11:31:00-04:00,MRK,neutral
851807.0,Merck CEO Quits Manufacturing Council To Stand Against Violence; Trump Promptly Calls Him Out About Drug Pricing,2017-08-14 09:58:00-04:00,MRK,negative
851808.0,"Donald Trump Tweets: Now that Ken Frazier of Merck Pharma has resigned from President's Manufacturing Council,he will have more time to LOWER RIPOFF DRUG PRICES!",2017-08-14 08:55:00-04:00,MRK,negative
851809.0,CNBC Now Tweets: JUST IN: Merck CEO resigns from Trump's manufacturing council amid fallout from the President's comments.,2017-08-14 08:51:00-04:00,MRK,negative
851810.0,Merck 10-Q Just Out,2017-08-08 16:49:00-04:00,MRK,neutral
851811.0,Nice Recommends Erbitux In Combination With Platinum-Based Chemotherapy For The Treatment Of Recurrent And/Or Metastatic Head And Neck Cancer In The Oral Cavity,2017-08-08 05:59:00-04:00,MRK,negative
851812.0,"Merck Animal Health to Acquire Austrian Manufacturing Facility, Terms Not Disclosed",2017-08-07 07:11:00-04:00,MRK,neutral
851813.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,MRK,neutral
851814.0,Merck To Collaborate With Generex Biotech For KEYTRUDA In Combination With AE37 Study,2017-07-31 10:01:00-04:00,MRK,neutral
851815.0,A Peek Into The Markets: U.S. Stock Futures Down; Amazon Earnings Miss Views,2017-07-28 07:38:00-04:00,MRK,neutral
851816.0,Merck Raises FY17 Sales Outlook From Feb. 2 Indication Of $38.6B-$40.1B To $39.4B-$40.4B vs $40.1B Est.,2017-07-28 06:49:00-04:00,MRK,neutral
851817.0,UPDATE: Merck Raises FY17 Adj. EPS Outlook From $3.72-$3.87 To $3.76-$3.88 vs $3.85 Est.,2017-07-28 06:46:00-04:00,MRK,neutral
851818.0,Merck Raises FY17 Adj. EPS Outlook,2017-07-28 06:46:00-04:00,MRK,neutral
851819.0,"Merck Reports Q2 Adj. EPS $1.01 vs $0.87 Est., Sales $9.93B vs $9.75B Est.",2017-07-28 06:45:00-04:00,MRK,neutral
851820.0,"10 Stocks To Watch For July 28, 2017",2017-07-28 04:35:00-04:00,MRK,neutral
851821.0,"Earnings Scheduled For July 28, 2017",2017-07-28 04:17:00-04:00,MRK,neutral
851822.0,Merck Shares Up 3.3% After Announcing Oncology Collaboration With AstraZeneca,2017-07-27 09:45:00-04:00,MRK,positive
851823.0,Why Is AstraZeneca Sinking Today?,2017-07-27 09:18:00-04:00,MRK,neutral
851824.0,"Samsung, Amazon â€” Everyone Is Getting Into Pharmaceuticals",2017-07-27 08:36:00-04:00,MRK,positive
851825.0,"AstraZeneca, Merck Announce Strategic Oncology Collaboration; Merck to pay AstraZeneca up to $8.5B in Total Consideration",2017-07-27 03:41:00-04:00,MRK,negative
851826.0,UPDATE: Merck Plans to Submit New Drug Applications with the U.S. FDA in Q4 2017 For Doravirine,2017-07-25 08:37:00-04:00,MRK,neutral
851827.0,"Merck's Doravirine Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection",2017-07-25 08:35:00-04:00,MRK,neutral
851828.0,UPDATE: Merck Reports No Safety Signals Identified In Phase 3 KEYTRUDA Study,2017-07-24 17:01:00-04:00,MRK,positive
851829.0,"Merck Reports Update On Phase 3 KEYTRUDA Study, Did Not Meet Primary Endpoint",2017-07-24 17:00:00-04:00,MRK,neutral
851830.0,What You Need To Know About Dow Components Reporting This Week,2017-07-24 16:08:00-04:00,MRK,neutral
851831.0,Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers,2017-07-24 15:29:00-04:00,MRK,neutral
851832.0,"Merck Gives Results from ONCEMRK, A Study of ISENTRESS HD",2017-07-24 07:10:00-04:00,MRK,neutral
851833.0,Merck Reports EMA CHMP Recommended Approval For Co.'s KEYTRUDA For Treatment Of Certain Patients With Locally-Advanced Or Metastatic Urothelial Carcinoma,2017-07-21 07:32:00-04:00,MRK,positive
851834.0,Merck and Pfizer's Avelumab Recommended for Approval by the EU Medicines Agency,2017-07-21 07:20:00-04:00,MRK,positive
851835.0,Hearing Merck Has Said Corning Will Make Initial $500M Investment Related To Modernization Of Pharmaceutical Glass Packaging,2017-07-20 15:21:00-04:00,MRK,neutral
851836.0,"Trump Says Merck, Pfizer And Corning Announce That Glass Packaging Will Be Made In America",2017-07-20 15:07:00-04:00,MRK,neutral
851837.0,Merck Reports FDA Granted Tentative Approvaal For LUSDUNA Nexvue,2017-07-20 07:30:00-04:00,MRK,positive
851838.0,5 Biggest Price Target Changes For Monday,2017-07-17 10:10:00-04:00,MRK,neutral
851839.0,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher",2017-07-13 14:43:00-04:00,MRK,positive
851840.0,J&J To Commence Pharma Q2 Earnings Season: What's Up?,2017-07-12 14:44:00-04:00,MRK,neutral
851841.0,The Royalty-Amassing Strategy Of Royalty Pharma,2017-07-10 16:11:00-04:00,MRK,neutral
851842.0,Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies,2017-07-06 15:09:00-04:00,MRK,neutral
851843.0,Merck to Present New Data from Clinical Trials Evaluating ISENTRESS HD and Investigational HIV Therapies Doravirine and MK-8591 at IAS 2017,2017-07-06 07:01:00-04:00,MRK,neutral
851844.0,"Merck Announces FDA Placed Clinical Hold On KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023 Following Review Of Data By Data Monitoring Committee; FDA Has Determined Risk Of KEYTRUDA In Compination With Pomalidomide Of Lenalidomide Outweigh Potential Benefits",2017-07-05 16:37:00-04:00,MRK,positive
851845.0,"Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks",2017-07-05 12:17:00-04:00,MRK,negative
851846.0,Watch These 5 Huge Put Purchases In Monday Trade,2017-07-03 04:24:00-04:00,MRK,positive
851847.0,Benzinga's Option Alert Recap From June 30,2017-06-30 16:10:00-04:00,MRK,positive
851848.0,Aduro Biotech Initiates Phase 2 Clinical Trial Of CRS-207 In Combination With KEYTRUDA,2017-06-29 16:13:00-04:00,MRK,neutral
851849.0,Russia In The Spotlight As Second Wave Of Ransomware Grips Globe,2017-06-28 15:39:00-04:00,MRK,neutral
851852.0,Ransomware Rears Its Head Again As 150 Countries Hit By New Virus,2017-06-27 14:31:00-04:00,MRK,neutral
851853.0,Hearing Merck Has Confirmed Co.'s Computer Network Was Compromised,2017-06-27 11:17:00-04:00,MRK,neutral
851854.0,"Merck Announces REVEAL Met its Primary Endpoint, Says Will Consult With External Experts and Consider Whether to File NDA",2017-06-27 06:56:00-04:00,MRK,neutral
851855.0,Ablynx Achieves â‚¬2.5M Milestone Iin Immuno-oncology Collaboration With Merck,2017-06-27 04:38:00-04:00,MRK,neutral
851856.0,"A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside",2017-06-26 14:03:00-04:00,MRK,positive
851860.0,"Merck, Premier Report Expanded Collaboration To Address Chronic Care, Vaccination Rates",2017-06-22 08:49:00-04:00,MRK,positive
851863.0,Leap Therapeutics Reports Collab With Merck For Evaluation Of KEYTRUDA In Combo With DKN-01 In Esophagogastric Cancer,2017-06-21 09:09:00-04:00,MRK,negative
851864.0,Merck Subsidiary Announces Collaboration With Serimmune,2017-06-20 13:04:00-04:00,MRK,neutral
851866.0,Merck Receives FDA Orphan Designation for Keytruda in Treatment of Esophageal Carcinoma,2017-06-18 21:56:00-04:00,MRK,neutral
851868.0,Cerveau Technologies Reports FDA Accepted IND For MK-6240; BZ NOTE: Merck Is A Development Partner For The Candidate,2017-06-16 08:18:00-04:00,MRK,positive
851869.0,Merck Reports Expansion Of Distribution Deal With Public Health England,2017-06-15 08:02:00-04:00,MRK,neutral
851872.0,"Merck Reports Update On Multiple Myeloma Studies KEYNOTE-183, 185 Of KEYTRUDA In Combo With Other Therapies: Has Accepted External Data Monitoring Committee Recommendation To Pause New Enrollment",2017-06-12 16:17:00-04:00,MRK,positive
851873.0,"Pre-Market Imbalance Update: Pfizer 74K Shares To Sell, Citi 61K To Sell, JP Morgan 35K Shares To Buy, Merck 33K To Buy",2017-06-12 08:52:00-04:00,MRK,positive
851874.0,"Merck, Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies at #2017ADA",2017-06-11 11:52:00-04:00,MRK,negative
851876.0,Dynavax +21% Premarket @$7.15; Co on Friday Presented Updated Data for SD-101 in Combination with KEYTRUDA,2017-06-05 07:52:00-04:00,MRK,neutral
851877.0,Merck Gives Update on Phase 2 I-SPY 2 Trial,2017-06-05 07:10:00-04:00,MRK,neutral
851878.0,Merck Announces Presentation of New Monotherapy Data for KEYTRUDA in Heavily Pre-Treated Patients with Advanced Gastric Cancer#ASCO17,2017-06-04 17:41:00-04:00,MRK,positive
851879.0,Merck Announces KEYTRUDA Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure #ASCO17,2017-06-04 09:09:00-04:00,MRK,positive
851880.0,Combination of Incyte's Epacadostat + Merck's KEYTRUDA Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer #ASCO17,2017-06-03 11:39:00-04:00,MRK,negative
851881.0,"Merck Announces New Data Show Durability of Response for KEYTRUDA in Advanced Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors, Regardless of Tumor Type #ASCO17",2017-06-03 08:48:00-04:00,MRK,neutral
851882.0,Merck Gives Update on KEYTRUDA Effectiveness with Over 2 Years of Follow Up,2017-06-02 07:33:00-04:00,MRK,neutral
851883.0,Tracking The Busy June PDUFA Calendar,2017-05-30 08:58:00-04:00,MRK,neutral
851884.0,A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Economic Data,2017-05-30 07:31:00-04:00,MRK,neutral
851885.0,Merck Gets FDA Approval of ISENTRESS for the Treatment of HIV-1,2017-05-30 07:02:00-04:00,MRK,positive
851886.0,Congo Approves Use of Merck Ebola Vaccine -DJ,2017-05-29 14:54:00-04:00,MRK,positive
851887.0,Reminder: Merck Has Isentress sNDA PDUFA Date Tomorrow May 27,2017-05-26 11:06:00-04:00,MRK,neutral
851888.0,Merck Reports Exclusive Global License Deal with Teijin Pharma for Investigational Antibody Candidate Targeting Tau,2017-05-25 08:00:00-04:00,MRK,positive
851889.0,FDA Approves Pembrolizumab for Pancreatic Cancers with Mismatch Repair Deficiency,2017-05-23 19:37:00-04:00,MRK,positive
851890.0,FDA Reports Approval for Merck's Solid Tumor with a Specific Genetic Feature Treatment,2017-05-23 14:56:00-04:00,MRK,positive
851891.0,"Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst",2017-05-23 14:09:00-04:00,MRK,positive
851892.0,"Pre-Market Imbalance Update: Ford 397K Shares to Buy, GE 200K to Buy, Nike 57K to Buy, GM 32K to Buy, Alibaba 30K to Buy, Merck 25K Shares to Sell",2017-05-23 08:57:00-04:00,MRK,positive
851893.0,"Companies Holding Annual Meetings Today Include Waste Connections, Eastman Kodak, Alarm.com, Amyris, Achillion Pharma, GNC, Amazon, Nokia, Merck, Nvidia, Pinnacle Foods, Wendy's, & Xerox",2017-05-23 08:43:00-04:00,MRK,negative
851894.0,Merck Gets Priority FDA Review for KYTRUDA sBLA,2017-05-23 06:56:00-04:00,MRK,neutral
851895.0,UPDATE: Merck Says Highest Dose of MK-7264 Evaluated Reduced Awake Cough Frequency by 37% from Baseline Relative to Placebo,2017-05-22 11:22:00-04:00,MRK,neutral
851896.0,Merck Reports Presentation of Phase 2 Results for MK-7264 for Treatment of Chronic Cough,2017-05-22 11:20:00-04:00,MRK,neutral
851897.0,The Most Notable Abstracts Released Ahead Of ASCO 2017,2017-05-19 08:21:00-04:00,MRK,neutral
851898.0,Merck Reports Received CHMP Opinion Recommending Approval of ISENTRESS 600 mg in EU,2017-05-19 08:00:00-04:00,MRK,positive
851899.0,Merck Issues Release Confirming FDA Has Approved KEYTRUDA for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma,2017-05-18 16:01:00-04:00,MRK,positive
851900.0,FDA Has Granted Approval for Merck's Pembrolizumab for Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,2017-05-18 12:41:00-04:00,MRK,positive
851901.0,"WHO Says Congo Ebola Cases Present High National, Low Global Risk -Reuters",2017-05-18 05:12:00-04:00,MRK,negative
851902.0,Incyte Issues Release Highlighting Co.'s IDO1 Enzyme Inhibitor in Combo with Merck's Anti-PD-1 Therapy is 'well-tolerated and demonstrates durable clinical responses across multiple solid tumors',2017-05-17 17:03:00-04:00,MRK,positive
851903.0,Merck's Glucophage SR Has Received Label Extension to Include Patients at High Risk of Type-2 Diabetes within UK,2017-05-17 12:56:00-04:00,MRK,negative
851904.0,"Aduro Biotech Reports Clinical Collaboration with Merck for Evaluation of CRS-207, KEYTRUDA Combo for Treatment of Mesothelioma",2017-05-17 09:07:00-04:00,MRK,neutral
851905.0,WHO Confirms Second Ebola Case in Congo -Reuters,2017-05-14 20:14:00-04:00,MRK,neutral
851906.0,"Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge",2017-05-12 11:55:00-04:00,MRK,positive
851907.0,"Here's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers",2017-05-11 11:52:00-04:00,MRK,positive
851908.0,Merck Press Release Confirms FDA Approval For KEYTRUDA,2017-05-10 17:43:00-04:00,MRK,positive
851909.0,Andy Biotech Tweets: '$MRK FDA approves Keytruda chemo combo in 1L NSCLC',2017-05-10 17:29:00-04:00,MRK,positive
851910.0,Reminder: Merck Has Keytruda PDUFA Date Today,2017-05-10 11:38:00-04:00,MRK,neutral
851911.0,OncoSec Medical +21.5% Premarket @$1.30 Following Announcement of  Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse IL-12 and KEYTRUDA,2017-05-10 07:27:00-04:00,MRK,neutral
851912.0,"OncoSec Medical Reports Clinical Trial Collaboration, Supply Deal with Merck to Evaluate Combo of ImmunoPulse IL-12 and KEYTRUDA",2017-05-10 06:16:00-04:00,MRK,neutral
851913.0,UPDATE: Merck 10-Q Filing Shows Co. Eliminated ~545 Positions in Q1'17 Under Restructuring Program Activities,2017-05-09 16:54:00-04:00,MRK,neutral
851914.0,Merck 10-Q Just Out,2017-05-09 16:53:00-04:00,MRK,neutral
851915.0,Array BioPharma Reports Strategic Partnership with Merck,2017-05-08 08:02:00-04:00,MRK,neutral
851916.0,Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers,2017-05-06 09:03:00-04:00,MRK,negative
851917.0,"Pre-Market Imbalance Update: IBM 110K Shares to Sell, Twitter 100K to Sell, Ford 63K Shares to Buy, Merck 62K to Sell, Disney 38K to Sell, P&G 20K to Sell",2017-05-05 08:54:00-04:00,MRK,positive
851918.0,"Merck Reports EC Approval of KEYTRUDA for Patients with Relapsed, Refractory Classical Hodgkin Lymphoma Who Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV",2017-05-05 07:02:00-04:00,MRK,negative
851919.0,"Ahead Of Merck's Keytruda PDUFA Date, Analyst Says Expect Approval",2017-05-03 14:41:00-04:00,MRK,positive
851920.0,"Apple Earnings In Focus, But Fed Meeting, Auto Sales Also Could Grab Headlines",2017-05-02 10:58:00-04:00,MRK,neutral
851921.0,A Peek Into The Markets: U.S. Stock Futures Mostly Lower; Apple Earnings In Focus,2017-05-02 07:15:00-04:00,MRK,negative
851922.0,"Merck Raises FY 2017 Guidance , Sees FY 2017 EPS $3.76 to $3.88 vs $3.81 Est, Sales $39.1B to $40.3B vs $39.7B Est",2017-05-02 06:49:00-04:00,MRK,neutral
851923.0,"Merck Q1 EPS $0.88 vs $0.83 Est, Sales $9.43B vs $9.25B Est",2017-05-02 06:48:00-04:00,MRK,neutral
851924.0,"12 Stocks To Watch For May 2, 2017",2017-05-02 05:06:00-04:00,MRK,neutral
851925.0,"Earnings Scheduled For May 2, 2017",2017-05-02 04:31:00-04:00,MRK,neutral
851926.0,"Earnings Preview: Q1 Results From Pfizer, Merck, And Gilead Sciences This Week",2017-05-01 10:56:00-04:00,MRK,neutral
851927.0,Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here',2017-05-01 09:24:00-04:00,MRK,negative
851928.0,"Looking For Action? Week Ahead Brings Heavy Load With Earnings, Data, Fed Meeting",2017-05-01 08:13:00-04:00,MRK,neutral
851929.0,Watching Volatility in Vaccine Names Here as Traders Circulating WSJ Article from Mon. Evening 'Vaunted Ebola Vaccine Faces Questions',2017-04-25 14:25:00-04:00,MRK,neutral
851930.0,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 13:44:00-04:00,MRK,positive
851931.0,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow",2017-04-24 13:45:00-04:00,MRK,neutral
851932.0,Merck Reports Study in US Veterans Affairs System Evaluating Use of ZEPATIER Showed High Sustained Virologic Response Rates in Patients with Chronic Hep C,2017-04-21 10:03:00-04:00,MRK,neutral
851933.0,Atara Bio Partners With Merck To Evaluate KEYTRUDA In Combination With ATA129 In NPC,2017-04-21 08:03:00-04:00,MRK,neutral
851934.0,What Would A $5.8 Billion NIH Cut Look Like? Devastation,2017-04-20 13:38:00-04:00,MRK,negative
851935.0,Exclusive: Leading Biosciences Execs Talk About How The Company Could Save Hospitals Millions Of Dollars Per Year,2017-04-19 08:09:00-04:00,MRK,positive
851936.0,Healthcare Sector Earnings: Making A Comeback In Q1 2017?,2017-04-12 11:46:00-04:00,MRK,neutral
851937.0,Cardiovascular Players Could Be Eyeing Esperion,2017-04-10 11:53:00-04:00,MRK,neutral
851938.0,"Barron's Picks And Pans: Gold, Energy, Dividends And More",2017-04-08 14:22:00-04:00,MRK,positive
851939.0,"Pre-Market Imbalance Update: AmEx 89K Shares to Sell, Ford 71K Shares to Buy, Merck 40K to Buy, BofA 29K to Sell, Morgan Stanley 22K to Sell, Nike, GE 20K to Sell",2017-04-07 09:10:00-04:00,MRK,positive
851940.0,Merck Reports Received CRL from FDA Related to TECOS Study with Sitagliptin,2017-04-07 07:30:00-04:00,MRK,neutral
851941.0,There Is Value To Be Had With The Right Healthcare ETFs,2017-04-05 08:32:00-04:00,MRK,positive
851942.0,"Benzinga Premarket Prep Host Dennis Dick Tweets: Notable opening imbalances: $PFE -243K, $MRK -93K, $BABA +115K, $KO +104K, $T +111K, $CAT -55K, $IBM -42K",2017-04-03 09:24:00-04:00,MRK,negative
851943.0,"UPDATE: Incyte, Merck Announce Clinical Program for Epacadostat, KEYTRUDA Includes 7 Registrational Trials Across 5 Tumor Types",2017-03-31 07:08:00-04:00,MRK,negative
851944.0,"Incyte, Merck Offer Added Details on Previously Announced Collab. Investigating Epacadostat, KEYTRUDA",2017-03-31 07:08:00-04:00,MRK,neutral
851945.0,European Medicines Agency's CHMP Recommends Approval of Merck's KEYTRUDA,2017-03-24 08:13:00-04:00,MRK,positive
851946.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,MRK,neutral
851947.0,Prima Biomed Completes Recruitment For Second Patient Cohort In Melanoma Trial,2017-03-15 06:36:00-04:00,MRK,neutral
851948.0,"Merck Says Submission Of Additional Data Is Considered Major Amendment to sBLA Under PDUFA; Thus, Extending  Target Action Date By 3 Months To June 9th, 2017",2017-03-14 16:44:00-04:00,MRK,neutral
851949.0,FDA Has Approved Merck's Keytruda For Intravenous Use In Hodgkin Lymphoma,2017-03-14 15:24:00-04:00,MRK,positive
851950.0,"Adam Feuerstein Talks Vulnerable Pharmaceuticals, Drug Pricing Under Trump",2017-03-10 11:32:00-05:00,MRK,negative
851951.0,Feuerstein on Benzinga's PreMarket Prep Discussing Stocks Which Could Be Impacted by Drug Pricing Changes: Believes Worst Case Scenario Would Create Vulnerabilities for Drugs with High Levels of Competition,2017-03-10 09:04:00-05:00,MRK,negative
851952.0,Here's Your March PDUFA Date Preview,2017-03-08 14:59:00-05:00,MRK,neutral
851953.0,Everything We Know About Merck's Keytruda,2017-03-08 14:22:00-05:00,MRK,neutral
851954.0,REMINDER: Merck's PDUFA Date For Keytruda In Microsatellite Instability-High Cancer Today,2017-03-08 08:36:00-05:00,MRK,negative
851955.0,"Merck, Pfizer Report U.S. FDA and EMA Filing Acceptances of 3 Marketing Applications for Ertugliflozin-Containing Medicines For Adult Type 2 Diabetes Patients",2017-03-06 08:02:00-05:00,MRK,positive
851956.0,Why Bermuda Could Be The Next Switzerland,2017-03-02 08:52:00-05:00,MRK,neutral
851957.0,Merck's Odactra Approved For House Dust Mite Allergies,2017-03-01 16:59:00-05:00,MRK,positive
851958.0,Merck Says Letermovir for Prevention of CMV)Infection in Bone Marrow Transplant Recipients is Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study,2017-02-26 18:09:00-05:00,MRK,positive
851959.0,"Big Business Delivers Christmas Wish List To Trump, 10 Months Early",2017-02-25 17:08:00-05:00,MRK,positive
851960.0,Merck Reports First Phase 3 Trial of V212 Reduced Incidence of Confirmed Herpes Zoster Cases by ~64% in Immunocompromised Subjects,2017-02-24 16:00:00-05:00,MRK,neutral
851961.0,Merck Receives Positive CHMP Opinion For New Pergoveris Fertility Pen,2017-02-24 08:06:00-05:00,MRK,positive
851962.0,"Merck Says Will Record Intangible Asset Impairment Charge Related To MK-3682 Program,  Previously Reported Q4 And FY Non-GAAP EPS Remain Unchanged",2017-02-23 17:17:00-05:00,MRK,positive
851963.0,Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market',2017-02-23 14:06:00-05:00,MRK,positive
851964.0,Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?,2017-02-21 16:48:00-05:00,MRK,neutral
851965.0,"Boeing, Pfizer And Others Band Together To Ask Congress For More Taxes",2017-02-21 13:28:00-05:00,MRK,neutral
851966.0,The Market In 5 Minutes,2017-02-17 09:16:00-05:00,MRK,neutral
851967.0,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?",2017-02-16 16:13:00-05:00,MRK,negative
851968.0,Merck Still Sees Path Forward For Failed Alzheimer's Drug,2017-02-15 16:13:00-05:00,MRK,negative
851969.0,"Merck, On Its Alzheimer's Drug Program, Tells Benzinga Too Early To Speculate What Verubecestat Trial Results Mean For Validity Of 'Amyloid Hypothesis', Hopes By Evaluating Drug In People W/Less Impairment Will Be Able To Slow Disease Progression",2017-02-15 15:30:00-05:00,MRK,positive
851970.0,Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers,2017-02-15 14:26:00-05:00,MRK,negative
851971.0,Merck Says APECS Study in People with Prodromal Alzheimer's Disease to Continue,2017-02-14 17:10:00-05:00,MRK,neutral
851972.0,"Meg Tirrell Tweets: $MRK stops study of BACE inhibitor in mild to moderate Alzheimer's for lack of efficacy, prodromal study continues",2017-02-14 17:10:00-05:00,MRK,negative
851973.0,Merck's Doravirine Meets Primary Efficacy Endpoint In Pivotal Phase 3 Trial,2017-02-14 16:07:00-05:00,MRK,neutral
851974.0,FDA to Review Two of Merck's Supplemental Biologics License Applications,2017-02-03 06:49:00-05:00,MRK,neutral
851975.0,Q4 2016 Real-Time Call Brief,2017-02-02 10:07:00-05:00,MRK,neutral
851976.0,"The Market In 5 Minutes: Facebook Beats, Trump Tweets",2017-02-02 09:27:00-05:00,MRK,neutral
851977.0,Merck CEO Says Trump Focus On Patients Being Able To Afford Co-Pays Rather Than Overall Cost of Drugs,2017-02-02 09:09:00-05:00,MRK,neutral
851978.0,"Merck Sees FY17 Adj. EPS $3.72-$3.87 vs $3.85 Est., Sales $38.6B-$40.1B vs $40B Est.",2017-02-02 06:46:00-05:00,MRK,neutral
851979.0,"Merck Reports Q4 Adj. EPS $0.89, Inline, Sales $10.1B vs $10.22B Est.",2017-02-02 06:45:00-05:00,MRK,neutral
851980.0,Earnings: Facebook and Merck Scheduled to Open Their Books,2017-02-01 11:09:00-05:00,MRK,neutral
851981.0,Ringing up the iPhones: Strong Apple Results Put A Charge Into Markets,2017-02-01 10:26:00-05:00,MRK,positive
851982.0,Merck Announces EU Approves KEYTRUDA For First-Line Pateitns,2017-01-31 16:12:00-05:00,MRK,positive
851983.0,Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail,2017-01-30 14:04:00-05:00,MRK,positive
851984.0,"Mixing It Up: Markets Await Host Of Economic Data, Key Earnings, And Fed Meeting",2017-01-30 10:07:00-05:00,MRK,positive
851985.0,"The Market In 5 Minutes: Walgreens-Rite Aid, Personal Income And Trump's Executive Order",2017-01-30 09:03:00-05:00,MRK,neutral
851986.0,Can Merck And Pfizer Beat Low Expectations?,2017-01-30 07:16:00-05:00,MRK,negative
851987.0,A CEO Who's Who Of Trump's Manufacturing Council,2017-01-27 16:36:00-05:00,MRK,neutral
851988.0,"Andrew Left Furthers Comments Following ESRX Release Today, Points To Comment Made By Merck President Of U.S. Commercial To Highlight Thesis That Drug Co.'s Offer Incentives To PBM's To Stay On Preferred Drug Lists",2017-01-27 14:29:00-05:00,MRK,positive
851989.0,WSJ Reporting Merck Raised List Prices By 9.6% Last Year,2017-01-27 07:12:00-05:00,MRK,neutral
851990.0,Merck Shares Falling As Ketruda Brain Tumor Trial Put On Hold Due To Adverse Event,2017-01-26 10:42:00-05:00,MRK,negative
851991.0,Merck's Keytruda Gains Momentum At The Expense Of Bristol-Myers,2017-01-26 10:33:00-05:00,MRK,positive
851992.0,Dow 10K's Hottest Stocks: Where Are They Now?,2017-01-25 15:17:00-05:00,MRK,neutral
851993.0,Which Pharma Players Dominate The Lung Cancer Space?,2017-01-25 14:40:00-05:00,MRK,negative
851994.0,"UPDATE: Merck's Payment To Bristol-Myers Will Be Recorded In Its Q4 And FY16 Results, Excluded From Non-GAAP Results",2017-01-20 16:05:00-05:00,MRK,negative
851995.0,"Merck Announces Setlement With Bristol-Myers Resolving KEYTRUDA Patent Litigation, Will Pay $625M And Provide Royalties On KEYTRUDA In Any Market In Which It's Approved",2017-01-20 16:02:00-05:00,MRK,positive
851996.0,Bristol-Myers Squibb Falls 10% After Opdivo Decision,2017-01-20 10:35:00-05:00,MRK,neutral
851997.0,Wall Street's M&A Chatter From January 19,2017-01-20 06:52:00-05:00,MRK,neutral
851998.0,Favorable News On Keytruda Drives Piper Jaffray's Upgrade Of Merck,2017-01-12 10:11:00-05:00,MRK,positive
851999.0,8 Biggest Price Target Changes For Thursday,2017-01-12 09:47:00-05:00,MRK,neutral
852000.0,"Benzinga's Top Upgrades, Downgrades For January 12, 2017",2017-01-12 09:31:00-05:00,MRK,positive
852001.0,Merck's Leadership Position In Immuno Oncology Is Improving,2017-01-12 09:06:00-05:00,MRK,positive
852002.0,"The Market In 5 Minutes: Jobless Claims Lower, Trump Conference Shakes Sectors",2017-01-12 08:55:00-05:00,MRK,negative
852003.0,"Guggenheim Upgrades Merck & Co to Buy, Announces $70.00 Target",2017-01-12 07:56:00-05:00,MRK,neutral
852004.0,"Morgan Stanley Upgrades Merck & Co to Overweight, Raises Target to $71.00",2017-01-12 06:14:00-05:00,MRK,negative
852005.0,All The Markets Trump Moved During His Speech Today,2017-01-11 15:51:00-05:00,MRK,neutral
852006.0,Here's What Merck's Keytruda News Means For Bristol-Myers,2017-01-11 14:26:00-05:00,MRK,neutral
852007.0,15 Biggest Mid-Day Gainers For Wednesday,2017-01-11 12:35:00-05:00,MRK,neutral
852008.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-01-11 08:22:00-05:00,MRK,neutral
852009.0,"Lilly and Merck Expand Immuno-Oncology Collaboration, Financial Terms Not Disclosed",2017-01-11 06:45:00-05:00,MRK,positive
852010.0,Bristol-Myers Shares Down 2.2% After Hours as Merck Shares Trade Up ~2.5% Following News KEYTRUDA Accepted for Supplemental BLA,2017-01-10 17:12:00-05:00,MRK,positive
852011.0,"Merck Reports KEYTRUDA Has FDA PDUFA Date Of May 10, 2017 Under Accelerated Approval",2017-01-10 16:07:00-05:00,MRK,positive
852012.0,Merck Receives FDA Acceptance Of Supplemental Biologics License Application for KEYTRUDA,2017-01-10 16:06:00-05:00,MRK,positive
852013.0,Option Alert: Merck Jan 61.5 Calls Sweep: 745 @  ASK  $0.64: 843 traded vs 562 OI:  Earnings 2/2 Before Open  $61.29 Ref,2017-01-09 13:25:00-05:00,MRK,positive
852014.0,"Exclusive: Ziopharm CEO Talks Partnerships, Balance Sheet And JPM Healthcare Conference Presentation",2017-01-09 11:40:00-05:00,MRK,positive
852015.0,"Incyte, Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA",2017-01-09 08:11:00-05:00,MRK,neutral
852016.0,The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know,2017-01-09 06:33:00-05:00,MRK,neutral
852017.0,Merck Acquires Biocontrol,2017-01-04 08:32:00-05:00,MRK,neutral
852018.0,UPDATE: Merck Says It Will Defend Itself Vigorously In Response To Government Notice; Given They Were Neither A Manufacturer Or A Marketer Of The Subject Drug,2016-12-30 07:39:00-05:00,MRK,positive
852019.0,Merck Says NPPA Alleges Overcharging Of Price Of Polybion Syrup Formulation From Jan. 2006-June 2009,2016-12-30 07:37:00-05:00,MRK,neutral
852020.0,Prima BioMed Announces First Clinical Data from Combination of IMP321 With Keytruda Show No Safety Concerns,2016-12-29 04:34:00-05:00,MRK,positive
852021.0,Merck Gets A Strong Sell From Vetr Crowd,2016-12-28 17:11:00-05:00,MRK,positive
852022.0,Technical Alert: Merck Lower,2016-12-28 13:48:00-05:00,MRK,neutral
852023.0,NewLink CFO: 'Ebola Vaccine Highly Unlikely To Drive Future Profit In Company',2016-12-23 14:54:00-05:00,MRK,positive
852024.0,Where Does Merck's Ebola Vaccine Breakthrough Leave Competitors?,2016-12-23 14:38:00-05:00,MRK,negative
852025.0,"Shares of NewLink Genetics Up 10%, Earlier Today, Traders Attributed Move To Partnership With Merck, Whose Ebola Vaccine Was Shown To Provide 100% Protection",2016-12-23 14:00:00-05:00,MRK,positive
852026.0,6 Worst Biotech Stocks Of 2016,2016-12-23 11:50:00-05:00,MRK,negative
852027.0,"Meet The New Dogs: 2017's Dogs Of The Dow Include Coca-Cola, Boeing",2016-12-22 09:55:00-05:00,MRK,neutral
852028.0,What Does Biogen's New CEO Mean For The Buyout Argument?,2016-12-20 10:58:00-05:00,MRK,negative
852029.0,Jefferies' 2017 Global Pharma Outlook,2016-12-19 10:56:00-05:00,MRK,neutral
852030.0,"Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell",2016-12-19 09:09:00-05:00,MRK,positive
852031.0,"Benzinga's Top Upgrades, Downgrades For December 19, 2016",2016-12-19 09:08:00-05:00,MRK,positive
852032.0,A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Yellen Speech,2016-12-19 07:39:00-05:00,MRK,neutral
852033.0,Merck Gets Approval for KEYTRUDA in Japan,2016-12-19 07:10:00-05:00,MRK,positive
852034.0,"Jefferies Downgrades Merck & Co to Underperform, Lowers Target to $48.00",2016-12-19 06:40:00-05:00,MRK,negative
852035.0,European Medicines Agency's CHMP Recommends Merck's KEYTRUDA For First-Line Treatment Of Patients With NSCLC,2016-12-16 07:26:00-05:00,MRK,positive
852036.0,Gilead To Pay Merck $2.54B In Hep. C Royalties,2016-12-15 16:30:00-05:00,MRK,negative
852037.0,"10 Notable Stocks Trading Ex-Dividend Tuesday, December 13",2016-12-12 11:38:00-05:00,MRK,neutral
852038.0,Merck Reports New KEYTRUDA Data In Combination With HALAVEN For Metastatic Triple-Negative Breast Cancer,2016-12-12 07:01:00-05:00,MRK,negative
852039.0,"European Crohn's, Colitis Organisation Issues New Statement Support a Switch to Biosimilar from Reference Product in Inflammatory Bowel Disease",2016-12-09 10:18:00-05:00,MRK,positive
852040.0,Merck Canada Says Zostavax II Showed Vaccine Effectiveness Against Shingles In Observational Effectiveness Study,2016-12-07 15:07:00-05:00,MRK,neutral
852041.0,What If Trump Keeps Badmouthing Drug Pricing?,2016-12-07 13:38:00-05:00,MRK,neutral
852042.0,Technical Alert: Merck Lower,2016-12-07 12:26:00-05:00,MRK,neutral
852043.0,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open",2016-12-07 09:34:00-05:00,MRK,negative
852044.0,Merck Announces KEYTRUDA Demonstrated Improved Health-Related Quality of Life vs Chemotherapy in First-Line Treatment of Patients with Metastatic NSCLC at WCLC 2016,2016-12-07 04:08:00-05:00,MRK,positive
852045.0,Merck KEYTRUDA Findings Show ORR Of 33.3% and 20% In Small Cell Lung Cancer and Malignant Pleural Mesothelioma Respectively In KEYNOTE-028,2016-12-06 08:23:00-05:00,MRK,negative
852046.0,Merck Announces KEYTRUDA Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at ASH 2016,2016-12-05 19:41:00-05:00,MRK,neutral
852047.0,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,2016-12-05 15:55:00-05:00,MRK,negative
852048.0,"Merck Says Will Present Updated KEYTRUDA Findings at ASH: Data Showed KEYNOTE-013 Overall Response Rate of 41%, with 86% of Responses Ongoing at the Time of Analysis",2016-12-05 10:44:00-05:00,MRK,neutral
852049.0,"Biothera, Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer",2016-12-05 09:34:00-05:00,MRK,negative
852050.0,CNBC's Meg Tirrell Tweets: $MRK CEO: We are now at the equivalent stage in immunotherapy where we were w first effective treatments for HIV #ForbesHealth,2016-12-01 09:43:00-05:00,MRK,positive
852051.0,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron",2016-12-01 08:21:00-05:00,MRK,neutral
852052.0,FDA Grants Priority Review to Supplemental Biologics License Application for Merck's KEYTRUDA in Relapsed or Refractory Classical Hodgkin Lymphoma,2016-12-01 07:01:00-05:00,MRK,positive
852053.0,FDA Grants Priority Review to Merck's Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA for New Indication in Microsatellite Instability-High Cancer,2016-11-28 07:00:00-05:00,MRK,negative
852054.0,Merck Increases Qtr. Dividend From $0.46 To $0.47/Share,2016-11-22 13:22:00-05:00,MRK,neutral
852055.0,"QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe",2016-11-22 08:04:00-05:00,MRK,neutral
852056.0,Vetr Opts To Hold On Merck Despite Biotech Optimism,2016-11-16 13:18:00-05:00,MRK,negative
852057.0,Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price,2016-11-14 16:57:00-05:00,MRK,positive
852058.0,"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection",2016-11-13 08:20:00-05:00,MRK,neutral
852059.0,Merck Announes KEYTRUDA Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder Cancer,2016-11-12 12:38:00-05:00,MRK,negative
852060.0,Merck Presents New Findings for ZEPATIER in Patients with Chronic Hepatitis C at The Liver Meeting,2016-11-12 08:07:00-05:00,MRK,neutral
852061.0,Technical Alert - Merck Lower,2016-11-11 12:10:00-05:00,MRK,neutral
852062.0,2 Big Medical Marijuana Stocks Riding High Post-Election,2016-11-10 10:45:00-05:00,MRK,neutral
852063.0,Technical Alert: Merck Reaches $65 And Retreats,2016-11-09 12:22:00-05:00,MRK,positive
852064.0,Stocks Hitting 52-Week Highs,2016-11-09 10:17:00-05:00,MRK,neutral
852065.0,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",2016-11-09 09:41:00-05:00,MRK,neutral
852066.0,Biotech Is Getting A Big Boost Following Clinton's Loss,2016-11-09 08:38:00-05:00,MRK,positive
852067.0,BZ NOTE Related to Traders Passing Around CNBC Story on New Cancer Drugs Possibly Damaging the Heart: NBC News via AP Published the Same Story ~7 p.m. EDT Wed. Evening,2016-11-03 11:19:00-04:00,MRK,negative
852068.0,Traders Passing Around Recent CNBC Article on Cancer Treatments: 'New cancer drugs may damage the heart',2016-11-03 11:16:00-04:00,MRK,negative
852069.0,"Merck Reports Publishing of New Research on Early Development of Verubecestat, Says 'Results of First Phase 3 Trial Anticipated in Late 2017'",2016-11-02 16:46:00-04:00,MRK,neutral
852070.0,The Election Can't Come Soon Enough For Biotechs,2016-11-01 10:39:00-04:00,MRK,neutral
852071.0,Technical Alert: Merck Higher After Q3 Report,2016-10-25 14:26:00-04:00,MRK,positive
852072.0,6 Big Pharma Companies Left To Report September Quarterly Figures,2016-10-25 13:45:00-04:00,MRK,neutral
852073.0,Epic Earnings: Many US Companies Beating Expectations As Season Continues,2016-10-25 11:52:00-04:00,MRK,negative
852074.0,"The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind",2016-10-25 09:19:00-04:00,MRK,neutral
852075.0,"A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus",2016-10-25 07:39:00-04:00,MRK,neutral
852076.0,"Merck's Q3 Results, Guidance Look Strong",2016-10-25 07:23:00-04:00,MRK,positive
852077.0,"Merck Narrows and Raises Guidance; Sees FY EPS $3.71 to $3.78 vs $3.75 est, Revenue $39.7B to $40.2B vs $39.7B est",2016-10-25 06:47:00-04:00,MRK,neutral
852078.0,"Merck Q3 EPS $1.07 vs $0.99 est, Revenue $10.54B vs $10.18B est",2016-10-25 06:45:00-04:00,MRK,neutral
852079.0,12 Stocks You Should Be Watching Today,2016-10-25 04:58:00-04:00,MRK,neutral
852080.0,"Earnings Scheduled For October 25, 2016",2016-10-25 04:15:00-04:00,MRK,neutral
852081.0,Merck Reports FDA Approval Of KEYTRUDA,2016-10-24 18:04:00-04:00,MRK,positive
852082.0,Big News Out Of Merck This Weekend,2016-10-24 10:09:00-04:00,MRK,neutral
852083.0,Merck Has An Upcoming PDUFA Date For Bezlotoxumab,2016-10-21 16:45:00-04:00,MRK,neutral
852084.0,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments,2016-10-21 11:36:00-04:00,MRK,negative
852085.0,Merck Has An Oct 23rd Pdufa Date For Bezlotoxumab; Drug Won FDA Advisory Panel Backing In June,2016-10-21 08:31:00-04:00,MRK,positive
852086.0,Jim Cramer Gives His Opinion On Merck And Smith & Wesson,2016-10-21 07:10:00-04:00,MRK,neutral
852087.0,"Merck Reports KEYNOTE-045 Studying KEYTRUDA in Advanced Bladder Cancer Meets Primary Endpoint, Stops Early",2016-10-21 06:45:00-04:00,MRK,negative
852088.0,"Fed Speakers And Beige Book, Bank Earnings, Rising Crude Take Center Stage",2016-10-19 12:38:00-04:00,MRK,negative
852089.0,"Roche Group, Competitor To Bristol-Myers And Merck, Has PDUFA DateFor Tecentriq Drug",2016-10-19 08:31:00-04:00,MRK,neutral
852090.0,Merck Announces Pivotal Phase 3 Study of Letermovir Met Primary Endpoint,2016-10-19 07:09:00-04:00,MRK,neutral
852091.0,7 Biggest Price Target Changes For Thursday,2016-10-13 09:58:00-04:00,MRK,neutral
852092.0,Benzinga's Top Upgrades,2016-10-13 09:09:00-04:00,MRK,positive
852093.0,A Peek Into The Markets: U.S. Stock Futures Tumble Ahead Of Jobless Claims Report,2016-10-13 07:49:00-04:00,MRK,neutral
852094.0,"Bank of America Upgrades Merck & Company to Buy, Raises  Price Target to $70.00",2016-10-13 07:18:00-04:00,MRK,neutral
852095.0,Technical Alert: Merck Surrenders Monday's Gains,2016-10-11 11:33:00-04:00,MRK,positive
852096.0,Aetna and Merck Sign a Unique Value-Based Contract for Januvia and Janumet,2016-10-11 08:45:00-04:00,MRK,neutral
852097.0,The ESMO Conference Proves Its Ability To Move Stocks,2016-10-10 14:44:00-04:00,MRK,positive
852098.0,Technical Alert: Merck Reaches Highest Level Since December 2001,2016-10-10 13:31:00-04:00,MRK,positive
852099.0,Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment,2016-10-10 10:25:00-04:00,MRK,neutral
852100.0,SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower,2016-10-10 10:08:00-04:00,MRK,negative
852101.0,New Data on the Combination of Lilly's ALIMTA and Merck's KEYTRUDA Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic NSCLC Presented at ESMO 2016,2016-10-09 08:42:00-04:00,MRK,positive
852102.0,Merck Announces Two Major Studies to Be Presented at ESMO 2016 Demonstrate Potential of KEYTRUDA for the First-Line Treatment of Metastatic NSLCL in a Broad Range of Patients,2016-10-09 08:40:00-04:00,MRK,neutral
852103.0,Merck Announces KEYTRUDA Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic NSCLC in Data to Be Presented at ESMO 2016,2016-10-09 08:27:00-04:00,MRK,positive
852104.0,Merck Presents Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA in Patients with Advanced Melanoma from KEYNOTE-002 at ESMO 2016,2016-10-09 08:19:00-04:00,MRK,positive
852105.0,Merck Announces New KEYTRUDA Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients,2016-10-09 08:06:00-04:00,MRK,negative
852106.0,Exclusive: Interview With DelMar Pharmaceutical CEO Jeffrey Bacha,2016-10-08 17:34:00-04:00,MRK,positive
852107.0,Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine,2016-10-07 16:06:00-04:00,MRK,positive
852108.0,Merck Shares Indicated Up 1+% Premarket; Shares Could Be Higher Amid Positive Trial News from Incyte; Incyte Shares Up ~5% in Pre-Open,2016-09-28 08:17:00-04:00,MRK,positive
852109.0,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target",2016-09-26 11:46:00-04:00,MRK,positive
852110.0,"The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen",2016-09-21 08:59:00-04:00,MRK,neutral
852111.0,Clovis Upgraded At Credit Suisse Following Acquisition Rumor,2016-09-21 07:38:00-04:00,MRK,positive
852112.0,"Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck",2016-09-20 17:03:00-04:00,MRK,neutral
852113.0,New 5-Year Contraceptive Coming To U.S. Adds To Long-Acting Reversible Contraceptives List,2016-09-20 15:18:00-04:00,MRK,neutral
852114.0,"Citi Research Reevaluates Bristol-Myers, Lowers Price Target",2016-09-20 09:13:00-04:00,MRK,negative
852115.0,Seattle Genetics No Longer On Goldman Sachs' Sell List,2016-09-15 09:48:00-04:00,MRK,negative
852116.0,"UPDATE: Pfizer, Merck's VERTIS SITA2 Also Achieved 4 Secondary Endpoints",2016-09-15 08:34:00-04:00,MRK,neutral
852117.0,"Merck, Pfizer Reports Ertugliflozin Met Primary Endpoint of A1C Reduction",2016-09-15 08:32:00-04:00,MRK,neutral
852118.0,"Presidential Merck: 'Jimmy Carter' Oncology Drug Expected To Dominate, Hep C Drug Approved Across EU",2016-09-13 15:36:00-04:00,MRK,positive
852119.0,"Barclays Raises Target On Merck, Lowers Target On Bristol-Myers",2016-09-09 09:56:00-04:00,MRK,negative
852120.0,Another Election Year View On Healthcare ETFs,2016-09-08 11:12:00-04:00,MRK,neutral
852121.0,Technical Alert: Merck Range-Bound For Third Day In A Row,2016-09-07 13:39:00-04:00,MRK,positive
852122.0,"UDPATE: Merck To Continue Distributing Product On Behalf of Aralez For 12 Months, Considerations Also Include Sales-Based Milestones And Graduated Royalties",2016-09-07 08:38:00-04:00,MRK,neutral
852123.0,Merck Gets FDA Priority Review and Breakthrough Therapy Designation for KEYTRUDA,2016-09-07 06:46:00-04:00,MRK,neutral
852124.0,Merck Remains Stable Following Discontinuation Of Odanacatib Development Program,2016-09-02 12:25:00-04:00,MRK,positive
852125.0,"Merck Provides Update on Odanacatib Development Program, Will Discontinue Development and Not Seek Regulatory Approval For Its Use",2016-09-02 07:00:00-04:00,MRK,negative
852126.0,"Shares Of Celgene Spiking Higher, Hearing Unconfirmed Rumors That Big Restructuring Under Way & Speculation Is That They Are Prepping Deal With Merck",2016-08-31 10:16:00-04:00,MRK,positive
852127.0,The 2015 Flash Crash Was One Year Ago Today. Why Did It Happen?,2016-08-24 13:57:00-04:00,MRK,negative
852128.0,Write A Prescription For More Pharma M&A With This ETF,2016-08-24 10:00:00-04:00,MRK,neutral
852129.0,"UPDATE: Reuters Says Merck, Sanofi, Pfizer, Gilead, Celgene Have Each Submitted Expressions of Interest for Medivation",2016-08-17 12:55:00-04:00,MRK,positive
852130.0,Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain,2016-08-16 10:11:00-04:00,MRK,positive
852131.0,Biogen Cancels Out Of Citigroup Conference Following Weeks Of Rumors,2016-08-11 15:02:00-04:00,MRK,negative
852132.0,"Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target",2016-08-10 11:42:00-04:00,MRK,neutral
852133.0,"Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict",2016-08-09 11:49:00-04:00,MRK,neutral
852134.0,Results from Merck's Phase 3 Study Of Zepatier Hep C Treatment Published In Annals Of Internal Medicine,2016-08-08 17:05:00-04:00,MRK,neutral
852135.0,Technical Alert: Merck Surrenders Some Of Friday's Huge Gain,2016-08-08 13:34:00-04:00,MRK,positive
852136.0,"After Roaring To New Highs on Jobs Data, Market Faces Retail Sales, Job Openings",2016-08-08 10:42:00-04:00,MRK,neutral
852137.0,"CheckMate Miss Is A Game Changer; Credit Suisse Downgrades Bristol, Upgrades Merck",2016-08-08 10:12:00-04:00,MRK,positive
852138.0,8 Biggest Price Target Changes For Monday,2016-08-08 09:58:00-04:00,MRK,neutral
852139.0,The Market in 5 Minutes: Can The Momentum Continue?,2016-08-08 09:02:00-04:00,MRK,neutral
852140.0,Benzinga's Top Upgrades,2016-08-08 09:01:00-04:00,MRK,positive
852141.0,Citi Doesn't See Merck's Lung Cancer Success Lasting Long,2016-08-08 07:36:00-04:00,MRK,negative
852142.0,FDA Approves Merck's KEYTRUDAÂ® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy,2016-08-08 06:58:00-04:00,MRK,positive
852143.0,"Credit Suisse Upgrades Merck & Co to Outperform, Raises PT to $73.00",2016-08-08 03:49:00-04:00,MRK,positive
852144.0,Watch These 5 Huge Put Purchases In Monday Trade,2016-08-08 02:50:00-04:00,MRK,positive
852145.0,"BMO Capital Upgrades Merck To Outperform, Bullish On Co",2016-08-06 11:52:00-04:00,MRK,neutral
852146.0,"BMO Capital Upgrades Merck & Co to Outperform, Raises PT to $72.00",2016-08-05 12:46:00-04:00,MRK,neutral
852147.0,25 Biggest Mid-Day Gainers For Friday,2016-08-05 12:43:00-04:00,MRK,neutral
852148.0,Benzinga's Volume Movers,2016-08-05 10:31:00-04:00,MRK,neutral
852149.0,Stocks Hitting 52-Week Highs,2016-08-05 10:14:00-04:00,MRK,neutral
852150.0,Option Alert: MRK Oct16 60.0 Puts Sweep: 594 @  ASK  $1.71: 605 traded vs 1589 OI: $61.04 Ref,2016-08-05 09:48:00-04:00,MRK,positive
852151.0,Bristol's Opdivo Misses Endpoint In Late-Stage Trial; Merck Rallies Sharply Amid Keytruda Potential,2016-08-05 09:03:00-04:00,MRK,negative
852152.0,The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher,2016-08-05 08:55:00-04:00,MRK,neutral
852153.0,UPDATE: Merck's KEYTRUDA is Viewed as Strongest Competitor to Bristol's Opdivo,2016-08-05 08:26:00-04:00,MRK,positive
852154.0,Merck Spike in Price Likely Attributed to Negative Results on Bristol-Myers' Opdivo,2016-08-05 08:23:00-04:00,MRK,negative
852155.0,Merck Shares Spiking ~$6 Over Last Min,2016-08-05 08:22:00-04:00,MRK,positive
852156.0,Merck Reports Acceptance of FDA Filing for NDA for MK-1293,2016-08-05 08:00:00-04:00,MRK,positive
852157.0,"Celgene Shares Spiking, Traders Circulating Takeover Chatter By Merck",2016-08-04 10:26:00-04:00,MRK,positive
852158.0,"Benzinga's M&A Chatter for Wednesday August 3, 2016",2016-08-03 20:26:00-04:00,MRK,neutral
852159.0,Terms Of The Trade: Dogs Of The Dow Investing Strategy,2016-08-03 14:38:00-04:00,MRK,neutral
852160.0,"Biogen Shares Down $3 Over Last Min Following Reuters Report Co. Not Soliciting Offers; Allergan, Merck Shares Relatively Quiet, Not Impacted",2016-08-03 14:16:00-04:00,MRK,positive
852161.0,The Market In 5 Minutes: Downtrend Continues,2016-08-03 08:59:00-04:00,MRK,neutral
852162.0,Why Is Biogen Attractive? Credit Suisse Sees 12-24% Upside Takeout Potential,2016-08-03 07:42:00-04:00,MRK,positive
852163.0,"Benzinga's M&A Chatter for Tuesday August 2, 2016",2016-08-02 19:35:00-04:00,MRK,neutral
852164.0,6 Stocks Moving In Tuesday's After-Hours Session,2016-08-02 17:03:00-04:00,MRK,neutral
852165.0,Merck Reports KEYTRUDA Has Received EC Approval for Patients with NSCLC Whose Tumors Express PD-L1,2016-08-02 17:02:00-04:00,MRK,positive
852166.0,"Wall Street Journal Reports Biogen Drawing Interest From Merck, Allergan On Possibility Of Huge Deal",2016-08-02 14:46:00-04:00,MRK,positive
852167.0,"Merck's Q2 Good, But Not Good Enough, Says BMO",2016-08-01 14:12:00-04:00,MRK,positive
852168.0,"Weak GDP Data, Plunging Oil Renew Questions About Strength Of Economy",2016-07-29 11:09:00-04:00,MRK,positive
852169.0,A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of GDP Report,2016-07-29 07:56:00-04:00,MRK,negative
852170.0,Investors Greet Merck Q2 Results As Key Launches Help Beat,2016-07-29 07:45:00-04:00,MRK,positive
852171.0,Merck Reports EC Granted Marketing Authorization for Co.'s ZEPATIER for Treatment of Chronic Hep C Infection,2016-07-29 07:08:00-04:00,MRK,positive
852172.0,"Merck Narrows, Raises FY16 Adj. EPS Outlook from $3.60-$3.75 to $3.67-$3.77 vs $3.72 Est., Sales from $38.7B-$40.2B to $39.1B-$40.1B vs $39.5B Est.",2016-07-29 06:47:00-04:00,MRK,neutral
852173.0,"Merck Reports Q2 Adj. EPS $0.93 vs $0.91 Est., Sales $9.844B vs $9.78B Est.",2016-07-29 06:45:00-04:00,MRK,neutral
852174.0,12 Stocks You Should Be Watching Today,2016-07-29 04:54:00-04:00,MRK,neutral
852175.0,"Earnings Scheduled For July 29, 2016",2016-07-29 04:03:00-04:00,MRK,neutral
852176.0,Can Keytruda Deliver Earnings Growth For Merck?,2016-07-27 11:22:00-04:00,MRK,positive
852177.0,Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine,2016-07-25 09:18:00-04:00,MRK,neutral
852178.0,"NewLink Genetics Announces Merck Receives Breakthrough Therapy Designation from FDA, PRIME Status from EMA for Investigational Ebola Zaire Vaccine",2016-07-25 08:05:00-04:00,MRK,neutral
852179.0,"Merck Reports Received Breakthrough Therapy Designation from FDA, PRIME Status from EMA for V920",2016-07-25 08:00:00-04:00,MRK,neutral
852180.0,Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine,2016-07-25 08:00:00-04:00,MRK,neutral
852181.0,Merck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS,2016-07-22 12:08:00-04:00,MRK,neutral
852182.0,"Merck Reports Investigational Once-Daily Formulation of ISENTRESS Showed Non-Inferior Efficacy, Safety to Regimen Containing Approved Twice-Daily Formulation",2016-07-22 07:02:00-04:00,MRK,positive
852183.0,"Merck Animal Health Receives FDA Approval of BRAVECTO For Cats And Dogs, Topical Treatment for Fleas and Ticks Effective for up to 12 Weeks",2016-07-21 17:00:00-04:00,MRK,positive
852184.0,Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab,2016-07-21 16:30:00-04:00,MRK,neutral
852185.0,The Market In 5 Minutes: Jam-Packed Day Of Earnings And Economic Data,2016-07-21 08:52:00-04:00,MRK,neutral
852186.0,"Benzinga's M&A Chatter for Wednesday July 20, 2016",2016-07-20 20:53:00-04:00,MRK,neutral
852187.0,BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations,2016-07-18 12:02:00-04:00,MRK,neutral
852188.0,Benzinga's Top Downgrades,2016-07-18 09:18:00-04:00,MRK,positive
852189.0,BMO Capital Downgrades Merck & Co to Market Perform,2016-07-18 06:29:00-04:00,MRK,neutral
852190.0,"Merck, Pfizer Report Initiation of Phase III Trial to Evaluate Avelumab as First-Line Treatment for Ovarian Cancer",2016-07-06 08:01:00-04:00,MRK,negative
852191.0,"Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company VallÃ©e S.A., Will Acquire 93% Of Shares For $400M",2016-07-01 12:06:00-04:00,MRK,positive
852192.0,Merck And Premier Join Hands To Prevent Fractures For Osteoporosis Patients,2016-06-30 10:32:00-04:00,MRK,positive
852193.0,"Merck, Premier Report Collaboration to Prevent Fractures for Osteoporosis Patients",2016-06-30 08:35:00-04:00,MRK,neutral
852194.0,"Merck, Moderna Therapeutics Report Strategic Collaboration Related to Advancement of Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA",2016-06-29 07:02:00-04:00,MRK,negative
852195.0,Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung Cancer Treatment,2016-06-27 08:41:00-04:00,MRK,positive
852196.0,Merck Receives CHMP Positive Opinion for KEYTRUDA for the Treatment of Advanced Non-Small Cell Lung Cancer,2016-06-27 06:01:00-04:00,MRK,positive
852197.0,UPDATE: Merck Says Pivotal Phase 3 Studies for Relebacatam Ongoing in Treatment of Serious Bacterial Infections,2016-06-20 12:31:00-04:00,MRK,negative
852198.0,Merck Offers Results of Phase 2 Study for Relebactam in Combo with Imipenem/Cilastatin,2016-06-20 12:30:00-04:00,MRK,neutral
852199.0,Cramer Talks About Merck's 'Fabulous News' And Why The Market Can't Rally,2016-06-16 13:10:00-04:00,MRK,positive
852200.0,Merck Rallies Of Drug Trial Results,2016-06-16 12:04:00-04:00,MRK,neutral
852201.0,Merck Announces Keytruda Met Primary and Secondary Endpoint,2016-06-16 06:46:00-04:00,MRK,neutral
852202.0,Jefferies Shares Pharma Stock Catalyst Outlook,2016-06-14 16:33:00-04:00,MRK,positive
852203.0,Merck Reports MK-1293 Met Primary Endpoint in Two Phase 3 Studies,2016-06-13 10:30:00-04:00,MRK,neutral
852204.0,"Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators",2016-06-13 09:37:00-04:00,MRK,negative
852205.0,"Merck, Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions",2016-06-12 08:29:00-04:00,MRK,positive
852206.0,"UPDATE: Merck To Pay $500M Cash Upfront, Afferent Holders Eligible FOr Addition $750M Tied To 'clinical development and commercial milestones for multiple indications and candidates, including AF-219'",2016-06-09 17:08:00-04:00,MRK,negative
852207.0,Merck To Acquire Afferent Pharmaceuticals,2016-06-09 17:07:00-04:00,MRK,neutral
852208.0,"Hearing FDA Panel Has Said Merck Has Provided Substantial Evidence of Safety, Effectiveness of Bezlotoxumab",2016-06-09 15:51:00-04:00,MRK,positive
852209.0,BZ NOTE: Relypsa Shares Still Up $0.20-$0.40 from Where Stock Was Trading Prior to Apparent Rumor Manipulation Ahead of Negative StreetSweeper Report (See Body of This Headline for More),2016-06-09 10:04:00-04:00,MRK,negative
852210.0,"Hearing Merck May Be Interested In RLYP, Unconfirmed Takeover Chatter",2016-06-09 09:52:00-04:00,MRK,positive
852211.0,"Agenus Reports Lead Product Candidate Selection in its Collab with Merck, Received First Milestone Payment of $2M",2016-06-09 08:50:00-04:00,MRK,neutral
852212.0,"Merck Says Ruling Reversal in Gilead Case 'Doesn't Reflect the Facts,' Co. Will Appeal Ruling Overturn",2016-06-07 15:53:00-04:00,MRK,neutral
852213.0,Goldman Confident In Merck's Keytruda,2016-06-07 14:43:00-04:00,MRK,positive
852214.0,FDA Staff Has Said Overall Clinical Results from Merck's Bezlotoxumab Trial Could Negatively Impact Cure Rate of Initial Episode of Infection with C. Difficile,2016-06-07 08:47:00-04:00,MRK,neutral
852215.0,US Judge Rules Gilead Won't have to Pay $200M Jury Verdict to Merck in Hepatitis C Patent Dispute -Reuters,2016-06-06 20:17:00-04:00,MRK,negative
852216.0,4 Key Takeaways From ASCO,2016-06-06 17:32:00-04:00,MRK,neutral
852217.0,"Merck, Pfizer Offers Results from Pivotal Avelumab Study",2016-06-06 09:09:00-04:00,MRK,neutral
852218.0,Merck Reports Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Respond with KEYTRUDA,2016-06-06 08:03:00-04:00,MRK,neutral
852219.0,Merck Announces New Data from Phase 2 Study Evaluating KEYTRUDA for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers at #ASCO16,2016-06-05 16:25:00-04:00,MRK,neutral
852220.0,Lilly Announces Encouraging Data of Early-Phase Immuno-Oncology Studies of ALIMTA and CYRAMZA with Merck's KEYTRUDA in NSCLC Presented at #ASCO16,2016-06-05 09:15:00-04:00,MRK,positive
852221.0,"Merck Announces New Data for KEYTRUDA in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at #ASCO16",2016-06-05 09:01:00-04:00,MRK,positive
852222.0,New Data Evaluating KEYTRUDA in Combination with Chemotherapy for First-Line Treatment of NSCLC Demonstrate Response Rates Ranging of 48%71%; Data to be Presented at #ASCO16,2016-06-04 09:57:00-04:00,MRK,neutral
852223.0,"New KEYTRUDA Data from KEYNOTE-010 and KEYNOTE-001 in Advanced NSCLC, Including Survival Data, to be Presented at #ASCO16",2016-06-04 09:42:00-04:00,MRK,positive
852224.0,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions",2016-06-03 13:49:00-04:00,MRK,negative
852225.0,Merck Gets Favorable Opinion From CHMP For Its ZEPATIER,2016-05-27 08:38:00-04:00,MRK,positive
852226.0,Merck Receives Positive CHMP Opinion for ZEPATIER in the European Union,2016-05-27 07:48:00-04:00,MRK,positive
852227.0,Celgene Rallies Of Possible Interest From Merck,2016-05-26 12:10:00-04:00,MRK,positive
852228.0,"Celgene Shares Spiking, Traders Passing Vague Comments Of Possible Interest From Merck",2016-05-26 10:45:00-04:00,MRK,positive
852229.0,Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness,2016-05-23 11:46:00-04:00,MRK,neutral
852230.0,JPMorgan's Take On Big Pharma's New ASCO Abstracts,2016-05-19 11:07:00-04:00,MRK,neutral
852231.0,Merck To Present New And Updated Data On KEYTRUDA,2016-05-16 09:45:00-04:00,MRK,neutral
852232.0,"Berenberg Unimpressed With Pfizer, Initiates Coverage At Hold",2016-05-12 17:59:00-04:00,MRK,negative
852233.0,Merck To Present Final Stage Data On Investigational Medicines Ertugliflozin And MK-1293,2016-05-12 10:59:00-04:00,MRK,neutral
852234.0,What's M&A Like In The Biotech Sector Right Now?,2016-05-06 08:40:00-04:00,MRK,positive
852235.0,Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Zynga Shares Rise Following Earnings Beat,2016-05-05 14:31:00-04:00,MRK,neutral
852236.0,Merck Lower After Mixed Q1 Report,2016-05-05 13:32:00-04:00,MRK,negative
852237.0,Mid-Day Market Update: Fitbit Slides  On Weak Outlook; Atlas Air Worldwide Shares Shares Spike Higher,2016-05-05 12:16:00-04:00,MRK,positive
852238.0,Mid-Morning Market Update: Markets Edge Higher; Merck Profit Beats Views,2016-05-05 09:54:00-04:00,MRK,positive
852239.0,"Merck Launch of Zepatier  in EU May be Delayed Until Late 2016, Early 2017 as Regulator Inspects Record-Keeping of Third Party Manufacturer -Reuters",2016-05-05 09:35:00-04:00,MRK,positive
852240.0,"Merck's Q1 Adjusted Profit beats, But Revenue Miss, Narrows Adjusted EPS FY16 Forecast",2016-05-05 07:41:00-04:00,MRK,neutral
852241.0,Merck Sees FY 2016 EPS $3.65 to $3.77 vs $3.71 est,2016-05-05 06:47:00-04:00,MRK,neutral
852242.0,"Merck Q1 EPS $0.89 vs $0.85 est, Revenue $9.3B vs $9.5B est",2016-05-05 06:46:00-04:00,MRK,neutral
852243.0,"12 Stocks To Watch For May 5, 2016",2016-05-05 05:04:00-04:00,MRK,neutral
852244.0,"Earnings Scheduled For May 5, 2016",2016-05-05 04:36:00-04:00,MRK,neutral
852245.0,"TheStreet's Adam Feuerstein Tweets '$MRK $BMY are not working with $NWBO on cancer immunotherapy combination clinical trials, per their respective spokespersons.'",2016-05-03 10:33:00-04:00,MRK,negative
852246.0,Earnings: Drug Makers Merck And Pfizer Report Q1 Results,2016-05-02 10:58:00-04:00,MRK,neutral
852247.0,"The Market In 5 Minutes: May, She Will Stay",2016-05-02 09:49:00-04:00,MRK,neutral
852248.0,Merck And Pfizer Earnings: Will They Beat Expectations Again?,2016-05-01 11:25:00-04:00,MRK,neutral
852249.0,Pharma Names Under Pressure Amid Perrigo Warning,2016-04-25 13:53:00-04:00,MRK,negative
852250.0,"Merck Animal Health To Acquire Rights To Whisper Veterinary Stethoscope System, Terms Not Disclosed",2016-04-19 17:01:00-04:00,MRK,neutral
852251.0,"Merck Gives Statement On Blueprint Project Findings AT AACR, Encouraged By Findings And Eager To Support Greater Biomarker Testing Use",2016-04-19 14:06:00-04:00,MRK,positive
852252.0,Merck Reports Received Breakthrough Therapy Designation from FDA for KEYTRUDA in cHL,2016-04-18 08:05:00-04:00,MRK,neutral
852253.0,Merck Announces Results From Phase 3 Studies of ZEPATIER in Chronic Hep C Patient Populations at ILC,2016-04-16 10:00:00-04:00,MRK,neutral
852254.0,"Jefferies Maintains Hold on Merck & Co, Raises PT to $54.00",2016-04-15 07:19:00-04:00,MRK,neutral
852255.0,"After-Hours Recap: Big Banks, Liquidity Services's DoD Deal, Haemonetics' CFO & More",2016-04-14 17:17:00-04:00,MRK,neutral
852256.0,Merck Kgaa Says Filed Answer in Response to Trademark Right Violation Claims Made By Merck,2016-04-14 08:18:00-04:00,MRK,negative
852257.0,Merck's ZEPATIER Showed Superiority on Efficacy and Safety Endpoints vs Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial,2016-04-14 04:18:00-04:00,MRK,positive
852258.0,Merck Says FDA Accepts Its sBLA For Keytruda And Grants Priority Review,2016-04-13 08:04:00-04:00,MRK,positive
852259.0,"FDA Accepts Supplemental Biologics License Application for Merck's KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review",2016-04-13 07:00:00-04:00,MRK,negative
852260.0,Merck Announces License Application for Investigational House Dust Mite SLIT-tablet Accepted for Review by FDA,2016-04-13 04:20:00-04:00,MRK,positive
852261.0,"Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term",2016-04-12 10:06:00-04:00,MRK,positive
852262.0,"Notable Imbalances Before Tuesday's Open Led By Under Armour, Boeing, Caterpillar",2016-04-12 09:25:00-04:00,MRK,neutral
852263.0,How One Analyst Is Playing The Biotech Rebound This Week,2016-04-07 15:45:00-04:00,MRK,positive
852264.0,"BZ NOTE: Relypsa Has Been Mentioned In Rumors Over Past 7 Months In Possible M&A Talk With Sanofi, Merck, Astra Zeneca",2016-04-07 13:05:00-04:00,MRK,positive
852265.0,"PPH May Be Home To Hedge Fund Hotels, But This ETF Can Endure",2016-04-06 14:26:00-04:00,MRK,neutral
852266.0,SocGen Picks New Favorites In Big Pharma,2016-04-06 13:44:00-04:00,MRK,positive
852267.0,Societe Generale Initiates Coverage on Merck & Co at Buy,2016-04-06 11:47:00-04:00,MRK,neutral
852268.0,Merck Will Present New KEYTRUDA Data At AACR Meeting Apr. 16-20th,2016-04-06 08:04:00-04:00,MRK,neutral
852269.0,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP,2016-04-06 04:52:00-04:00,MRK,positive
852270.0,"Advaxis, Merck Combination Trial Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort",2016-04-05 08:01:00-04:00,MRK,neutral
852271.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-04-04 16:52:00-04:00,MRK,neutral
852272.0,This Data Signals The End For Merck's Anacetrapib,2016-04-04 11:33:00-04:00,MRK,neutral
852273.0,Make A House Call With A Familiar Healthcare ETF,2016-04-04 08:28:00-04:00,MRK,neutral
852274.0,"Biopharma Names LLY, PFE, MRK, And More Popping Higher Following Reports China FDA To Investigate Improper Vaccine Trading",2016-03-28 11:29:00-04:00,MRK,neutral
852275.0,Data Shows Gilead's HCV Franchise Is Surviving New Competition,2016-03-28 10:47:00-04:00,MRK,positive
852276.0,"Patent Expert: It's Not Over For Gilead, Still Has Strong Defense Against Merck",2016-03-24 15:20:00-04:00,MRK,positive
852277.0,Jury Rules Merck Patents Validâ€¦Bad For Gilead?,2016-03-23 10:58:00-04:00,MRK,neutral
852278.0,Gilead -2.5% Premarket Following Verdict Tuesday Validating Merck's Hep C Patents,2016-03-23 06:30:00-04:00,MRK,positive
852279.0,Organovo Is A Company 3D Printing Human Tissue And Its CEO Is Excited About Creating Livers,2016-03-17 15:57:00-04:00,MRK,positive
852280.0,Agenus Shares Spike Higher Following Mid-Day Upgrade To Buy From Maxim,2016-03-12 12:04:00-05:00,MRK,positive
852281.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-10 16:46:00-05:00,MRK,neutral
852282.0,Jimmy Carter Boosts Social Media Buzz For Merck's Blockbuster Drug,2016-03-08 13:30:00-05:00,MRK,positive
852283.0,"Sanofi Pasteur, Merck Report Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies",2016-03-08 08:04:00-05:00,MRK,positive
852284.0,Gilead Vs. Merck: What To Know,2016-03-07 15:19:00-05:00,MRK,neutral
852285.0,FDA Accepts Supplemental Biologics License Application For Keytruda,2016-03-07 08:02:00-05:00,MRK,positive
852286.0,"UPDATE: Merck, Pfizer, and Verastem Combination Trial Of Avelumab and VS-6063 Expected To Begin In 2nd Half 2016",2016-03-03 07:16:00-05:00,MRK,neutral
852287.0,"Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Report Combination Trial of Avelumab and VS-6063 in Ovarian Cancer",2016-03-03 07:10:00-05:00,MRK,negative
852288.0,"Watch Pharma Names Following FDA Issuance Of New Mandatory Clinical Study For Bayer's 'Essure', Requires Product Labeling, Including Box Warnings And Patient Decision Checklist",2016-02-29 15:39:00-05:00,MRK,negative
852289.0,3 Mega Biotechs Leerink Loves,2016-02-29 13:25:00-05:00,MRK,positive
852290.0,AureoGen Announces Licensing Agreement with Merck,2016-02-24 10:05:00-05:00,MRK,positive
852291.0,Will Merck Encroach On Gilead's Harvoni Territory?,2016-02-23 11:36:00-05:00,MRK,neutral
852292.0,"8,383 Patients Contacted to Arrange Blood Test Following Possible Exposure to ex-NHS Worker with Hepatitis C -Sky News",2016-02-23 05:41:00-05:00,MRK,neutral
852293.0,"Merck Reports Investigational One-Daily Formulation of ISENTRESS Met Primary, Secondary Endpoints in Pivotal Phase 3 Trial",2016-02-22 08:00:00-05:00,MRK,neutral
852294.0,ALK Announces Merck Submits BLA to FDA for Investigational House Dust Mite SLIT-tablet,2016-02-10 04:15:00-05:00,MRK,neutral
852295.0,How To Invest In An Aging World With The 'Live Long & Prosper' ETF,2016-02-08 10:53:00-05:00,MRK,neutral
852296.0,A Checkup On A Big Healthcare ETF,2016-02-05 13:19:00-05:00,MRK,neutral
852297.0,How To Build A Defensive Portfolio,2016-02-04 15:13:00-05:00,MRK,neutral
852298.0,25 Companies That Could Still Buy Back Mountains Of Stock,2016-02-04 12:39:00-05:00,MRK,neutral
852299.0,"ImmunoGen, Merck Partner For Clincial Evaluation Of Mirvetuximab Soravtansine With Keytruda Combination For Ovarian Cancer Treatment",2016-02-04 08:01:00-05:00,MRK,negative
852300.0,"Merck & Co., Inc. Falters After Q4 Report",2016-02-03 14:00:00-05:00,MRK,neutral
852301.0,Joe McCann: Here's How To Play Biotech Market In Earnings Season,2016-02-03 11:48:00-05:00,MRK,positive
852302.0,Shares Of Merck Dip Lower Following Q4 Print,2016-02-03 08:42:00-05:00,MRK,neutral
852303.0,"Merck Sees FY16 EPS $3.60-$3.75 vs. Est. $3.72, Rev. $38.7-$40.2B vs. Est. $40.25B",2016-02-03 08:05:00-05:00,MRK,neutral
852304.0,"Merck Reports Q4 EPS $0.93 vs. Est. $0.91, Rev. $10.215B vs. Est. $10.35B",2016-02-03 08:04:00-05:00,MRK,neutral
852305.0,Merck Sees FY 2016 EPS $3.60 to $3.75 vs $3.72 est,2016-02-03 06:53:00-05:00,MRK,neutral
852306.0,Merck Sees FY 2016 Revenue $38.7B vs $40.2B est,2016-02-03 06:53:00-05:00,MRK,neutral
852307.0,"Merck Q4 EPS $0.93 vs $0.91 est, Revenue $10.2B vs $10.4B est",2016-02-03 06:46:00-05:00,MRK,neutral
852308.0,"Keep an Eye on These 10 Stocks for February 3, 2016",2016-02-03 04:28:00-05:00,MRK,neutral
852309.0,"Earnings Scheduled For February 3, 2016",2016-02-03 04:16:00-05:00,MRK,neutral
852310.0,"Merck, Sanofi Exploring Potential End To Joint Venture In Europe",2016-02-02 10:18:00-05:00,MRK,neutral
852311.0,"Sanofi, Merck Considering Ending JV to Sell Vaccines in Europe -Bloomberg",2016-02-02 04:21:00-05:00,MRK,neutral
852312.0,"Earnings: Pharma Tends to Top Street Estimateâ€”Can PFE, MRK Repeat?",2016-02-01 10:38:00-05:00,MRK,positive
852313.0,"Stock Marquee is Crowded in Week Ahead: Oil, Earnings, Labor Data",2016-02-01 10:28:00-05:00,MRK,neutral
852314.0,Mixed Earnings Expectations For Merck And Pfizer,2016-01-31 19:21:00-05:00,MRK,neutral
852315.0,Gilead Hits New 52-Week Low; Here Are Two Reasons Why,2016-01-29 13:32:00-05:00,MRK,negative
852316.0,"Merck Confirms FDA Approval Of Hep C Drug At A Cost Of $54,600 Per Patient",2016-01-29 11:29:00-05:00,MRK,positive
852317.0,From Conf Call: Abbvie Says Merck's New Hep C Drug Will Crimp Viekira Pak Sales,2016-01-29 10:14:00-05:00,MRK,neutral
852318.0,"Merck Receives FDA Approval of Hep C Drug ZEPATIER; To Cost $54,600/Patient for 12-Week Course",2016-01-28 19:11:00-05:00,MRK,positive
852319.0,Adam Feurestein Reminds Twitter Followers 'Today Is Merck's HepC elbasvir/grazoprevir PDUFA',2016-01-28 11:48:00-05:00,MRK,neutral
852320.0,Adam Feuerstein @adamfeuerstein Tweet: Reminder: Today is $MRK HepC elbasvir/grazoprevir PDUFA. Co. spox knows first and most important post-approval question is: What price?,2016-01-28 10:18:00-05:00,MRK,positive
852321.0,Fast Money Picks For January 28,2016-01-28 06:36:00-05:00,MRK,neutral
852322.0,Abbott to Sell ALK's House Dust Mite Sublingual Allergy Immunotherapy Tablet in SE Asia,2016-01-28 04:16:00-05:00,MRK,neutral
852323.0,Bank of America Downgrades Merck & Co to Neutral,2016-01-27 08:48:00-05:00,MRK,neutral
852324.0,Merck Reports FDA Acceptance of Biologics License Application for Bezlotoxumab,2016-01-27 08:33:00-05:00,MRK,positive
852325.0,Merck Reports FDA Acceptance of BLA for Bezlotoxumab,2016-01-27 08:30:00-05:00,MRK,positive
852326.0,ACARIZAX Receives Marketing Authorization in France,2016-01-27 04:13:00-05:00,MRK,neutral
852327.0,US Big Pharma: What To Watch For In Q4 Results,2016-01-25 11:16:00-05:00,MRK,neutral
852328.0,Affimed to Collaborate with Merck to Evaluate AFM13 in Combination with KEYTRUDA for Patients with Hodgkin Lymphoma,2016-01-25 05:02:00-05:00,MRK,neutral
852329.0,Sierra Leone Confirms Second New Ebola Case in Less than a Week -Reuters,2016-01-20 16:33:00-05:00,MRK,neutral
852330.0,"Credit Suisse Sets Outperform Rating, $125 Target On Gilead Story",2016-01-20 08:26:00-05:00,MRK,positive
852331.0,Global Vaccine's Alliance Signs $5M Advance Order for Merck's Ebola Vaccine -Reuters,2016-01-20 04:27:00-05:00,MRK,neutral
852332.0,Write A Prescription For This Healthcare ETF,2016-01-15 08:24:00-05:00,MRK,neutral
852333.0,"Merck Announces Resolution of Vioxx Class Action Lawsuit, Cash Payment ~$680M",2016-01-15 07:00:00-05:00,MRK,negative
852334.0,UPDATE: Sierra Leone Ebola Victim Said to have Exposed 27 to Disease; Woman was Living in House With 22 People When She Became Ill -Reuters,2016-01-15 06:46:00-05:00,MRK,negative
852335.0,UPDATE: Sierra Leone Health Ministry Confirms Death from Ebola -Reuters,2016-01-15 05:40:00-05:00,MRK,negative
852336.0,Sierra Leone Health Ministry Investigating Suspected Death from Ebola -Reuters,2016-01-14 16:19:00-05:00,MRK,negative
852337.0,WHO to Announce End of Ebola Outbreak on Thursday -AFP,2016-01-13 04:27:00-05:00,MRK,neutral
852338.0,Fast Money Traders Share Their Biotech Picks,2016-01-12 07:14:00-05:00,MRK,positive
852339.0,"Merck Acquires IOmet Pharma, Terms Not Disclosed",2016-01-11 16:09:00-05:00,MRK,neutral
852340.0,Why This Codexis Analyst Is Confident Stock Is Worth $6,2016-01-06 12:51:00-05:00,MRK,positive
852341.0,Washington University Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer,2016-01-06 07:53:00-05:00,MRK,negative
852342.0,"Watch Stocks of Small-, Mid-Cap Cos. with Experimental Drugs as AP Reporting Merck CEO Frazier at Goldman Healthcare Conference Said Co. 'Raring to Go' on M&A Deals This Year",2016-01-05 13:15:00-05:00,MRK,neutral
852343.0,ANI Pharma Reports Closing of Deal to Purchase Two NDAs from Merck for $75M,2016-01-05 08:05:00-05:00,MRK,neutral
852344.0,"Pfizer, Merck KGaA Report Syndax to Collab to Investigate Safety, Tolerability, Prelim. Efficacy of Avelumab, Entinostat in Advanced Ovarian Cancer",2016-01-04 08:01:00-05:00,MRK,negative
852345.0,WHO Declares End of Ebola Virus Transmission in  Republic of Guinea,2015-12-29 05:49:00-05:00,MRK,neutral
852346.0,Peering Through The Fog To Find The Best Sectors Into Year End,2015-12-23 13:08:00-05:00,MRK,positive
852347.0,"Merck KGaA, Pfizer Report Advancement of Clinical Development Program with Two Added Phase III Trials of Avelumab",2015-12-22 08:03:00-05:00,MRK,neutral
852348.0,Merck CEO: Using Keytruda Could Extend Patient's Life By 13 Months On Average,2015-12-21 13:43:00-05:00,MRK,positive
852349.0,ALK Sells European Veterinary Business to Fidelio Capital; Terms Not Disclosed,2015-12-21 04:13:00-05:00,MRK,neutral
852350.0,Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook,2015-12-19 17:08:00-05:00,MRK,positive
852351.0,Merck's KEYTRUDA Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1,2015-12-19 11:52:00-05:00,MRK,negative
852352.0,Merck Reports FDA Approval of Expanded Indication for KEYTRUDA for Treatment of Patients with Advanced Melanoma,2015-12-18 16:05:00-05:00,MRK,positive
852353.0,"Merck Reports EMA's CHMP Has Responded to MAA for elbasvir/grazoprevir (50mg/100mg), Application Will Now Be Reviewed on Standard Timetable",2015-12-18 08:03:00-05:00,MRK,neutral
852354.0,"Codexis +7.1% Premarket @$4.50;, Co Announces Agreement Extension With Merck",2015-12-18 07:54:00-05:00,MRK,positive
852355.0,UPDATE: Merck Says Expanded Age Indication for GARDASIL 9 Includes 16-26 Age Range,2015-12-15 17:09:00-05:00,MRK,neutral
852356.0,Merck Announces FDA Approval for Expanded Age Indication for GARDASIL 9 in Males,2015-12-15 17:08:00-05:00,MRK,positive
852357.0,FDA Approves Bridion To Reverse Effects Of Neuromuscular Blocking Drugs Used In Surgery,2015-12-15 15:18:00-05:00,MRK,neutral
852358.0,Fast Money Picks For December 15,2015-12-15 07:18:00-05:00,MRK,neutral
852359.0,Hearing FDA Panel Has Voted IMPROVE-IT Data for Merck's Zetia to Statin Therapy Does Not Support Claim of Reduced Risk of CV Events,2015-12-14 16:19:00-05:00,MRK,negative
852360.0,Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds,2015-12-12 14:05:00-05:00,MRK,neutral
852361.0,9 Healthcare Picks For 2016,2015-12-10 14:26:00-05:00,MRK,neutral
852362.0,UPDATE: Merck Says Biothera Research Shows Imprime PGG Activates Key Immune Responses,2015-12-10 09:02:00-05:00,MRK,positive
852363.0,Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG,2015-12-10 09:00:00-05:00,MRK,neutral
852364.0,Eli Lilly and Merk Announces Expansion of Immuno Oncology Collaboration,2015-12-10 06:31:00-05:00,MRK,neutral
852365.0,"Merck Reports Samsung Bioepis Receives Approval of RENFLEXIS, a Biosimilar of Remicade, in Korea",2015-12-07 08:00:00-05:00,MRK,positive
852366.0,Must Watch Stocks for Today,2015-12-07 04:25:00-05:00,MRK,neutral
852367.0,Benzinga's Weekend M&A Chatter,2015-12-06 20:45:00-05:00,MRK,neutral
852368.0,Merck Spokesperson Declines Comment on Speculation Related to Relypsa,2015-12-04 13:39:00-05:00,MRK,neutral
852369.0,EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer',2015-12-04 13:14:00-05:00,MRK,positive
852370.0,EXCLUSIVE: Wedbush's Liana Moussatos Tells Benzinga Sanofi 'is a natural buyer of Relypsa',2015-12-04 12:43:00-05:00,MRK,positive
852371.0,EXCLUSIVE: Source Tells Benzinga Merck Is Not Involved With Relypsa Bid; Calls To Merck Were Not Immediately Returned,2015-12-04 12:26:00-05:00,MRK,positive
852372.0,Hearing Unconfirmed Marker Chatter of Potential Merck Bid for Relypsa,2015-12-04 11:46:00-05:00,MRK,negative
852373.0,"Amgen, Merck Report Cancer Immunotherapy Partnership For Patients With Non-Hodgkin Lymphoma",2015-12-04 08:01:00-05:00,MRK,negative
852374.0,Barclays' Biopharmaceuticals Blueprint For 2016,2015-12-01 11:54:00-05:00,MRK,neutral
852375.0,Barclays On Merck: Too Much Underlying Value To Ignore,2015-12-01 07:36:00-05:00,MRK,neutral
852376.0,"Barclays Upgrades Merck & Co to Overweight, Raises PT to $66.00",2015-12-01 05:04:00-05:00,MRK,negative
852377.0,"Deere Announces Factory Workforce Adjustments, 220 Employees On Indefinite Leave Starting Feb 2016",2015-11-30 09:01:00-05:00,MRK,negative
852378.0,MITICURE for house Dust Mite Allergic Rhinitis Now Available in Japan,2015-11-25 20:42:00-05:00,MRK,negative
852379.0,Merck Increases Qtr. Dividend From $0.45 To $0.46/Share,2015-11-24 12:35:00-05:00,MRK,neutral
852380.0,Benzinga's Top Initiations,2015-11-24 09:43:00-05:00,MRK,positive
852381.0,Berenberg Initiates Coverage on Merck & Co at Buy,2015-11-24 05:19:00-05:00,MRK,neutral
852382.0,15-Year Old Boy is First Ebola Fatality in Liberia Since Country was Declared Ebola Free in September -Reuters,2015-11-24 04:26:00-05:00,MRK,negative
852383.0,Three New Ebola Cases Reported in Liberia; 153 Persons Under Observation -Reuters,2015-11-22 09:22:00-05:00,MRK,neutral
852384.0,Merck Announces Initial Results for KEYTRUDA with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress,2015-11-21 20:55:00-05:00,MRK,positive
852385.0,"Hearing Merck Planning to Expand Presence in African, Wants to More Than Double Sales in Africa by '20",2015-11-20 08:11:00-05:00,MRK,positive
852386.0,US Stock Futures Edge Higher Ahead Of Jobless Claims Report,2015-11-19 08:06:00-05:00,MRK,neutral
852387.0,Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial,2015-11-19 06:33:00-05:00,MRK,negative
852388.0,"Shares of Sigma Aldrich Halted, is Being Taken Out by Merck KGaA",2015-11-18 08:33:00-05:00,MRK,positive
852389.0,"Merck, Darmstadt, Pfizer Report FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma",2015-11-18 07:00:00-05:00,MRK,neutral
852390.0,Cambodia Reports Outbreak Of Highly Pathogenic H5N1 Bird Flu -Reuters,2015-11-16 10:19:00-05:00,MRK,negative
852391.0,"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting",2015-11-15 09:55:00-05:00,MRK,neutral
852392.0,"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy",2015-11-15 09:55:00-05:00,MRK,neutral
852393.0,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Celgene,2015-11-13 10:58:00-05:00,MRK,negative
852394.0,Merck Issues Update on REVEAL Outcomes Sutdy,2015-11-13 08:02:00-05:00,MRK,neutral
852395.0,"Merck Issues Statement Regarding CUBICIN Patent Litigation; Says Reviewing Decision, Considering Next Steps",2015-11-12 11:52:00-05:00,MRK,negative
852396.0,Patient in Brazil Being Tested for Ebola; 46 Year Old Man Came from Guniea -Reuters,2015-11-11 11:18:00-05:00,MRK,neutral
852397.0,WHO Declares Sierra Leone Ebola-Free,2015-11-09 04:26:00-05:00,MRK,neutral
852398.0,UPDATE: Merck Says 'We believe that BRIDION has the potential to offer anesthesia professionals an important new option to reverse neuromuscular blockade in the surgical setting',2015-11-06 14:19:00-05:00,MRK,positive
852399.0,Merck Issues Statement on FDA Panel Meeting for BRIDION,2015-11-06 14:18:00-05:00,MRK,neutral
852400.0,FDA Panel Votes 13-1 In Favor Of Merck Presenting Sufficient Data To Characterize Risk Of Hypersensitivity With Sugammadex -Reuters,2015-11-06 13:16:00-05:00,MRK,positive
852401.0,Are You Investing Like A Millennial Or A Baby Boomer?,2015-11-06 07:09:00-05:00,MRK,positive
852402.0,Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting,2015-11-05 08:43:00-05:00,MRK,neutral
852403.0,"Merck, Pfizer Report Initiation of Phase III First-Line Trial of Avelumab",2015-11-04 08:01:00-05:00,MRK,neutral
852404.0,"GSK, Merck to Study Immunotherapy Combination as Potential Cancer Treatment",2015-11-03 06:58:00-05:00,MRK,negative
852405.0,Merck Receives Breakthrough Therapy Designation from U.S.FDA for KEYTRUDA(R) (pembrolizumab) in Advanced Colorectal Cancer,2015-11-02 08:10:00-05:00,MRK,negative
852406.0,These Three Pharma Giants Just Crushed Earnings,2015-10-27 10:09:00-04:00,MRK,negative
852407.0,UPDATE: Merck Sees FY15 Sales $39.2B-$39.8B vs $39.67B Est.,2015-10-27 07:14:00-04:00,MRK,neutral
852408.0,Merck Sees FY EPS $3.55 to $3.60 vs $3.51 est,2015-10-27 06:52:00-04:00,MRK,neutral
852409.0,"Merck Reports Q3 EPS $0.96 vs. Est. $0.92, Rev. $10.073B vs. Est. $10.08B",2015-10-27 06:51:00-04:00,MRK,neutral
852410.0,"Earnings Scheduled For October 27, 2015",2015-10-27 04:14:00-04:00,MRK,neutral
852411.0,"Earnings Boom This Week: Big Pharma, E-Commerce Giant BABA And More",2015-10-26 15:57:00-04:00,MRK,neutral
852412.0,Fed Meeting A Mid-Week Bump In Flurry Of Earnings News,2015-10-26 14:02:00-04:00,MRK,neutral
852413.0,Merck's KEYTRUDA Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1,2015-10-26 09:01:00-04:00,MRK,neutral
852414.0,"Merck Trading Higher Off Of Abbvie, Gilead FDA Comments, Up 3.62% On The Day At $52.42/Share",2015-10-22 15:28:00-04:00,MRK,neutral
852415.0,Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund,2015-10-14 14:09:00-04:00,MRK,negative
852416.0,Nurse who Contracted Ebola in West Africa Now Critically Ill from Complications -BBC,2015-10-14 12:10:00-04:00,MRK,negative
852417.0,Tianjin CanSino Biotechnology to Mass Produce Ebola Vaccine -Xinhua,2015-10-14 04:25:00-04:00,MRK,neutral
852418.0,"Incyte, Merck Increase Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytrudaas First-line Treatment for Advanced Melanoma",2015-10-13 07:30:00-04:00,MRK,positive
852419.0,Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with KeytrudaÂ® (pembrolizumab) as First-line Treatment for Advanced Melanoma,2015-10-13 07:30:00-04:00,MRK,positive
852420.0,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt,2015-10-12 07:48:00-04:00,MRK,neutral
852421.0,"WHO Says Nigerian Suspected of Dying from Ebola, Did Not have the Virus -Reuters",2015-10-09 08:26:00-04:00,MRK,negative
852422.0,KEYTRUDAÂ® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma,2015-10-09 07:00:00-04:00,MRK,positive
852423.0,Ten People Quarantined Due to Possible Ebola Cases in Nigeria's Calabar City,2015-10-08 14:55:00-04:00,MRK,neutral
852424.0,Dynavax Reports Initiation of Immuno-Oncology Clinical Trial of SD-101 in Combo with Merck's KEYTRUDA,2015-10-08 07:01:00-04:00,MRK,neutral
852425.0,"Guinea, Liberia, Sierra Leone See No New Cases for Week to October 4 -Reuters",2015-10-07 14:01:00-04:00,MRK,negative
852426.0,"Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Given FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma",2015-10-07 07:01:00-04:00,MRK,neutral
852427.0,"Agilent Company Dako, Announces FDA Approval of New Companion Diagnostic for Lung Cancer",2015-10-05 04:11:00-04:00,MRK,negative
852428.0,Merck PR Confirms FDA Approves KEYTRUDA for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy,2015-10-02 14:50:00-04:00,MRK,negative
852429.0,Bristol-Myers Spikes to High Following FDA Approval of Merck's Keytruda,2015-10-02 13:58:00-04:00,MRK,positive
852430.0,FDA Approves Merck's Keytruda For Advanced Non-Small Cell Lung Cancer,2015-10-02 13:44:00-04:00,MRK,negative
852431.0,"Merck, DNAtrix Report Phase 2 Immuno-Oncology Partnership in Patients with Aggressive Form of Brain Cancer",2015-10-01 08:01:00-04:00,MRK,negative
852432.0,Roth Capital Upgrades ANI Pharmaceuticals To Buy On Valuation,2015-09-28 14:22:00-04:00,MRK,neutral
852433.0,"Merck, Syndax Pharma Announce First Patients Dosed in Phase 1b/2 Trial of Entinostat, KEYTRUDA",2015-09-28 08:06:00-04:00,MRK,neutral
852434.0,"Merck Reports Japan's PMDA Approved MARIZEV 25, 12.5mg Tablets",2015-09-28 07:35:00-04:00,MRK,positive
852435.0,"Merck Announces New Data from KEYNOTE-028 Trial Evaluating KEYTRUDA Across Range of Cancer Types, Presented at 2015 ECC",2015-09-27 07:54:00-04:00,MRK,negative
852436.0,Merck Presents New Findings Showing Anti-Tumor Activity of KEYTRUDA in Patients with Advanced NPC,2015-09-26 07:33:00-04:00,MRK,positive
852437.0,"Merck, Pfizer Reports FDA Orphan Drug Designation for Investigation Avelumab",2015-09-25 07:01:00-04:00,MRK,neutral
852438.0,"Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab",2015-09-24 17:01:00-04:00,MRK,neutral
852439.0,ANI Pharmaceuticals to Acquire Two NDAs from Merck for $75M,2015-09-21 08:04:00-04:00,MRK,neutral
852440.0,Data in Nine Difficult-to-Treat Cancers from Merck's KEYTRUDA Development Program to be Presented at European Cancer Congress 2015,2015-09-21 08:01:00-04:00,MRK,negative
852441.0,Merck's Bezlotoxumab Met Primary Endpoint in Phase 3 Studies,2015-09-20 13:08:00-04:00,MRK,neutral
852442.0,"UPDATE: Merck Phase 2 Primary Efficacy Endpoint Was Similar Across Both Relebactam Groups Along With Placebo Group, All 95% Or Higher",2015-09-18 15:03:00-04:00,MRK,neutral
852443.0,Merck Offers Results from Phase 2 Study of Investigational Beta-Lactamase Inhibitor at ICAAC/ICC '15: Met Primary Endpoint,2015-09-18 15:02:00-04:00,MRK,negative
852444.0,"Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley",2015-09-18 11:00:00-04:00,MRK,neutral
852445.0,Merck To Submit Applications To U.S. For Approval Of Ertugliflozin By End Of 2016,2015-09-17 08:37:00-04:00,MRK,positive
852446.0,"Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes",2015-09-17 08:30:00-04:00,MRK,positive
852447.0,Merck Offers Highlights for Commitment to Infectious Disease with 40 Presentations of Data at ICAAC/ICC '15,2015-09-16 07:34:00-04:00,MRK,positive
852448.0,Amgen And Biogen Lead Short Interest Surge In Biotechs,2015-09-14 16:01:00-04:00,MRK,positive
852449.0,"Merck, Samsung Bioepis Report Approval of BRENZYS, a Biosimilar of Enbrel, in Korea",2015-09-08 08:31:00-04:00,MRK,positive
852450.0,MKM Partners Would Sell These Healthcare Stocks On Weaker Relative Trends,2015-09-08 07:59:00-04:00,MRK,negative
852451.0,Sierra Leone to Vaccinate 200 People Who Came in Contact With Latest Ebola Victim -Reuters,2015-09-02 16:57:00-04:00,MRK,negative
852452.0,FDA Approves Pediatric Indication for EMENDÂ® (aprepitant) Capsules in Combination with Other Antiemetic Agents,2015-09-02 08:04:00-04:00,MRK,positive
852453.0,Organovo CEO Keith Murphy: 'People Are Missing The Forest For The Trees',2015-09-01 14:42:00-04:00,MRK,negative
852454.0,"It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod",2015-09-01 14:40:00-04:00,MRK,neutral
852455.0,"Hearing Buyside Volume Coming Into Staples, Drug, And Chemical Names",2015-09-01 14:40:00-04:00,MRK,neutral
852456.0,New Analyses from the IMPROVE-IT Study with VYTORIN (ezetimibe and simvastatin),2015-09-01 09:06:00-04:00,MRK,neutral
852457.0,Barron's Recap: What's Next?,2015-08-30 20:37:00-04:00,MRK,neutral
852458.0,Sierra Leone Released its Last Confirmed Ebola Patient from Hospital on Monday -Reuters,2015-08-24 12:57:00-04:00,MRK,neutral
852459.0,New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN and the TECOS Cardiovascular Safety Trial of JANUVIA  Will Be Presented at the European Society of Cardiology Congress,2015-08-20 08:31:00-04:00,MRK,positive
852460.0,"FDA Accepts Supplemental Biologics License Application for KEYTRUDA, Merck's Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review",2015-08-18 08:03:00-04:00,MRK,positive
852461.0,Calls Of Note: Wall Street Research Moving The Market On Thursday,2015-08-13 13:35:00-04:00,MRK,neutral
852462.0,What Are Payors Saying About Managed Care Giants?,2015-08-13 09:31:00-04:00,MRK,positive
852463.0,Good Data May Be Coming For Merck (And This Analyst Is Bullish),2015-08-13 09:14:00-04:00,MRK,positive
852464.0,Benzinga's Top Upgrades,2015-08-13 09:13:00-04:00,MRK,positive
852465.0,"US Stock Futures Rise Ahead of Jobless Claims, Retail Sales Data",2015-08-13 07:32:00-04:00,MRK,neutral
852466.0,"BMO Capital Upgrades Merck & Co to Outperform, Raises PT to $70.00",2015-08-13 06:35:00-04:00,MRK,neutral
852467.0,"Sigma-Aldrich, Merck, Darmstadt, Germany, Report Antitrust Approval in Brazil for Planned Purchase",2015-08-11 07:32:00-04:00,MRK,positive
852468.0,Here's Which IT Stocks Benefit From Healthcare M&A,2015-08-10 12:23:00-04:00,MRK,positive
852469.0,"ALK's Partner, Torii Pharmaceutical, Reports Positive Phase II/III Trial Results for Japanese Cedar SLIT-tablet",2015-08-07 04:22:00-04:00,MRK,positive
852470.0,"Guinea, Sierra Leone Each Recorded Single Cases of Ebola in Past Week; WHO Says Risks Remain -Reuters",2015-08-04 10:05:00-04:00,MRK,negative
852471.0,Morning Market Gainers,2015-08-04 09:45:00-04:00,MRK,neutral
852472.0,"Codexis Reports CodeEvolver Technology Transfer, License Deal with Merck; Will Receive Up to $5M Upfront Payment, Eligibile for Up to $18M in Milestones",2015-08-03 16:34:00-04:00,MRK,neutral
852473.0,Merck Announces Global Collaboration Enabled Vaccine for Ebola Will Move from First-in-Human to Initial Phase 3 Results Within One Year,2015-07-31 08:10:00-04:00,MRK,neutral
852474.0,WHO Says Initial Results from Merck/Newlink VSV-EBOV Ebola Vaccine Look Promising -Reuters,2015-07-31 06:44:00-04:00,MRK,positive
852475.0,Merck Q2 Profit Beats Estimates,2015-07-28 07:43:00-04:00,MRK,positive
852476.0,UPDATE: Merck Sees FY15 Adj. EPS $3.45-$3.55 vs $3.45 Est.,2015-07-28 07:04:00-04:00,MRK,neutral
852477.0,"Merck Narrows, Raises FY15 Adj. EPS Outlook",2015-07-28 07:04:00-04:00,MRK,neutral
852478.0,"Merck Reports Q2 Adj. EPS $0.86 vs $0.81 Est., Sales $9.8B, Inline",2015-07-28 07:00:00-04:00,MRK,neutral
852479.0,Merck Boosts Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics,2015-07-28 06:45:00-04:00,MRK,positive
852480.0,Merck Announces FDA Priority Review For NDA For Hepatits C Treatment,2015-07-28 06:31:00-04:00,MRK,neutral
852481.0,"Earnings Scheduled For July 28, 2015",2015-07-28 04:38:00-04:00,MRK,neutral
852482.0,10 Stocks You Should Be Watching Today,2015-07-28 04:16:00-04:00,MRK,neutral
852483.0,Dollar Plagues Pharma Earnings But Did Street Get It Right?,2015-07-27 13:06:00-04:00,MRK,neutral
852484.0,Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA,2015-07-27 08:30:00-04:00,MRK,positive
852485.0,"MSD Reports European Medicines Agency Acceptance of Marketing Authorisation Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection",2015-07-23 11:02:00-04:00,MRK,positive
852486.0,RaNA Therapeutics Announces $55 Million in Oversubscribed Series B Financing Led by Merck,2015-07-23 07:06:00-04:00,MRK,neutral
852487.0,What's Coming For Large-Cap Pharma Stocks This Earnings Season?,2015-07-22 16:13:00-04:00,MRK,neutral
852488.0,"European Commission Approves MSD's Anti-PD-1 Therapy, KEYTRUDAÂ® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma",2015-07-22 07:00:00-04:00,MRK,positive
852489.0,Strong Dollar? Not So Good For Johnson & Johnson Earnings,2015-07-10 11:41:00-04:00,MRK,positive
852490.0,"Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz",2015-07-09 08:56:00-04:00,MRK,positive
852491.0,"Allergan, Merck Enter Licensing Agreement to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program",2015-07-07 07:00:00-04:00,MRK,positive
852492.0,9 Top Sell Ideas From Oppenheimer's Technical Analysis Division,2015-07-06 12:16:00-04:00,MRK,positive
852493.0,Merck Announces Phase 3 Study of Single-Dose EMENDÂ® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint,2015-06-29 08:31:00-04:00,MRK,neutral
852494.0,Barron's Recap: Airline Stocks Ready To Soar,2015-06-21 19:13:00-04:00,MRK,positive
852495.0,Barron's Says Merck Shares Could Rise More than 20% to $70,2015-06-21 15:15:00-04:00,MRK,positive
852496.0,Hearing Dept. of Justice Has Said Merck's Inspire Pharma to Pay $5.9M to Settle Civil Claims of Fraud,2015-06-17 16:13:00-04:00,MRK,positive
852497.0,The Note Moving Pharma Giants Today,2015-06-17 16:06:00-04:00,MRK,neutral
852498.0,"Organovo Has Upside To $6/Share, Cantor Fitzgerald Says",2015-06-17 09:27:00-04:00,MRK,neutral
852499.0,Piper Jaffray Initiates Coverage on Merck & Co at Neutral,2015-06-17 07:12:00-04:00,MRK,neutral
852500.0,"Benzinga's M&A Chatter for Tuesday June 16, 2015",2015-06-16 18:04:00-04:00,MRK,neutral
852501.0,New Report: Abbvie Is Jefferies' Top Global Pharma Stock,2015-06-16 12:15:00-04:00,MRK,positive
852502.0,Alkermes Declines Comment on Rumored Potential Bid from Merck,2015-06-16 11:03:00-04:00,MRK,neutral
852503.0,"Alkermes Shares Off the Highs; Shares Moving Higher on Takeover Chatter, Upcoming Presentation of Data from Late-Stage CNS Portfolio",2015-06-16 10:17:00-04:00,MRK,positive
852504.0,Hearing Merck Approached Dublin Based Alkermes With $12.4B Offer-Market Sources,2015-06-16 09:55:00-04:00,MRK,neutral
852505.0,JMP Sees A 'Negative Market Tone' In Biotechnology,2015-06-15 13:31:00-04:00,MRK,negative
852506.0,"Merck, Samsung Bioepis Report Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints",2015-06-10 08:46:00-04:00,MRK,neutral
852507.0,US Stock Futures Signal Higher Start On Wall Street,2015-06-10 07:30:00-04:00,MRK,neutral
852508.0,Merck Publishes ALK's Data On Phase II House Dust Mite SLIT-Tablet In Leading Allergy Journal,2015-06-10 07:22:00-04:00,MRK,neutral
852509.0,"TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes",2015-06-10 07:02:00-04:00,MRK,positive
852510.0,"Benzinga's M&A Chatter for  Monday June 8, 2015",2015-06-08 20:17:00-04:00,MRK,neutral
852511.0,"TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes",2015-06-08 16:30:00-04:00,MRK,positive
852512.0,"This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says",2015-06-08 14:03:00-04:00,MRK,positive
852514.0,UPDATE: Celgene Shares at High Following Early Rumored Bid from Merck,2015-06-08 12:10:00-04:00,MRK,positive
852515.0,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Celgene,2015-06-08 11:07:00-04:00,MRK,negative
852516.0,"Merck KGaA, Darmstadt, Germany, Illumina and Genea Create the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment",2015-06-08 07:02:00-04:00,MRK,positive
852517.0,ALK Announces Merck's North American Phase III Trial of House Dust Mite SLIT-Tablet Meets Primary Endpoint,2015-06-04 03:32:00-04:00,MRK,neutral
852518.0,Merck Announces Results from Investigational IMPROVE-IT Study of VYTORIN Published in NEJoM,2015-06-03 17:00:00-04:00,MRK,neutral
852519.0,"Merck Reports Acceptance of sBAL for KEYTRUDA in Advanced Non-Small Cell Lung Cancer, Priority Review Granted",2015-06-01 16:35:00-04:00,MRK,positive
852520.0,"Merck, Dynavax Partner On Investigating Combination Of Immuno-Oncology Therapies",2015-06-01 08:30:00-04:00,MRK,neutral
852521.0,Merck Announces New Data on Breadth of KEYTRUDA at ASCO: Anti-Tumor Activity Now Shown in 13 Different Tumor Types,2015-06-01 08:03:00-04:00,MRK,negative
852522.0,"TESARO, Merck to Collaborate on Combination Study of Niraparib, KEYTRUDA",2015-05-30 20:24:00-04:00,MRK,neutral
852523.0,Merck Shares Spike Higher Following Report on Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with KEYTRUDA,2015-05-29 14:20:00-04:00,MRK,positive
852524.0,Merck Shares Spiking Higher on Durable Anti-Tumor Activity With KEYTRUDA,2015-05-29 14:18:00-04:00,MRK,positive
852525.0,Initial Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck's KEYTRUDA (pembrolizumab) Showcased at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine,2015-05-29 14:05:00-04:00,MRK,neutral
852526.0,"Amgen, Merck Report Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combo with KEYTRUDA in Patients with Head and Neck Cancer",2015-05-29 08:31:00-04:00,MRK,negative
852527.0,Merck Announces Has Submitted NDA for Grazoprevir/Elbasvir in US,2015-05-28 16:30:00-04:00,MRK,neutral
852529.0,Expert Explains How To Play Merck In 2 Charts,2015-05-22 13:57:00-04:00,MRK,positive
852530.0,Merck Release Confirms CHMP Positive Recommendation for KEYTRUDA,2015-05-22 07:12:00-04:00,MRK,positive
852531.0,EMA Gives Positive Opinion for Merck's Melanoma Drug Keytruda,2015-05-22 07:03:00-04:00,MRK,positive
852532.0,"GSK, NewLink Vaccine Trials May Not Produce Useful Efficacy Data as Ebola Disappears in W. Africa -Reuters",2015-05-12 08:36:00-04:00,MRK,negative
852533.0,"Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers",2015-05-05 08:51:00-04:00,MRK,positive
852534.0,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Lilly,2015-05-01 10:14:00-04:00,MRK,negative
852535.0,Bank Of America Reviews Gilead Earnings,2015-05-01 08:46:00-04:00,MRK,neutral
852536.0,What's Wall Street Been Saying About Gilead Lately?,2015-04-29 12:34:00-04:00,MRK,neutral
852537.0,Morning Market Gainers,2015-04-28 09:45:00-04:00,MRK,neutral
852538.0,Bank Of America On Merck: 'MAGNIF-TECOS!',2015-04-28 09:30:00-04:00,MRK,neutral
852539.0,Benzinga's Top #PreMarket Gainers,2015-04-28 08:21:00-04:00,MRK,positive
852540.0,"Merck Beats Q1 Estimates, Shares Rise",2015-04-28 08:08:00-04:00,MRK,positive
852541.0,"Merck Raises FY15 Adj. EPS Outlook from $3.32-$3.47 Previously to $3.35-$3.48 vs $3.37 Est., Affirms Sales Outlook",2015-04-28 07:03:00-04:00,MRK,neutral
852542.0,"Merck Reports Q1 EPS $0.85 vs. Est. $0.74, Rev. $9.4B vs. Est. $8.99B",2015-04-28 07:01:00-04:00,MRK,neutral
852543.0,"Earning & Economic Calendar for Thursday April 28, 2015",2015-04-28 06:14:00-04:00,MRK,neutral
852544.0,"Earnings Scheduled For April 28, 2015",2015-04-28 04:35:00-04:00,MRK,neutral
852545.0,Merck Offers Results of Trial Evaluating CV Outcomes with Sitagliptin: Says Met Primary Endpoint,2015-04-27 17:01:00-04:00,MRK,neutral
852546.0,Merck Earnings: The Street And The Crowd Expect A Double-Digit Year-Over-Year Decline,2015-04-27 12:36:00-04:00,MRK,neutral
852547.0,Does Apple Hide More Cash Abroad Than Anyone?,2015-04-26 13:21:00-04:00,MRK,negative
852548.0,"U.S. Tech, Dollar & Health Care ETFs To Watch This Week",2015-04-26 10:52:00-04:00,MRK,positive
852549.0,Apple & Other Earnings Expected To Dominate The Week Of April 27,2015-04-26 10:45:00-04:00,MRK,negative
852550.0,Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story,2015-04-24 08:33:00-04:00,MRK,positive
852551.0,Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni,2015-04-24 06:36:00-04:00,MRK,negative
852552.0,Merck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection,2015-04-24 04:25:00-04:00,MRK,neutral
852553.0,"FDA Sentinel Study Finds No Association Between Venous Thromboembolism, Gardasil Vaccination -Reuters",2015-04-23 11:53:00-04:00,MRK,negative
852554.0,Merck Announces 99% of Patients in Phase 2/3 Study of Grazoprevir/Elbasvir Achieved Sustained Virologic Response,2015-04-23 04:26:00-04:00,MRK,neutral
852555.0,"Goat Plague (PPR) Affecting Herds in Africa, Asia -Reuters",2015-04-22 12:54:00-04:00,MRK,neutral
852556.0,UPDATE: Organovo Shares Rise 15% Following Announcement of Deal With Merck,2015-04-22 08:18:00-04:00,MRK,positive
852557.0,Organovo Announces Multi-Year Research Collaboration Agreement With Merck Sharp & Dohme Corp,2015-04-22 08:12:00-04:00,MRK,positive
852558.0,Morgan Stanley Awaits This Merck Data,2015-04-21 10:40:00-04:00,MRK,positive
852559.0,CAR-T Therapy Stocks Hit Hard Following AACR Data,2015-04-20 13:44:00-04:00,MRK,negative
852560.0,"Merck Will File ""Totality Of Data"" Regarding Hep C Drugs To FDA; Won't Limit FDA Filing To Breakthrough Status According To Phonecall With VP, Infectious Diseases Eliav Barr",2015-04-20 12:08:00-04:00,MRK,neutral
852561.0,Morning Market Gainers,2015-04-20 09:41:00-04:00,MRK,neutral
852562.0,"Tetralogic Announces Co., Merck Will Collaborate Related to Evaluation of Birinapant In Combo With KEYTRUDA in Solid Tumors",2015-04-20 08:05:00-04:00,MRK,positive
852563.0,Early Findings with Merck's Pembrolizumab in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting,2015-04-19 13:36:00-04:00,MRK,positive
852564.0,"Merck Announces New Data on Treatment of Advanced NSCLC with Pembrolizumab Presented at AACR Annual Meeting, Published in NEJM",2015-04-19 13:06:00-04:00,MRK,positive
852565.0,Early Findings with KEYTRUDA in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting,2015-04-19 13:01:00-04:00,MRK,positive
852567.0,It's A Big Weekend For Biotech,2015-04-17 16:31:00-04:00,MRK,neutral
852568.0,SunTrust's Latest Comments On Merck,2015-04-15 15:32:00-04:00,MRK,neutral
852569.0,Canine Flu Outbreak Reported in Chicago Area -Wall Street Journal,2015-04-15 11:40:00-04:00,MRK,negative
852570.0,Morgan Stanley's Major Pharma Q1 Preview,2015-04-14 16:47:00-04:00,MRK,neutral
852571.0,UPDATE: Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone,2015-04-14 13:30:00-04:00,MRK,neutral
852572.0,Ebola vaccine trial begins in Sierra Leone,2015-04-14 10:50:00-04:00,MRK,neutral
852573.0,Biotech Investors: Nomura Says To Watch These Dates,2015-04-10 13:10:00-04:00,MRK,neutral
852574.0,The Biotech Stocks JMP Is Watching,2015-04-09 17:23:00-04:00,MRK,neutral
852575.0,"Advaxis, Merck Report Initiation of Enrollment in Phase 1/2 Study of ADXS-PSA in Combo with Anti-PD-1 Therapy",2015-04-08 07:33:00-04:00,MRK,neutral
852576.0,"Grazoprevir/Elbasvir, Merck's Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2, 3 Data in Multiple HCV Patient Types Will Be Presented At The International Liver Congress TM 2015",2015-04-08 07:04:00-04:00,MRK,positive
852577.0,Sector ETFs And Earnings,2015-04-07 14:19:00-04:00,MRK,neutral
852578.0,Arvinas in Strategic R&D Collaboration With Merck to Study Novel Protein Degradation Technology,2015-04-07 06:35:00-04:00,MRK,negative
852579.0,Gilead Alert: What Deutsche Bank Is Saying,2015-04-06 12:36:00-04:00,MRK,positive
852580.0,Merck Shares Teetering On The Brink Of A Further Downside Correction,2015-04-06 10:20:00-04:00,MRK,positive
852581.0,Top 4 Large-Cap Stocks In The Drug Manufacturers Industry With The Highest ROE,2015-04-06 04:46:00-04:00,MRK,positive
852582.0,Syndax and Merck to Partner on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA (pembrolizumab) in Lung Cancer and Melanoma,2015-03-31 08:00:00-04:00,MRK,negative
852583.0,EMA Recommends Approval of Merck's Gardasil 9 Vaccine,2015-03-27 08:12:00-04:00,MRK,positive
852584.0,Merck Announces Deal with American Diabetes Association for Education of Adults with Diabetes,2015-03-26 08:31:00-04:00,MRK,neutral
852585.0,"Key Catalysts Are Coming For Merck, Analyst Predicts",2015-03-25 14:08:00-04:00,MRK,neutral
852586.0,Merck Announces New $10B Share Repurchase Program,2015-03-24 17:00:00-04:00,MRK,positive
852587.0,"Merck's Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints, Will be Stopped Early",2015-03-24 08:31:00-04:00,MRK,neutral
852588.0,"SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms",2015-03-23 12:21:00-04:00,MRK,neutral
852590.0,Merck Announced Results From Investigational IMPROVE-IT Study That Shows VYTORIN Reduced Total Cardiovascular Events By 9% Vs. SIMVASTATIN,2015-03-16 15:35:00-04:00,MRK,neutral
852591.0,Merck Provides Regulatory Update On Sugammadex Injection,2015-03-13 16:02:00-04:00,MRK,neutral
852592.0,Measles Cases Could ~Double in W African Countries Due to Stain on Health Systems from Ebola Outbreak; Inability to Maintain Child Immunizations -Reuters,2015-03-12 15:04:00-04:00,MRK,negative
852593.0,US Stock Futures Signal Higher Start On Wall Street,2015-03-11 07:39:00-04:00,MRK,neutral
852594.0,Merck Announces KEYTRUDA is First Medicine to be Made Available to Patients Through UK EAMS for Advanced Melanoma,2015-03-11 04:42:00-04:00,MRK,positive
852595.0,8 Healthcare Names Cowen & Co Are Talking About,2015-03-10 18:02:00-04:00,MRK,neutral
852597.0,"Merck Announces Co. Eisai Enter Deal to Explore Novel Combo Regimens Anti-PD-1 Therapy with RTK Inhibitor, Microtubule Dynamics Inhibitor for Cancers",2015-03-04 18:33:00-05:00,MRK,positive
852598.0,Fast Money Picks For March 2,2015-03-01 18:54:00-05:00,MRK,neutral
852599.0,"Merck HPV Vaccine GARDASILÂ®9, Recommended by CDC's Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21",2015-02-26 15:18:00-05:00,MRK,positive
852600.0,Heavy News Day For Several Biotech Stocks,2015-02-25 15:34:00-05:00,MRK,neutral
852601.0,Merck Collaborates with Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Developing Countries,2015-02-24 04:43:00-05:00,MRK,positive
852602.0,Evercore ISI Technical Analysis: The 'Single Best Idea',2015-02-23 07:34:00-05:00,MRK,positive
852603.0,UPDATE: Merck to Make Upfront Payment  NGM of $94M; Acquire 15% Stake in NGM for $106M,2015-02-23 07:06:00-05:00,MRK,neutral
852604.0,"Merck, NGM Report Broad Strategic Deal to Discover, Develop, Commercialize Novel Biologic Therpeutics",2015-02-23 07:03:00-05:00,MRK,positive
852605.0,NewLink Genetics Announces $20M Milestone Payment From MERCK,2015-02-19 08:41:00-05:00,MRK,neutral
852606.0,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?",2015-02-06 15:28:00-05:00,MRK,positive
852607.0,Fast Money Halftime Report Final Trade From February 5,2015-02-06 06:45:00-05:00,MRK,neutral
852608.0,Merck Prices $8B Debt Offering,2015-02-05 19:58:00-05:00,MRK,negative
852609.0,"UPDATE: Merck Posts Upbeat Q4 Earnings, Sales Decline",2015-02-04 08:03:00-05:00,MRK,neutral
852610.0,"Merck Sees FY15 Adj. EPS $3.32-$3.47 Including Items, Sales $38.3B-$39.8B Including Items",2015-02-04 07:05:00-05:00,MRK,neutral
852611.0,"Merck & Co Reports Q4 Adj. EPS $0.87 Vs Est $0.86, Sales $10.48B Vs Est $10.50B",2015-02-04 07:04:00-05:00,MRK,neutral
852612.0,"Earning & Economic Calendar for Wednesday February 4, 2015",2015-02-04 05:13:00-05:00,MRK,neutral
852613.0,"Earnings Scheduled For February 4, 2015",2015-02-04 05:08:00-05:00,MRK,neutral
852614.0,"Keep an Eye on These 10 Stocks for February 4, 2015",2015-02-04 04:08:00-05:00,MRK,neutral
852615.0,"Merck's Insomnia Medicine BELSOMRAÂ® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States",2015-02-03 08:05:00-05:00,MRK,neutral
852616.0,"Earnings Expectations For The Week Of February 2: Disney, Exxon, GM And More",2015-02-01 13:38:00-05:00,MRK,neutral
852617.0,What Investors Are Watching For In Regulus Therapeutics' Next Data Release,2015-01-30 14:32:00-05:00,MRK,neutral
852618.0,#Premarket Prep Technical Update - Merck Lower,2015-01-29 11:56:00-05:00,MRK,negative
852619.0,Fast Money Halftime Report Final Trade From January 27,2015-01-27 21:27:00-05:00,MRK,neutral
852620.0,White House Budget To Support Biotech Rally,2015-01-27 16:00:00-05:00,MRK,positive
852621.0,Merck Reports CHMP Positive Opinion for Investigational Antibiotic SIVEXTRO,2015-01-26 08:32:00-05:00,MRK,positive
852622.0,EMA Recommends Merck's Combination of Lamivudine/Raltegravir for Approval -Reuters,2015-01-23 07:09:00-05:00,MRK,positive
852623.0,The 5 Best Dow Stocks So Far In 2015,2015-01-20 17:33:00-05:00,MRK,positive
852624.0,#Premarket Prep Technical Update - Merck Lower,2015-01-20 14:34:00-05:00,MRK,negative
852625.0,"Barclays Issues 3 Upgrades, 1 Downgrade On Pharma Stocks",2015-01-16 15:12:00-05:00,MRK,neutral
852626.0,'Merck Acquires OncoEthix',2015-01-16 14:12:00-05:00,MRK,neutral
852627.0,Barclays Upgrades Merck to Equalweight,2015-01-16 07:16:00-05:00,MRK,neutral
852628.0,#Premarket Prep Technical Update - Merck Lower,2015-01-15 13:35:00-05:00,MRK,negative
852629.0,Fast Money Halftime Report Final Trade From January 14,2015-01-15 06:26:00-05:00,MRK,neutral
852630.0,Practice Fusion Announces Positive Results of Population Health Vaccine Initiative,2015-01-14 08:35:00-05:00,MRK,positive
852631.0,Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel',2015-01-13 08:20:00-05:00,MRK,neutral
852632.0,Merck and Eli Lilly Announce Agreement For Collaboration on Cancer Clinical Trial,2015-01-13 08:01:00-05:00,MRK,negative
852633.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,MRK,neutral
852634.0,Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014,2015-01-12 08:42:00-05:00,MRK,positive
852635.0,"FDA Has Approved Merck's Request to Supplement Pneumovax BLA, Will Add 2D Barcode on Label",2015-01-06 08:49:00-05:00,MRK,positive
852636.0,Bernstein Upgrades Merck to Outperform,2015-01-05 06:43:00-05:00,MRK,neutral
852637.0,What Investors Should Be Watching In The Antibiotic Space,2014-12-31 15:44:00-05:00,MRK,neutral
852638.0,19 Lesser-Known Biotech Stocks With Robust Drug Pipelines,2014-12-31 08:59:00-05:00,MRK,positive
852639.0,US Dept. of Health & Human Services Issues Release: 'HHS supports efforts to speed Ebola vaccine delivery',2014-12-23 16:44:00-05:00,MRK,positive
852640.0,Health Care And Biotech Sector Looking Sick,2014-12-23 15:42:00-05:00,MRK,neutral
852641.0,"FTC Requests Public Comment on Merck & Co., Inc.'s Application to Approve Sale of Facilities",2014-12-23 15:22:00-05:00,MRK,neutral
852642.0,#Premarket Prep Technical Update - Merck Lower,2014-12-22 14:11:00-05:00,MRK,negative
852643.0,NewLink Genetics Surges 3% Following Ebola Contract News,2014-12-22 09:32:00-05:00,MRK,neutral
852644.0,"NewLink Genetics Announces Collaboration with Merck for Manufacture of Ebola Vaccine, Deal Supported by $30M Award",2014-12-22 08:02:00-05:00,MRK,positive
852645.0,Merck Begins Tender Offer To Acquire Cubist,2014-12-19 08:01:00-05:00,MRK,neutral
852646.0,"Merck Reports Acquisition of OncoEthix for $110M Upfront Payment, Could Pay Added $265M in Milestone Payment",2014-12-18 07:32:00-05:00,MRK,negative
852647.0,Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines,2014-12-11 14:14:00-05:00,MRK,neutral
852648.0,These 4 Charts Highlight Twitter Sentiment For Today's Movers,2014-12-11 10:39:00-05:00,MRK,positive
852649.0,"Sky News Newsdesk Tweets: 'Reuters: Geneva University Hospital suspends trials of #Ebola vaccine one week early ""as a measure of precaution""'",2014-12-11 07:59:00-05:00,MRK,neutral
852650.0,Global Vaccines Alliance GAVI Said Thursday it was Committing up to $300M to Buy Ebola Vaccines -Reuters,2014-12-11 07:03:00-05:00,MRK,positive
852651.0,FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by 5 Additional Types of HPV,2014-12-10 13:43:00-05:00,MRK,positive
852652.0,"Data Investigating KEYTRUDA, Merck's Anti-PD-1 Therapy, In Patients With Advanced Triple-Negative Breast Cancer Presented At 2014 San Antonio Breast Cancer Symposium",2014-12-10 08:34:00-05:00,MRK,negative
852653.0,Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO,2014-12-09 15:02:00-05:00,MRK,neutral
852654.0,Mizuho Securities Downgrades Cubist Pharmaceuticals Post Acquisition Announcement,2014-12-09 12:14:00-05:00,MRK,positive
852655.0,#Premarket Prep Technical Update - Merck Lower,2014-12-09 12:10:00-05:00,MRK,negative
852656.0,"Hospira, Inc. Ticks Up On Favorable Patent Ruling vs. Cubist Pharmaceuticals Inc",2014-12-09 11:09:00-05:00,MRK,positive
852657.0,Merck & Co. Under Pressure Following Patent Ruling,2014-12-09 09:30:00-05:00,MRK,negative
852658.0,Cellceutix Corp Shares Rise On Two Catalysts,2014-12-09 09:28:00-05:00,MRK,positive
852659.0,Merck Issues Statement Regarding CUBICIN Patent Litigation; Reaffirms Transaction To Proceed As Planned,2014-12-09 08:12:00-05:00,MRK,negative
852660.0,"Benzinga's M&A Chatter for Monday December 8, 2014",2014-12-08 18:27:00-05:00,MRK,neutral
852661.0,3 Biotech ETFs Rally On Merger News,2014-12-08 17:43:00-05:00,MRK,neutral
852662.0,Cubist Shares Fall Almost 5% After-Hours,2014-12-08 16:50:00-05:00,MRK,positive
852663.0,Mid-Afternoon Market Update: Dow Slides Over 100 Points; Oil Futures Down 4%,2014-12-08 15:37:00-05:00,MRK,neutral
852664.0,"Fitch Says Cubist Acquisition Will Strengthen Merck's Growth Opportunities, Particularly in Non-U.S./European Markets",2014-12-08 13:58:00-05:00,MRK,positive
852665.0,Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump,2014-12-08 12:56:00-05:00,MRK,negative
852666.0,Merck's CEO Doesn't Think That Valuations In The Biotech Industry Are 'Rich',2014-12-08 12:46:00-05:00,MRK,neutral
852667.0,Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For $102/Share,2014-12-08 10:46:00-05:00,MRK,neutral
852668.0,Benzinga's Volume Movers,2014-12-08 10:20:00-05:00,MRK,neutral
852669.0,Stocks Hitting 52-Week Highs,2014-12-08 10:08:00-05:00,MRK,neutral
852670.0,Morning Market Movers,2014-12-08 09:44:00-05:00,MRK,neutral
852671.0,Pharmaceutical Stocks In Play Following Merck/Cubist Deal,2014-12-08 09:09:00-05:00,MRK,positive
852672.0,Benzinga's Top #PreMarket Gainers,2014-12-08 08:11:00-05:00,MRK,positive
852673.0,Advaxis Announces FDA Acceptance of Investigational NDA to Begin Clinical Trials of ADXS-PSA in Combo with Merck's KEYTRUDA(R),2014-12-08 07:32:00-05:00,MRK,positive
852674.0,Merck to Acquire Cubist Pharmaceuticals for $102/Share in Cash,2014-12-08 07:03:00-05:00,MRK,neutral
852675.0,UPDATE: Merck Says Cubist Deal Includes $1.1B In Net Debt,2014-12-08 07:02:00-05:00,MRK,negative
852676.0,US Stock Futures Point To Lower Open Monday,2014-12-08 07:01:00-05:00,MRK,negative
852677.0,Merck To Acquire Cubist Pharmaceuticals For $102 Per Share In Cash,2014-12-08 07:01:00-05:00,MRK,positive
852678.0,Cubist Shares Bid 28% Higher Premarket on Rumor of Merck $100/Share Bid,2014-12-08 05:27:00-05:00,MRK,positive
852679.0,"Must Watch Stocks for December 8, 2014",2014-12-08 04:32:00-05:00,MRK,neutral
852680.0,Benzinga's Weekend M&A Chatter,2014-12-07 18:24:00-05:00,MRK,neutral
852681.0,"Merck Announces Anti-PD-1 Therapy, KEYTRUDA, Achieves Overall Response Rate of 66% in Classical Hodgkin Lymphoma Study",2014-12-06 17:33:00-05:00,MRK,neutral
852682.0,Merck in Talks to Acquire Cubist for ~$100/Share,2014-12-05 23:24:00-05:00,MRK,neutral
852683.0,Merck in Talks to Acquire Cubist Pharmaceuticals for More Than $7B; Could be Announced as Early as Next Week -NYT Dealbook,2014-12-05 23:14:00-05:00,MRK,neutral
852684.0,Markets Marginally Lower Ahead Of Friday's Jobs Report,2014-12-04 17:00:00-05:00,MRK,negative
852685.0,"Jefferies Maintains Hold on Merck & Company, Inc., Raises PT to $65.00",2014-12-04 08:00:00-05:00,MRK,neutral
852686.0,"No Serious Side Effects Reported in Early Test of Experimental Ebola Vaccine Being Develped by Merck, NewLink -Reuters",2014-12-02 05:10:00-05:00,MRK,negative
852687.0,"8-K from Gilead Sciences Shows UK Court Invalidated Idenix 489 Patent, Trials Will Be Held on Merck's Idenix Patents in Canada in Jan.",2014-12-01 14:40:00-05:00,MRK,neutral
852688.0,Merck Announces Increased Quarterly Dividend From $0.44 To $0.45/share,2014-11-25 13:00:00-05:00,MRK,positive
852689.0,#Premarket Prep Technical Update - Merck Trading Lower,2014-11-24 15:33:00-05:00,MRK,negative
852690.0,"Merck Reports Submission to Japanese Pharma, Medical Devices Agency for Omarigliptin",2014-11-24 08:00:00-05:00,MRK,neutral
852691.0,"Merck, NewLink Genetics Announce Licensing and Collaboration Agreement for Investigational Ebola Vaccine",2014-11-24 07:32:00-05:00,MRK,positive
852692.0,"Merck, NewLink Genetics Report Entering of Licensing, Collaboration Deal for Investigational Ebola Vaccine",2014-11-24 07:30:00-05:00,MRK,neutral
852693.0,EMA Recommends Merck's Blood Clot Preventer Vorapaxar,2014-11-21 07:09:00-05:00,MRK,positive
852694.0,"Hearing Newlink, Merck Working on Producing Ebola Vaccine",2014-11-20 16:17:00-05:00,MRK,neutral
852695.0,Merck Announces Its Vytorin Reduces Heart Disease Risk By 6.4% Over Statin Alone,2014-11-17 11:38:00-05:00,MRK,negative
852696.0,Merck Announces That IMPROVE-IT Achieved Primary Endpoint; Data To Be Presented At American Heart Association Scientific Sessions Today,2014-11-17 08:31:00-05:00,MRK,neutral
852697.0,"Pfizer Will Study Merck's PDL-1 in Combo with Pfizer Assets; to Start 20 Clinical Dev Programs with Merck, Six Registration Programs",2014-11-17 08:19:00-05:00,MRK,positive
852698.0,Merck Announces Positive Study Investigating Use of KEYTRUDA Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma,2014-11-16 07:05:00-05:00,MRK,positive
852699.0,Merck Announces Results From Phase 2 Study Of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir In Genotype 1 Infected Treatment-NaÃ¯ve And Difficult-To-Cure Patients,2014-11-11 08:05:00-05:00,MRK,negative
852700.0,"Merck Offers Results of Phase 2 Study of Investigational Chronic Hep C Treatment Grazoprevir/Elbasvir; First Wave of Phase 3 Enrolled, Co. Will Submit NDA App in 2015",2014-11-11 08:02:00-05:00,MRK,neutral
852701.0,Merck Shares May Have Hit A Ceiling For The Most Recent Upside Move,2014-11-10 17:32:00-05:00,MRK,positive
852702.0,Merck Has Said Taking No Impairment Charge Following Results of Cholesterol-Drug Study,2014-11-10 12:56:00-05:00,MRK,negative
852703.0,RBC Sees Weak Merck Data As Positive For Gilead,2014-11-10 09:29:00-05:00,MRK,positive
852704.0,Interim Data from C-SWIFT Study of Merck's Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor Presented at The Liver Meeting,2014-11-09 19:04:00-05:00,MRK,negative
852705.0,"US Stock Futures Edge Lower Ahead Of Earnings, Jobless Claims ",2014-11-06 07:47:00-05:00,MRK,negative
852706.0,BIND Therapeutics Announces Joint Research Agreement with Merck ,2014-11-06 07:27:00-05:00,MRK,positive
852707.0,Merck Animal Health Provides Update on Zilmax Five-Step Plan; Announces Next Steps ,2014-11-05 08:31:00-05:00,MRK,neutral
852708.0,Merck Reports Data from 48-Week Phase 2B Study of Investigational HIV Therapy Doravirine in Treatment-Naive Patients; Phase 3 Clinical Trial Enrollment Scheduled to Begin by End of 2014,2014-11-03 05:25:00-05:00,MRK,neutral
852709.0,"#PreMarket Primer: Tuesday, October 28: CDC Warns That Involuntary Quarantines Could Discourage Progress On Ebola",2014-10-28 08:00:00-04:00,MRK,negative
852710.0,"Fast Money Traders Discuss Merck, Garmin And Sarepta Therapeutics",2014-10-27 20:18:00-04:00,MRK,neutral
852711.0,"Markets Virtually Flat, Oil Continues To Decline Following Bearish Outlook",2014-10-27 16:58:00-04:00,MRK,neutral
852712.0,Merck Conference Call Highlights,2014-10-27 15:34:00-04:00,MRK,neutral
852713.0,Mid-Afternoon Market Update: NQ Mobile Climbs On SEC Filing; Huntsman Shares Slide,2014-10-27 15:15:00-04:00,MRK,positive
852714.0,#Premarket Prep Technical Update - Merck Trading Lower,2014-10-27 14:38:00-04:00,MRK,negative
852715.0,Mid-Day Market Update: Micron Gains On Buyback Announcement; Sarepta Shares Dip,2014-10-27 12:41:00-04:00,MRK,positive
852716.0,Mid-Morning Market Update: Markets Down; Merck Posts Upbeat Earnings,2014-10-27 11:12:00-04:00,MRK,neutral
852717.0,"#PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations",2014-10-27 08:19:00-04:00,MRK,negative
852718.0,US Stock Futures Down Ahead Of Economic Data,2014-10-27 07:35:00-04:00,MRK,neutral
852719.0,UPDATE: Merck Q3 Earnings Top Street View,2014-10-27 07:28:00-04:00,MRK,positive
852720.0,"Merck & Company, Inc. Narrows FY2014 EPS Guidance from $3.43-3.53 to $3.46-3.50 vs $3.47 Est",2014-10-27 07:02:00-04:00,MRK,neutral
852721.0,"Merck & Company, Inc. Reports Q3 EPS of $0.31 vs $0.88 Est; Revenue of $10.60B vs $10.68B Est",2014-10-27 07:00:00-04:00,MRK,neutral
852722.0,Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA in Advanced NSCLC,2014-10-27 06:50:00-04:00,MRK,positive
852723.0,"Earnings Scheduled For October 27, 2014",2014-10-27 05:06:00-04:00,MRK,neutral
852724.0,"Keep an Eye on These 7 Stocks for October 27, 2014",2014-10-27 04:21:00-04:00,MRK,neutral
852725.0,"Earnings Expectations For The Week Of October 27: Facebook, Exxon, Pfizer And Much More",2014-10-26 16:55:00-04:00,MRK,neutral
852726.0,Fast Money Halftime Report Final Trade From October 24,2014-10-24 16:50:00-04:00,MRK,neutral
852727.0,Fast Money Picks For October 23,2014-10-23 07:00:00-04:00,MRK,neutral
852728.0,Drug ETFs Attractive Buys On Pullback,2014-10-22 17:10:00-04:00,MRK,positive
852729.0,#Premarket Technical Update - Merck Trading Higher,2014-10-21 15:05:00-04:00,MRK,neutral
852730.0,US FDA Accepts For Review A Biologics License Application For Merck And Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine,2014-10-20 08:02:00-04:00,MRK,positive
852731.0,Will Actavis Win Competition For Allergan's Affection?,2014-10-16 11:10:00-04:00,MRK,positive
852732.0,Merck Announces Final Results of Tender Offers for Eight Series of Notes ,2014-10-15 08:07:00-04:00,MRK,neutral
852733.0,Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level,2014-10-13 16:57:00-04:00,MRK,negative
852734.0,#Premarket Prep Technical Update - Merck Trading Lower,2014-10-13 14:12:00-04:00,MRK,negative
852735.0,"Jefferies Maintains Hold on Merck & Company, Inc., Lowers PT to $60.00",2014-10-13 08:39:00-04:00,MRK,negative
852736.0,5 Companies That Could Develop An Enterovirus Treatment,2014-10-13 08:07:00-04:00,MRK,neutral
852737.0,#Premarket Prep Technical Update - Merck Trading Sharply Higher,2014-10-08 14:40:00-04:00,MRK,neutral
852738.0,Merck Prices $3.1B Debt Offering ,2014-10-06 12:29:00-04:00,MRK,negative
852739.0,2 Mutual Funds Holding Hospital Stocks ,2014-10-06 10:38:00-04:00,MRK,neutral
852740.0,Merck CommencesTender Offers for Eight Series of Notes ,2014-10-06 05:19:00-04:00,MRK,neutral
852741.0,Merck Commences Public Debt Offering ,2014-10-06 05:18:00-04:00,MRK,negative
852742.0,#Premarket Prep Technical Update - Merck Trading Higher,2014-10-03 14:27:00-04:00,MRK,neutral
852743.0,Markets Little Changed Ahead Of Friday's Jobs Report,2014-10-02 17:10:00-04:00,MRK,neutral
852744.0,"Guggenheim Securities Initiates Coverage on Merck & Company, Inc. at Neutral, Announces $65.00 PT",2014-10-02 06:08:00-04:00,MRK,positive
852745.0,"Merck & Co., Inc. Stock Still Holding Its Position As A Big-Pharma Leader",2014-09-29 13:31:00-04:00,MRK,neutral
852746.0,Merck Presents Early Data on Investigational Use of KEYTRUDA in Patients with Advanced Bladder Cancer at ESMO 2014 ,2014-09-29 05:05:00-04:00,MRK,negative
852747.0,"Fast Money Halftime Report Final Trade From September 26 - Merck & Co., Inc., NCR Corporation And BP plc",2014-09-26 14:26:00-04:00,MRK,neutral
852748.0,"Citigroup Inc, Hertz Global Holdings, Inc. Highlight Fast Money Halftime Report Final Trade From September 22",2014-09-22 14:54:00-04:00,MRK,positive
852749.0,Merck Reports Entered Into License Deal with Sun Pharma for Tildrakizumab,2014-09-17 13:39:00-04:00,MRK,neutral
852750.0,"Merck Presents First Phase 3 Data In Japanese Patients for Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes",2014-09-17 09:34:00-04:00,MRK,negative
852751.0,Sun Pharma and Merck Enter into Licensing Agreement for Tildrakizumab ,2014-09-17 08:32:00-04:00,MRK,positive
852752.0,#Premarket Prep Technical Update - Merck Trading Higher,2014-09-16 15:31:00-04:00,MRK,neutral
852753.0,Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib; Expects to Submit NDA to FDA in 2015,2014-09-15 13:32:00-04:00,MRK,neutral
852754.0,#Premarket Prep Technical Update - Merck Trading Lower,2014-09-12 15:10:00-04:00,MRK,negative
852755.0,"Is Merck & Co., Inc. A Leader In A Red Hot Market?",2014-09-10 14:50:00-04:00,MRK,neutral
852756.0,"Option Alert: Merck Jan 15 $50 Call; 32,105 Traded vs 12,719 OI; Currently $60.78",2014-09-10 13:29:00-04:00,MRK,positive
852757.0,Merck CEO Says Tax Inversion Deals Would Not Fit Corporate Strategy -Reuters,2014-09-09 08:25:00-04:00,MRK,negative
852758.0,"Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug",2014-09-05 16:04:00-04:00,MRK,negative
852759.0,Shares of Bristol-Myers Edge Off Session Lows as Bloomberg Reporting Co. Has Filed Suit Against Merck Related to Patent for Immunotherapy Drugs,2014-09-05 10:57:00-04:00,MRK,positive
852760.0,Merck Wins FDA Approval For Pembrolizumab In Melanoma,2014-09-04 14:27:00-04:00,MRK,positive
852761.0,Merck & Co (MK-7655) Gets Fast Track Designation From FDA,2014-09-04 09:01:00-04:00,MRK,neutral
852762.0,Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend,2014-08-27 17:17:00-04:00,MRK,negative
852763.0,"Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)",2014-08-27 15:22:00-04:00,MRK,neutral
852764.0,"Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold",2014-08-27 12:32:00-04:00,MRK,neutral
852765.0,UPDATE: Deutsche Bank Initiates Coverage On Merck,2014-08-27 09:17:00-04:00,MRK,neutral
852766.0,"Deutsche Bank Initiates Coverage on Merck & Company, Inc. at Hold, Announces $63.00 PT",2014-08-27 06:41:00-04:00,MRK,neutral
852767.0,"S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally",2014-08-26 16:42:00-04:00,MRK,neutral
852768.0,Fast Money Halftime Report Final Trade From August 26,2014-08-26 14:23:00-04:00,MRK,neutral
852769.0,"Pfizer, Merck Report Collaboration on Study Evaluating Novel Anti-Cancer Combo Regimen",2014-08-26 08:01:00-04:00,MRK,positive
852770.0,#Premarket Prep Technical Update - Merck Approaches $60.00,2014-08-25 13:55:00-04:00,MRK,neutral
852771.0,US Stock Futures Rise Ahead Of Economic Data,2014-08-25 07:28:00-04:00,MRK,neutral
852772.0,US Regulators Have Approved Merck's Pembrolizumab Soon - Reuters,2014-08-25 07:24:00-04:00,MRK,positive
852773.0," Advaxis, Merck to Collaborate on Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer",2014-08-25 05:26:00-04:00,MRK,negative
852774.0,Merck Issues Statement Related to Role of PNEUMOVAX 23 in Updated ACIP Recommendations,2014-08-13 18:00:00-04:00,MRK,neutral
852775.0,UPDATE: FDA Approves Belsomra Tablets for Use as Sleep Aid,2014-08-13 16:50:00-04:00,MRK,positive
852776.0,FDA Approves Belsomra Tablets for Use as Sleep Aid,2014-08-13 15:39:00-04:00,MRK,positive
852777.0,"Medicare Spokesperson Tells CDC Vaccine Advisory Panel, Medicare Would Need to Change Current Policy to Cover Pfizer's Prevnar 13 for Elderly Previously Vaccinated With Merck's Pneumovax -Reuters",2014-08-13 15:21:00-04:00,MRK,neutral
852778.0,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments,2014-08-11 16:46:00-04:00,MRK,positive
852779.0,Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower,2014-08-05 16:46:00-04:00,MRK,negative
852780.0,#Premarket Prep Technical Update - Merck Trading Sharply Lower,2014-08-05 14:56:00-04:00,MRK,negative
852781.0,Merck Says on July 30 Was Advised by British Columbia Medical Beneficiary and Pharmaceutical Services Division of Delisting of Sitagliptin Products,2014-08-05 11:04:00-04:00,MRK,positive
852782.0,Merck Successfully Completes Tender Offer to Acquire Idenix for $24.50/Share,2014-08-05 06:12:00-04:00,MRK,positive
852783.0,"Glaxo, Sanofi Trend Up On Potential Deal For Established Brands",2014-08-04 12:55:00-04:00,MRK,neutral
852784.0,3 Reasons To Buy Merck For The Long Term,2014-07-31 15:30:00-04:00,MRK,neutral
852785.0,Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties,2014-07-29 16:37:00-04:00,MRK,negative
852786.0,Pharmaceutical ETFs Are Health Care Sector Standouts,2014-07-29 15:49:00-04:00,MRK,positive
852787.0,Indices Remain Mixed; Merck Beats Expectations,2014-07-29 15:26:00-04:00,MRK,neutral
852788.0,Tuesday Morning Earnings Releases,2014-07-29 14:38:00-04:00,MRK,neutral
852789.0,#Premarket Prep Technical Update - Merck Trading Higher,2014-07-29 14:27:00-04:00,MRK,neutral
852790.0,Herbalife Falls On Downbeat Results; Windstream Shares Spike Higher,2014-07-29 13:22:00-04:00,MRK,positive
852791.0,Markets Open Higher; Merck Posts Upbeat Profit,2014-07-29 11:00:00-04:00,MRK,positive
852792.0,"US Stock Futures Rise Ahead Of Earnings, Consumer Confidence Data",2014-07-29 07:32:00-04:00,MRK,positive
852793.0,"UPDATE: Merck Q2 Profit Beats Street View, Shares Rise",2014-07-29 07:27:00-04:00,MRK,positive
852794.0,"Merck & Company, Inc. Raises FY2014 EPS Guidance from $3.35-3.53 to $3.43-3.53 vs $3.48 Est, Reaffirms Sales Outlook",2014-07-29 06:57:00-04:00,MRK,neutral
852795.0,"Merck & Company, Inc. Reports Q2 EPS of $0.85 vs $0.80 Est; Revenue of $10.93B vs $10.60B Est",2014-07-29 06:56:00-04:00,MRK,neutral
852796.0,"Earnings Scheduled For July 29, 2014",2014-07-29 05:16:00-04:00,MRK,neutral
852797.0,"Stocks To Watch For July 29, 2014",2014-07-29 04:02:00-04:00,MRK,neutral
852798.0,Markets Little Changed Ahead Of The Federal Reserve's Policy Decision,2014-07-28 16:36:00-04:00,MRK,neutral
852799.0,"Earnings Expectations For The Week Of July 28: Exxon, Pfizer, Twitter And Much More",2014-07-27 20:58:00-04:00,MRK,neutral
852800.0,Benzinga Weekly Preview: FOMC In Focus As Earnings Season Progresses,2014-07-26 13:58:00-04:00,MRK,neutral
852801.0,Merck Announces Initiation of Phase 3 For Letermovir,2014-07-24 08:31:00-04:00,MRK,neutral
852802.0,Idenix Pharma Shares Spiking Higher following SEC Filing Showing HSR Approval of Purchase by Merck,2014-07-21 12:14:00-04:00,MRK,positive
852803.0,Markets Marginally Lower Ahead Of Earnings Season,2014-07-07 16:37:00-04:00,MRK,negative
852804.0,#Premarket Prep Technical Update - Merck Trading Lower,2014-07-07 14:34:00-04:00,MRK,negative
852805.0,Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline,2014-07-03 09:39:00-04:00,MRK,positive
852806.0,Markets Little Changed Ahead Of 4th Of July Break,2014-07-02 16:34:00-04:00,MRK,neutral
852807.0,Barclays Downgrades Pharmaceutical Sector,2014-07-02 15:31:00-04:00,MRK,neutral
852808.0,"Bayer Could Keep Scholl's, Coppertone Brands from Merck - Reuters",2014-07-01 08:36:00-04:00,MRK,neutral
852809.0,Merck Announces Investigational Data From Phase 3 Emend,2014-06-30 08:02:00-04:00,MRK,neutral
852810.0,US Stock Futures Fall Ahead Of Home Sales Report,2014-06-30 07:20:00-04:00,MRK,neutral
852811.0,"Merck's Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review by EMA for Treatment of Advanced Melanoma ",2014-06-30 06:02:00-04:00,MRK,positive
852812.0,Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly,2014-06-27 15:49:00-04:00,MRK,positive
852813.0,#Premarket Prep Technical Update - Merck Trading Lower,2014-06-26 14:28:00-04:00,MRK,negative
852814.0,"Market Wrap For June 20: Yet Again, Dow And S&P 500 Indices Hit New Highs",2014-06-20 16:40:00-04:00,MRK,neutral
852815.0,5-Star Biotech Stock Watch: Synta Pharmaceuticals,2014-06-18 15:26:00-04:00,MRK,neutral
852816.0,"UPDATE: Merck Research Head Says Company Aims to Capture Big Share of Hep C Market, Selling Best Drugs at Fair Cost",2014-06-12 11:23:00-04:00,MRK,positive
852817.0,Merck Research Head Says Company Open to Big Acquisition for Biotech Products -Reuters,2014-06-12 11:10:00-04:00,MRK,neutral
852818.0,UPDATE: Bank Of America Reiterates On Merck & Co. On Higher Sales Estimates,2014-06-12 07:59:00-04:00,MRK,neutral
852819.0,Takeover Whispers Add To Achillion Pharmaceuticals' Momentum,2014-06-11 16:22:00-04:00,MRK,neutral
852820.0,"ETF Outlook For Tuesday, June 10, 2014 (IAT, FXE, PBE, HYHG, IDIX, MRK)",2014-06-10 11:21:00-04:00,MRK,neutral
852821.0,"Benzinga's M&A Chatter for Monday June 9, 2014",2014-06-09 18:29:00-04:00,MRK,neutral
852822.0,"Market Wrap For June 9: Markets Higher On St. Louis Fed Comments, Low Volume",2014-06-09 16:42:00-04:00,MRK,negative
852823.0,"Mid-Afternoon Market Update; Icahn's 9% Stake In Family Dollar, Tyson Foods Wins Bid For Hillshire Brands",2014-06-09 15:01:00-04:00,MRK,positive
852824.0,Are Gilead Shares Overreacting To Merck's Idenix Acquisition?,2014-06-09 14:34:00-04:00,MRK,positive
852825.0,Mid-Day Market Update: Idenix Pharma Surges On Merck Buyout; Pilgrim's Pride Shares Slide,2014-06-09 12:41:00-04:00,MRK,positive
852826.0,Benzinga's Volume Movers,2014-06-09 10:23:00-04:00,MRK,neutral
852827.0,Stocks Hitting 52-Week Highs,2014-06-09 10:13:00-04:00,MRK,neutral
852828.0,Mid-Morning Market Update: Markets Edge Higher; Tyson Wins Bidding Battle To Buy Hillshire Brands For $63/Share,2014-06-09 10:12:00-04:00,MRK,positive
852829.0,Morning Market Movers ,2014-06-09 09:36:00-04:00,MRK,neutral
852830.0,"UPDATE: Merck Says Dual Therapy of MK-5172, MK-8742 Cures High 90's% of Patients In 12 Weeks; Triple Therapy Could Be More Effective, Faster",2014-06-09 09:00:00-04:00,MRK,positive
852831.0,Hepatitis C Stocks Move After Idenix Rockets Up 235%,2014-06-09 08:59:00-04:00,MRK,neutral
852832.0,"Merck Research Head Says Combination of Idenix Nucleotide Inhibitor IDX21437, Plus Leading Two Experimental Merck Drugs Could Produce Cures In 4-6 Weeks",2014-06-09 08:48:00-04:00,MRK,negative
852833.0,Benzinga's Top #PreMarket Losers,2014-06-09 08:08:00-04:00,MRK,negative
852834.0,Benzinga's Top #PreMarket Gainers,2014-06-09 08:03:00-04:00,MRK,positive
852835.0,Achillion Pharmaceuticals Shares Rise 38% Premarket on News of Merck-Idenix Deal,2014-06-09 07:44:00-04:00,MRK,positive
852836.0,Shares of Idenix Pharma Now Up 200+% to ~$22,2014-06-09 07:34:00-04:00,MRK,positive
852837.0,UPDATE: Merck Announces Will Purchase Idenix for $3.85Bn,2014-06-09 07:31:00-04:00,MRK,neutral
852838.0,Merck Announces Will Purchase Idenix for $24.50/Share,2014-06-09 07:30:00-04:00,MRK,neutral
852839.0,#Premarket Prep Technical Update - Merck Trading Lower,2014-06-06 11:44:00-04:00,MRK,negative
852840.0,Merck Announces Will Present New Clinical Data on JANUVIA at SSADA,2014-06-06 08:01:00-04:00,MRK,neutral
852841.0,Merck Announces First Patient in Phase 3 Trial of ISENTRESS Enrolled,2014-06-05 17:01:00-04:00,MRK,neutral
852842.0,#Premarket Prep Technical Update - Merck Trading Higher,2014-06-05 12:44:00-04:00,MRK,neutral
852843.0,ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy,2014-06-04 14:08:00-04:00,MRK,positive
852844.0,"Merck Presents Early Data for Pembrolizumab in Patients with PD-L1 Positive, Advanced Head and Neck Cancer at ASCO",2014-06-01 10:04:00-04:00,MRK,positive
852845.0,"Merck Announces Generic Name for MK-3475, Pembrolizumab",2014-05-30 09:20:00-04:00,MRK,neutral
852846.0,#Premarket Prep Technical Update - Merck Trading Higher,2014-05-29 11:34:00-04:00,MRK,neutral
852847.0,#Premarket Technical Update - Merck Trading Higher,2014-05-23 14:19:00-04:00,MRK,neutral
852848.0,Merck Reports Animal Health Has Announced FDA Approval of BRAVECTO,2014-05-20 08:02:00-04:00,MRK,positive
852849.0,"Merck, Endocyte Report Withrdrawal of Conditional Marketing Authorization for Vintafolide, Companion Imaging from EMA",2014-05-19 17:01:00-04:00,MRK,neutral
852850.0,"Chimerix Announces Has Regained Worldwide Rights to CMX157 from Merck, Says Co. Will No Longer Pursue Development",2014-05-16 08:03:00-04:00,MRK,negative
852851.0,"Merck VP Schechter Sells 10,527 Shares @$55.91/Share -Form 4",2014-05-14 14:52:00-04:00,MRK,positive
852852.0,"R&D Tax Credit Passed In The House, Faces Challenges Ahead",2014-05-14 12:08:00-04:00,MRK,positive
852853.0,The 5 Most Overvalued Dow Stocks,2014-05-14 10:32:00-04:00,MRK,neutral
852854.0,"New Data on Merck's Investigational Anti-PD1 Antibody, MK-3475 to be Presented at ASCO 2014",2014-05-14 08:08:00-04:00,MRK,neutral
852855.0,US Stock Futures Up Ahead Of Retail Sales Report,2014-05-13 07:34:00-04:00,MRK,neutral
852856.0,"Merck to Sell Ophthalmology Products in Japan, Key Markets in Europe and Asia Pacific to Santen for $600M Upfront Payment",2014-05-13 05:36:00-04:00,MRK,neutral
852857.0,UPDATE: Merck Reports FDA Okay of Zontivity,2014-05-12 07:38:00-04:00,MRK,positive
852858.0,Merck Reports FDA Okay o f Zontivity ,2014-05-12 07:33:00-04:00,MRK,positive
852859.0,#Premarket Prep Technical Update - Merck Trading Lower Again,2014-05-08 14:35:00-04:00,MRK,negative
852860.0,"This Morning BMO Capital Downgraded Merck & Company to Market Perform, Lowered PT to $60.00",2014-05-08 09:42:00-04:00,MRK,negative
852861.0,Merck Announces Results Show Letermovir In CMV-Seropositive Allogeneic Human Blood Precursor Cell Recipients Met Study's Two Primary Efficacy Endpoints,2014-05-08 09:03:00-04:00,MRK,neutral
852862.0,Market Wrap For May 7: Dow Banks Triple-Digit Point Gain While Nasdaq Closes Lower,2014-05-07 16:35:00-04:00,MRK,positive
852863.0,#Premarket Technical Update -  Merck Trading Lower,2014-05-07 15:04:00-04:00,MRK,negative
852864.0,Merck Shares Tumble 2+% Following Morgan Stanley Downgrade,2014-05-07 10:25:00-04:00,MRK,positive
852865.0,"Market Wrap For May 6: Dow Suffers Triple-Digit Point Loss, Nasdaq Underperforms Once Again",2014-05-06 16:42:00-04:00,MRK,negative
852866.0,#Premarket Prep Technical Update - Merck Trading Sharply Lower,2014-05-06 15:41:00-04:00,MRK,negative
852867.0,Fitch Says Merck Consumer Business Sale Improves Its Core Focus,2014-05-06 14:46:00-04:00,MRK,positive
852868.0,Merck Says Global Cancer Sales Could Reach $120B by 2020 ,2014-05-06 12:29:00-04:00,MRK,negative
852869.0,Merck CEO Says Would be Interested in Acquiring Animal Health Brands with the Right Products at the Right Price -Reuters,2014-05-06 12:22:00-04:00,MRK,positive
852870.0,Merck Says May Look to M&A For Biotech Expansion- Bloomberg,2014-05-06 12:16:00-04:00,MRK,neutral
852871.0,UPDATE: Merck Highlights Strategic Initiative,2014-05-06 09:01:00-04:00,MRK,neutral
852872.0,"Merck Offers Details of Plans to File Odanacatib for Osteoporoisis in 2H, Will Continue to Explore Ways to Augment Animal Health Unit",2014-05-06 09:00:00-04:00,MRK,neutral
852873.0,Merck Announces FDA Acceptance for Review of MK-3475,2014-05-06 08:40:00-04:00,MRK,positive
852874.0,US Stock Futures Flat Ahead Of International Trade Data ,2014-05-06 07:29:00-04:00,MRK,neutral
852875.0,Merck Announces Sale of Consumer Care Business to Bayer for $14.2B,2014-05-06 06:05:00-04:00,MRK,positive
852876.0, Bayer to Buy Merck Consumer Care Ops for $14.2B,2014-05-06 06:02:00-04:00,MRK,positive
852877.0,"ETF Outlook For The Week Of May 5, 2014 (NGE, XLU, USMV, JJN)",2014-05-05 09:07:00-04:00,MRK,neutral
852878.0,Market Wrap For May 2: Markets Slip On Ukraine Tensions Despite Positive Jobs Data ,2014-05-02 16:58:00-04:00,MRK,negative
852879.0,"Sanofi, Merck Rumored to Each Weigh Sale of Mature-Drug Portfolios - Bloomberg",2014-05-02 15:05:00-04:00,MRK,neutral
852880.0,#Premarket Preo Technical Update - Merck Trading Lower,2014-05-02 11:05:00-04:00,MRK,negative
852881.0,Endocyte to Resume Trading at 8:30 AM ET,2014-05-02 08:10:00-04:00,MRK,neutral
852882.0,Merck Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis ,2014-05-02 08:06:00-04:00,MRK,neutral
852883.0,"Merck, Endocyte Report DSMB Has Recommended Vintafolide Trial Be Suspended, Cites Trial Not Showing Efficacy",2014-05-02 08:03:00-04:00,MRK,negative
852884.0,"Benzinga's M&A Chatter for Thursday May 1, 2014",2014-05-01 18:51:00-04:00,MRK,neutral
852885.0,Bayer Could Be Preparing ~$14B Bid for Merck's Consumer Unit - Bloomberg,2014-05-01 14:43:00-04:00,MRK,neutral
852886.0,#Premarket Prep Technical Update - Merck Trading Lower,2014-04-30 14:38:00-04:00,MRK,negative
852887.0,Reckitt Benckiser Confirms it is No Longer in Talks with Merck Regarding Bid for Consumer Health Business,2014-04-30 12:54:00-04:00,MRK,negative
852888.0,"#PreMarket Primer: Wednesday, April 30: No BOJ Stimulus On The Horizon ",2014-04-30 09:12:00-04:00,MRK,negative
852889.0,Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting ,2014-04-29 16:43:00-04:00,MRK,positive
852890.0,Mid-Afternoon Market Update: Markets Show Strength as Prothena Shares Plummet,2014-04-29 15:45:00-04:00,MRK,positive
852891.0,"Bids for Merck Consumer-Health Unit Said to Be Over $14B, Bayer Looking to Weigh JV with Merck as Part of Offer - Bloomberg",2014-04-29 15:41:00-04:00,MRK,neutral
852892.0,#Premarket Technical Update -Merck Trading Higher,2014-04-29 13:41:00-04:00,MRK,neutral
852893.0,Mid-Day Market Update: Coach Slips After Q3 Results; Orbital Shares Spike Higher,2014-04-29 12:48:00-04:00,MRK,positive
852894.0,Mid-Morning Market Update: Markets Rise; Merck Earnings Beat Street View,2014-04-29 10:23:00-04:00,MRK,neutral
852895.0,UPDATE: Merck Posts Upbeat Q1 Profit,2014-04-29 07:39:00-04:00,MRK,positive
852896.0,"#PreMarket Primer: Tuesday, April 29: US Steps Up Sanctions Against Russia",2014-04-29 07:08:00-04:00,MRK,neutral
852897.0,"Merck & Company, Inc. Reports Q1 EPS of $0.88 vs $0.79 Est; Revenue of $10.30B vs $10.44B Est; Reaffirms Outlook",2014-04-29 07:01:00-04:00,MRK,neutral
852898.0,Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile Start To the Trading Week,2014-04-28 16:34:00-04:00,MRK,neutral
852899.0,"Reckitt Benckiser Confirms Talks With Merck Regarding Bid for Consumer Health Business, Bayer Also Rumored Bidder",2014-04-28 12:11:00-04:00,MRK,neutral
852900.0,"Agenus Announces License Deal with Merck Related to Novel Checkpoint Antibody-Based Cancer Immunotherapies, Eligible for ~$100M in Milestone Payments",2014-04-28 07:17:00-04:00,MRK,negative
852901.0,Benzinga's Weekend M&A Chatter,2014-04-27 20:21:00-04:00,MRK,neutral
852902.0,"Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And More",2014-04-27 11:58:00-04:00,MRK,neutral
852903.0,"Reuters Reports Merck in Talks to Sell Consumer Health Unit to Bayer, Reckitt Benckiser for Approximately $14B, According to Sources ",2014-04-26 14:41:00-04:00,MRK,neutral
852904.0,Benzinga Weekly Preview: Earnings Season Continues As Biotech & Pharmaceutical Companies Report,2014-04-25 16:41:00-04:00,MRK,neutral
852905.0,3 Ways To Profit From Merger Activity In The Pharmaceutical Sector,2014-04-25 10:20:00-04:00,MRK,positive
852906.0,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns,2014-04-24 16:41:00-04:00,MRK,neutral
852907.0,Fitch Affirms Merck's LT IDR at A+; Outlook Negative,2014-04-24 14:12:00-04:00,MRK,negative
852908.0,"Bank of America Maintains Buy on Merck & Company, Inc., Raises PT to $62.00",2014-04-24 06:51:00-04:00,MRK,neutral
852909.0,#Premarket Technical Update -Merck Trading Lower,2014-04-23 15:13:00-04:00,MRK,negative
852910.0,Bill Ackman Talks Partnership With Valeant For Allergan Deal ,2014-04-23 09:38:00-04:00,MRK,neutral
852911.0,The Top 21 African-American CEOs In Business,2014-04-21 12:50:00-04:00,MRK,positive
852912.0,FDA Clears Merck's Ragwitek ,2014-04-17 14:42:00-04:00,MRK,positive
852913.0,Merck Announces FDA Has Approved Grastek Sublingual Tablet for Treatment of Grass Pollen-Induced Allergic Rhinitis,2014-04-14 17:59:00-04:00,MRK,positive
852914.0,"Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings",2014-04-14 16:36:00-04:00,MRK,positive
852915.0,Markets Falling? Get Your Defense Ready,2014-04-14 15:47:00-04:00,MRK,positive
852916.0,No Legwork Mondays â€“ Merck And Vioxx,2014-04-14 09:45:00-04:00,MRK,negative
852917.0,Top 40 Upcoming Earnings Releases  ,2014-04-11 16:08:00-04:00,MRK,positive
852918.0,Google Honors Chemist Percy Julian & His Contributions ,2014-04-11 15:45:00-04:00,MRK,positive
852919.0,US Stock Futures Slip Ahead Of Consumer Sentiment Report,2014-04-11 07:41:00-04:00,MRK,neutral
852920.0,Phase 2 Trial of Merck's Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity,2014-04-11 05:37:00-04:00,MRK,neutral
852921.0,"When It Comes To Drug Stocks, Do Not Always Buy The News",2014-04-10 11:30:00-04:00,MRK,neutral
852922.0,US Stock Futures Edge Lower Ahead Of Jobless Claims Data,2014-04-10 07:27:00-04:00,MRK,negative
852923.0,"Merck Announces Results from Studies Evaluating MK-5172 and MK-8742 Investigational Hepatitis C Treatments, ",2014-04-10 05:44:00-04:00,MRK,neutral
852924.0,Biotechs Struggling To Find A Bottom,2014-04-08 10:24:00-04:00,MRK,negative
852925.0,"Express Scripts Reports Spending on Hepatitis C Medications in US to Rise 1,800% by 2016",2014-04-08 08:11:00-04:00,MRK,neutral
852926.0,Merck Presents Early Findings from MK-3475 Treatment at AARC 2014,2014-04-06 19:46:00-04:00,MRK,neutral
852927.0,Merck Shares Volatile This Afternoon; Reuters Earlier Reported Co. is Seeing Resistance from Beef Industry for Test of Zilmax on 200K+ Cattle ,2014-04-04 14:21:00-04:00,MRK,positive
852928.0,"Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007",2014-03-27 07:22:00-04:00,MRK,positive
852929.0,"Merck Names Robert Davis as CFO, Succeeding Peter Kellogg",2014-03-27 07:21:00-04:00,MRK,positive
852930.0,Nanobio Announces Licensing Agreement With Unit of Merck for Use of its Nanoemulsion Adjuvant Technology,2014-03-26 10:10:00-04:00,MRK,positive
852931.0,Nanobio Announces Licensing Agreement With Unit of Merck for Use of its Nanoemulsion Adjuvant Technology,2014-03-26 10:10:00-04:00,MRK,positive
852932.0,"Reckitt Benckiser a Frontrunner for Merck's OTC Segment, Sanofi Rumored to Join Bidders, Final Bids Are Due Next Week - Bloomberg",2014-03-24 15:49:00-04:00,MRK,positive
852933.0,Google Honors Activist Dorothy Height & Her Contributions,2014-03-24 14:56:00-04:00,MRK,positive
852934.0,Mid-Day Market Update: Nike Drops On Cautious Forecast; Endocyte Shares Spike Higher,2014-03-21 12:44:00-04:00,MRK,positive
852935.0,"""Premarket Prep"" Technical Update - Merck Trading Lower After Higher Open",2014-03-21 11:07:00-04:00,MRK,negative
852936.0,Mid-Morning Market Update: Markets Open Higher; Tiffany Posts Downbeat Earnings,2014-03-21 10:46:00-04:00,MRK,neutral
852937.0,Benzinga's Volume Movers,2014-03-21 10:26:00-04:00,MRK,neutral
852938.0,UPDATE: Endocyte Shares Rise 158%,2014-03-21 08:51:00-04:00,MRK,positive
852939.0,UPDATE: Endocyte Shares Rise 91% on European CHMP Positive Opinions for VYNFINIT,2014-03-21 08:35:00-04:00,MRK,positive
852940.0,PREVIEW: Endocyte to Resume Trading at 8:30AM ET,2014-03-21 08:19:00-04:00,MRK,neutral
852941.0,Benzinga's Top #PreMarket Gainers,2014-03-21 08:17:00-04:00,MRK,positive
852942.0,"Merck, Endocyte Announce European CHMP Positive Opinions for VYNFINIT, Companion Agents FOLCEPRI, NEOCEPRI",2014-03-21 08:07:00-04:00,MRK,positive
852943.0,Ligand Pharma Announces $1M Milestone Payment Triggered Following FDA Approval of Merck's Noxafil,2014-03-17 08:20:00-04:00,MRK,positive
852944.0,UPDATE: FDA Approves Merck Noxafi Injection for IV Use,2014-03-14 13:44:00-04:00,MRK,positive
852945.0,FDA Approves Merck Noxafi Injection for Intravenous Use ,2014-03-14 13:43:00-04:00,MRK,positive
852946.0,Merck Unchanged,2014-03-12 15:02:00-04:00,MRK,neutral
852947.0,Merck Trading Higher,2014-03-06 14:19:00-05:00,MRK,neutral
852948.0,"Merck Announces MK-1439 Shows Antiviral Activity in Phase 2b Trial, Co. Planning to Initiate Phase 2 Development Program During 2H'14",2014-03-05 12:17:00-05:00,MRK,neutral
852949.0,UPDATE: Merck Plans to Initiate Phase 3 Clinical Development Program In Second Half Of 2014 ,2014-03-05 12:17:00-05:00,MRK,neutral
852950.0,"Merck's Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-NaÃ¯ve Adults ",2014-03-05 12:16:00-05:00,MRK,neutral
852951.0,"Merck Issues Results from Phase 2b Study of MK-8237, Says Secondary Efficacy Endpoints Average TNSS, DU Made Significant Dose, Time Dependent Reduction",2014-03-04 17:36:00-05:00,MRK,positive
852952.0,Biotechs vs. Pharmaceuticals: What's the Difference?,2014-03-04 10:30:00-05:00,MRK,neutral
852953.0,The Top Five Dow Stocks In February,2014-03-03 10:39:00-05:00,MRK,positive
852954.0,"Overvaluing Liquidity: Invest For The Future, Not For Today",2014-02-28 15:56:00-05:00,MRK,neutral
852955.0,CHMP Issues Positive Opinion For Tablet Formulation Of Merck's NOXAFIL,2014-02-28 08:35:00-05:00,MRK,positive
852956.0,HB Reporting (via Bloomberg) Merck is Still Interested in More Purchases in the Pharma Group,2014-02-20 15:15:00-05:00,MRK,positive
852957.0,Merck Testing Multi-Year Highs,2014-02-20 14:56:00-05:00,MRK,neutral
852958.0,Merck Reports FDA Acceptance for Review of BLA for V503,2014-02-20 08:35:00-05:00,MRK,positive
852959.0,"FDA Accepts for Review Merck's Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine",2014-02-20 08:35:00-05:00,MRK,positive
852960.0,Merck Finds Resistance,2014-02-12 16:03:00-05:00,MRK,neutral
852961.0,"Three ETFs To Buy On The Pullback (PJP, SKYY, SPY)",2014-02-10 09:13:00-05:00,MRK,neutral
852962.0,"Merck, Samsung Bioepis Announce Deal to Develop Insulin Glargine Candidate",2014-02-10 08:31:00-05:00,MRK,neutral
852963.0,"Market Wrap For February 7: Jobs Report Not Great, But Not Too Bad",2014-02-07 16:36:00-05:00,MRK,positive
852964.0,Bloomberg Reporting Merck Has Reached Agreement in Principle to Resolve Suits Related to NuvaRing,2014-02-07 09:41:00-05:00,MRK,positive
852965.0,Bloomberg Reporting Merck Said to Agree to Pay $100M Related to NuvaRing Settlement,2014-02-06 15:47:00-05:00,MRK,positive
852966.0,"#PreMarket Primer: Thursday, February 6: Markets Taking A Breather After Twitter Earnings",2014-02-06 07:11:00-05:00,MRK,neutral
852967.0,Market Wrap For February 5: Markets Unsure Of Which Direction To Take,2014-02-05 16:47:00-05:00,MRK,negative
852968.0,Merck Retreats From Highs,2014-02-05 14:25:00-05:00,MRK,neutral
852969.0,Top Trending Tickers On StockTwits For February 5,2014-02-05 10:41:00-05:00,MRK,positive
852970.0,Stocks Hitting 52-Week Highs,2014-02-05 10:08:00-05:00,MRK,neutral
852971.0,Benzinga's Top #PreMarket Gainers,2014-02-05 08:06:00-05:00,MRK,positive
852972.0,UPDATE: Merck Posts Drop In Q4 Profit,2014-02-05 07:24:00-05:00,MRK,positive
852973.0,"Merck & Company, Inc. Sees FY2014 EPS $3.35-3.53 vs $3.47 Est; Sees Sales $42.40B-43.20B vs $43.54B Est",2014-02-05 07:14:00-05:00,MRK,neutral
852974.0,US Stock Futures Flat; All Eyes On ADP Report,2014-02-05 07:12:00-05:00,MRK,neutral
852975.0,"Merck & Company, Inc. Reports Q4 Adjusted EPS of $0.88, Inline; Revenue of $11.32B vs $11.36B Est",2014-02-05 07:02:00-05:00,MRK,neutral
852976.0,Pfizer Confirms Collaboration with Merck on Innovative Anti-Cancer Combination Studies ,2014-02-05 06:55:00-05:00,MRK,positive
852977.0,Incyte Confirms Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies ,2014-02-05 06:54:00-05:00,MRK,positive
852978.0,"Merck Confirms Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 ",2014-02-05 06:42:00-05:00,MRK,positive
852979.0,"Amgen,Merck Announce Collaboration to Evaluate Investigational Combination Treatment for Advanced Melanoma",2014-02-05 06:21:00-05:00,MRK,positive
852980.0,"Earnings Scheduled For February 5, 2014",2014-02-05 04:21:00-05:00,MRK,neutral
852981.0,"Stocks To Watch For February 5, 2014",2014-02-05 04:09:00-05:00,MRK,neutral
852982.0,Merck Rallies Back,2014-02-04 16:02:00-05:00,MRK,neutral
852983.0,"SunTrust Robinson Humphrey Upgrades Merck & Company, Inc. to Buy",2014-02-04 07:50:00-05:00,MRK,neutral
852984.0,Merck Receives Canadian Approval of Grastek,2014-02-03 08:31:00-05:00,MRK,positive
852985.0,"Earnings Expectations For The Week Of February 3: GM, Twitter, Disney And More",2014-02-03 06:42:00-05:00,MRK,neutral
852986.0,Market Wrap For January 31: Markets End January On Sour Note,2014-01-31 16:38:00-05:00,MRK,neutral
852987.0,Reuters Reporting Merck Consumer Health Unit Could Get $8-10B in Sale,2014-01-31 14:02:00-05:00,MRK,neutral
852988.0,"Market Wrap For January 27: China Concerns, Declining Home Sales, Tomorrow's Fed Meeting and Obama's Speech Keep Markets Lower",2014-01-27 16:48:00-05:00,MRK,negative
852989.0,Winter's Stock Knockdown May Give Way To A Spring Thaw,2014-01-27 11:57:00-05:00,MRK,neutral
852990.0,UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism,2014-01-27 11:06:00-05:00,MRK,positive
852991.0,Stocks Hitting 52-Week Highs,2014-01-27 10:54:00-05:00,MRK,neutral
852992.0,Benzinga's Top Upgrades,2014-01-27 07:51:00-05:00,MRK,positive
852993.0,US Stock Futures Gain Ahead Of Home-Sales Data,2014-01-27 07:35:00-05:00,MRK,positive
852994.0,"Morgan Stanley Upgrades Merck & Company, Inc. to Overweight, Announces $60.00 PT",2014-01-27 06:42:00-05:00,MRK,negative
852995.0,Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment,2014-01-24 15:21:00-05:00,MRK,negative
852996.0,Merck Pleased with FDA Advisory Committee Recommendation for Approval of Vorapaxar,2014-01-15 19:01:00-05:00,MRK,positive
852997.0,Market Wrap For January 15: Bulls Take Over As Economic Growth Remains Healthy,2014-01-15 16:45:00-05:00,MRK,positive
852998.0,Bloomberg First Word Reporting Merck Has Won FDA Advisory Panel Support for Vorapaxar,2014-01-15 16:01:00-05:00,MRK,positive
852999.0,"Merck Voluntarily Recalls All Lots of Liptruzet, Cites Packaging Defects",2014-01-14 09:17:00-05:00,MRK,negative
853000.0,"Benzinga's M&A Chatter for Monday January 13, 2014",2014-01-13 18:05:00-05:00,MRK,neutral
853001.0,Market Wrap For January 13: Markets Showing Weakness Ahead Of Major Earning Releases,2014-01-13 16:52:00-05:00,MRK,negative
853002.0,Mid-Afternoon Market Update: Markets Dip Despite Large Amount of M&A,2014-01-13 16:14:00-05:00,MRK,neutral
853003.0,Mid-Day Market Update: SodaStream Drops After Weak Outlook; Beam Shares Spike Higher,2014-01-13 12:52:00-05:00,MRK,negative
853004.0,Mid-Morning Market Update: Markets Open Lower; Lululemon Lowers Q4 Outlook,2014-01-13 10:39:00-05:00,MRK,negative
853005.0,Morning Market Movers ,2014-01-13 09:54:00-05:00,MRK,neutral
853006.0,Merck Initiates Rolling Submission to FDA of US Biologics License Application for MK-3475,2014-01-13 08:52:00-05:00,MRK,neutral
853007.0,"Merck Begins Enrollment of BLA for MK-3475, Sees Completing Application in 1H'14",2014-01-13 08:35:00-05:00,MRK,neutral
853008.0,Benzinga's Top #PreMarket Gainers,2014-01-13 08:21:00-05:00,MRK,positive
853009.0,"UPDATE: Novartis Could Swap Its Animal-Health, Human Vaccines Units for Merck's OTC Health-Products Unit",2014-01-08 14:54:00-05:00,MRK,neutral
853010.0,Bloomberg Reporting Novartis Said to Be in Talks with Merck on $5B Unit Swap,2014-01-08 14:52:00-05:00,MRK,neutral
853011.0,Merck Receives FDA Approval for Isentress for Pediatric ,2014-01-08 08:30:00-05:00,MRK,positive
853012.0,WSJ Reporting Merck on 'Radically Reshaping R&D',2013-12-27 16:42:00-05:00,MRK,neutral
853013.0,ALK Reports FDA Panel Will Revie Ragweed Tablet,2013-12-26 17:27:00-05:00,MRK,neutral
853014.0,Merck Sues to Stop Generic NuvaRing,2013-12-26 16:50:00-05:00,MRK,negative
853015.0,Merck Spikes Higher on Positive Jim Cramer/Mad Money Comments,2013-12-18 18:18:00-05:00,MRK,positive
853016.0,Merck Collaborates with GlaxoSmithKline on MK-3475,2013-12-18 07:51:00-05:00,MRK,neutral
853017.0,Merck Says Vintafolide Has Won Orphan Drug Designation for Ovarian Cancer,2013-12-17 18:03:00-05:00,MRK,negative
853018.0,"EMA Says Will Discuss Extension of Indication for Merck's Noxafil, Isentress, Pfizer's Vfend, Amgen's Xgeva, Vertex Pharma's Kalydeco",2013-12-17 11:55:00-05:00,MRK,neutral
853019.0,FDA Reviewing Merck's Bid for Grastek; Panel Recommends Approval of Grastek; ,2013-12-12 16:05:00-05:00,MRK,positive
853020.0,"#PreMarket Primer: Thursday, December 12: US Budget Deal Gaining Momentum",2013-12-12 07:12:00-05:00,MRK,positive
853021.0,Merck Says Data Monitoring Committee Recommending Continuation of Phase II/III EPOCH Study for MK-8931,2013-12-10 07:10:00-05:00,MRK,neutral
853022.0,Merck Agrees to settle Litigation over Jaw Injuries Caused by Fosamax -Reuters,2013-12-09 14:57:00-05:00,MRK,neutral
853023.0,"Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit",2013-12-03 12:20:00-05:00,MRK,positive
853024.0, Merck Raises Quarterly Dividend to $0.44 from $0.43,2013-11-26 14:19:00-05:00,MRK,neutral
853025.0,FDA Okays Merck's Noxafil DR Tablets,2013-11-26 09:02:00-05:00,MRK,positive
853026.0,Merck Announces Position Opinion from CHMP on Update for Erbitux Metastatic Colorectal Cancer Labeling,2013-11-22 12:17:00-05:00,MRK,negative
853027.0,Investing in Companies Developing Promising Immunotherapy Drugs for Melanoma ,2013-11-18 10:42:00-05:00,MRK,positive
853028.0,Merck's NDA for Noxafil Wins FDA Priority Review ,2013-11-18 08:31:00-05:00,MRK,positive
853029.0,Merck's MK-7243 Significantly Reduced Allergy Symptoms in Adults and Children in Pivotal Phase III Study ,2013-11-09 12:06:00-05:00,MRK,neutral
853030.0,Job Cuts Higher in October; Pharmaceutical & Financial Sectors Took Biggest Hits,2013-11-06 15:09:00-05:00,MRK,negative
853031.0,Analysts Comment on Merck's Hep C Regiment Advances,2013-11-04 10:39:00-05:00,MRK,neutral
853032.0,"Merck Says Investigational V503 Prevented 97% of Cervical, Vaginal, Vulvar Pre-Cancers Caused by Five Added HPV Types",2013-11-04 07:31:00-05:00,MRK,neutral
853033.0,"BMO Capital Upgrades Merck & Company, Inc. to Outperform",2013-11-01 10:35:00-04:00,MRK,neutral
853034.0,Market Wrap for October 31: Fed Worries Pull Stocks Lower,2013-10-31 17:00:00-04:00,MRK,negative
853035.0,US Stock Futures Flat Ahead Of Fed,2013-10-29 07:12:00-04:00,MRK,neutral
853036.0,"#PreMarket Primer: Tuesday, October 29: Fed Meeting Likely Uneventful",2013-10-29 06:47:00-04:00,MRK,neutral
853037.0,Merck Presents Interim Data from Phase 1B Study of MK-3475 at 15th World Conference on Lung Cancer ,2013-10-29 05:56:00-04:00,MRK,negative
853038.0,Think Silver: Top Stocks Catering to Seniors,2013-10-28 17:43:00-04:00,MRK,positive
853039.0,Mid-Afternoon Market Update: Markets Mixed as JC Penney Rises,2013-10-28 15:46:00-04:00,MRK,neutral
853040.0,Mid-Day Market Update: Burger King Surges On Upbeat Earnings; Sohu Shares Dip,2013-10-28 12:31:00-04:00,MRK,positive
853041.0,Mid-Morning Market Update: Markets Mixed; Merck Profit Beats Estimates,2013-10-28 10:35:00-04:00,MRK,positive
853042.0,Merck's Q3 Call Just Beginning,2013-10-28 08:13:00-04:00,MRK,neutral
853043.0,UPDATE: Merck Posts Upbeat Q3 Profit,2013-10-28 07:26:00-04:00,MRK,positive
853044.0,"Merck & Company, Inc. Narrows FY2013 EPS Guidance from $3.45-3.55 to $3.48-3.52 vs $3.47 Est",2013-10-28 07:02:00-04:00,MRK,neutral
853045.0,"Merck & Company, Inc. Reports Q3 EPS of $0.92 vs $0.88 Est; Revenue of $11.03B vs $11.19B Est",2013-10-28 07:01:00-04:00,MRK,neutral
853046.0,"#PreMarket Primer: Monday, October 28: All Eyes On Apple",2013-10-28 06:51:00-04:00,MRK,neutral
853047.0,"Earnings Scheduled For October 28, 2013",2013-10-28 05:31:00-04:00,MRK,neutral
853048.0,"Stocks To Watch For October 28, 2013",2013-10-28 05:27:00-04:00,MRK,neutral
853049.0,"Earnings Expectations For The Week Of October 28: Apple, Facebook, GM and More",2013-10-27 19:10:00-04:00,MRK,neutral
853050.0,Benzinga Weekly Preview: FOMC Meeting Closely Watched,2013-10-25 16:18:00-04:00,MRK,neutral
853051.0,"Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)",2013-10-25 15:36:00-04:00,MRK,positive
853052.0,"Merck Says Primary Endpoints Met for Investigational 9-Valent HPV Vaccine, Expecting to Submit BLA for V503 in 2013",2013-10-24 10:28:00-04:00,MRK,neutral
853053.0,"Merck Says Primary Endpoints Met for Investigational 9-Valent HPV Vaccine, Expecting to Submit BLA for V503 in 2013",2013-10-24 10:28:00-04:00,MRK,neutral
853054.0,"How Investors Can Play the ""Losers"" in Blue Chips",2013-10-23 10:50:00-04:00,MRK,positive
853055.0,Merck's MK-5172/MK-8742 Receives Breakthrough Therapy Designation from FDA,2013-10-22 17:01:00-04:00,MRK,neutral
853056.0,"Merck Confirms Development of Investigational Dosing ISENTRESS, Will Begin Phase III Trial Early 2014",2013-10-16 08:34:00-04:00,MRK,neutral
853057.0,"Merck, Endocyte Report Vintafolide-PLD Generaly Well Tolerated, Showed Median PFS of Five Months",2013-10-14 17:07:00-04:00,MRK,positive
853058.0,UPDATE: Bernstein Downgrades Merck & Co. on Negative Outlook,2013-10-14 11:05:00-04:00,MRK,negative
853059.0,"Barclays Downgrades Merck & Company, Inc. to Equalweight",2013-10-14 10:05:00-04:00,MRK,neutral
853060.0,Benzinga's Top Downgrades,2013-10-14 07:46:00-04:00,MRK,positive
853061.0,"Bernstein Downgrades Merck & Company, Inc. to Market Perform, Lowers PT to $50.00",2013-10-14 06:52:00-04:00,MRK,negative
853062.0,"Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)",2013-10-11 14:33:00-04:00,MRK,neutral
853063.0,"Jefferies Downgrades Merck & Company, Inc. to Hold, Lowers PT to $50.00",2013-10-11 07:37:00-04:00,MRK,negative
853064.0,"Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral",2013-10-08 16:57:00-04:00,MRK,positive
853065.0,FDA Postpones Advisory Committee Meeting for Grass Ait Tablet Due to US Government Shutdown,2013-10-08 12:00:00-04:00,MRK,negative
853066.0,Merck Says Data Shows Cognigram as Sensitive Assessment,2013-10-07 08:12:00-04:00,MRK,neutral
853067.0,Pharmaceutical Industry Expected To Collect Billions From Obamacare,2013-10-02 12:51:00-04:00,MRK,neutral
853068.0,Merck Shares Soar After Announcing More Job Cuts,2013-10-01 14:28:00-04:00,MRK,negative
853069.0,Merck Says Interim Data for MK-3475 to be Presented at 15th World Conference on Lung Cancer,2013-10-01 13:03:00-04:00,MRK,negative
853070.0,"PreMarket Info Recap for October 1, 2013: Government Shutdown Gives Markets A Boost",2013-10-01 09:22:00-04:00,MRK,positive
853071.0,"Merck Says Will Close Summit Campus, Will Move Global HQ to Kenilworth",2013-10-01 08:30:00-04:00,MRK,neutral
853072.0,UPDATE: Merck Announces Global Initiative to Sharpen Commercial and R&D Focus; Cutting 8500 Jobs; Affirms FY Target,2013-10-01 07:33:00-04:00,MRK,negative
853073.0,"Merck Cutting 8,500 Jobs Related to Global Initiative to 'Sharpen Commercial, R&D Focus,' Sees Pretax Charge $2.5-3B, Reaffirms FY13 Outlook",2013-10-01 07:32:00-04:00,MRK,negative
853074.0,Merck Receives CRL for Investigational Medicine Sugammadex Sodium Injection,2013-09-23 08:01:00-04:00,MRK,neutral
853075.0,Write A Prescription For Health Care ETFs,2013-09-19 08:06:00-04:00,MRK,positive
853076.0,"Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)",2013-09-14 11:47:00-04:00,MRK,positive
853077.0,"Watch Shares of Caterpillar, Deere, Devon, Merck, and Oracle to the Downside on a Bearish Article from Jim Cramer Tweeted Out by Carl Icahn",2013-09-12 16:18:00-04:00,MRK,positive
853078.0,US Stock Futures Flat; Apple Shares Drop In Pre-Market Trading,2013-09-11 07:07:00-04:00,MRK,neutral
853079.0,"Merck, AstraZeneca Announce License Agreement for MK-1775",2013-09-11 05:39:00-04:00,MRK,positive
853080.0,USA TD Ameritrade's Investor Movement Index for Aug 5.16 vs 4.87 Prior,2013-09-09 12:30:00-04:00,MRK,neutral
853081.0,Merck Reports FDA Acceptance of NDA for Investigational Fertility Treatment,2013-09-09 08:35:00-04:00,MRK,positive
853082.0,Merck's Durham Site Receives US FDA License for Varicella Bulk,2013-09-04 15:56:00-04:00,MRK,neutral
853083.0,Plenty Of ETFs With Favorable Risk Traits,2013-08-30 07:59:00-04:00,MRK,positive
853084.0,"Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)",2013-08-27 13:29:00-04:00,MRK,positive
853085.0,"Chicago Tribune Running Story 'Cargill to stop buying cows fed with questionable growth drug,' Related to Merck's Zillmax",2013-08-26 13:46:00-04:00,MRK,negative
853086.0,"Merck Shares Down ~0.75% Today, But Have Been Relatively Quiet/Rangebound All Day; Traders Seemed to Shrug at Earlier Report Co. to Temporarily Halt Zilmax Sales",2013-08-16 13:13:00-04:00,MRK,positive
853087.0,"13F from Leon Cooperman's Omega Advisors Shows New Stakes in Thermo-Fisher, McKesson, Liquidated Stakes in Freeport-McMoRan, Facebook, Covidien, Raised Stakes in DISH, Citi, Lowered Stakes in Merck, AIG, Polycom",2013-08-14 11:08:00-04:00,MRK,negative
853088.0,"Mid-Afternoon Market Update: Apple Rises Sharply On Icahn Stake, NASDAQ Pulled Upward",2013-08-13 15:43:00-04:00,MRK,neutral
853089.0,Mid-Day Market Update: US Stocks Edge Higher; Valspar Shares Decline On Downbeat Results,2013-08-13 12:52:00-04:00,MRK,positive
853090.0,"Mid-Morning Market Update: Markets Drop, Yum China Same-Store Sales Down 13%",2013-08-13 10:42:00-04:00,MRK,negative
853091.0,Benzinga's Top Pre-Market Gainers,2013-08-13 08:11:00-04:00,MRK,positive
853092.0,Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck ,2013-08-12 16:00:00-04:00,MRK,positive
853093.0,Hearing Unconfirmed Takeover Chatter in Inovio,2013-08-05 15:05:00-04:00,MRK,negative
853094.0,"Apple, Wal-Mart And Other Companies With Monster Share Buyback (AAPL, WMT)",2013-08-05 13:10:00-04:00,MRK,positive
853095.0,S&P: Heaping Praise For Some Health Care ETFs,2013-08-02 16:00:00-04:00,MRK,positive
853096.0,"Three Soaring, But Overlooked Health Care ETFs",2013-08-02 14:19:00-04:00,MRK,positive
853097.0,Bionomics Signs Option and License Agreement With Merck ,2013-07-31 06:41:00-04:00,MRK,positive
853098.0,"Benzinga Market Primer: Wednesday, July 31: Futures Higher Heading Into FOMC Decision",2013-07-31 06:33:00-04:00,MRK,neutral
853099.0,SLIDESHOW: 8 Stocks to Benefit From a Repatriation Deal In Congress,2013-07-30 13:06:00-04:00,MRK,positive
853100.0,"Benzinga's PreMarket Info Recap for July 30, 2013: Potash Smash!",2013-07-30 09:26:00-04:00,MRK,neutral
853101.0,UPDATE: Merck Posts Drop In Q2 Profit,2013-07-30 07:45:00-04:00,MRK,positive
853102.0,"Merck & Company, Inc. Reports Q2 EPS of $0.84 vs $0.83 Est; Revenue of $11.0B vs $11.22B Est",2013-07-30 07:00:00-04:00,MRK,neutral
853103.0,"Benzinga Market Primer: Wednesday, July 30: Futures Higher After Asia Turnaround",2013-07-30 06:46:00-04:00,MRK,neutral
853104.0,Earnings Expectations for the Week of July 29,2013-07-28 14:00:00-04:00,MRK,neutral
853105.0,"Weekly Preview: Earnings Season Continues, Fed In Focus, Economic Maelstrom Expected",2013-07-26 16:05:00-04:00,MRK,neutral
853106.0,"Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)",2013-07-26 10:46:00-04:00,MRK,positive
853107.0,"Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin ",2013-07-26 09:15:00-04:00,MRK,neutral
853108.0,"UPDATE: Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine ",2013-07-24 08:05:00-04:00,MRK,positive
853109.0,Merck Announces FDA Acceptance of NDA for Vorapaxar,2013-07-24 08:02:00-04:00,MRK,positive
853110.0,"BMO Capital Downgrades Merck & Company, Inc. to Market Perform",2013-07-18 08:13:00-04:00,MRK,neutral
853111.0,Merck in Talks with FDA to Identify Steps Needed for Review of Sugammadex Sodium Injection,2013-07-16 12:00:00-04:00,MRK,neutral
853112.0,Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY),2013-07-16 11:30:00-04:00,MRK,neutral
853113.0,Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization ,2013-07-16 08:03:00-04:00,MRK,neutral
853114.0,Health Care ETFs Looking Healthy Ahead of Earnings,2013-07-15 15:43:00-04:00,MRK,positive
853115.0,Sanofi Pasteur Vaccine Suspended as Precautionionary Measury - WHO Citing Quality Problem,2013-07-12 09:59:00-04:00,MRK,negative
853116.0,UPDATE: Jefferies Lowers PT on Merck on Challenges Ahead,2013-07-12 08:53:00-04:00,MRK,negative
853117.0,"Jefferies Maintains Buy on Merck & Company, Inc., Lowers PT to $54.00",2013-07-12 07:27:00-04:00,MRK,negative
853118.0,"Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)",2013-07-11 12:47:00-04:00,MRK,positive
853119.0,Financial Times Reporting That China Is Investigating 33 Foreign Pharmaceutical Companies For Pricing Irregularities,2013-07-04 07:27:00-04:00,MRK,neutral
853120.0,"Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)",2013-07-02 08:58:00-04:00,MRK,neutral
853121.0,FDA Approves New U.S. Labeling for ISENTRESSÂ® (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients ,2013-07-01 17:05:00-04:00,MRK,negative
853122.0,"Merck Receives Complete Response Letter for Suvorexant, Merck's Investigational Medicine for Insomnia; FDA Says Data Does Not Support Approval of Suvorexant 30mg and 40mg",2013-07-01 08:03:00-04:00,MRK,negative
853123.0,Merck Receives CRL for Suvorexant,2013-07-01 08:02:00-04:00,MRK,neutral
853124.0,"Aspen Pharmacare to Acquire Netherlands Plant, Portfolio of 11 Drug Brands from Merck for $1B -Reuters",2013-06-27 06:58:00-04:00,MRK,neutral
853125.0,"Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)",2013-06-26 13:17:00-04:00,MRK,positive
853126.0,UPDATE: BMO Capital Markets Lowers PT on Merck Following New SGLT2 Data,2013-06-24 09:30:00-04:00,MRK,negative
853127.0,"BMO Capital Maintains Outperform on Merck & Company, Inc., Lowers PT to $52.00",2013-06-24 08:41:00-04:00,MRK,negative
853128.0,Interesting Similarities Among 2013's Top-Performing ETFs,2013-06-18 16:09:00-04:00,MRK,positive
853129.0,"Mylan Being Sued by Pfizer, Merck, Want Blockage of Proposed Copy of Azasite",2013-06-17 11:35:00-04:00,MRK,positive
853130.0,"Dow Jones Reporting Merck to Cut Jobs, Change Organizational Structure of R&D Unit",2013-06-14 13:30:00-04:00,MRK,negative
853131.0,"Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)",2013-06-12 13:29:00-04:00,MRK,positive
853132.0,"FDA Says Considering New Study of Incretin Mimetic Diabetes Drug, Says May Need to Look for Cancer-Link Patterns",2013-06-12 08:18:00-04:00,MRK,neutral
853133.0,Merck Loses US Appeal of Apotex Patent Win Over Nasonex,2013-06-10 11:40:00-04:00,MRK,positive
853134.0,UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review,2013-06-07 12:32:00-04:00,MRK,neutral
853135.0,"Jefferies Maintains Buy on Merck & Company, Inc., Raises PT to $56.00",2013-06-07 07:50:00-04:00,MRK,neutral
853136.0,"With Bond Yields So Low, Reluctant Investors Are Now Making the Move into These Stocks",2013-06-04 09:44:00-04:00,MRK,negative
853137.0,"ISM Manufacturing Index Drops in May, Shows Contraction",2013-06-03 10:44:00-04:00,MRK,neutral
853138.0,Benzinga's Top Pre-Market Gainers,2013-06-03 08:10:00-04:00,MRK,positive
853139.0,"SunTrust Robinson Humphrey Initiates Coverage on Merck & Company, Inc. at Neutral, Announces $47.00 PT",2013-05-29 17:22:00-04:00,MRK,neutral
853140.0,"Short Interest in Vertex Rises, in Biogen Idec Falls",2013-05-29 13:19:00-04:00,MRK,positive
853141.0,"UPDATE: Jefferies Upgrades Merck to Buy, Raises PT Following SOTP Analysis",2013-05-28 10:50:00-04:00,MRK,neutral
853142.0,"PreMarket Info Recap for May 28, 2013",2013-05-28 09:25:00-04:00,MRK,neutral
853143.0,"Jefferies Upgrades Merck & Company, Inc. to Buy, Raises PT to $54.00",2013-05-28 07:55:00-04:00,MRK,neutral
853144.0,Merck Issues Update on Phase III Trial for Preladenant,2013-05-23 17:00:00-04:00,MRK,neutral
853145.0,Merck Issues Statement on FDA Advisory Committee Meeting Results for Suvorexant ,2013-05-22 20:24:00-04:00,MRK,neutral
853146.0,FDA Panel Votes 8-7 Merck's Suvorexant Unsafe in Higher Doses,2013-05-22 16:37:00-04:00,MRK,neutral
853147.0,FDA Panel Votes 13-3 Merck's Suvorexant is Safe in Low Doses,2013-05-22 16:17:00-04:00,MRK,positive
853148.0,FDA Panel Finds Merck Doesn't Need to Study 10mg Suvorexant,2013-05-22 15:36:00-04:00,MRK,neutral
853149.0,FDA Says Merck Insomnia Drug Helps Patients Stay Asleep -Bloomberg,2013-05-22 14:54:00-04:00,MRK,positive
853150.0,FDA Panel Votes 12 Yes 4 No on Effectiveness of Merck Insomnia Drug,2013-05-22 14:53:00-04:00,MRK,positive
853151.0,"PreMarket Info Recap for May 22, 2013",2013-05-22 09:17:00-04:00,MRK,neutral
853152.0,Merck FDA Advisory Committee Meeting for Insomnia Drug Suvorexant Begins at 8 AM ET,2013-05-22 07:36:00-04:00,MRK,neutral
853153.0,Merck to Take Initial Delivery of ~99.5M Shares,2013-05-21 17:01:00-04:00,MRK,positive
853154.0,Merck Announces $5B Accelerated Buyback Plan,2013-05-21 17:00:00-04:00,MRK,neutral
853155.0,ISI Suggesting the FDA Report on Merck Points to 'Some Risk' from Panel,2013-05-20 09:38:00-04:00,MRK,negative
853156.0,Merck Prices $6.5B Debt Offering,2013-05-15 18:30:00-04:00,MRK,negative
853157.0,Moody's Downgrades Merck's Guaranteed Senior Unsecured Rating from Aa3 to A1,2013-05-14 17:37:00-04:00,MRK,negative
853158.0,"Short Interest in Vertex Rises, in Celgene Falls",2013-05-11 10:45:00-04:00,MRK,positive
853159.0,"Merck, Glaxo Reduce Prices 95% for HPV Vaccine in Poor Nations",2013-05-09 07:16:00-04:00,MRK,negative
853160.0,Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet,2013-05-08 08:32:00-04:00,MRK,positive
853161.0,Barron's Recap: Apple Tops the Barron's 500,2013-05-06 06:32:00-04:00,MRK,positive
853162.0,FDA Approves Merck's LIPTRUZET for Hyperlipidemia Treatment,2013-05-03 15:02:00-04:00,MRK,positive
853163.0,UPDATE: Fitch Affirms Ratings on Merck; Outlook Lowered from Positive to Negative,2013-05-03 10:24:00-04:00,MRK,negative
853164.0,Fitch Affirms ratings on Merck; Outlook Lowered from Positive to Negative,2013-05-03 10:22:00-04:00,MRK,negative
853165.0,Earnings Trigger Volume Spike in Pharma ETF,2013-05-01 14:41:00-04:00,MRK,neutral
853166.0,May 1st Watchlist ,2013-05-01 09:37:00-04:00,MRK,neutral
853167.0,"Merck (CC): R&D Chief Calls Erosion on Singulair Sales 'Faster Than Expected,' Says Victrelis Sales Harmed in US, France, Germany",2013-05-01 08:22:00-04:00,MRK,negative
853168.0,From Merck Conference Call: Q1 Results 'Not Indicative of the Future',2013-05-01 08:14:00-04:00,MRK,neutral
853169.0,"UPDATE: Merck Posts 8.3% Drop In Q1 Profit, Lowers Forecast",2013-05-01 07:34:00-04:00,MRK,positive
853170.0,Merck Announces New $15B Buyback Plan,2013-05-01 07:14:00-04:00,MRK,neutral
853171.0,"Merck & Company, Inc. Lowers FY2013 EPS Guidance from $3.60-3.70 to $3.45-3.55 vs $3.63 Est",2013-05-01 07:14:00-04:00,MRK,negative
853172.0,"Merck & Company, Inc. Reports Q1 EPS of $0.85 vs $0.79 Est; Revenue of $10.70B vs $11.09B Est",2013-05-01 07:04:00-04:00,MRK,neutral
853173.0,Merck Announces New $15B Share Repurchase Program ,2013-05-01 07:00:00-04:00,MRK,positive
853174.0,"Pfizer Tanks on Earnings, Unhealthy Guidance",2013-04-30 10:36:00-04:00,MRK,negative
853175.0,Merck Wins FOSAMAX Federal Bellwether Trial Involving Atypical Femur Fracture Claims ,2013-04-29 17:00:00-04:00,MRK,positive
853176.0,"Market Wrap for Monday, April 29: Stocks Start Week With a Rally",2013-04-29 16:12:00-04:00,MRK,neutral
853177.0,"Merck, Pfizer Announce Worldwide Collaboration Deal for Development, Commercialization of Ertugliflozin",2013-04-29 07:32:00-04:00,MRK,neutral
853178.0,Earnings Expectations for the Week of April 29,2013-04-28 17:31:00-04:00,MRK,neutral
853179.0,A Look Ahead: This Week's ETFs to Watch,2013-04-28 17:28:00-04:00,MRK,neutral
853180.0,Weekly Preview: Focus Shifts from Earnings to Economy,2013-04-26 16:35:00-04:00,MRK,neutral
853181.0,"Short Sellers Move into Celgene, Regeneron",2013-04-26 13:25:00-04:00,MRK,neutral
853182.0,"Stocks to Watch for April 25, 2013",2013-04-25 09:12:00-04:00,MRK,neutral
853183.0,Merck & Co. Currently up $0.33 to $47.82; $0.17 Away from 52-Week and Multi-Year High,2013-04-22 14:35:00-04:00,MRK,neutral
853184.0,"UPDATE: BMO Capital Markets Raises PT on Merck & Co. on 1Q13 Preview, Long-Term Outlook",2013-04-19 10:59:00-04:00,MRK,neutral
853185.0,"BMO Capital Maintains Outperform on Merck & Company, Inc., Raises PT to $51.00",2013-04-19 07:46:00-04:00,MRK,neutral
853186.0,"Merck Sees Odanacatib US, EU Filing in 2014",2013-04-12 10:22:00-04:00,MRK,neutral
853187.0,"Benzinga Market Primer: Friday, April 12",2013-04-12 06:34:00-04:00,MRK,neutral
853188.0,ETF Showdown: A Pharma Fight,2013-04-11 16:21:00-04:00,MRK,negative
853189.0,"Court Says Merck Victory Upholding Vytorin Patents Will Stand, Says Mylan Can't Sell Copies of Vytorin, Zetia Before Apr. 2017",2013-04-11 11:21:00-04:00,MRK,neutral
853190.0,"Short Sellers Move Out of Amgen, Celgene, Pharmacyclics",2013-04-10 13:30:00-04:00,MRK,neutral
853191.0,UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook,2013-04-10 12:11:00-04:00,MRK,positive
853192.0,Merck Announces FDA Acceptance of NDA for NOXAFIL Investigational Tablet Formulation,2013-04-10 08:31:00-04:00,MRK,positive
853193.0,"Jefferies Maintains Hold on Merck & Company, Inc., Raises PT to $48.00",2013-04-10 08:04:00-04:00,MRK,neutral
853194.0,Merck Receives Positive Mad Money/Jim Cramer Mention -CNBC,2013-04-09 19:11:00-04:00,MRK,positive
853195.0,"Golden Crosses Over The Past Trading Week (50 SMA Cross Above 200 SMA) CMG, LO, MRK, PRGO, SO, WMT, YUM",2013-04-08 13:28:00-04:00,MRK,neutral
853196.0,Cheap Does not Always Mean BUY,2013-04-08 08:25:00-04:00,MRK,neutral
853197.0,2 New Dividend ETFs to Consider,2013-04-04 16:26:00-04:00,MRK,neutral
853199.0,Merck Announces FDA Acceptance of Biologics License App for Investigational Grass Pollen Allergy Immunotherapy Tablet,2013-03-27 08:01:00-04:00,MRK,positive
853200.0,The Supreme Court is About to Stick it to Big Pharma,2013-03-26 12:22:00-04:00,MRK,positive
853201.0,Risk On Rally? These ETFs Say No,2013-03-26 11:37:00-04:00,MRK,negative
853202.0,EMA Investigating Pancreatic Risks with GLP-1 Diabetes Drugs,2013-03-26 11:19:00-04:00,MRK,negative
853203.0,"Bank of America Reiterates Buy Rating, $47 PT on Merck & Co. Ahead of Potential Approvals",2013-03-25 08:53:00-04:00,MRK,neutral
853205.0,Reuters Reporting Merck Saying FDA Extended Review of Sugammadex,2013-03-15 10:08:00-04:00,MRK,neutral
853206.0,Embrace These New ETFs,2013-03-14 14:42:00-04:00,MRK,positive
853207.0,The Top 20 African-American CEOs in Business Today,2013-03-13 13:42:00-04:00,MRK,positive
853208.0,"Bank of America Reiterates Buy Rating, $47 PT on Merck & Co. Following IMPROVE-IT Trial Review",2013-03-13 08:07:00-04:00,MRK,neutral
853209.0,Unusual Options Alert: Merck & Co. Continues To Do Extremely Heavy Volume,2013-03-12 13:24:00-04:00,MRK,positive
853210.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)",2013-03-12 13:19:00-04:00,MRK,positive
853211.0,Lawyer Tells Jury in Merck Case Over Fosamax Co. Hid Product's Bone-Weakening Risks,2013-03-12 12:51:00-04:00,MRK,negative
853212.0,"Merck Issues Update on IMPROVE-IT Trial, Says DSMB Recommend Study to Continue",2013-03-12 08:01:00-04:00,MRK,positive
853214.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2013-03-08 06:15:00-05:00,MRK,positive
853215.0,"Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire ",2013-03-07 07:32:00-05:00,MRK,neutral
853216.0,3 Sector ETFs Outpacing Larger Rivals,2013-03-06 13:39:00-05:00,MRK,neutral
853217.0,"From Merck Presentation for Cowen Healthcare Conference: Sees V503 for Cancer Endpoint Driven Trial Filing This Year, V212 Filing for HCT, V419 Pediatric Combo Vaccine Filing Next Year",2013-03-06 10:11:00-05:00,MRK,negative
853218.0,Hedging The Dow At Its All-Time High,2013-03-06 08:29:00-05:00,MRK,neutral
853220.0,An HIV Cure Is Great News For These Drug Manufacturers,2013-03-04 15:22:00-05:00,MRK,positive
853221.0,"Cardiome Ends Line of Credit Merck, to Buy Added $3M of Vernakalant IV Inventory",2013-03-04 08:54:00-05:00,MRK,positive
853222.0,UPDATE: Bank of America Upgrades Merck to Buy; Pullback Creates Meaningful Upside Potential,2013-03-04 07:10:00-05:00,MRK,positive
853223.0,"Bank of America Upgrades Merck & Company, Inc. to Buy, Maintains $47.00 PO",2013-03-04 06:23:00-05:00,MRK,negative
853224.0,"If The Market Falls, Try These Low Beta ETFs",2013-02-28 18:27:00-05:00,MRK,negative
853225.0,Still No Herbalife in 13F ETFs,2013-02-27 13:48:00-05:00,MRK,negative
853226.0,"UPDATE: Jefferies Reiterates Hold Rating, Lowers PT on Merck & Co. on IMPROVE-IT Overhang Removal",2013-02-25 10:35:00-05:00,MRK,negative
853227.0,"Jefferies Maintains Hold on Merck & Company, Inc., Lowers PT to $46.00",2013-02-25 06:41:00-05:00,MRK,negative
853228.0,"BMO Capital Maintains Outperform on Merck & Company, Inc., Lowers PT to $47.00",2013-02-15 08:00:00-05:00,MRK,negative
853229.0,"Merck Resolves Securities Class-Action Suit Related to ENHANCE, to Record $493M Charge",2013-02-14 08:01:00-05:00,MRK,positive
853230.0,Merck Shares Down 0.6% Premarket Following Outlook Update,2013-02-13 09:06:00-05:00,MRK,positive
853231.0,Merck Sees Q1 Adj.EPS $0.76-0.78 vs $0.86 Est,2013-02-13 09:00:00-05:00,MRK,neutral
853232.0,Merck Reaffirms Outlook,2013-02-13 09:00:00-05:00,MRK,neutral
853233.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)",2013-02-12 13:29:00-05:00,MRK,positive
853234.0,Mylan Loses Appeals Court Bid to Invalidate Zetia Patents,2013-02-07 11:43:00-05:00,MRK,negative
853235.0,"Merck Serono, Opexa Therapeutics Enter Option, License Agreement for Development of Tcelna",2013-02-05 07:41:00-05:00,MRK,positive
853236.0,"UPDATE: BMO Capital Markets Reiterates Outperform Rating, Lowers PT on Merck & Co.",2013-02-04 09:04:00-05:00,MRK,negative
853237.0,UPDATE: Morgan Stanley Downgrades Merck to Underweight Ahead of Key March Trial,2013-02-04 09:03:00-05:00,MRK,neutral
853238.0,"Leerink Swann Downgrades Merck & Company, Inc. to Market Perform",2013-02-04 09:00:00-05:00,MRK,neutral
853239.0,"Morgan Stanley Downgrades Merck & Company, Inc. to Underweight, Removes $43.00 PT",2013-02-04 06:37:00-05:00,MRK,neutral
853240.0,Hearing Merck Defded at Credit Suisse,2013-02-01 09:54:00-05:00,MRK,positive
853241.0,"Merck & Company, Inc. Reports Q4 EPS of $0.83 vs $0.81 Est; Revenue of $11.74B vs $11.54B Est",2013-02-01 07:05:00-05:00,MRK,neutral
853242.0,US Stock Futures Up; All Eyes On Payroll Data ,2013-02-01 06:11:00-05:00,MRK,neutral
853243.0,"Earnings Scheduled For February 1, 2013",2013-02-01 04:14:00-05:00,MRK,neutral
853244.0,"Stocks To Watch For February 1, 2013",2013-02-01 02:38:00-05:00,MRK,neutral
853245.0,Isis and Sanofi's Drug OK'd to Treat Inherited Cholesterol Disease,2013-01-30 12:52:00-05:00,MRK,positive
853246.0,FDA Approves OXYTROL for Women,2013-01-25 11:11:00-05:00,MRK,positive
853247.0,"UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Merck & Co.",2013-01-16 09:31:00-05:00,MRK,negative
853248.0,"Jefferies Maintains Hold on Merck & Company, Inc., Lowers PT to $47.00",2013-01-16 08:52:00-05:00,MRK,negative
853249.0,Three Stocks to Buy for Flu Season,2013-01-11 13:57:00-05:00,MRK,negative
853250.0,Merck to Suspend Availability of TREDAPTIVE Worldwide,2013-01-11 07:46:00-05:00,MRK,negative
853251.0,"Microbiotix, Merck Announce Licensing Pact for HCV NS5B",2013-01-09 09:57:00-05:00,MRK,neutral
853252.0,4 Health Care ETFs Your Broker Forgot to Mention,2013-01-07 15:52:00-05:00,MRK,positive
853253.0,Merck Receives FDA Acceptance of Resubmission of NDA for Sugammadex Sodium Injection,2013-01-07 08:01:00-05:00,MRK,positive
853254.0,"Merck, Pfizer, Abbott, J&J, Sanofi Said to Show Interest in Bausch & Lomb Bid - Bloomberg",2013-01-03 16:00:00-05:00,MRK,positive
853255.0,"Merck Says FDA Acknowledged Resubmission of NDA for Ezetimibe, Atorvastatin Tablets",2013-01-02 16:47:00-05:00,MRK,neutral
853256.0,"Merck Sends Dear Doctor Letter Related to Tredaptive's Failed Study, Says Side Effects Include Muscle, Skin, Blood Damage",2012-12-28 10:27:00-05:00,MRK,negative
853257.0,"Option Alert: Merck January 45 Call; Block Trade: 7,000 Contracts @$0.03; Currently $41.31",2012-12-26 12:16:00-05:00,MRK,negative
853258.0,"Goldman Sachs Maintains Neutral on Merck & Company, Inc., Lowers PT to $47.00",2012-12-20 12:31:00-05:00,MRK,negative
853259.0,"Mid-Morning Market Update: Rite Aid Rallies, New York Stock Exchange Acquired by ICE",2012-12-20 10:35:00-05:00,MRK,neutral
853260.0,Merck Says HPS2-THRIVE Study of TREDAPTIVE Did Not Achieve Primary Endpoint,2012-12-20 08:35:00-05:00,MRK,neutral
853261.0,"Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program",2012-12-18 07:31:00-05:00,MRK,negative
853262.0,These 2 Dow Laggards Could Rebound in 2013,2012-12-16 13:41:00-05:00,MRK,neutral
853263.0,"Benzinga's Small Cap Movers for Tuesday December 11, 2012",2012-12-11 19:09:00-05:00,MRK,neutral
853264.0,"Benzinga's M&A Chatter for Tuesday December 11, 2012",2012-12-11 17:23:00-05:00,MRK,neutral
853265.0,"Warburg Pincus Said to Hire Goldman Sachs to Sell Bausch & Lomb, Seeking At Least $10B; Abbott, Glaxo, Merck, Sanofi Said to Be Contacted - Bloomberg",2012-12-11 16:56:00-05:00,MRK,neutral
853266.0,Cardiome Reaches Deal with Merck to Retire Debt/Close Line of Credit; Will Pay Merck $20M,2012-12-11 08:10:00-05:00,MRK,positive
853267.0,"Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)",2012-12-10 15:12:00-05:00,MRK,positive
853268.0,Barron's Recap (12/8/12): Ten Stock Picks for 2013,2012-12-08 13:07:00-05:00,MRK,neutral
853269.0,Merck Files Debt Securities Shelf,2012-12-03 17:28:00-05:00,MRK,negative
853270.0,"Merck Begins Phase II/III Study of Investigational BACE Inhibitor, MK-8931",2012-12-03 07:50:00-05:00,MRK,negative
853271.0,"Citigroup Initiates Coverage on Merck & Company, Inc. at Neutral, Announces $44.00 PT",2012-11-30 14:31:00-05:00,MRK,neutral
853272.0,Merck Increases Dividend to $0.43 from $0.42,2012-11-27 14:59:00-05:00,MRK,neutral
853273.0,Merck Receives FDA Orphan Status for Melanoma Treatment,2012-11-20 13:04:00-05:00,MRK,neutral
853274.0,"MKM Partners Upgrades Merck & from Neutral to Buy, Raises PT from $47 to $51",2012-11-20 12:11:00-05:00,MRK,neutral
853275.0,Benzinga's Top Upgrades,2012-11-20 08:44:00-05:00,MRK,positive
853276.0,S&P Reiterates Bullish View on Health Care ETFs,2012-11-16 12:56:00-05:00,MRK,positive
853277.0,These ETFs Offer Solid Yield in Uncertain Times,2012-11-14 08:58:00-05:00,MRK,negative
853278.0,"Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)",2012-11-12 13:24:00-05:00,MRK,positive
853279.0,"UPDATE: BMO Capital Markets Upgrades Merck & Co. to Outperform, Reiterates $50 PT",2012-11-12 11:19:00-05:00,MRK,neutral
853280.0,"BMO Capital Markets Upgrades Merck & from Market Perform to Outperform, Maintains PT at $50",2012-11-12 07:49:00-05:00,MRK,neutral
853281.0,Merck Presents Early-Stage Interim Data for MK-3475  Study for Treatment of Advanced Melanoma ,2012-11-12 06:16:00-05:00,MRK,positive
853282.0,"Futures Flat, Euro Falls Ahead of Central Banks",2012-11-08 06:19:00-05:00,MRK,neutral
853283.0,"Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)",2012-11-03 10:07:00-04:00,MRK,positive
853284.0,More Equal-Weight ETFs Your Broker Forgot to Mention ,2012-10-30 15:01:00-04:00,MRK,neutral
853285.0,"UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Merck & Co.",2012-10-29 12:31:00-04:00,MRK,neutral
853286.0,"BMO Capital Markets Maintains Merck & at Market Perform, Raises PT from $46 to $50",2012-10-29 08:45:00-04:00,MRK,neutral
853287.0,Merck Begins Earnings Call,2012-10-26 08:23:00-04:00,MRK,neutral
853288.0,S&P Bullish on Select Dividend ETFs,2012-10-26 07:16:00-04:00,MRK,neutral
853289.0,Merck & Reports Q3 EPS $0.92 vs $0.92 Est; Revenues $11.49B vs $11.57B Est,2012-10-26 07:11:00-04:00,MRK,neutral
853290.0,"Benzinga Market Primer, Friday, October 26",2012-10-26 06:15:00-04:00,MRK,neutral
853291.0,US Stock Futures Down After Apple Earnings,2012-10-26 06:12:00-04:00,MRK,neutral
853292.0,"Earnings Scheduled For October 26, 2012",2012-10-26 03:42:00-04:00,MRK,neutral
853293.0,"Stocks To Watch For October 26, 2012",2012-10-26 03:13:00-04:00,MRK,neutral
853294.0,"Stocks To Watch For October 26, 2012",2012-10-26 03:13:00-04:00,MRK,neutral
853295.0,S&P Likes a Trio of Biotech ETFs ,2012-10-24 16:09:00-04:00,MRK,positive
853296.0,Earnings Expectations for the Week of October 22,2012-10-22 08:15:00-04:00,MRK,neutral
853297.0,"Barclays Maintains Merck & at Overweight, Raises PT from $46 to $50",2012-10-15 12:12:00-04:00,MRK,negative
853298.0,A Peek Into The Market Before The Trading Starts,2012-10-15 07:21:00-04:00,MRK,neutral
853299.0,"AiCuris, Merck Enter Exclusive Worldwide License Agreement ",2012-10-15 06:16:00-04:00,MRK,positive
853300.0,Merck BMD Data from a Phase II Study of Odanacatib Shows Significantly Increased Bone Mineral Density,2012-10-13 15:27:00-04:00,MRK,positive
853301.0,"Jefferies & Company Maintains Merck & at Hold, Raises PT from $44 to $47",2012-10-12 06:59:00-04:00,MRK,neutral
853302.0,Part I: Must Know ETFs For Q3 Earnings ,2012-10-09 14:37:00-04:00,MRK,neutral
853303.0,Merck to Move Global Headquarters Within New Jersey  ,2012-10-09 08:10:00-04:00,MRK,neutral
853304.0,Delphi Genetics Grants Merck License for the Use of the StabyExpress System,2012-10-08 08:11:00-04:00,MRK,positive
853305.0,Deutsche Bank Suspends Coverage on Merck &,2012-10-01 16:28:00-04:00,MRK,neutral
853306.0,Merck HPV Vaccine Shown to be Safe in a Kaiser Study,2012-10-01 16:01:00-04:00,MRK,positive
853307.0,Merck Returns Rights for Vernakalant to Cardiome,2012-09-26 08:09:00-04:00,MRK,neutral
853308.0,S&P Highlights Election ETFs,2012-09-25 16:24:00-04:00,MRK,neutral
853309.0,"Pfizer, Merck Set Up Chinese Joint Ventures for Generic Drugs -WantChinaTimes",2012-09-19 09:37:00-04:00,MRK,neutral
853310.0,Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer ,2012-09-13 07:01:00-04:00,MRK,neutral
853311.0,"Merck Announces New Phase III Data for Suvorexant, Says Patients Normal Sleep Patterns Return After Stopping Use",2012-09-10 08:35:00-04:00,MRK,negative
853312.0,Merck Provides Update on Cardiovascular Development Programs,2012-08-26 09:07:00-04:00,MRK,neutral
853313.0,"UPDATE: Bank of America Merrill Lynch Downgrades Merck to Neutral, Reiterates $45 PT",2012-08-24 12:05:00-04:00,MRK,neutral
853314.0,"Bank of America Downgrades Merck & from Buy to Neutral, Announces PO of $45",2012-08-24 07:13:00-04:00,MRK,negative
853315.0,S&P Still Bullish on Health Care ETFs,2012-08-16 17:03:00-04:00,MRK,positive
853316.0,"Jefferies & Company Maintains Merck & Co. at Hold, Raises PT from $42 to $44",2012-08-13 06:50:00-04:00,MRK,neutral
853317.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2012-08-13 00:25:00-04:00,MRK,positive
853318.0,Under The Hood: Tempting Technicals And a Dividend,2012-08-09 07:06:00-04:00,MRK,neutral
853319.0,"Credit Suisse Maintains Merck & at Outperform, Lowers PT from $48 to $47",2012-08-09 06:25:00-04:00,MRK,positive
853320.0,"UBS Maintains Merck & at Buy, Raises PT from $45 to $50",2012-07-30 11:40:00-04:00,MRK,neutral
853321.0,"BMO Capital Markets Maitnains Merck & at Market Perform, Raises PT from $43 to $46",2012-07-30 07:57:00-04:00,MRK,neutral
853322.0,"Benzinga Market Primer, Monday July 30",2012-07-30 07:07:00-04:00,MRK,neutral
853323.0,Merck on Call Says Expecting Multiple Generic Singulair Entrants on Day One,2012-07-27 08:24:00-04:00,MRK,neutral
853324.0,UPDATE: Merck Beats EPS Estimates by $0.03 and Beats Revenues Estimates While Reaffirming FY2012 Guidance,2012-07-27 07:42:00-04:00,MRK,neutral
853325.0,Merck Reports Q2 Vytorin Sales $445M vs $432.3M Est; Q2 Remicade Sales $518M vs $545M Est,2012-07-27 07:24:00-04:00,MRK,neutral
853326.0,"Benzinga Market Primer, Friday July 27",2012-07-27 07:23:00-04:00,MRK,neutral
853327.0,"Merck says Suvorexant, Odanacatib Filings on Track",2012-07-27 07:23:00-04:00,MRK,neutral
853328.0,Merck & Reports Q2 EPS $1.05 vs $1.01 Est; Revenues $12.2B vs $12.15B Est,2012-07-27 07:01:00-04:00,MRK,neutral
853329.0,US Stock Futures Up; GDP Data In Focus,2012-07-27 06:42:00-04:00,MRK,neutral
853330.0,Earnings Scheduled For July 27,2012-07-27 03:43:00-04:00,MRK,neutral
853331.0,Stocks To Watch For July 27,2012-07-27 03:38:00-04:00,MRK,neutral
853332.0,"From Earlier: Merck ISENTRESS in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks  ",2012-07-23 07:10:00-04:00,MRK,positive
853333.0,Earnings Expectations for the Week of July 23,2012-07-23 07:07:00-04:00,MRK,neutral
853334.0,"ISENTRESS in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 ",2012-07-22 19:25:00-04:00,MRK,positive
853335.0,"Alnylam In Talks On Cholesterol Drug Partnership, CEO Says, Has Completed Phase I Clinical Trial Of Drug",2012-07-19 11:14:00-04:00,MRK,neutral
853336.0,"Kapito: 'We Like ATT, VZ, MRK, JNJ for Yields''",2012-07-18 12:23:00-04:00,MRK,positive
853337.0,"Morgan Stanley Maintains Merck & Co. at Equal-weight, Raises PT from $37 to $43",2012-07-18 06:10:00-04:00,MRK,neutral
853338.0,Merck Says Court Approves Proposed Erisa Settlement,2012-07-17 11:38:00-04:00,MRK,positive
853339.0,Popular Drug Manufacturing Stocks Among Hedge Funds,2012-07-17 07:47:00-04:00,MRK,positive
853340.0,"Low Volume, High Returns for These ETFs (BIB, FHC, DRW)",2012-07-13 15:25:00-04:00,MRK,negative
853341.0,"5 Market-Based ETFs Your Broker Forgot to Mention (HDIV, OFF, PDP)",2012-07-13 14:26:00-04:00,MRK,neutral
853342.0,"Social Media Outlook, Friday July 13",2012-07-13 12:24:00-04:00,MRK,neutral
853343.0,"Jefferies & Company Maintains Merck & Co. at Hold, Raises PT from $40 to $42",2012-07-13 07:00:00-04:00,MRK,neutral
853344.0,Merck Hits 4-Year High Thursday on Positive Phase 3 Osteoporosis Drug Data -IBD,2012-07-12 11:22:00-04:00,MRK,positive
853345.0,Thursday Market Movers,2012-07-12 10:51:00-04:00,MRK,neutral
853346.0,UPDATE: Citigroup Upgrades Merck; Raises PT,2012-07-12 10:48:00-04:00,MRK,neutral
853347.0,"From Earlier: Update on Phase III Trial for Odanacatib, Merck's Investigational Cat-K Inhibitor for Osteoporosis ",2012-07-12 08:42:00-04:00,MRK,negative
853348.0,Benzinga's Top Pre-Market Gainers,2012-07-12 08:13:00-04:00,MRK,positive
853349.0,"Goldman Sachs Maintains Merck & Co. at Neutral, Raises PT from $41 to $45",2012-07-12 07:58:00-04:00,MRK,neutral
853350.0,Benzinga's Top Upgrades,2012-07-12 07:23:00-04:00,MRK,positive
853351.0,"Citigroup Upgrades Merck & from Neutral to Buy, Raises PT from $34 to $50",2012-07-12 05:52:00-04:00,MRK,neutral
853352.0,Study for Merck's Investigational Cat-K Inhibitor for Osteoporosis Meets Outcomes and Is Concluded Early,2012-07-11 17:13:00-04:00,MRK,negative
853353.0,Merck Announces Collaboration to Improve Maternal Health through Expanded Access to Family Planning   ,2012-07-11 10:15:00-04:00,MRK,positive
853354.0,"Deutsche Bank Maintains Merck & at Buy, Raises PT from $43 to $47.25",2012-07-10 16:05:00-04:00,MRK,neutral
853355.0,"Dendreon, Pharmacyclics and Other Biotech Takeover Targets",2012-07-10 14:07:00-04:00,MRK,neutral
853356.0,ALPS Unveils Dogs of the Dow ETF,2012-06-29 12:51:00-04:00,MRK,neutral
853357.0,Ultimate Stock Watch List for The Supreme Court's Health Care Ruling,2012-06-28 09:51:00-04:00,MRK,positive
853358.0,A Peek Into The Market Before The Trading Starts,2012-06-27 07:22:00-04:00,MRK,neutral
853359.0,Merck and AstraZeneca Agree to Amend Partnership   ,2012-06-27 07:01:00-04:00,MRK,positive
853360.0,Leveraged ETFs for the Obamacare Ruling,2012-06-26 18:07:00-04:00,MRK,neutral
853361.0,"Benzinga's M&A Chatter for Tuesday June 26, 2012",2012-06-26 18:04:00-04:00,MRK,neutral
853362.0,Spokesperson for Amylin Pharmaceuticals Won't Comment on Rumor of Bids from Pharma Companies,2012-06-26 13:17:00-04:00,MRK,neutral
853363.0,Amylin Pharmaceuticals Spiking to Highs on Earlier Bid Reports,2012-06-26 11:57:00-04:00,MRK,neutral
853364.0,"Novartis, Sanofi, Merck, Bristol, AstraZeneca Weigh Amylin Final Bids; Amylin Expects Final Bids Starting End of the Week -Reuters ",2012-06-26 11:38:00-04:00,MRK,neutral
853365.0,"Ahead of Obamacare Ruling, S&P Likes Health Care SPDR",2012-06-25 14:02:00-04:00,MRK,positive
853366.0,Merck Spikes to New 52-Week High on Heavy Volume; $40.18,2012-06-22 10:59:00-04:00,MRK,neutral
853367.0,Merck Statement on CDC Advisory Committee on Immunization Practices' Recommendation for Pneumococcal Vaccination in Immunocompromised Adults   ,2012-06-20 13:33:00-04:00,MRK,neutral
853368.0,"Geisinger and Merck to Collaborate on Multi-year Effort to Improve Patient Adherence, Engagement and Care Delivery   ",2012-06-18 08:01:00-04:00,MRK,positive
853369.0,From Earlier: U.S. District Court Rules Against Merck in NASONEX Patent Lawsuit  ,2012-06-18 07:26:00-04:00,MRK,negative
853370.0,US District Court Rules Against Merck in NASONEX Patent Lawsuit,2012-06-15 17:12:00-04:00,MRK,negative
853371.0,"Believe In The Rally? Try These ETFs (HDV, IYZ, HYD)",2012-06-14 15:33:00-04:00,MRK,neutral
853372.0,Johnson & Johnson to Complete Synthes Acquisition ,2012-06-14 08:25:00-04:00,MRK,neutral
853374.0,Pfizer Plans to IPO Part of its Animal Health Segment,2012-06-07 15:46:00-04:00,MRK,neutral
853375.0,"Merck Sues Sandoz, Accord Healthcare on Proposed Emend Copy, Claims Infringement of Patents Expiring in 2015 and 2019",2012-06-05 16:51:00-04:00,MRK,negative
853376.0,"Merck Gets Response Letter for Ridaforolimus, Says Added Clinical Trials Would Need to be Conducted; In Talks with EU Health Authorities -Bloomberg",2012-06-05 16:37:00-04:00,MRK,neutral
853377.0,The US Economy and the United Nations: Bold Strategies Needed - Tax Reform and Benefits Reform,2012-06-04 12:16:00-04:00,MRK,positive
853378.0,"Benzinga's M&A Chatter for  Friday June 1, 2012",2012-06-03 10:47:00-04:00,MRK,neutral
853379.0,Amylin Pharmaceuticals Spokesperson Declines Comment on Renewed Takeover Chatter,2012-06-01 15:14:00-04:00,MRK,neutral
853380.0,Hearing Renewed Takeover Chatter in Amylin Pharmaceuticals,2012-06-01 13:50:00-04:00,MRK,neutral
853381.0,15 Great Stocks with Great Yield,2012-05-31 15:40:00-04:00,MRK,positive
853382.0,Merck CEO Says He Isn't Interested in Breaking Up the Company -Bloomberg,2012-05-31 08:49:00-04:00,MRK,negative
853383.0,"Benzinga's M&A Chatter for Wednesday May 30, 2012",2012-05-30 17:08:00-04:00,MRK,neutral
853384.0,5 Healthcare Stocks With The Highest Cash,2012-05-29 07:32:00-04:00,MRK,neutral
853385.0,"Benzinga's M&A Chatter for Friday May 25, 2012",2012-05-28 01:21:00-04:00,MRK,neutral
853386.0,"Amylin Shares Jump as Sanofi, Merck Sumbit Bids",2012-05-25 15:15:00-04:00,MRK,positive
853387.0,Merck Spokesperson Would Not Comment on Reports of Bid for Amylin,2012-05-25 14:24:00-04:00,MRK,neutral
853388.0,Amylin Spokesperson Would Not Comment on Bloomberg Report of Bids from Merck and Sanofi,2012-05-25 14:18:00-04:00,MRK,neutral
853389.0,"Amylin Said to Get First-Round Bids from Sanofi, Merck -Bloomberg",2012-05-25 14:01:00-04:00,MRK,neutral
853390.0,Government of Rwanda Introduces Merck's ROTATEQ,2012-05-25 07:20:00-04:00,MRK,neutral
853391.0,Health Care SPDR In Focus Ahead Of Obamacare Decision,2012-05-22 12:34:00-04:00,MRK,positive
853392.0,"Merck: FDA Approves New Labeling for ISENTRESS to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability",2012-05-21 08:02:00-04:00,MRK,positive
853393.0,"BMO Capital Markets Initiates Coverage on Merck & at Market Perform, Announces PT of $43",2012-05-18 07:58:00-04:00,MRK,neutral
853394.0,"S&P Bullish On Biotech ETFs (FBT, IBB, XBI)",2012-05-15 14:31:00-04:00,MRK,neutral
853395.0,The Shorts Report: 10 Mega-Caps With Increased Short Selling,2012-05-11 11:12:00-04:00,MRK,positive
853396.0,J.P. Morgan Reiterates Overweight Rating for Merck,2012-05-07 12:21:00-04:00,MRK,negative
853397.0,Goldman Sachs Reiterates Neutral Rating for Merck,2012-05-07 10:06:00-04:00,MRK,neutral
853398.0,"Pfizer, Merck Pulled Into Expanded Congressional Investigation, Republicans Seeking Documents Over Obama Deal -Bloomberg",2012-05-04 09:56:00-04:00,MRK,neutral
853399.0,New Kids: Do These New ETFs Have The Right Stuff?,2012-04-30 15:43:00-04:00,MRK,neutral
853400.0,FDA Considering Letting Patients Purchase Drugs Without Prescriptions,2012-04-30 12:09:00-04:00,MRK,neutral
853401.0,Merck & Reports Q1 EPS $0.99 vs $0.98 Est; Revenues $11.7B vs $11.82B Est,2012-04-27 07:05:00-04:00,MRK,neutral
853402.0,US Stock Futures Flat; GDP Data In Focus,2012-04-27 06:35:00-04:00,MRK,neutral
853403.0,Earnings Scheduled For April 27,2012-04-27 02:39:00-04:00,MRK,neutral
853404.0,"Earnings Expectations for the Week of April 23 (AAPL, XOM, UPS)",2012-04-22 11:23:00-04:00,MRK,neutral
853405.0,S&P: Bullish On Pharma ETFs Long-Term,2012-04-19 14:45:00-04:00,MRK,neutral
853406.0,Merck Reports Phase III Study Results Evaluating Anaemia Management Strategies Used With VICTRELISÂ® (boceprevir) Combination Therapy   ,2012-04-19 07:00:00-04:00,MRK,neutral
853407.0,Merck Wins Another FOSAMAX State Court Trial   ,2012-04-18 15:43:00-04:00,MRK,positive
853408.0,"Benzinga's Microcap Movers for Monday April 16, 2012",2012-04-17 08:54:00-04:00,MRK,neutral
853409.0,Benzinga's Top Pre-Market Gainers,2012-04-17 08:13:00-04:00,MRK,positive
853410.0,Option Alert: Endocyte Call Volume at 818% of Average on Merck Deal,2012-04-16 10:47:00-04:00,MRK,positive
853411.0,Morning Market Movers,2012-04-16 09:49:00-04:00,MRK,neutral
853412.0,Benzinga's Top Pre-Market Gainers,2012-04-16 08:12:00-04:00,MRK,positive
853413.0,Endocyte Rises 100% Pre-Market on Merck Deal,2012-04-16 07:34:00-04:00,MRK,neutral
853414.0,"Financial Breakfast: Morning News Summary for April 16, 2012",2012-04-16 07:33:00-04:00,MRK,neutral
853415.0,Endocyte Resumes Trading,2012-04-16 07:30:00-04:00,MRK,neutral
853416.0,PREVIEW: Endocyte to Resume Trading at 7:30am,2012-04-16 07:11:00-04:00,MRK,neutral
853417.0,Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide,2012-04-16 07:06:00-04:00,MRK,negative
853418.0,Decoding Wall St.: Express Scripts and Medco Merger is No Joke,2012-04-04 07:43:00-04:00,MRK,neutral
853419.0,Merck,2012-04-03 18:47:00-04:00,MRK,neutral
853420.0,Codexis and Merck Develop Prototype Enzyme-Based Method for Production of Boceprevir  ,2012-04-03 16:06:00-04:00,MRK,neutral
853421.0,"Benzinga's M&A Chatter for Tuesday March 27, 2012",2012-03-27 19:50:00-04:00,MRK,neutral
853422.0,"Merck Spokesperson, Responding to Chatter of $26 Offer for Amarin, Says Company Policy is Not to Respond to Rumors Regarding Business Development Deals",2012-03-27 11:25:00-04:00,MRK,neutral
853423.0,Hearing Chatter Merck Making $26/Share Bid for Amarin,2012-03-27 10:21:00-04:00,MRK,neutral
853424.0,Victrelis Available for Eligible Patients in British Columbia,2012-03-26 16:44:00-04:00,MRK,neutral
853425.0,Merck Reports C$35M Investment and Start of Merck Lumira Fund,2012-03-26 10:09:00-04:00,MRK,neutral
853426.0,Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events,2012-03-24 19:21:00-04:00,MRK,positive
853427.0,UPDATE: Merck and ARIAD Pharmaceuticals Provide Update on FDA Advisory Committee Vote; Voted 13 To 1 Against The Use of Ridaforolimus,2012-03-21 07:52:00-04:00,MRK,neutral
853428.0,Ariad Pharmaceuticals Falls 5% on FDA Panel Vote,2012-03-20 16:28:00-04:00,MRK,neutral
853429.0,FDA Panel Votes 13-1 Against Recommending Taltorvic As Maintenance Treatment For Soft-tissue And Bone Sarcoma -Reuters ,2012-03-20 16:27:00-04:00,MRK,neutral
853430.0,"ETF Showdown: Dividend Dilemma (HDV, HDIV, JNJ)",2012-03-16 14:55:00-04:00,MRK,negative
853431.0,"Briefing Information for the March 20, 2012 Meeting of the Oncologic Drugs Advisory Committee",2012-03-16 08:12:00-04:00,MRK,neutral
853432.0,"A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)",2012-03-15 14:55:00-04:00,MRK,neutral
853433.0,"Benzinga's M&A Chatter for  Monday March 12, 2012",2012-03-12 18:39:00-04:00,MRK,neutral
853434.0,Merck Repeats 2012 Forecast in Presentation Slides -Bloomberg,2012-03-12 15:31:00-04:00,MRK,neutral
853435.0,Merck Spokesperson Would Not Comment on Earlier Speculation of Idenix Pharmaceuticals Takeover Bid,2012-03-12 15:23:00-04:00,MRK,neutral
853436.0,"Hearing Renewed Takeover Chatter in Idenix Pharmaceuticals, Merck Rumored Buyer",2012-03-12 13:35:00-04:00,MRK,neutral
853437.0,Positive Rumors Circulate About Idenix Pharmaceuticals,2012-03-12 13:35:00-04:00,MRK,positive
853438.0,Merck Gives Weak Q1 Outlook,2012-03-07 09:07:00-05:00,MRK,negative
853439.0,From Earlier: Merck Announces Results from Investigational Studies with VICTRELIS Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1  ,2012-03-07 07:26:00-05:00,MRK,neutral
853440.0,Oncothyreon Analyst: Stimulax Continuation Was Expected; as Likely Outcome for Trial to be Completed Rather Than Stop Early for Positive Efficacy or Futility,2012-03-06 15:19:00-05:00,MRK,positive
853441.0,Merck Down 2% After Reaffirming 2012 Guidance,2012-03-06 12:48:00-05:00,MRK,neutral
853442.0,Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy,2012-03-06 09:01:00-05:00,MRK,negative
853443.0,Merck Issues Q1 Profit Forecast,2012-03-06 08:24:00-05:00,MRK,positive
853444.0,UPDATE: Merck Confirms 2012 Full-Year Guidance,2012-03-06 08:01:00-05:00,MRK,neutral
853445.0,Merck Guides Q1 EPS $0.95-0.98 vs $1.01 Est; Confirms 2012 Guidance,2012-03-06 08:00:00-05:00,MRK,neutral
853446.0,Oncothyreon Falls 47% Pre-Market on Stimuvax Report,2012-03-06 07:07:00-05:00,MRK,neutral
853447.0,UPDATE: Merck Says Stimuvax Trial to Continue to Final Analysis; Says Final Result Expected in 2013,2012-03-06 07:05:00-05:00,MRK,neutral
853448.0,Merck Says FDA Declines To Approve Its New Drug Application For Ezetimibe And Atorvastatin Tablets -Reuters ,2012-03-05 14:58:00-05:00,MRK,neutral
853449.0,Merck's Investigational Allergy Immunotherapy Tablet Significantly Reduced the Combination of Ragweed Allergy Symptoms,2012-03-05 08:32:00-05:00,MRK,neutral
853450.0,Merck Says FDA Says Added Data Needed on Ezetimibe/Atorvastatin -Bloomberg,2012-03-05 08:07:00-05:00,MRK,neutral
853451.0,"The Rick Santorum ETF Portfolio (KOL, PBS, IYZ)",2012-02-28 16:21:00-05:00,MRK,neutral
853452.0,FDA Approves Important Safety Label Changes For The Class Of Cholesterol-Lowering Drugs Known As Statins -Reuters,2012-02-28 13:20:00-05:00,MRK,positive
853453.0,"Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)",2012-02-23 00:05:00-05:00,MRK,neutral
853454.0,Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil  ,2012-02-15 07:00:00-05:00,MRK,positive
853455.0,"FDA Approves ZIOPTAN, Merck's Once-Daily, Preservative-Free Ophthalmic Medication",2012-02-13 10:15:00-05:00,MRK,positive
853456.0,UPDATE: Morgan Stanley Raises PT to $37 on Merck,2012-02-13 07:16:00-05:00,MRK,neutral
853457.0,Grandpa's 2012 ETF Portfolio,2012-02-10 13:48:00-05:00,MRK,neutral
853458.0,Merck Analyst: Effectiveness of Vorapaxar Was Surprise; But Ability to Reach Market is Limited Due to Bleeding Risk,2012-02-07 11:42:00-05:00,MRK,negative
853459.0,Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar,2012-02-07 08:30:00-05:00,MRK,neutral
853460.0,"Benzinga's M&A Chatter for Monday February 6, 2012",2012-02-06 19:26:00-05:00,MRK,neutral
853461.0,Idenix Pharmaceuticals Spokesperson Has No Comment on Renewed Merck Takeover Chatter,2012-02-06 12:47:00-05:00,MRK,negative
853462.0,UPDATE: Idenix Pharmaceuticals Spiking Higher on Renewed Takeover Chatter; Merck Rumored Buyer,2012-02-06 12:28:00-05:00,MRK,neutral
853463.0,Merck Confirms Plans to File NDA for Suvorexant in 2012   ,2012-02-06 08:45:00-05:00,MRK,neutral
853464.0,Candlesticks â€“ Bears Appeared on Merck ,2012-02-03 13:33:00-05:00,MRK,neutral
853465.0,From Earlier: Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302  ,2012-02-03 07:33:00-05:00,MRK,positive
853466.0,FDA Approves JANUMET XR for Type 2 Diabetes,2012-02-02 14:44:00-05:00,MRK,positive
853467.0,UPDATE: Merck Swings To Q4 Profit,2012-02-02 12:03:00-05:00,MRK,positive
853468.0,"Merck's Earnings Are Up, But a Huge Drop may be Coming",2012-02-02 07:31:00-05:00,MRK,positive
853469.0,"Financial Breakfast: Morning News Summary for February 2, 2012",2012-02-02 07:27:00-05:00,MRK,neutral
853470.0,Merck & Reports Q4 EPS $0.97 vs $0.95 Est; Revenues $12.30B vs $12.53B Est				 ,2012-02-02 07:01:00-05:00,MRK,neutral
853471.0,Earnings Scheduled For February 2,2012-02-02 04:06:00-05:00,MRK,neutral
853472.0,Merck Wins Patent Ruling Over Sandoz Version of Cancidas -Bloomberg,2012-01-31 17:32:00-05:00,MRK,positive
853473.0,Earnings Expectations for the Week of January 30,2012-01-29 09:53:00-05:00,MRK,neutral
853474.0,"Benzinga's M&A Chatter for Thursday January 26, 2012",2012-01-26 18:24:00-05:00,MRK,neutral
853475.0,Seattle Genetics Spokesperson Would Not Comment on Earlier Merck Takeover Rumor,2012-01-26 12:01:00-05:00,MRK,neutral
853476.0,"Benzinga's M&A Chatter for Wednesday January 25, 2012",2012-01-25 20:04:00-05:00,MRK,neutral
853477.0,Merck Spokesperson Would Not Comment on Earlier Speculation of Idenix Pharmaceuticals Takeover,2012-01-25 17:43:00-05:00,MRK,neutral
853478.0,Idenix Pharmaceuticals Spokesperson Has No Comment on Earlier Merck Takeover Chatter,2012-01-25 13:41:00-05:00,MRK,negative
853479.0,Idenix Pharmaceuticals Spiking Higher on Renewed Takeover Chatter; Merck Rumored Buyer,2012-01-25 09:47:00-05:00,MRK,neutral
853480.0,UPDATE: Merck: FDA Did Not Approve New Indication For Vytorin Because of Study Design,2012-01-25 08:34:00-05:00,MRK,neutral
853481.0,Merck Announces New FDA Approved Labeling For VYTORIN Includes Results From the Study of Heart and Renal Protection in Patients With Moderate to Severe Chronic Kidney Disease   ,2012-01-25 08:30:00-05:00,MRK,positive
853482.0,"UPDATE: ISI Group Initiates Buy, $45 on Merck",2012-01-24 10:25:00-05:00,MRK,neutral
853483.0,Merck Receives Positive Mad Money/Jim Cramer Mention -CNBC,2012-01-23 18:17:00-05:00,MRK,positive
853484.0,Merck Announces Remicade Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients  ,2012-01-20 12:34:00-05:00,MRK,positive
853485.0,What's the Future Like For Health Care?,2012-01-20 11:00:00-05:00,MRK,positive
853486.0,Merck & Hits 52-Week High of $39.01,2012-01-19 09:33:00-05:00,MRK,neutral
853487.0,"Benzinga's M&A Chatter for Wednesday January 18, 2012",2012-01-18 18:53:00-05:00,MRK,neutral
853488.0,Positive Rumors Circulate About Vertex Pharmaceuticals,2012-01-18 09:43:00-05:00,MRK,positive
853489.0,"Hearing Wedbush Says Idenix Pharmaceuticals Takeover Target of Merck, Johnson & Johnson, Abbott Labs; $24/Share",2012-01-18 08:07:00-05:00,MRK,neutral
853490.0,How to Trade Biotechs Based on the JP Morgan Health Care Conference,2012-01-11 15:48:00-05:00,MRK,positive
853491.0,Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?,2012-01-10 14:54:00-05:00,MRK,neutral
853492.0,"Feuerstein: Merck for Idenix Pharma was Just a Prediction, Not a Rumor",2012-01-10 14:49:00-05:00,MRK,neutral
853493.0,Jefferies Downgrades Merck & Company to Hold ,2012-01-09 07:30:00-05:00,MRK,neutral
853494.0,Merck Says FDA Approves Isentress for Children in Ages 2 & Up -Bloomberg,2012-01-06 14:50:00-05:00,MRK,positive
853495.0,Merck & Hits 52-Week High of $38.57,2012-01-05 09:54:00-05:00,MRK,neutral
853496.0,Will Alnylam's Prospective Obesity Drug Change the World Forever?,2012-01-04 14:45:00-05:00,MRK,neutral
853497.0,Bark At The Dow's Dogs With These ETFs,2012-01-04 13:40:00-05:00,MRK,neutral
853498.0,Merck & Hits 52-Week High of $37.98,2012-01-03 09:30:00-05:00,MRK,neutral
853499.0,Can Germany's Employers Turn Europe Around? ,2012-01-03 07:54:00-05:00,MRK,neutral
853500.0,ETF Showdown: Fun With Pharma,2011-12-30 16:10:00-05:00,MRK,positive
853501.0,Inside: 2012's Best Value Investment,2011-12-27 14:55:00-05:00,MRK,positive
853502.0,Merck & Hits 52-Week High of $37.76,2011-12-23 09:43:00-05:00,MRK,neutral
853503.0,Merck & Hits 52-Week High of $37.66,2011-12-22 11:58:00-05:00,MRK,neutral
853504.0,Exelixis Trading Higher After Licensing Agreement with Merck ,2011-12-21 12:46:00-05:00,MRK,positive
853505.0,Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV   ,2011-12-21 11:19:00-05:00,MRK,positive
853506.0,Exelixis Licenses PI3K-Delta Program to Merck   ,2011-12-21 06:56:00-05:00,MRK,neutral
853507.0,Can a Picture of the CEO Predict Stock Performance?,2011-12-19 07:14:00-05:00,MRK,neutral
853508.0,Benzinga's Top Pre-Market Losers,2011-12-13 08:28:00-05:00,MRK,negative
853509.0,Are You Guaranteed Profits if These Rumors are True?,2011-12-09 14:35:00-05:00,MRK,positive
853510.0,Five Biotech Stocks to Watch Going into Big Doctors' Meeting,2011-12-09 13:06:00-05:00,MRK,neutral
853511.0,Are the Samsung M&A Rumors True?,2011-12-01 14:52:00-05:00,MRK,positive
853512.0,These Stocks May Be Better Than Their Dow Equivalents,2011-12-01 04:03:00-05:00,MRK,positive
853513.0,Is Arena Pharma Going to Cure Obesity?,2011-11-28 16:57:00-05:00,MRK,neutral
853514.0,Merck KGAA Says Merck & Co Has Taken Over Its Facecbook Page; Asks Court to Order Facebook to Give Information,2011-11-22 17:26:00-05:00,MRK,neutral
853515.0,"End-of-Day Market Summary for November 22, 2011",2011-11-22 16:15:00-05:00,MRK,neutral
853516.0,UPDATE: Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney's Office for the District of Massachusetts Related to Vioxx,2011-11-22 15:23:00-05:00,MRK,positive
853517.0,Merck Will Pay $950M to Settle Government Vioxx Probe,2011-11-22 14:55:00-05:00,MRK,negative
853518.0,"Merck Settles Vioxx Suits From NY, Florida, S Carolina -Reuters ",2011-11-15 13:17:00-05:00,MRK,neutral
853519.0,"Appaloosa Took Stakes in ETrade, BP, and Dana Holding in Q3; Exited Pfizer, Bank of America, Hewlett-Packard, Wells Fargo, Merck, Unitedhealth Group and MetLife in Q3",2011-11-14 16:24:00-05:00,MRK,positive
853520.0,Morgan Stanley Maintains Equal-Weight Rating and $34 PT on Merck & Co ,2011-11-11 08:48:00-05:00,MRK,neutral
853521.0,Merk CEO Saying Will Not Make Disproportionate Changes to R&D Spending ,2011-11-10 13:04:00-05:00,MRK,neutral
853522.0,Merck Increase Quarterly Dividend by 11%,2011-11-10 08:56:00-05:00,MRK,positive
853523.0,Citi Maintains Neutral Rating and $34 PT on Merck ,2011-11-10 08:37:00-05:00,MRK,neutral
853524.0,UPDATE: Merck To Pay $49.5M To Settle Certain Vioxx-Related Lawsuits,2011-11-09 12:42:00-05:00,MRK,neutral
853525.0,"Merck Gets Justice Dept. Requests For Information On Drug Marketing Relate To Marketing Of Integrilin, Avelox And AzaSite",2011-11-09 12:41:00-05:00,MRK,positive
853526.0,Merck: FDA Declines To Approve Merck Eye-Disease Drug Tafluprost -DJ,2011-11-09 11:00:00-05:00,MRK,neutral
853527.0,Merck Launches NEXPLANON 68 mg in the United States,2011-11-09 09:01:00-05:00,MRK,positive
853528.0,JP Morgan Maintains Overweight Rating and $44 PT on Merck & Co ,2011-11-07 08:52:00-05:00,MRK,neutral
853529.0,Merck Announces Interim Data for Merck's VICTRELISTM in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1,2011-11-05 14:51:00-04:00,MRK,neutral
853530.0,FDA Advisory Committee Unanimously Recommends Approval of Merck's VYTORIN for Use in Patients with Pre-Dialysis Chronic Kidney Disease,2011-11-02 17:37:00-04:00,MRK,positive
853531.0,"FDA Advisers Vote 16-0 Efficacy, Safety data Support Approval of Merck's Vytorin ",2011-11-02 15:31:00-04:00,MRK,positive
853532.0,Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals?,2011-11-02 08:46:00-04:00,MRK,neutral
853533.0,Which Pharma Stock Should You Short?,2011-11-01 14:11:00-04:00,MRK,neutral
853534.0,"One Pill Makes You Stronger: Pfizer Earnings Are the ""White Knight""",2011-11-01 11:53:00-04:00,MRK,positive
853535.0,A Look at The New DRGS ETN,2011-10-31 13:34:00-04:00,MRK,neutral
853536.0,Merck Can Block Teva on Generic Temodar as Court Rejects Appeal -Bloomberg,2011-10-31 10:06:00-04:00,MRK,negative
853537.0,Citi Maintains Neutral Rating and $34 PT on Merck ,2011-10-31 08:22:00-04:00,MRK,neutral
853538.0,Merck Announces Increased Earnings,2011-10-28 08:40:00-04:00,MRK,positive
853539.0,"Financial Breakfast: Morning News Summary for October 28, 2011",2011-10-28 07:45:00-04:00,MRK,neutral
853540.0,Merck & Co Reports Q3 EPS $0.94 vs $0.91 Est; Revenues $12.02B vs $11.61B Est			,2011-10-28 07:01:00-04:00,MRK,neutral
853541.0,US Stock Futures Signal Lower Start On Wall Street,2011-10-28 06:50:00-04:00,MRK,negative
853542.0,Earnings Scheduled For October 28,2011-10-28 03:33:00-04:00,MRK,neutral
853543.0,Deutsche Bank Maintains Buy Rating on Merck & Co,2011-10-26 07:32:00-04:00,MRK,neutral
853544.0,Merck Announces CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASILÂ® in Boys and Young Men   ,2011-10-25 14:18:00-04:00,MRK,neutral
853545.0,What Does Novartis' Earnings Release Really Mean for the Company?,2011-10-25 14:11:00-04:00,MRK,neutral
853546.0,"Merck Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-25 12:10:00-04:00,MRK,neutral
853547.0,Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA Inhalation Aerosol in Chronic Obstructive Pulmonary Disease ,2011-10-24 16:30:00-04:00,MRK,neutral
853548.0,Earnings Expectations for the Week of October 24,2011-10-23 13:40:00-04:00,MRK,neutral
853549.0,"Mylan Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-21 16:07:00-04:00,MRK,neutral
853550.0,Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2011-10-14 04:31:00-04:00,MRK,positive
853551.0,Under The Hood: Emerging Markets Health Care,2011-10-13 13:01:00-04:00,MRK,positive
853552.0,Merck Announces Retirement of Chairman and Former CEO Richard T. Clark   ,2011-10-06 11:15:00-04:00,MRK,neutral
853553.0,Bristol-Myers and Quidel to Open Near 52-Week Highs,2011-10-06 07:37:00-04:00,MRK,neutral
853554.0,"FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor   ",2011-10-05 07:35:00-04:00,MRK,positive
853555.0,Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX,2011-10-03 11:54:00-04:00,MRK,positive
853556.0,Merck Announces New Data Analyses for VICTRELIS will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting   ,2011-09-30 10:55:00-04:00,MRK,neutral
853557.0,Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals for $175M   ,2011-09-28 16:10:00-04:00,MRK,positive
853558.0,Merck Names Cuong Viet Do as Chief Strategy Officer,2011-09-27 08:30:00-04:00,MRK,neutral
853559.0,"Merck's Iss=entress Combo Showed Efficacy, Tolerability",2011-09-19 08:01:00-04:00,MRK,neutral
853560.0,S&P Likes Three Health Care ETFs,2011-09-14 16:18:00-04:00,MRK,positive
853561.0,Bounce-Back Kings: 9 Stocks Up More Than 30% in the Past Month,2011-09-14 08:23:00-04:00,MRK,neutral
853562.0,Merck Issues Statement on HPV Vaccine,2011-09-13 18:30:00-04:00,MRK,neutral
853563.0,A Peek Into The Market Before The Trading Starts,2011-09-13 07:31:00-04:00,MRK,neutral
853564.0,Merck and BGI Establish Strategic Collaboration focused on Biomarkers and Genomic Technologies  ,2011-09-13 06:33:00-04:00,MRK,positive
853565.0,Bank of America Merrill Lynch Maintains Buy on Merck & Co.,2011-09-08 07:20:00-04:00,MRK,neutral
853566.0,Stocks Going Ex Dividend the Third Week of September,2011-09-07 23:25:00-04:00,MRK,neutral
853567.0,Merck Millipore Strengthens Bioscience Business by acquiring Amnis Corporation,2011-08-30 07:03:00-04:00,MRK,positive
853568.0,Zymeworks Announces Collaboration with Merck to Develop Bi-specific Antibody Therapeutics,2011-08-29 08:05:00-04:00,MRK,neutral
853569.0,Texas Supreme Court Rules in Favor of Merck in Vioxx Case; Overturns Judgement in Favor of Garza Family,2011-08-26 15:04:00-04:00,MRK,positive
853570.0,12 Most Popular Healthcare Stocks Among Hedge Funds,2011-08-25 17:10:00-04:00,MRK,positive
853571.0,12 Most Popular Healthcare Stocks Among Hedge Funds,2011-08-25 11:36:00-04:00,MRK,positive
853572.0,Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus,2011-08-18 07:32:00-04:00,MRK,positive
853573.0, Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus,2011-08-18 07:30:00-04:00,MRK,positive
853574.0,Mad Money Lightning Round: Cramer Likes Cummins,2011-08-11 03:42:00-04:00,MRK,negative
853575.0,UPDATE: Jefferies Upgrades Merck & Co To Buy,2011-08-09 08:10:00-04:00,MRK,neutral
853576.0,"News Summary for August 9, 2011",2011-08-09 07:47:00-04:00,MRK,neutral
853577.0,Benzinga's Top Upgrades,2011-08-09 07:39:00-04:00,MRK,positive
853578.0,"Jefferies Upgrades Merck & Co. To Buy, Lowers PT To $37",2011-08-09 05:56:00-04:00,MRK,negative
853579.0,Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine ,2011-08-03 08:01:00-04:00,MRK,positive
853580.0,"Aw Snap, Is Market Gonna Crackle or Pop?",2011-08-02 15:53:00-04:00,MRK,neutral
853581.0,Weak Data in Focus  08-01-2011,2011-08-01 14:40:00-04:00,MRK,negative
853582.0,Merck To Close Mission Bay Research Center,2011-08-01 13:15:00-04:00,MRK,neutral
853583.0,J.P. Morgan Maintains Overweight Rating On Merck & Co,2011-08-01 08:24:00-04:00,MRK,negative
853584.0,"ARIAD Announces That Merck Has Submitted for Approval of Ridaforolimus, an Investigational mTOR Inhibitor, in the EU",2011-08-01 07:38:00-04:00,MRK,positive
853586.0,6 Deeply Undervalued Biotech Stocks,2011-07-29 16:26:00-04:00,MRK,neutral
853587.0,Looking at T. Boone Pickens' 6 Newest Energy Stock Buys,2011-07-29 16:23:00-04:00,MRK,positive
853588.0,5 Dividend Stocks to Hold Forever,2011-07-29 16:20:00-04:00,MRK,neutral
853589.0,5 Stocks You Can Buy for Less Than Bill Gates Paid,2011-07-29 16:16:00-04:00,MRK,neutral
853590.0,AUD/USD: Trading the Reserve Bank of Australia Interest Rate Decision,2011-07-29 16:16:00-04:00,MRK,positive
853591.0,6 Safe Stocks for an Inflation Proof Portfolio,2011-07-29 16:11:00-04:00,MRK,positive
853592.0,US Debt Ceiling Negotiations At Risk as Boehner Plan Vote Looms,2011-07-29 15:57:00-04:00,MRK,negative
853593.0,6 Companies That Could Be Acquired This Year,2011-07-29 15:56:00-04:00,MRK,neutral
853594.0,8 REITs at High Risk of Cutting Dividends and 3 Safer Options,2011-07-29 15:53:00-04:00,MRK,positive
853595.0,10 Stocks Near $30 That Could Trade for $40,2011-07-29 15:50:00-04:00,MRK,neutral
853596.0,5 Core Dividend Stocks Underappreciated by Investors,2011-07-29 15:47:00-04:00,MRK,neutral
853597.0,Invest Like a Billionaire: John Paulson's 6 New Stock Picks,2011-07-29 15:44:00-04:00,MRK,positive
853598.0,Merck Cites Brand and Emerging Market Investment for Higher Quarter Costs,2011-07-29 08:34:00-04:00,MRK,neutral
853599.0,Merck Doubles Profits In Second Quarter,2011-07-29 07:59:00-04:00,MRK,positive
853600.0,"News Summary for July 29, 2011",2011-07-29 07:52:00-04:00,MRK,neutral
853601.0,"Merck: FDA Accepts SNDAs For Vytorin, Zetia Indications For Review",2011-07-29 07:41:00-04:00,MRK,positive
853602.0,Merck to Cut Workforce by Added 12-13% From 2009 Levels,2011-07-29 07:14:00-04:00,MRK,negative
853603.0,Merck Guides FY 2011 EPS $3.68-$3.76 vs $3.74 Est,2011-07-29 07:02:00-04:00,MRK,neutral
853604.0,Merck Reports Q2 EPS $0.95 vs $0.95 Est; Revenues $12.15B vs $11.78B Est	,2011-07-29 07:01:00-04:00,MRK,neutral
853605.0,US Stock Futures Down On Debt Worries,2011-07-29 06:13:00-04:00,MRK,negative
853606.0,Earnings Scheduled For July 29,2011-07-29 04:18:00-04:00,MRK,neutral
853607.0,Stocks To Watch For July 29,2011-07-29 03:39:00-04:00,MRK,neutral
853608.0,High Yield Birth Control Stocks,2011-07-28 21:45:00-04:00,MRK,neutral
853609.0,How to Profit from Exploding Government Healthcare Costs ,2011-07-28 09:37:00-04:00,MRK,positive
853610.0,Hearing Supreme Court Asked to Overturn Obama's Health Care Reform,2011-07-27 15:19:00-04:00,MRK,positive
853611.0,"Earnings Preview: Merck EPS, Revenue Expected to Rise from Previous Quarter",2011-07-26 13:00:00-04:00,MRK,neutral
853612.0,"Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas ",2011-07-26 07:39:00-04:00,MRK,positive
853613.0,Ratchet Back The Risk With These ETFs,2011-07-25 14:00:00-04:00,MRK,negative
853614.0,Earnings Expectations for the Week of July 25,2011-07-24 09:40:00-04:00,MRK,neutral
853615.0,"Earnings Preview: Mylan Laboratories EPS, Revenue Expected to Rise from Previous Quarter",2011-07-22 11:38:00-04:00,MRK,neutral
853616.0,Fifteen Health Care ETFs Trading Near 52-Week Highs,2011-07-21 13:57:00-04:00,MRK,positive
853617.0,"Earnings Preview: Gilead Sciences EPS, Revenue Expected to Rise from Previous Quarter",2011-07-21 13:12:00-04:00,MRK,neutral
853618.0,Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C,2011-07-20 07:12:00-04:00,MRK,positive
853619.0,Dow Jones Industrial Average Companies Increase Expected Dividend Distribution by 12.66% From a Year Ago,2011-07-19 10:14:00-04:00,MRK,positive
853620.0,"Merck Announces VICTRELIS First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the EU for Treatment of Chronic Hepatitis C   ",2011-07-18 11:32:00-04:00,MRK,positive
853622.0,Merck's ISENTRESS in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1 ,2011-07-18 08:06:00-04:00,MRK,neutral
853623.0,5 High Dividend Names For Sound Sleeping,2011-07-14 14:30:00-04:00,MRK,neutral
853624.0,Twelve Health Care ETFs Trading Near 52-Week Highs,2011-07-13 07:38:00-04:00,MRK,positive
853625.0,Twelve ETFs Trading Near 52-Week Highs,2011-07-12 06:56:00-04:00,MRK,neutral
853626.0,Merck to Participate in New Research Efforts to Eradicate HIV   ,2011-07-11 12:36:00-04:00,MRK,neutral
853627.0,Hottest and Coldest Sectors for Friday 7/8/11,2011-07-08 17:24:00-04:00,MRK,neutral
853628.0,Teva and Merck Settle Patent Dispute Over Generic Vytorin; Teva Will Not Sell Generic Until 2017,2011-07-08 16:23:00-04:00,MRK,negative
853629.0,Goldman Sachs Suggests Buying Calls on Merck & Co.,2011-07-07 09:16:00-04:00,MRK,neutral
853630.0,"Merck Receives Approval to Market GARDASIL, ZOLINZA and CUBICIN in Japan",2011-07-01 07:01:00-04:00,MRK,positive
853631.0,A Peek Into The Market Before The Trading Starts,2011-06-28 07:22:00-04:00,MRK,neutral
853632.0,UPS and Merck Expand Their Distribution and Logistics Agreement,2011-06-28 07:01:00-04:00,MRK,positive
853633.0,"Stocks Shrug Off Greece, Deficit Uncertainty",2011-06-27 13:35:00-04:00,MRK,negative
853634.0,Morgan Stanley Reiterates Equal-Weight on Merck,2011-06-24 09:20:00-04:00,MRK,neutral
853635.0,High Yield Big Pharmaceutical Stocks,2011-06-24 01:19:00-04:00,MRK,neutral
853636.0,Ligand Enters into Captisol Commercial Supply Agreement with Merck   ,2011-06-20 08:03:00-04:00,MRK,positive
853637.0,Build a Wealthy Portfolio with These Economic Moats,2011-06-14 01:33:00-04:00,MRK,positive
853639.0,5-Alpha Reductase Inhibitors May Increase Risk of Prostate Cancer -FDA,2011-06-09 12:22:00-04:00,MRK,negative
853640.0,Merck Announces U.S. Prescribing Information for Simvastatin Revised to Include New Limits on the Use of the Highest Dose and Updated Drug Interaction Information  ,2011-06-08 14:49:00-04:00,MRK,neutral
853641.0,"UPDATE: Merck and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 ",2011-06-08 07:26:00-04:00,MRK,neutral
853642.0,Bank of America Merrill Lynch Maintains Buy on Merck & Co.,2011-06-07 08:07:00-04:00,MRK,neutral
853643.0,Roche and Merck Collaborate to Develop Diagnostic Tests for Merck's Investigational Cancer Therapies   ,2011-06-07 07:38:00-04:00,MRK,negative
853644.0,Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting ,2011-06-06 07:31:00-04:00,MRK,positive
853645.0,Hepatitis C Virus (HCV) Updates from Biotech/Pharma Stocks,2011-06-03 11:35:00-04:00,MRK,neutral
853646.0,"Pimco's Gross Likes P&G and Merck, Offer Better Yields and Conservative -Bloomberg",2011-06-03 09:26:00-04:00,MRK,positive
853647.0,Pimco's Gross Says Procter & Gamble and Merck are Relatively Attractive to Savers -Bloomberg,2011-06-03 08:53:00-04:00,MRK,negative
853648.0,My Top 20 Defensive Stock Plays,2011-06-02 14:24:00-04:00,MRK,positive
853649.0,FDA: Treatment With Angiotensin Receptor Blockers for High Blood Pressure Does Not Increase Risk of Cancer ,2011-06-02 13:49:00-04:00,MRK,negative
853650.0,FDA Says that High Blood Pressure Drugs Do Not Increase Cancer Risk -Bloomberg,2011-06-02 11:13:00-04:00,MRK,positive
853651.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,MRK,positive
853652.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,MRK,negative
853653.0,Health Canada Approves Gardasil to Prevent Anal Cancer,2011-05-31 10:15:00-04:00,MRK,negative
853654.0,Morgan Stanley Reports on Merck,2011-05-27 08:08:00-04:00,MRK,neutral
853655.0,InSite Vision Announces Joint Patent Infringement Lawsuit with Merck Against Sandoz   ,2011-05-26 15:54:00-04:00,MRK,negative
853656.0,Joel Greenblatt: One Bubble After Another,2011-05-26 08:40:00-04:00,MRK,neutral
853657.0,FTC Files Amicus Brief In K-dur Antitrust Litigation -Bloomberg,2011-05-24 12:33:00-04:00,MRK,negative
853658.0,Europe's sovereign-debt crisis Effects on Drug Stocks,2011-05-23 14:27:00-04:00,MRK,negative
853659.0,Vertex Hepatitis C Drug Approved by the FDA -Bloomberg,2011-05-23 09:20:00-04:00,MRK,positive
853660.0,Top Healthcare and Major Drugs stocks to watch- Sector Performance,2011-05-22 14:55:00-04:00,MRK,positive
853661.0,"CHMP Issues Positive Opinion for Merck's VICTRELISTM, Oral Hepatitis C Virus Protease Inhibitor   ",2011-05-20 07:35:00-04:00,MRK,positive
853662.0,Exclusive â€“ Merck Talks To Benzinga About Collaboration With Roche (MRK),2011-05-19 10:50:00-04:00,MRK,positive
853663.0,Deutsche Bank Comments On Merck And Roche Collaboration,2011-05-19 07:55:00-04:00,MRK,neutral
853664.0,"Biotech/Pharma Stocks News Alert; Hepatitis C Virus (HCV) FDA News from Aethlon Medical, Vertex Pharmaceuticals, Merck & Company ",2011-05-17 11:46:00-04:00,MRK,positive
853665.0,Merck and Roche Establish Strategic Agreements in Fight Against Chronic Hepatitis C ,2011-05-17 11:30:00-04:00,MRK,negative
853666.0,"Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)",2011-05-17 09:00:00-04:00,MRK,positive
853667.0,"Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)",2011-05-17 09:00:00-04:00,MRK,positive
853668.0,Piper Jaffray Discontinues Coverage On ISPH,2011-05-17 07:31:00-04:00,MRK,neutral
853669.0,Goldman Sachs Reports on Merck & Co (MRK),2011-05-16 08:21:00-04:00,MRK,neutral
853670.0,Deutsche Bank Comments on Victrelis FDA Approval,2011-05-16 08:16:00-04:00,MRK,positive
853671.0,"J.P. Morgan Calls Merck & Co's Hep C Treatment A ""Modest Positive""",2011-05-16 07:37:00-04:00,MRK,positive
853672.0,Bank Of America Raises PT To $29 On MRK,2011-05-16 07:31:00-04:00,MRK,neutral
853673.0,"Biotech/Pharma Stock News Alert: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)",2011-05-13 13:09:00-04:00,MRK,positive
853674.0,"Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)",2011-05-13 09:00:00-04:00,MRK,positive
853675.0,"Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)",2011-05-13 09:00:00-04:00,MRK,positive
853676.0,The Father of Growth Investing: T. Rowe Price Screen,2011-05-11 18:04:00-04:00,MRK,positive
853677.0,"UPDATE: FDA Approves New Treatment for Rare Type of Pancreatic Cancer (PFE, MRK, GSK)",2011-05-06 09:58:00-04:00,MRK,negative
853678.0,May Catalysts for Biotech and Drug Stocks,2011-05-04 12:32:00-04:00,MRK,neutral
853679.0,"Morning News Summary for May 3, 2011",2011-05-03 09:20:00-04:00,MRK,neutral
853680.0,"Earnings Preview For Allergan (AGN, MRK, ISPH, VRX, CEPH)",2011-05-03 04:25:00-04:00,MRK,neutral
853681.0,"Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Lowest PEG Ratio (GSK, ABT, MRK, JNJ)",2011-05-03 00:38:00-04:00,MRK,negative
853682.0,UPDATE: J.P. Morgan Raises PT on Merck & Co. to $44 (MRK),2011-05-02 07:21:00-04:00,MRK,neutral
853683.0,Citi Updates FY Estimates On Merck After Reporting Solid Earnings,2011-05-02 07:14:00-04:00,MRK,positive
853684.0,JP Morgan Raises PT On Merck & Company To $44,2011-05-02 06:04:00-04:00,MRK,positive
853685.0,"CEOWORLD Top 5 Analyst Calls of the Week- DNDN, INSP, MCP, SIRI, VICL",2011-05-02 03:32:00-04:00,MRK,positive
853686.0,Royal Put(z) Not to Be Confused with Married Put(z)  04-29-2011,2011-04-29 18:35:00-04:00,MRK,positive
853687.0,Married Put(z)  04-29-2011,2011-04-29 14:51:00-04:00,MRK,neutral
853688.0,Merck Up On Strong Earnings Today (MRK),2011-04-29 12:48:00-04:00,MRK,positive
853689.0,Citi Reports Strong 1Q11 Results For Merck,2011-04-29 11:03:00-04:00,MRK,positive
853690.0,Friday Morning Market Summary 4/29/2011,2011-04-29 09:00:00-04:00,MRK,neutral
853691.0,A Peek Into The Market Before The Trading Starts,2011-04-29 07:34:00-04:00,MRK,neutral
853692.0,UPDATE: Merck Reports Upbeat Q1 Earnings; Shares Rise In Pre-Market trading,2011-04-29 07:28:00-04:00,MRK,positive
853693.0,Merck Announces First Quarter 2011 Financial Results   ,2011-04-29 07:09:00-04:00,MRK,neutral
853694.0,Merck Guides FY 2011 EPS $3.66-3.76 vs. $3.69 Est. (MRK),2011-04-29 07:08:00-04:00,MRK,neutral
853695.0,Merck Reports EPS of $0.92 vs. $0.84 Estimate; Revenues $11.58B vs. $11.37B Estimate ,2011-04-29 07:04:00-04:00,MRK,neutral
853696.0,"US Stock Futures Mixed As Investors Await Economic Data, Earnings Reports; Research In Motion Shares Decline In Pre-Market trading",2011-04-29 06:21:00-04:00,MRK,positive
853697.0,"Earnings Scheduled For April 29 (WY, AXL, NWL, ITT, MRK, PBI, MI, CPN, GT, CAT, AGP, NEE, CVX, PPC, DHI, ETR, VFC)",2011-04-29 02:35:00-04:00,MRK,positive
853698.0,"Stocks To Watch For April 29 (CVX, RIMM, CAT, MSFT, MRK)",2011-04-29 02:07:00-04:00,MRK,neutral
853699.0,"  Merck and Inspire Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire (ISPH, MRK)",2011-04-28 08:34:00-04:00,MRK,positive
853700.0,VICTRELISâ„¢ Unanimously Recommended for Approval by FDA Advisory Committee (MRK),2011-04-27 16:54:00-04:00,MRK,positive
853701.0,VICTRELIS Unanimously Recommended for Approval by FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection   ,2011-04-27 16:54:00-04:00,MRK,positive
853702.0,Hepatitis Treatment Wins Over the U.S. FDA Panel -Bloomberg (MRK),2011-04-27 15:33:00-04:00,MRK,positive
853703.0,Deutsche Bank To Hold 36th Annual Healthcare Conference Next Week,2011-04-27 08:00:00-04:00,MRK,neutral
853704.0,Merck Announces New $5 Billion Share Repurchase Program (MRK),2011-04-27 07:45:00-04:00,MRK,positive
853705.0, Vertex Stock Booms After FDA Reports New Drug is Effective (VRTX),2011-04-26 14:00:00-04:00,MRK,positive
853706.0,"Rwanda, Merck and QIAGEN Launch Africa's First Comprehensive Cervical Cancer Prevention Program Incorporating Both HPV Vaccination and HPV Testing   ",2011-04-25 08:35:00-04:00,MRK,negative
853707.0,"Merck's Hepatitis C Drug Increases Anemia Risk, FDA Staff Says -Bloomberg (MRK)",2011-04-25 08:09:00-04:00,MRK,negative
853708.0,Merck and Sanofi Pasteur Initiate Phase III Study in the United States of Pediatric Combination Vaccine to Help Prevent Six Infectious Diseases   ,2011-04-21 08:05:00-04:00,MRK,positive
853709.0,Don't Fall For The 'Defensive Portfolio' Hype,2011-04-18 12:37:00-04:00,MRK,neutral
853710.0,J.P. Morgan Adjusting Estimates On Merck & Co,2011-04-18 07:33:00-04:00,MRK,neutral
853711.0,Weird Dynamic at Play  04-15-2011,2011-04-15 15:35:00-04:00,MRK,positive
853712.0,Merck Commences Tender Offer for Inspire Pharmaceuticals at $5.00 per Share    ,2011-04-15 09:02:00-04:00,MRK,positive
853713.0,A Peek Into The Market Before The Trading Starts,2011-04-15 07:38:00-04:00,MRK,neutral
853714.0,Merck Reaffirms 2011 Non-GAAP EPS Target of $3.64 to $3.76,2011-04-15 07:29:00-04:00,MRK,neutral
853715.0,"Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck (JNJ, MRK)",2011-04-15 07:29:00-04:00,MRK,positive
853716.0,"  Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADEÂ® and SIMPONIÂ® (MRK, JNJ)",2011-04-15 07:05:00-04:00,MRK,positive
853717.0,"Inspire Pharmaceuticals Shareholder Sues Over Merck Deal (MRK, ISPH)",2011-04-12 11:44:00-04:00,MRK,positive
853718.0,"FDA Approves Merck's SYLATRON for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement   ",2011-04-11 17:01:00-04:00,MRK,negative
853719.0,Merck & Co and Sun Pharma Establish Joint Venture (MRK),2011-04-11 08:06:00-04:00,MRK,neutral
853720.0,Merck Loses U.K. Appeal Against Teva to Reinstate Cosopt Patent (MRK),2011-04-08 08:34:00-04:00,MRK,negative
853721.0,"LifeTech Capital Comments On Merck Acquisition (MRK, ISPH)",2011-04-07 08:42:00-04:00,MRK,neutral
853722.0,Experts Think Merck's Gardasil Could Be Widely Distributed (MRK),2011-04-06 12:59:00-04:00,MRK,neutral
853723.0,"Mid Afternoon Top-5 and Bottom-5 Percentage Gainers (NSM, ISPH, MRK, QCOR, PK, AAU, DGW, LEDS, MERU, WMGI, ZSTN)",2011-04-05 13:54:00-04:00,MRK,neutral
853724.0,"Merck to Acquire Inspire Pharmaceuticals, Inc. for $5.00 per Share Totaling $430M",2011-04-05 09:30:00-04:00,MRK,positive
853725.0,"Biotech/Pharma Stocks; Merck (NYSE:MRK) to Acquire Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH)",2011-04-05 09:00:00-04:00,MRK,positive
853726.0,"Biotech/Pharma Stocks; Merck (NYSE:MRK) to Acquire Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH)",2011-04-05 09:00:00-04:00,MRK,positive
853727.0,April Catalysts For Biotech And Drug Stocks,2011-04-01 12:36:00-04:00,MRK,neutral
853728.0,"VICTRELIS, Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control   ",2011-03-31 08:35:00-04:00,MRK,neutral
853729.0,"Mad Money Lightning Round: Cramer Likes Alcoa, Health Care REIT (AA, SPPI, PANL, PFE, GILD, CELG, MRK, ABT, AGNC, NLY, HCN)",2011-03-28 02:03:00-04:00,MRK,positive
853730.0,March Market Madness:  Merck (MRK),2011-03-25 15:35:00-04:00,MRK,negative
853731.0,"Citi Comments On MRK's Return Of Betrixaban, Maintains EPS Estimate",2011-03-25 07:33:00-04:00,MRK,neutral
853732.0,Merck Announces FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age ,2011-03-24 16:00:00-04:00,MRK,positive
853733.0,Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck   ,2011-03-24 08:32:00-04:00,MRK,neutral
853734.0,"Zings Of The Day (SNY, MRK, AAPL, AMZN)",2011-03-22 15:57:00-04:00,MRK,neutral
853735.0,Committee for Medicinal Products for Human Use (CHMP) Issues Positive Opinion for New Contraception Offering,2011-03-18 08:43:00-04:00,MRK,positive
853736.0,ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval ,2011-03-17 07:38:00-04:00,MRK,positive
853737.0,"Some High Dividend Paying Stocks For A Weak Market (MO, MRK, JNJ, NLY)",2011-03-16 15:59:00-04:00,MRK,negative
853738.0,Health Insurers Triple S&P 500 Returns,2011-03-10 12:21:00-05:00,MRK,neutral
853739.0,Merck Announces New Data Analyses for VICTRELIS Will Be Presented at The International Liver Congress,2011-03-07 10:45:00-05:00,MRK,neutral
853740.0,Merck Wins First FOSAMAX State Court Trial ,2011-02-14 11:07:00-05:00,MRK,positive
853741.0,Jefferies Raises PT On Merck & Company To $34.50,2011-02-14 07:51:00-05:00,MRK,neutral
853742.0,Two ETFs for the Recovery in Big Pharma,2011-02-11 14:59:00-05:00,MRK,neutral
853743.0,Value In Valspar (VAL),2011-02-04 16:01:00-05:00,MRK,positive
853744.0,UBS Price Target Research Summary,2011-02-04 10:31:00-05:00,MRK,neutral
853745.0,Merck Beats but Guides Lower - Analyst Blog,2011-02-03 13:31:00-05:00,MRK,negative
853746.0,Merck Beats but Guides Lower - Analyst Blog,2011-02-03 12:48:00-05:00,MRK,negative
853747.0,A Peek Into The Market Before The Trading Starts,2011-02-03 07:49:00-05:00,MRK,neutral
853748.0,Merck Reports Q4 EPS of $0.88,2011-02-03 07:05:00-05:00,MRK,neutral
853749.0,"US Stock Futures Mixed As Investors Await Earnings Reports, Economic Data; Merck Earnings In Focus",2011-02-03 06:45:00-05:00,MRK,positive
853750.0,"US Stock Futures Mixed As Investors Await Earnings Reports, Economic Data; Merck Earnings In Focus",2011-02-03 06:44:00-05:00,MRK,positive
853751.0,"Earnings Scheduled For February 3 (K, MA, CI, ITT, SUN, CAH, MRK, NYT, DOW, BX, LVS, DO, CSTR, CME, IP, GR, MCO, HOT)",2011-02-03 03:28:00-05:00,MRK,neutral
853752.0,Busy Earnings Week Ahead - Earnings Preview,2011-01-28 16:31:00-05:00,MRK,neutral
853753.0,AstraZeneca Revenues Disappoint - Analyst Blog,2011-01-28 13:39:00-05:00,MRK,negative
853754.0,AstraZeneca Revenues Disappoint - Analyst Blog,2011-01-28 13:12:00-05:00,MRK,negative
853755.0,Busy Earnings Week Ahead - Earnings Preview,2011-01-28 00:00:00-05:00,MRK,neutral
853756.0,Earnings Preview: Eli Lilly - Analyst Blog,2011-01-25 11:00:00-05:00,MRK,neutral
853757.0,Earnings Preview: Eli Lilly - Analyst Blog,2011-01-25 10:45:00-05:00,MRK,neutral
853758.0,Priority Review for Vertex HCV Drug - Analyst Blog,2011-01-21 18:01:00-05:00,MRK,neutral
853759.0,Priority Review for Vertex HCV Drug - Analyst Blog,2011-01-21 17:40:00-05:00,MRK,neutral
853760.0,"Deutsche Bank Lowers MRK Target To $43, Reiterates Buy Rating",2011-01-21 07:42:00-05:00,MRK,negative
853761.0,Deutsche Bank Lowers PT On Merck & Co.,2011-01-21 07:10:00-05:00,MRK,negative
853762.0,Bleeding Risk with MRK's Candidate  - Analyst Blog,2011-01-20 11:01:00-05:00,MRK,negative
853763.0,Bleeding Risk with MRK's Candidate  - Analyst Blog,2011-01-20 10:30:00-05:00,MRK,negative
853764.0,4 Drug Stocks Poised to Stage Comeback,2011-01-20 07:00:00-05:00,MRK,positive
853765.0,Merck Says Additional Information Provided to Investigators in Clinical Study of Vorapaxar (MRK),2011-01-19 17:02:00-05:00,MRK,neutral
853766.0,Ariad Scores With SUCCEED - Analyst Blog,2011-01-19 13:01:00-05:00,MRK,positive
853767.0,Ariad Scores With SUCCEED - Analyst Blog,2011-01-19 12:30:00-05:00,MRK,positive
853768.0,Ariad Pharmaceuticals Skyrocketing (ARIA),2011-01-18 13:04:00-05:00,MRK,neutral
853769.0,Ariad Sarcoma Drug Delays Progression,2011-01-18 08:16:00-05:00,MRK,neutral
853770.0,"Company News for January 17, 2011 - Corporate Summary",2011-01-17 10:31:00-05:00,MRK,neutral
853771.0,"Company News for January 17, 2011 - Corporate Summary",2011-01-17 09:13:00-05:00,MRK,neutral
853772.0,Merck's Blood Thinner in Trouble - Analyst Blog,2011-01-14 16:31:00-05:00,MRK,negative
853773.0,Merck's Blood Thinner in Trouble - Analyst Blog,2011-01-14 16:01:00-05:00,MRK,negative
853774.0,"Stock Market News for Jan 14, 2011  - Market News",2011-01-14 09:31:00-05:00,MRK,neutral
853775.0,"Stock Market News for Jan 14, 2011  - Market News",2011-01-14 09:07:00-05:00,MRK,neutral
853776.0,"Merck: Analysts' Upgrades, Downgrades",2011-01-14 08:28:00-05:00,MRK,neutral
853777.0,Jefferies Cuts Price Target On Merck (MRK),2011-01-14 07:19:00-05:00,MRK,negative
853778.0,Jefferies Lowers PT On Merck & Co.,2011-01-14 06:56:00-05:00,MRK,negative
853779.0,The Fed Takes Credit: Dave's Daily,2011-01-13 18:29:00-05:00,MRK,positive
853780.0,Two Biggies Due to Report Earnings  01-13-2011,2011-01-13 15:03:00-05:00,MRK,neutral
853781.0,Merck Pipeline Setback: Big Pharma Losers,2011-01-13 11:47:00-05:00,MRK,negative
853782.0,Merck & Parexel Enter Pact - Analyst Blog,2011-01-13 10:01:00-05:00,MRK,neutral
853783.0,Merck & Parexel Enter Pact - Analyst Blog,2011-01-13 09:45:00-05:00,MRK,neutral
853784.0,Merck Announces FDA Acceptance of New Drug Application for JANUMETÂ®   ,2011-01-11 08:18:00-05:00,MRK,positive
853785.0,Priority Review for Merck's HCV Drug - Analyst Blog,2011-01-07 12:33:00-05:00,MRK,neutral
853786.0,Priority Review for Merck's HCV Drug - Analyst Blog,2011-01-07 12:00:00-05:00,MRK,neutral
853787.0,Enzon Pharm Upped to Neutral - Analyst Blog,2011-01-06 18:30:00-05:00,MRK,neutral
853788.0,Enzon Pharm Upped to Neutral - Analyst Blog,2011-01-06 17:57:00-05:00,MRK,neutral
853789.0,"Goldman Sachs Healthcare CEO's Conference (BMY, MRK, CELG)",2011-01-06 11:14:00-05:00,MRK,neutral
853790.0,'Mutts of the Dow' Have No Bite,2011-01-05 07:00:00-05:00,MRK,negative
853791.0,Cramer's 'Mad Money' Recap: Stellar Year for Stocks (Update 1),2011-01-03 18:44:00-05:00,MRK,negative
853792.0,"XOMA Shares Climb 8.6% (XOMA, NVG, MRK)",2010-12-30 14:23:00-05:00,MRK,positive
853793.0,"5 Best & Worst Performers In The Dow (AA, MRK, BAC, DIS, TRV)",2010-12-23 10:52:00-05:00,MRK,neutral
853794.0,FDA's Approves Gardasil to Prevent Anal Cancer ,2010-12-22 14:03:00-05:00,MRK,negative
853795.0,"World stock markets daily report (December 20, 2010)",2010-12-20 10:24:00-05:00,MRK,neutral
853796.0,CPI: Inflation Still Tame - Analyst Blog,2010-12-15 13:33:00-05:00,MRK,neutral
853797.0,CPI: Inflation Still Tame - Analyst Blog,2010-12-15 13:03:00-05:00,MRK,neutral
853798.0,10 Best Dow Dividend Stocks for 2011,2010-12-13 06:00:00-05:00,MRK,positive
853799.0,Merck Closes on $2 Billion Notes Sale,2010-12-10 18:07:00-05:00,MRK,neutral
853800.0,"Mad Money Lightning Round: Cramer Advises Investors To Buy BlackRock (LLY, DECK, CMI, OXPS, AXP, V, MRK, ABT, BLK)",2010-12-10 03:21:00-05:00,MRK,negative
853801.0,'Mad Money Lightning Round': Go for BlackRock,2010-12-09 19:29:00-05:00,MRK,negative
853802.0,Best Stocks For Creating A Passive Income Stream,2010-12-09 11:00:00-05:00,MRK,positive
853803.0,Positive Data on Roche's Drug - Analyst Blog,2010-12-07 10:33:00-05:00,MRK,positive
853804.0,Positive Data on Roche's Drug - Analyst Blog,2010-12-07 10:02:00-05:00,MRK,positive
853805.0,ETFs For Biotech M&A Mania,2010-12-06 14:05:00-05:00,MRK,neutral
853806.0,Change at Pfizer's Helm - Analyst Blog,2010-12-06 12:13:00-05:00,MRK,neutral
853807.0,Change at Pfizer's Helm - Analyst Blog,2010-12-06 11:20:00-05:00,MRK,neutral
853808.0,Goldman Recommends Stocks For 2011 ,2010-12-06 10:17:00-05:00,MRK,positive
853809.0,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,2010-12-03 16:01:00-05:00,MRK,neutral
853810.0,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,2010-12-03 15:32:00-05:00,MRK,neutral
853811.0,Merck Strikes Deal with SmartCells  - Analyst Blog,2010-12-03 11:16:00-05:00,MRK,negative
853812.0,Merck Strikes Deal with SmartCells  - Analyst Blog,2010-12-03 10:11:00-05:00,MRK,negative
853813.0,"J&J, Merck Recall Mylanta, AlternaGel",2010-12-02 10:08:00-05:00,MRK,neutral
853814.0,A Peek Into The Market Before The Trading Starts,2010-12-02 08:23:00-05:00,MRK,neutral
853815.0,"Merck to Acquire SmartCells, Inc; Transaction May Exceed $500M",2010-12-02 07:44:00-05:00,MRK,neutral
853816.0,Merck May Buy Biotech Firm SmartCells,2010-12-02 04:26:00-05:00,MRK,neutral
853817.0,SurModics Cut to Underperform - Analyst Blog,2010-12-01 14:51:00-05:00,MRK,negative
853818.0,SurModics Cut to Underperform - Analyst Blog,2010-12-01 08:58:00-05:00,MRK,negative
853819.0,Merck Down Slightly On New CEO (MRK),2010-11-30 13:29:00-05:00,MRK,neutral
853820.0,Merck Halts Isentress Study - Analyst Blog,2010-11-30 10:00:00-05:00,MRK,neutral
853821.0,News Summary,2010-11-30 09:33:00-05:00,MRK,neutral
853822.0,Bootstrap Like Spanx to Start a Business,2010-11-30 08:00:00-05:00,MRK,positive
853823.0,Merck Names Kenneth Frazier as CEO,2010-11-30 07:17:00-05:00,MRK,neutral
853824.0,Merck Board Elects Kenneth C. Frazier as Next CEO,2010-11-30 07:14:00-05:00,MRK,neutral
853825.0,Merck Halts Isentress Study - Analyst Blog,2010-11-30 04:28:00-05:00,MRK,neutral
853826.0,Vertex Eyes Telaprevir Approval - Analyst Blog,2010-11-24 18:30:00-05:00,MRK,positive
853827.0,Vertex Eyes Telaprevir Approval - Analyst Blog,2010-11-24 13:01:00-05:00,MRK,positive
853828.0,"Stock Market News for November 24, 2010 - Market News",2010-11-24 09:30:00-05:00,MRK,neutral
853829.0,"Stock Market News for November 24, 2010 - Market News",2010-11-24 04:11:00-05:00,MRK,neutral
853830.0,Top 5 Wellington Positions,2010-11-23 12:47:00-05:00,MRK,positive
853831.0,Vertex Files for Hep C Drug Approval,2010-11-23 07:38:00-05:00,MRK,positive
853832.0,Positive Data on Merck's Vytorin - Analyst Blog,2010-11-22 14:00:00-05:00,MRK,positive
853833.0,Positive Data on Merck's Vytorin - Analyst Blog,2010-11-22 08:33:00-05:00,MRK,positive
853834.0,Goldman Sachs Comments On Merck's SHARP Results,2010-11-22 08:29:00-05:00,MRK,neutral
853835.0,Merck Stabilizes After SHARP Results (MRK),2010-11-22 06:46:00-05:00,MRK,neutral
853836.0,Study: Merck Drug Helps Kidney Patients,2010-11-20 18:46:00-05:00,MRK,positive
853837.0,Merck's Candidate Impresses - Analyst Blog,2010-11-18 09:33:00-05:00,MRK,positive
853838.0,Merck's Candidate Impresses - Analyst Blog,2010-11-18 04:09:00-05:00,MRK,positive
853839.0,Consumer Price Index Tame - Analyst Blog,2010-11-17 13:03:00-05:00,MRK,neutral
853840.0,"Merck Adding To Its List Of Late stage Revenue Generating Assets, Citigroup Reports",2010-11-17 11:03:00-05:00,MRK,positive
853841.0,Consumer Price Index Tame - Analyst Blog,2010-11-17 07:43:00-05:00,MRK,neutral
853842.0,Goldman Sachs Adjusts MHS And ESRX Estimates,2010-11-16 07:51:00-05:00,MRK,neutral
853843.0,Merck Plans New India Drug Launches,2010-11-15 12:52:00-05:00,MRK,neutral
853844.0,"Lowe's Earnings Rise, But Sales, Outlook Miss Estimates",2010-11-15 12:49:00-05:00,MRK,negative
853845.0,Week Ahead Market Report: 11/15/2010,2010-11-15 12:42:00-05:00,MRK,neutral
853846.0,El Paso Pipeline Partners Acquires Assets from El Paso Corporation,2010-11-15 12:30:00-05:00,MRK,positive
853847.0,EMC to Buy Isilon Systems,2010-11-15 12:21:00-05:00,MRK,neutral
853848.0,Caterpillar to Buy Bucyrus,2010-11-15 12:16:00-05:00,MRK,neutral
853849.0,Retail Sales Surprise to the Upside,2010-11-15 11:28:00-05:00,MRK,positive
853850.0,Retail Sales Surprise to the Upside,2010-11-15 11:28:00-05:00,MRK,positive
853851.0,Jefferies & Company Adjusts Merck Estimates,2010-11-15 08:10:00-05:00,MRK,neutral
853852.0,"Stocks To Watch For November 15 (JWN, LOW, URBN, MRK, GYMB)",2010-11-15 03:16:00-05:00,MRK,negative
853853.0,Rolls for Breakfast  11-10-2010,2010-11-10 17:54:00-05:00,MRK,neutral
853854.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews,2010-11-09 17:03:00-05:00,MRK,neutral
853855.0,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook,2010-11-09 17:03:00-05:00,MRK,neutral
853856.0,Merck Wins TEMODAR Patent Infringement Lawsuit ,2010-11-09 14:47:00-05:00,MRK,negative
853857.0,3 High Paying Dividend Stocks To Consider,2010-11-03 13:23:00-04:00,MRK,neutral
853858.0,"Sectors To Benefit From Republican Victory: Oil Services, Healthcare (MRK, PFE, DO, RIG) ",2010-11-02 12:38:00-04:00,MRK,positive
853859.0,"Zacks Analyst Blog Highlights: Monster Worldwide, Yahoo, Merck & Co., Johnson & Johnson and VeriSign     - Press Releases",2010-11-02 11:00:00-04:00,MRK,neutral
853860.0,Citigroup Reiterates Buy Rating on Merck (MRK),2010-11-01 10:16:00-04:00,MRK,neutral
853861.0,"Steve Grasso's Health Care Trades (UNH, CI, AET, AGP, HS, PFE, MRK, WLP)",2010-10-29 21:14:00-04:00,MRK,positive
853862.0,"Markets Yawn at Data, Earnings Deluge ",2010-10-29 13:18:00-04:00,MRK,neutral
853863.0,"Stock Market News for October 29, 2010 - Market News",2010-10-29 10:03:00-04:00,MRK,neutral
853864.0,"Company News for October 29, 2010 - Corporate Summary",2010-10-29 10:03:00-04:00,MRK,neutral
853865.0,News Summary,2010-10-29 09:53:00-04:00,MRK,neutral
853866.0,"Merck Beats on EPS, Misses on Revs - Analyst Blog",2010-10-29 09:03:00-04:00,MRK,negative
853867.0,US Stock Futures Down As Investors Await Q3 GDP Data,2010-10-29 06:54:00-04:00,MRK,positive
853868.0,"Earnings Scheduled For October 29 (CVX, POM, CEG, MRK, PGN, NEE, SNE, D, EL, ITT, CI, WY, EIX, LNT)",2010-10-29 05:46:00-04:00,MRK,neutral
853869.0,"Stocks To Watch For October 29 (MSFT, MRK, EXPE, CVX, MXIM)",2010-10-29 05:45:00-04:00,MRK,neutral
853870.0,"Merck In Talks To Acquire InterMune (MRK, ITMN)",2010-10-27 15:25:00-04:00,MRK,neutral
853871.0,"Stock Market News for October 25, 2010 - Market News",2010-10-25 10:03:00-04:00,MRK,neutral
853872.0,Citi Says Merger Should Help Merck (MRK),2010-10-25 07:39:00-04:00,MRK,positive
853873.0,Viagra Treatment for Muscular Dystrophy,2010-10-20 12:11:00-04:00,MRK,neutral
853874.0,CPI Tame in September - Analyst Blog,2010-10-18 14:03:00-04:00,MRK,neutral
853875.0,"Zacks Analyst Blog Highlights: KR,TBT,PFE,MRK,GCI - Press Releases",2010-10-18 10:36:00-04:00,MRK,neutral
853876.0,Citigroup Expects Big Things From Merck's New Osteoporosis Medication,2010-10-18 07:55:00-04:00,MRK,neutral
853877.0,Highest Yielding Dow Jones Industrial Average Stocks,2010-10-12 14:22:00-04:00,MRK,neutral
853878.0,Goldman Buying Hedges on Merck (MRK),2010-10-06 10:16:00-04:00,MRK,neutral
853879.0,10 Dow Dividend Stocks for Weary Investors,2010-10-05 08:05:00-04:00,MRK,negative
853880.0,J&J-Galapagos in Anti-Cancer Deal - Analyst Blog,2010-10-04 23:21:00-04:00,MRK,neutral
853881.0,Male Menopause: Another Treatment for Pharmaceutical Companies,2010-10-04 19:26:00-04:00,MRK,neutral
853882.0,Merck to Appeal Reduced Jury Verdict in Federal FOSAMAX Case ,2010-10-04 16:16:00-04:00,MRK,positive
853883.0,Structured Notes: The Retail Broker's Own Little Synthetic CDO,2010-10-03 17:36:00-04:00,MRK,neutral
853884.0,Merck Announces Pivotal Phase III Data for Boceprevir will be Presented at Liver Diseases Meeting  ,2010-10-01 10:34:00-04:00,MRK,neutral
853885.0,FDA Restricts Use of Glaxo Drug - Analyst Blog,2010-09-24 21:51:00-04:00,MRK,negative
853886.0,"The Rapid Growth Of Layoffs In Pharma, As Industry Despairs Of Its Future (BMY, ABT, PFE, MRK)",2010-09-24 11:49:00-04:00,MRK,negative
853887.0,Travelers Mad As Hell ,2010-09-23 12:48:00-04:00,MRK,negative
853888.0,BMY's Diabetes Candidate Encourages - Analyst Blog,2010-09-21 14:33:00-04:00,MRK,positive
853889.0,"Zacks Analyst Blog Highlights: ProShares UltraShort 20+ Year ETF, Pfizer, Merck, Ford and CarMax  - Press Releases",2010-09-21 08:04:00-04:00,MRK,neutral
853890.0,"Zacks Analyst Blog Highlights: Johnson & Johnson, Crucell NV, GlaxoSmithKline, Merck and Sanofi-Aventis    - Press Releases",2010-09-21 07:34:00-04:00,MRK,neutral
853891.0,Under The Hood: WisdomTree LargeCap Dividend Fund,2010-09-21 05:27:00-04:00,MRK,neutral
853892.0,J&J Makes a Pitch for Crucell - Analyst Blog,2010-09-18 11:06:00-04:00,MRK,neutral
853893.0,Unconfirmed Chatter that Merck & Co. Inc. (MRK) will buy Medicines Co. (MDCO) at $23.00 a share,2010-09-16 10:09:00-04:00,MRK,positive
853894.0,Jefferies Initiates Hold Rating on Merck (MRK),2010-09-16 09:07:00-04:00,MRK,neutral
853895.0,SurModics Stays Neutral - Analyst Blog,2010-09-13 16:36:00-04:00,MRK,neutral
853896.0,Top 10 'Buy'-Rated Stocks Under $5,2010-09-09 06:52:00-04:00,MRK,positive
853897.0,Goldman Sachs: Buy MRK Puts As Hedge,2010-09-08 10:35:00-04:00,MRK,neutral
853898.0,You'd Have To Be Sick To Touch This Drug Stock (PFE),2010-08-31 11:18:00-04:00,MRK,negative
853899.0,Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals,2010-08-30 11:20:00-04:00,MRK,neutral
853900.0,Sunday Morning Coffee,2010-08-29 08:38:00-04:00,MRK,neutral
853901.0,Birth Control Stocks: A Recession Play,2010-08-27 18:07:00-04:00,MRK,negative
853902.0,A New Round Of Corporate Layoffs?,2010-08-26 09:32:00-04:00,MRK,neutral
853903.0,Generic Risk For Gilead's Hepsera  - Analyst Blog,2010-08-23 08:21:00-04:00,MRK,negative
853904.0,10 Highest-Rated Dow Dividend Stocks ,2010-08-18 09:16:00-04:00,MRK,neutral
853905.0,Oppenheimer Remains Buyer Of VRTX,2010-08-17 11:11:00-04:00,MRK,neutral
853906.0,All Is Not Well In The Pharmaceutical Industry,2010-08-13 14:14:00-04:00,MRK,negative
853907.0,"U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)",2010-08-13 10:57:00-04:00,MRK,neutral
853908.0,Merck Announces Mandatory Conversion of its 6.00% Mandatory Convertible Preferred Stock,2010-08-12 13:40:00-04:00,MRK,positive
853909.0,"Dogs Of The Dow: 5 Highest Yielding Dow Stocks (MRK, PFE, PG, T, VZ)",2010-08-11 10:01:00-04:00,MRK,neutral
853910.0,Cost Reduction Lowers ENZN Loss - Analyst Blog,2010-08-09 17:52:00-04:00,MRK,negative
853911.0,Finally There Is A Cure For Tobacco Addiction (CIGX),2010-08-09 10:17:00-04:00,MRK,neutral
853912.0,"Best Stocks For A Deflationary Environment (NEM, ABX, GG, DLTR, FDO, MRK, JNJ)",2010-08-06 14:48:00-04:00,MRK,positive
853913.0,Oncothyreon Phase 3 Breast Cancer Trial Shut Down,2010-08-06 07:42:00-04:00,MRK,negative
853914.0,"Vertex Loss Narrows, Reaffirms Guidance  - Analyst Blog",2010-08-04 16:10:00-04:00,MRK,negative
853915.0,Santarus Beats on Higher Revs - Analyst Blog,2010-08-04 13:34:00-04:00,MRK,neutral
853916.0,"Zacks Analyst Blog Highlights: The Clorox, AstraZeneca, Merck, Dean Foods and Coach - Press Releases",2010-08-04 10:26:00-04:00,MRK,neutral
853917.0,AstraZeneca EPS Beats & Ups - Analyst Blog,2010-08-03 14:45:00-04:00,MRK,neutral
853918.0,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Free Cash Flow (PFE, JNJ, MRK, LLY) ",2010-08-02 07:20:00-04:00,MRK,positive
853919.0,Hapoalim Securities Downgrades Merck to Hold from Buy (MRK),2010-07-30 14:11:00-04:00,MRK,positive
853920.0,"Company News for July 30, 2010 - Corporate Summary",2010-07-30 09:45:00-04:00,MRK,neutral
853921.0,US Stock Futures Point To Weak Day Today,2010-07-30 09:05:00-04:00,MRK,negative
853922.0,Merck Posts Mixed Results (MRK),2010-07-30 07:36:00-04:00,MRK,neutral
853923.0,"ETFs To Watch July 30, 2010 (HAO, PPH, YCS, PALL)",2010-07-30 07:24:00-04:00,MRK,neutral
853924.0,"Merckâ€™s Q2 Earnings Beat Targets, Revenue Misses",2010-07-30 07:16:00-04:00,MRK,negative
853925.0,"Earnings Scheduled For July 30 (MRK, AON, CVX, CVH, WY, PPC)",2010-07-30 06:47:00-04:00,MRK,neutral
853926.0,"Stocks To Watch For July 30 (FSLR, MRK, CVX, AON, CSTR)",2010-07-30 05:22:00-04:00,MRK,neutral
853927.0,Fast Money 360: Leerink Swann Is A Buyer Of Merck (MRK),2010-07-28 18:39:00-04:00,MRK,neutral
853928.0,Huge Call Purchase on Merck & Co. (MRK),2010-07-27 11:53:00-04:00,MRK,positive
853929.0,A Peek Into The Market At The Start Of The Trading Day,2010-07-27 09:49:00-04:00,MRK,neutral
853930.0,Sanofi-aventis and Merck Appoint CEO for Joint Venture,2010-07-27 09:15:00-04:00,MRK,neutral
853931.0,Merk and Sinopharm Sign Statement of Mutual Intent,2010-07-27 08:28:00-04:00,MRK,neutral
853932.0,Corporate Catalysts For The Week Starting July 26 ,2010-07-26 06:51:00-04:00,MRK,neutral
853933.0,"Ryan Recommends Bristol-Myers and Merck (BMY, MRK, PFE)",2010-07-14 16:48:00-04:00,MRK,positive
853934.0,10 Firms Expecting Clinical Trial Results,2010-07-14 07:14:00-04:00,MRK,neutral
853935.0,"Miller Tabak Likes Bristol Myers Squibb (BMY), Novartis (NVS) And Merck (MRK)",2010-07-13 14:30:00-04:00,MRK,positive
853936.0,GlaxoSmithKline: Another Drug Company Runs Afoul Of The Truth ,2010-07-13 07:20:00-04:00,MRK,positive
853937.0,Late Market Roundup,2010-07-08 15:25:00-04:00,MRK,neutral
853938.0,"News Summary (HRB, BP, MRK)",2010-07-08 11:01:00-04:00,MRK,neutral
853939.0,Merck Details Global Restructuring Program,2010-07-08 09:10:00-04:00,MRK,neutral
853940.0,Top Yielding Big Pharmaceutical Stocks,2010-07-08 00:02:00-04:00,MRK,positive
853941.0,Puts Purchased on Millipore Corp. (MIL),2010-07-07 16:29:00-04:00,MRK,neutral
853942.0,"Stock Market News for July 7, 2010 - Market News",2010-07-07 10:13:00-04:00,MRK,neutral
853943.0,"Stock Market News for July 2, 2010 - Market News",2010-07-02 10:10:00-04:00,MRK,neutral
853944.0,Pharmaceutical ETFs on the Rise ,2010-06-30 14:49:00-04:00,MRK,neutral
853945.0,Good News for NVO's Victoza - Analyst Blog,2010-06-29 16:42:00-04:00,MRK,positive
853946.0,Soleil Initiates MRK With Hold,2010-06-29 06:19:00-04:00,MRK,neutral
853947.0,Citi (C) Has A Price Target Of $30 For Bristol Myers Squibb  (BMY) ,2010-06-28 14:36:00-04:00,MRK,neutral
853948.0,Late Market Roundup,2010-06-22 15:02:00-04:00,MRK,neutral
853949.0,"Dorfman Recommends Merck, Cal-Maine Foods, and Paycheck (MRK, CALM, PAYX)",2010-06-15 12:20:00-04:00,MRK,positive
853950.0,"Fast Money Halftime Recommendations (OXY, CVX, ABT, PFE, MRK, AXP, C, BAC, JPM)",2010-05-28 17:33:00-04:00,MRK,neutral
853951.0,"Citigroup Outlook For U.S. Major Pharmaceuticals (MRK, PFE, BMY)",2010-05-27 12:39:00-04:00,MRK,neutral
853952.0,"Deutsche Bank Sees A Brighter Future for Drug Stocks (MRK, PFE)",2010-05-27 11:29:00-04:00,MRK,positive
853953.0,"Bill Smead Likes Merck And Disney (MRK, DIS)",2010-05-26 08:11:00-04:00,MRK,positive
853954.0,"Citi Says DMARDs ""Not Immune to Tough Economy"" (JNJ, MRK, BMY, AMGN, ABT)",2010-05-24 14:08:00-04:00,MRK,negative
853955.0,"All 30 Dow Components In The Red (MRK, GE)",2010-05-20 11:15:00-04:00,MRK,neutral
853956.0,"US Stocks End Lower Yesterday After Soaring On Monday, Dow And S&P Down, Nasdaq Bucks Trend",2010-05-12 06:27:00-04:00,MRK,negative
853957.0,Five New Drugs On Cards for Merck (MRK),2010-05-11 11:02:00-04:00,MRK,neutral
853958.0,Citi Gives Thoughts  On MRKâ€™s 2010 Annual Briefing And Its $45.00 Price Target,2010-05-10 06:45:00-04:00,MRK,neutral
853959.0,"Merck And Ariad Re-Write Ridaforolimus Contract (MRK, ARIA)",2010-05-05 13:52:00-04:00,MRK,neutral
853960.0,"Stock Market News for May 5, 2010 - Market News",2010-05-05 09:30:00-04:00,MRK,neutral
853961.0,"Company News for May 5, 2010 - Corporate Summary",2010-05-05 09:30:00-04:00,MRK,neutral
853962.0,"Benzingaâ€™s Top Pre-Market Gainers (AMMD, HNSN, ACAS, ARIA, ERTS)",2010-05-05 09:10:00-04:00,MRK,positive
853963.0,Goldman Downgrades MRK To Neutral,2010-05-05 08:29:00-04:00,MRK,neutral
853964.0,"FOREX, COMMODITIES, STOCKS OUTLOOK May 5th: SPECIAL EU CRISIS MARKET CORRECTION 10:30 GMT",2010-05-05 06:20:00-04:00,MRK,negative
853965.0,"US Stocks Dive, Hit By Europe Crisis, Investors Take Refuge In Dollar & Bonds",2010-05-05 05:49:00-04:00,MRK,negative
853966.0,Jim Cramerâ€™s Short Term Plays,2010-05-04 14:47:00-04:00,MRK,positive
853967.0,Pfizer (PFE) Breaches Above its 50 Day MA  ,2010-05-04 13:10:00-04:00,MRK,neutral
853968.0,US Stock Futures Fall On Greece Worries,2010-05-04 11:18:00-04:00,MRK,negative
853969.0,"MRK Shares Rise As Q1 Profits, Sales Exceeds Expectations",2010-05-04 10:22:00-04:00,MRK,positive
853970.0,"Stock Market News for May 4, 2010 - Market News",2010-05-04 09:30:00-04:00,MRK,neutral
853971.0,"Company News for May 4, 2010 - Corporate Summary",2010-05-04 09:30:00-04:00,MRK,neutral
853972.0,Merck & Co.â€™s (MRK) First-Quarter Profit Down By 77%,2010-05-04 07:44:00-04:00,MRK,positive
853973.0,"Jimâ€™s Game Plan For This Week (SMG, CLNE, CPNO, JDSU, APA, DVN, RIG, MRK, PFE, SHOO, SBA, AMT, VMC, SYY)",2010-05-03 15:17:00-04:00,MRK,negative
853974.0,"Stock Market News for May 3, 2010 - Market News",2010-05-03 14:07:00-04:00,MRK,neutral
853975.0,"DOW Gains The Highest Since March 5, Led By Q1 Gains",2010-04-30 07:50:00-04:00,MRK,positive
853976.0,"Fast Money Picks For April 30th (MRK, RIG, GLW, XOM)",2010-04-29 19:07:00-04:00,MRK,negative
853977.0,"Afternoon Market Update - Goldman Sachs (NYSE: GS), Merck (NYSE: MRK), AstraZeneca (NYSE: AZN)",2010-04-28 15:28:00-04:00,MRK,neutral
853978.0,Investors Allowed To Sue Merck Over Vioxx (MRK),2010-04-28 12:26:00-04:00,MRK,neutral
853979.0,Merck To Lose $170 Million In Revenue (MRK),2010-04-23 18:25:00-04:00,MRK,negative
853980.0,Merck & Co. (MRK) Says U.S. Health-Care Legislation To Reduce 2010 Revenue By $170 Million,2010-04-23 17:35:00-04:00,MRK,neutral
853981.0,"Market Roundup (MS, C, HLS, UBS, HBC, USB, MRK)",2010-04-23 14:35:00-04:00,MRK,neutral
853982.0,US Stock Ended In Positive Territory After Losing 100 Points,2010-04-23 07:03:00-04:00,MRK,positive
853983.0,"Stock Market News for April 22, 2010 - Market News",2010-04-22 09:30:00-04:00,MRK,neutral
853984.0,Top Stocks of New Jersey,2010-04-21 15:19:00-04:00,MRK,positive
853985.0,"Mad Money Lightning Round: Jim Likes AMD, APC, ARMH, IMAX, YHOO, EXC, MUR",2010-04-15 07:41:00-04:00,MRK,negative
853986.0,"Stock Market News for April 8, 2010 - Market News",2010-04-08 09:30:00-04:00,MRK,neutral
853987.0,"U.S. Equity Market Preview (AAPL, EXC, HSP, ITMN, MRK)",2010-04-05 07:33:00-04:00,MRK,neutral
853988.0,"Top Five Dow Stocks With High Yields (DD, MRK, PFE, T, VZ)",2010-03-25 05:46:00-04:00,MRK,positive
853989.0,The High Yielders of the Dow,2010-03-25 01:58:00-04:00,MRK,neutral
853990.0,Before Jumping Into A Single Health Care Stock Consider This ETF,2010-03-23 23:22:00-04:00,MRK,positive
853991.0,"Fast Money Picks For March 24th (MPEL, APA, PLL, BAC)",2010-03-23 20:12:00-04:00,MRK,neutral
853992.0,Investors Flock To Healthcare ETFs On Historic Reform,2010-03-22 16:13:00-04:00,MRK,neutral
853993.0,"US Stocks Jump Up; Rally Driven By Health, Pharma Stocks (AXP, DD, MRK, PFE, MRK, THC, HMA)",2010-03-22 15:48:00-04:00,MRK,neutral
853994.0,FDA Asks Doctors To Suspend Use Of GlaxoSmithKline (GSK) Rotavirus Vaccine,2010-03-22 15:37:00-04:00,MRK,negative
853995.0,Pfizer (PFE) and Merck (MRK) Advance Following Approval of Healthcare Legislation,2010-03-22 13:34:00-04:00,MRK,positive
853996.0,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying,2010-03-17 13:42:00-04:00,MRK,neutral
853997.0,"Benzingaâ€™s News Roundup (PEP, ALKS, MRK)",2010-03-15 09:37:00-04:00,MRK,neutral
853998.0,"Merck To Continue Its M&A Spree (MRK, MIL)",2010-03-12 18:04:00-05:00,MRK,neutral
853999.0,Overhang On Merck & Company (MRK) Lifted By IMPROVE-IT Update,2010-03-12 10:04:00-05:00,MRK,neutral
854000.0,"Stock Market News for March 12, 2010 - Market News",2010-03-12 08:49:00-05:00,MRK,neutral
854001.0,Sonofi-Merck (MRK) Deal Positive,2010-03-09 12:10:00-05:00,MRK,positive
854002.0,"ThinkEquity Reiterates Buy on OraSure Technologies (OSUR, MRK, PFE)",2010-03-08 12:29:00-05:00,MRK,neutral
854003.0,Simple Quantitative View of Goldman's VIP List Generates Some Other Long Ideas,2010-03-08 09:01:00-05:00,MRK,positive
854004.0,Goldman Sachs (GS) VIP List of Top Hedge Fund Holdings,2010-03-05 12:19:00-05:00,MRK,positive
854005.0,Karen Finerman Thinks There Might Be Other Bidders For MIL,2010-03-01 18:01:00-05:00,MRK,neutral
854006.0,Eli Lilly Banks On Its Restructured Development Process To Offset Sales Loss (LLY),2010-02-25 13:06:00-05:00,MRK,negative
854007.0,"Large Hacking Instance Detected (MRK, CAH)",2010-02-18 11:36:00-05:00,MRK,neutral
854008.0,"John Paulson Sells Merck (MRK), Buys Bank Of America (BAC)",2010-02-16 19:02:00-05:00,MRK,neutral
854009.0,"Movement Expected In The Shares Of These Companies Amid Significant Events (BRK.B, BX, JPM, ORCL,YHOO) ",2010-02-16 16:32:00-05:00,MRK,positive
854010.0,"Merck & Co. (MRK) Reports Bigger Profit, Helped By Schering-Ploug Deal ",2010-02-16 15:58:00-05:00,MRK,positive
854011.0,Merck Posts Bigger Profit (MRK),2010-02-16 10:07:00-05:00,MRK,positive
854012.0,"Company News for February 16, 2010 - Corporate Summary",2010-02-16 09:38:00-05:00,MRK,neutral
854013.0,MRK Shares Up As 4Q Earnings Match Expectations,2010-02-16 09:34:00-05:00,MRK,negative
854014.0,"Stock Market News for February 16, 2010 - Market News",2010-02-16 09:30:00-05:00,MRK,neutral
854015.0,Merck & Co. (MRK) Reports Schering Fueled Profit Jump,2010-02-16 08:24:00-05:00,MRK,positive
854016.0,"Merck Reports Inline, Stock Off To Good Start In Premarket (MRK)",2010-02-16 08:12:00-05:00,MRK,positive
854017.0,"Top 5 Large Cap Growth Stocks (ESRX, MRK, VALE, AAPL, BHP)",2010-02-16 07:16:00-05:00,MRK,positive
854018.0,"Credit Suisse Lowers Estimates, Price Targets On Merck, Pfizer",2010-02-11 15:11:00-05:00,MRK,positive
854019.0,Merck & Co. To Change Safety Procedures (MRK),2010-02-10 16:06:00-05:00,MRK,positive
854020.0,Merck & Co. (MRK) Agrees To Changes In Vioxx Settlement,2010-02-10 15:10:00-05:00,MRK,positive
854021.0,"Market Roundup (AAPL, MRK, FITB, PNC, TTWO, GOOG)",2010-02-10 13:40:00-05:00,MRK,neutral
854022.0,"Market Round-up (UBS, GOOGÂ¸ AAPL, MOTÂ¸ PG, PFE, MRK, LLY, CVS, WAG)",2010-02-05 14:08:00-05:00,MRK,neutral
854023.0,Merck (MRK) Is A Frontrunner Among Pharma Stocks,2010-02-04 05:25:00-05:00,MRK,neutral
854024.0,"Mad Money Lightning Round: Jim Prefers MRK, SYK, INTC, AAPL To COMS, ZMH, EBIX, MSFT, MOT ",2010-02-03 13:18:00-05:00,MRK,negative
854025.0,Invest In High Quality Stocks Like Merck (MRK) : Analyst Says On CNBC,2010-01-29 09:58:00-05:00,MRK,positive
854026.0,"Merck (MRK) Doing Well, But Becoming More Transparent",2010-01-25 08:24:00-05:00,MRK,positive
854027.0,Big Pharma Will Trade On the Following Fundamentals:   Morningstar Says Big Pharma Well Positioned,2010-01-22 13:14:00-05:00,MRK,positive
854028.0,"Stock Market News for January 20, 2010 - Market News",2010-01-20 09:23:00-05:00,MRK,neutral
854029.0,Merck Has The Best Pharma Bet (MRK),2010-01-18 12:17:00-05:00,MRK,positive
854030.0,"Pete Najarian Sees An Opportunity In Pharma (XLV, WLP, AET, UNH, HUM, MRK, PFE, JNJ) ",2010-01-14 19:17:00-05:00,MRK,positive
854031.0,Merck & Co (MRK) Submits New Data To FDA To Widen Gardasil Use,2010-01-14 16:26:00-05:00,MRK,neutral
854032.0,"Stock Market News for January 14, 2010 - Market News",2010-01-14 09:22:00-05:00,MRK,neutral
854033.0,"Top 5 Large-Cap Stocks In The Healthcare Sector With The Highest ROE (GSK, GILD, AZN, ACL, MRK) ",2010-01-14 09:02:00-05:00,MRK,positive
854034.0,Merck leads drug stocks up,2010-01-13 14:01:00-05:00,MRK,neutral
854035.0,Merck & Co. (MRK) Soars On Upgrade By Credit Suisse,2010-01-13 11:38:00-05:00,MRK,positive
854036.0,Merck Upgraded At Credit Suisse (MRK),2010-01-13 10:51:00-05:00,MRK,positive
854037.0,"Benzingaâ€™s Top Upgrades (BIDU, MRK, NTAP, UPS, AAWW)",2010-01-13 09:32:00-05:00,MRK,positive
854038.0,"Company News for January 13, 2010 - Corporate Summary",2010-01-13 09:20:00-05:00,MRK,neutral
854039.0,"Investment Mantra 2010: Be Bullish On Mega Caps In â€˜The Dogs Of The Dowâ€™. (XOM, WFC, BA, CVX, DU, MCD, MRK, PFE) ",2010-01-08 14:22:00-05:00,MRK,neutral
854040.0,"Drug Pipeline Targeting High Growth Markets May Boost Merck Prospects (MRK, C)",2010-01-05 08:30:00-05:00,MRK,positive
854041.0,"Biotech Listings To Form A Major Chunk Of IPO Market (JNJ, PFE, MRK, CDXS,TNGN, MBGI)",2010-01-04 14:02:00-05:00,MRK,neutral
854042.0,"The World's Largest M&A Deals in 2009 (PFE, WLA, GM, SGP, MRK)",2009-12-28 13:35:00-05:00,MRK,neutral
854043.0,Merck Decides To Discontinue Its Collaboration With ARNA For Dyslipidemia,2009-12-24 10:35:00-05:00,MRK,neutral
854044.0,Above Average EPS Growth Projected For MRK,2009-12-23 11:52:00-05:00,MRK,positive
854045.0,FDA Indicates Role Of Vytorin and Zetia In Increased Cancer Risk Unlikely,2009-12-23 11:51:00-05:00,MRK,negative
854046.0,Merck & Co. Inc (MRK) Gets A Hold Rating,2009-12-23 11:22:00-05:00,MRK,neutral
854047.0,Walmart (WMT) And Comcast (CMCSA) For 2010,2009-12-22 13:00:00-05:00,MRK,neutral
854048.0,Buying Value for 2010,2009-12-22 03:23:00-05:00,MRK,positive
854049.0,"Health Brings Wealth To The Street (PFE, MRK, AET, UNH, SNY, CHTT)",2009-12-21 14:23:00-05:00,MRK,positive
854050.0,New PBM President Good For Caremark (CVS),2009-12-21 13:26:00-05:00,MRK,positive
854051.0,2010 Dogs Of The Dow ,2009-12-21 10:30:00-05:00,MRK,neutral
854052.0,Peak Sales Of MRKâ€™s Isentress May Touch $2 Billion,2009-12-18 12:29:00-05:00,MRK,neutral
854053.0,"Top 5 Large-Cap Stocks with Highest Sales Growth Estimate for Next Year (TM, SU, MRK, ESRX, POT)",2009-12-16 08:26:00-05:00,MRK,positive
854054.0,"Large Caps Breaking Out - Johnson & Johnson (JNJ), Coke (KO), IBM (IBM), Merck (MRK), Verizon (VZ), Disney (DIS), 3M (MMM)",2009-12-14 10:08:00-05:00,MRK,neutral
854055.0,SEC On Trail Of Insider Trading Transactions,2009-12-10 09:41:00-05:00,MRK,neutral
854056.0,"Stock Market News for December 08, 2009 - Market News",2009-12-08 09:13:00-05:00,MRK,neutral
854057.0,"Cowen stays Neutral On Santarus (SNTS), Cites Litigation Concerns , PRX, MRK, AZN, NVS",2009-12-02 12:20:00-05:00,MRK,negative
854058.0,"Google's Most Popular Stock Searches Today, SNTS, MRK, ITVI, DYAX, SNDA",2009-12-02 09:24:00-05:00,MRK,positive
854059.0,"Taking A Look At Two Pharma ETFs (IHE, PPH)",2009-11-28 19:50:00-05:00,MRK,neutral
854060.0,"Stocks That Will Continue to Achieve New Highs (BBY, SJM, AGU, KO, TRA, MRK, CTL)",2009-11-20 16:21:00-05:00,MRK,neutral
854061.0,JPMorgan Likes Abbott (ABT) Because of Niaspan,2009-11-16 06:22:00-05:00,MRK,positive
854062.0,Merck Sends Letter To NYT Editor About Arbiter Story,2009-11-14 08:12:00-05:00,MRK,neutral
854063.0,Merck (MRK) Drugs Under Scanner Of Cholesterol Study,2009-11-13 11:32:00-05:00,MRK,neutral
854064.0,Leerink Swann Upgrades Merck To Outperform,2009-11-09 08:00:00-05:00,MRK,neutral
854065.0,The ETF Professor Told You To Watch This Healthcare ETF (XLV),2009-11-06 14:04:00-05:00,MRK,neutral
854066.0,Merck Says It Won't Seek Another Larger Merger,2009-11-04 16:02:00-05:00,MRK,neutral
854067.0,"Fitch Downgrades Merck, Outlook Stable",2009-11-04 15:38:00-05:00,MRK,positive
854068.0,Sanofi-aventis (SNY) Completes Acquisition of Merial ,2009-09-18 03:38:00-04:00,MRK,neutral
854069.0,"BenchmarkJournal.com Free Analyst Review for ABK, EQR, KMB, BBD, FIG and MRK",2009-08-17 08:14:00-04:00,MRK,positive
854070.0,"Trends in the U.K. and Irish Pharmaceutical and Biotechnology Industry, an Industrial Info News Alert",2009-08-17 05:01:00-04:00,MRK,positive
854071.0,"ParagonReport.com Complimentary Market Update on Freddie Mac (NYSE: FRE), Best Buy Co. Inc. (NYSE: BBY), American Express Company (NYSE: AXP), and Merck & Co. Inc. (NYSE: MRK)",2009-08-10 13:35:00-04:00,MRK,positive
854072.0,"ParagonReport.com Complimentary Market Update on Alumina Ltd. (NYSE: AWC), CSB Corporation (NYSE: CBS), Merck & Co. Inc. (NYSE: MRK) and NVIDIA Corporation (NASDAQ: NVDA)",2009-08-07 11:30:00-04:00,MRK,positive
854073.0,"Wall Street News Alert:  Stocks This Morning: Green Star Alternative Energy -- July 27, 2009",2009-07-27 08:33:00-04:00,MRK,positive
